US20210363491A1 - Production of insulin producing cells - Google Patents
Production of insulin producing cells Download PDFInfo
- Publication number
- US20210363491A1 US20210363491A1 US17/334,933 US202117334933A US2021363491A1 US 20210363491 A1 US20210363491 A1 US 20210363491A1 US 202117334933 A US202117334933 A US 202117334933A US 2021363491 A1 US2021363491 A1 US 2021363491A1
- Authority
- US
- United States
- Prior art keywords
- cells
- inhibitor
- wnt
- expression
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 title claims abstract description 266
- 108090001061 Insulin Proteins 0.000 title claims abstract description 135
- 102000004877 Insulin Human genes 0.000 title claims abstract description 133
- 229940125396 insulin Drugs 0.000 title claims abstract description 133
- 238000004519 manufacturing process Methods 0.000 title description 13
- 210000004027 cell Anatomy 0.000 claims abstract description 383
- 239000003112 inhibitor Substances 0.000 claims abstract description 205
- 210000000130 stem cell Anatomy 0.000 claims abstract description 111
- 102000013814 Wnt Human genes 0.000 claims abstract description 100
- 108050003627 Wnt Proteins 0.000 claims abstract description 100
- 108010070047 Notch Receptors Proteins 0.000 claims abstract description 74
- 239000012190 activator Substances 0.000 claims abstract description 41
- 102100032063 Neurogenic differentiation factor 1 Human genes 0.000 claims abstract description 30
- 108050000588 Neurogenic differentiation factor 1 Proteins 0.000 claims abstract description 30
- 239000012824 ERK inhibitor Substances 0.000 claims abstract description 18
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 claims abstract description 18
- 102000014736 Notch Human genes 0.000 claims abstract 7
- 238000000034 method Methods 0.000 claims description 77
- DWJXYEABWRJFSP-XOBRGWDASA-N DAPT Chemical compound N([C@@H](C)C(=O)N[C@H](C(=O)OC(C)(C)C)C=1C=CC=CC=1)C(=O)CC1=CC(F)=CC(F)=C1 DWJXYEABWRJFSP-XOBRGWDASA-N 0.000 claims description 35
- SYENTKHGMVKGAQ-UHFFFAOYSA-N N-cyclopropyl-5-thiophen-2-yl-3-isoxazolecarboxamide Chemical compound C1=C(C=2SC=CC=2)ON=C1C(=O)NC1CC1 SYENTKHGMVKGAQ-UHFFFAOYSA-N 0.000 claims description 35
- 238000011977 dual antiplatelet therapy Methods 0.000 claims description 35
- 150000003839 salts Chemical class 0.000 claims description 29
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims description 25
- 230000007067 DNA methylation Effects 0.000 claims description 18
- 102100031036 Leucine-rich repeat-containing G-protein coupled receptor 5 Human genes 0.000 claims description 15
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims description 12
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims description 12
- NMUSYJAQQFHJEW-UHFFFAOYSA-N 5-Azacytidine Natural products O=C1N=C(N)N=CN1C1C(O)C(O)C(CO)O1 NMUSYJAQQFHJEW-UHFFFAOYSA-N 0.000 claims description 11
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 claims description 11
- 229960002756 azacitidine Drugs 0.000 claims description 11
- 150000001875 compounds Chemical class 0.000 claims description 11
- 102000019058 Glycogen Synthase Kinase 3 beta Human genes 0.000 claims description 10
- 108010051975 Glycogen Synthase Kinase 3 beta Proteins 0.000 claims description 10
- 101001063456 Homo sapiens Leucine-rich repeat-containing G-protein coupled receptor 5 Proteins 0.000 claims description 9
- XAUDJQYHKZQPEU-KVQBGUIXSA-N 5-aza-2'-deoxycytidine Chemical compound O=C1N=C(N)N=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 XAUDJQYHKZQPEU-KVQBGUIXSA-N 0.000 claims description 8
- 230000000968 intestinal effect Effects 0.000 claims description 8
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 claims description 6
- 229960004308 acetylcysteine Drugs 0.000 claims description 6
- 230000003111 delayed effect Effects 0.000 claims description 5
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical compound IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 claims description 3
- SUDAHWBOROXANE-SECBINFHSA-N PD 0325901 Chemical compound OC[C@@H](O)CONC(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1F SUDAHWBOROXANE-SECBINFHSA-N 0.000 claims description 2
- 229940035722 triiodothyronine Drugs 0.000 claims description 2
- 230000014509 gene expression Effects 0.000 abstract description 231
- 230000004069 differentiation Effects 0.000 abstract description 147
- 150000003384 small molecules Chemical class 0.000 abstract description 127
- 210000003158 enteroendocrine cell Anatomy 0.000 abstract description 110
- 101150075558 CHGA gene Proteins 0.000 abstract description 89
- 230000001965 increasing effect Effects 0.000 abstract description 84
- 238000003556 assay Methods 0.000 abstract description 44
- 239000003102 growth factor Substances 0.000 abstract description 28
- 108010033040 Histones Proteins 0.000 abstract description 23
- 239000003276 histone deacetylase inhibitor Substances 0.000 abstract description 23
- 230000011987 methylation Effects 0.000 abstract description 22
- 238000007069 methylation reaction Methods 0.000 abstract description 22
- 229940121372 histone deacetylase inhibitor Drugs 0.000 abstract description 21
- 238000012744 immunostaining Methods 0.000 abstract description 14
- 210000004962 mammalian cell Anatomy 0.000 abstract description 11
- 230000003827 upregulation Effects 0.000 abstract description 6
- 102000005650 Notch Receptors Human genes 0.000 description 67
- 108020004999 messenger RNA Proteins 0.000 description 66
- 230000037361 pathway Effects 0.000 description 47
- -1 Gcg Proteins 0.000 description 41
- 108090000623 proteins and genes Proteins 0.000 description 36
- 230000000694 effects Effects 0.000 description 33
- 210000004966 intestinal stem cell Anatomy 0.000 description 32
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 28
- 102400001368 Epidermal growth factor Human genes 0.000 description 27
- 101800003838 Epidermal growth factor Proteins 0.000 description 27
- 229940116977 epidermal growth factor Drugs 0.000 description 27
- IGLYMJRIWWIQQE-QUOODJBBSA-N (1S,2R)-2-phenylcyclopropan-1-amine (1R,2S)-2-phenylcyclopropan-1-amine Chemical compound N[C@H]1C[C@@H]1C1=CC=CC=C1.N[C@@H]1C[C@H]1C1=CC=CC=C1 IGLYMJRIWWIQQE-QUOODJBBSA-N 0.000 description 25
- 210000003134 paneth cell Anatomy 0.000 description 25
- 239000000126 substance Substances 0.000 description 25
- 229960003741 tranylcypromine Drugs 0.000 description 25
- 102000004232 Mitogen-Activated Protein Kinase Kinases Human genes 0.000 description 24
- GOVYBPLHWIEHEJ-UHFFFAOYSA-N tubastatin A Chemical compound C1N(C)CCC2=C1C1=CC=CC=C1N2CC1=CC=C(C(=O)NO)C=C1 GOVYBPLHWIEHEJ-UHFFFAOYSA-N 0.000 description 23
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 description 21
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 description 21
- 102400000322 Glucagon-like peptide 1 Human genes 0.000 description 21
- 230000002779 inactivation Effects 0.000 description 21
- 102000045246 noggin Human genes 0.000 description 21
- 108700007229 noggin Proteins 0.000 description 21
- AQGNHMOJWBZFQQ-UHFFFAOYSA-N CT 99021 Chemical compound CC1=CNC(C=2C(=NC(NCCNC=3N=CC(=CC=3)C#N)=NC=2)C=2C(=CC(Cl)=CC=2)Cl)=N1 AQGNHMOJWBZFQQ-UHFFFAOYSA-N 0.000 description 20
- 101150017554 LGR5 gene Proteins 0.000 description 20
- NIJJYAXOARWZEE-UHFFFAOYSA-N Valproic acid Chemical compound CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 description 20
- 230000005764 inhibitory process Effects 0.000 description 19
- 239000000523 sample Substances 0.000 description 18
- 239000003795 chemical substances by application Substances 0.000 description 17
- 239000003550 marker Substances 0.000 description 17
- KHZOJCQBHJUJFY-UHFFFAOYSA-N 2-[4-(2-methylpyridin-4-yl)phenyl]-n-(4-pyridin-3-ylphenyl)acetamide Chemical compound C1=NC(C)=CC(C=2C=CC(CC(=O)NC=3C=CC(=CC=3)C=3C=NC=CC=3)=CC=2)=C1 KHZOJCQBHJUJFY-UHFFFAOYSA-N 0.000 description 16
- 241000124008 Mammalia Species 0.000 description 15
- 238000011529 RT qPCR Methods 0.000 description 15
- 210000002175 goblet cell Anatomy 0.000 description 15
- 210000002220 organoid Anatomy 0.000 description 15
- 210000001519 tissue Anatomy 0.000 description 15
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 14
- 102100028098 Homeobox protein Nkx-6.1 Human genes 0.000 description 14
- 101000578254 Homo sapiens Homeobox protein Nkx-6.1 Proteins 0.000 description 14
- IBCXZJCWDGCXQT-UHFFFAOYSA-N LY 364947 Chemical compound C=1C=NC2=CC=CC=C2C=1C1=CNN=C1C1=CC=CC=N1 IBCXZJCWDGCXQT-UHFFFAOYSA-N 0.000 description 14
- FHYUGAJXYORMHI-UHFFFAOYSA-N SB 431542 Chemical compound C1=CC(C(=O)N)=CC=C1C1=NC(C=2C=C3OCOC3=CC=2)=C(C=2N=CC=CC=2)N1 FHYUGAJXYORMHI-UHFFFAOYSA-N 0.000 description 14
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 14
- 230000024245 cell differentiation Effects 0.000 description 14
- 239000008103 glucose Substances 0.000 description 14
- 239000000203 mixture Substances 0.000 description 14
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 14
- LBPKYPYHDKKRFS-UHFFFAOYSA-N 1,5-naphthyridine, 2-[3-(6-methyl-2-pyridinyl)-1h-pyrazol-4-yl]- Chemical compound CC1=CC=CC(C2=C(C=NN2)C=2N=C3C=CC=NC3=CC=2)=N1 LBPKYPYHDKKRFS-UHFFFAOYSA-N 0.000 description 13
- 239000002771 cell marker Substances 0.000 description 13
- 231100000673 dose–response relationship Toxicity 0.000 description 13
- 230000008569 process Effects 0.000 description 13
- 235000018102 proteins Nutrition 0.000 description 13
- 102000004169 proteins and genes Human genes 0.000 description 13
- 230000004913 activation Effects 0.000 description 12
- 230000003247 decreasing effect Effects 0.000 description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 12
- 230000006870 function Effects 0.000 description 12
- 238000001727 in vivo Methods 0.000 description 12
- 238000012216 screening Methods 0.000 description 12
- DKPQHFZUICCZHF-UHFFFAOYSA-N 6-[2-tert-butyl-5-(6-methyl-2-pyridinyl)-1H-imidazol-4-yl]quinoxaline Chemical compound CC1=CC=CC(C2=C(N=C(N2)C(C)(C)C)C=2C=C3N=CC=NC3=CC=2)=N1 DKPQHFZUICCZHF-UHFFFAOYSA-N 0.000 description 11
- 241000282414 Homo sapiens Species 0.000 description 11
- 102100024193 Mitogen-activated protein kinase 1 Human genes 0.000 description 11
- 239000002253 acid Substances 0.000 description 11
- 229940054066 benzamide antipsychotics Drugs 0.000 description 11
- 150000003936 benzamides Chemical class 0.000 description 11
- 201000010099 disease Diseases 0.000 description 11
- 108010082117 matrigel Proteins 0.000 description 11
- 230000007246 mechanism Effects 0.000 description 11
- 230000001737 promoting effect Effects 0.000 description 11
- 230000019491 signal transduction Effects 0.000 description 11
- 101000825954 Homo sapiens R-spondin-1 Proteins 0.000 description 10
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 10
- 102100022762 R-spondin-1 Human genes 0.000 description 10
- 230000007423 decrease Effects 0.000 description 10
- 239000001963 growth medium Substances 0.000 description 10
- 230000011664 signaling Effects 0.000 description 10
- HIJMSZGHKQPPJS-UHFFFAOYSA-N 3-(6-methylpyridin-2-yl)-n-phenyl-4-quinolin-4-ylpyrazole-1-carbothioamide Chemical compound CC1=CC=CC(C=2C(=CN(N=2)C(=S)NC=2C=CC=CC=2)C=2C3=CC=CC=C3N=CC=2)=N1 HIJMSZGHKQPPJS-UHFFFAOYSA-N 0.000 description 9
- 101150108034 LYZ1 gene Proteins 0.000 description 9
- VIUAUNHCRHHYNE-JTQLQIEISA-N N-[(2S)-2,3-dihydroxypropyl]-3-(2-fluoro-4-iodoanilino)-4-pyridinecarboxamide Chemical compound OC[C@@H](O)CNC(=O)C1=CC=NC=C1NC1=CC=C(I)C=C1F VIUAUNHCRHHYNE-JTQLQIEISA-N 0.000 description 9
- 230000004156 Wnt signaling pathway Effects 0.000 description 9
- 239000003814 drug Substances 0.000 description 9
- 229940121647 egfr inhibitor Drugs 0.000 description 9
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 9
- 238000000338 in vitro Methods 0.000 description 9
- 230000006698 induction Effects 0.000 description 9
- 230000001939 inductive effect Effects 0.000 description 9
- 230000028327 secretion Effects 0.000 description 9
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 8
- 102000001301 EGF receptor Human genes 0.000 description 8
- 108060006698 EGF receptor Proteins 0.000 description 8
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 8
- 241000283973 Oryctolagus cuniculus Species 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- OHRURASPPZQGQM-GCCNXGTGSA-N romidepsin Chemical compound O1C(=O)[C@H](C(C)C)NC(=O)C(=C/C)/NC(=O)[C@H]2CSSCC\C=C\[C@@H]1CC(=O)N[C@H](C(C)C)C(=O)N2 OHRURASPPZQGQM-GCCNXGTGSA-N 0.000 description 8
- BERLXWPRSBJFHO-UHFFFAOYSA-N 2-(5-chloro-2-fluorophenyl)-n-pyridin-4-ylpteridin-4-amine Chemical compound FC1=CC=C(Cl)C=C1C1=NC(NC=2C=CN=CC=2)=C(N=CC=N2)C2=N1 BERLXWPRSBJFHO-UHFFFAOYSA-N 0.000 description 7
- BTUOOXPZOVNPMF-UHFFFAOYSA-N 2-[4-(1,3-benzodioxol-5-yl)-2-tert-butyl-1h-imidazol-5-yl]-6-methylpyridine;hydrochloride Chemical compound Cl.CC1=CC=CC(C2=C(N=C(N2)C(C)(C)C)C=2C=C3OCOC3=CC=2)=N1 BTUOOXPZOVNPMF-UHFFFAOYSA-N 0.000 description 7
- JQGOCCALXFSRHZ-UHFFFAOYSA-N 2-[4-[2-fluoro-5-[5-(6-methylpyridin-2-yl)-1h-pyrazol-4-yl]phenyl]pyrazol-1-yl]ethanol Chemical compound CC1=CC=CC(C=2C(=CNN=2)C=2C=C(C(F)=CC=2)C2=CN(CCO)N=C2)=N1 JQGOCCALXFSRHZ-UHFFFAOYSA-N 0.000 description 7
- FJCDSQATIJKQKA-UHFFFAOYSA-N 2-fluoro-n-[[5-(6-methylpyridin-2-yl)-4-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-1h-imidazol-2-yl]methyl]aniline Chemical compound CC1=CC=CC(C2=C(N=C(CNC=3C(=CC=CC=3)F)N2)C2=CN3N=CN=C3C=C2)=N1 FJCDSQATIJKQKA-UHFFFAOYSA-N 0.000 description 7
- IVRXNBXKWIJUQB-UHFFFAOYSA-N LY-2157299 Chemical compound CC1=CC=CC(C=2C(=C3CCCN3N=2)C=2C3=CC(=CC=C3N=CC=2)C(N)=O)=N1 IVRXNBXKWIJUQB-UHFFFAOYSA-N 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 7
- 101150058357 Muc2 gene Proteins 0.000 description 7
- FABQUVYDAXWUQP-UHFFFAOYSA-N N4-(1,3-benzodioxol-5-ylmethyl)-6-(3-methoxyphenyl)pyrimidine-2,4-diamine Chemical compound COC1=CC=CC(C=2N=C(N)N=C(NCC=3C=C4OCOC4=CC=3)C=2)=C1 FABQUVYDAXWUQP-UHFFFAOYSA-N 0.000 description 7
- 239000006143 cell culture medium Substances 0.000 description 7
- 229960002584 gefitinib Drugs 0.000 description 7
- 229940088597 hormone Drugs 0.000 description 7
- 239000005556 hormone Substances 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 210000000056 organ Anatomy 0.000 description 7
- 108090000765 processed proteins & peptides Proteins 0.000 description 7
- 230000003248 secreting effect Effects 0.000 description 7
- 238000010186 staining Methods 0.000 description 7
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 6
- OHCQJHSOBUTRHG-KGGHGJDLSA-N FORSKOLIN Chemical compound O=C([C@@]12O)C[C@](C)(C=C)O[C@]1(C)[C@@H](OC(=O)C)[C@@H](O)[C@@H]1[C@]2(C)[C@@H](O)CCC1(C)C OHCQJHSOBUTRHG-KGGHGJDLSA-N 0.000 description 6
- 101150003028 Hprt1 gene Proteins 0.000 description 6
- 101710174256 Leucine-rich repeat-containing G-protein coupled receptor 5 Proteins 0.000 description 6
- WRKPZSMRWPJJDH-UHFFFAOYSA-N N-(6-methyl-1,3-benzothiazol-2-yl)-2-[(4-oxo-3-phenyl-6,7-dihydrothieno[3,2-d]pyrimidin-2-yl)thio]acetamide Chemical compound S1C2=CC(C)=CC=C2N=C1NC(=O)CSC1=NC=2CCSC=2C(=O)N1C1=CC=CC=C1 WRKPZSMRWPJJDH-UHFFFAOYSA-N 0.000 description 6
- 101150106167 SOX9 gene Proteins 0.000 description 6
- 238000004113 cell culture Methods 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 229950000456 galunisertib Drugs 0.000 description 6
- 230000002496 gastric effect Effects 0.000 description 6
- 230000003914 insulin secretion Effects 0.000 description 6
- 239000003446 ligand Substances 0.000 description 6
- 239000008194 pharmaceutical composition Substances 0.000 description 6
- VAZAPHZUAVEOMC-UHFFFAOYSA-N tacedinaline Chemical compound C1=CC(NC(=O)C)=CC=C1C(=O)NC1=CC=CC=C1N VAZAPHZUAVEOMC-UHFFFAOYSA-N 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 241000283074 Equus asinus Species 0.000 description 5
- 102000003964 Histone deacetylase Human genes 0.000 description 5
- 108090000353 Histone deacetylase Proteins 0.000 description 5
- 241000282412 Homo Species 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- PAWIYAYFNXQGAP-UHFFFAOYSA-N N-hydroxy-2-[4-[[(1-methyl-3-indolyl)methylamino]methyl]-1-piperidinyl]-5-pyrimidinecarboxamide Chemical compound C12=CC=CC=C2N(C)C=C1CNCC(CC1)CCN1C1=NC=C(C(=O)NO)C=N1 PAWIYAYFNXQGAP-UHFFFAOYSA-N 0.000 description 5
- 208000008589 Obesity Diseases 0.000 description 5
- 102100037505 Secretin Human genes 0.000 description 5
- 102000006757 Wnt Receptors Human genes 0.000 description 5
- 108010047118 Wnt Receptors Proteins 0.000 description 5
- 239000000556 agonist Substances 0.000 description 5
- 125000001931 aliphatic group Chemical group 0.000 description 5
- 206010012601 diabetes mellitus Diseases 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 239000012634 fragment Substances 0.000 description 5
- 210000002894 multi-fate stem cell Anatomy 0.000 description 5
- 150000007523 nucleic acids Chemical group 0.000 description 5
- 235000020824 obesity Nutrition 0.000 description 5
- FWZRWHZDXBDTFK-ZHACJKMWSA-N panobinostat Chemical compound CC1=NC2=CC=C[CH]C2=C1CCNCC1=CC=C(\C=C\C(=O)NO)C=C1 FWZRWHZDXBDTFK-ZHACJKMWSA-N 0.000 description 5
- 229960005184 panobinostat Drugs 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 229950010654 quisinostat Drugs 0.000 description 5
- 108010091666 romidepsin Proteins 0.000 description 5
- OHRURASPPZQGQM-UHFFFAOYSA-N romidepsin Natural products O1C(=O)C(C(C)C)NC(=O)C(=CC)NC(=O)C2CSSCCC=CC1CC(=O)NC(C(C)C)C(=O)N2 OHRURASPPZQGQM-UHFFFAOYSA-N 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 229960000604 valproic acid Drugs 0.000 description 5
- JNTMAZFVYNDPLB-PEDHHIEDSA-N (2S,3S)-2-[[[(2S)-1-[(2S,3S)-2-amino-3-methyl-1-oxopentyl]-2-pyrrolidinyl]-oxomethyl]amino]-3-methylpentanoic acid Chemical compound CC[C@H](C)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(O)=O JNTMAZFVYNDPLB-PEDHHIEDSA-N 0.000 description 4
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 4
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 4
- CJLMANFTWLNAKC-UHFFFAOYSA-N 3-[6-amino-5-(3,4,5-trimethoxyphenyl)pyridin-3-yl]phenol Chemical compound COC1=C(OC)C(OC)=CC(C=2C(=NC=C(C=2)C=2C=C(O)C=CC=2)N)=C1 CJLMANFTWLNAKC-UHFFFAOYSA-N 0.000 description 4
- IHLVSLOZUHKNMQ-UHFFFAOYSA-N 4-[2-[4-(2-pyridin-2-yl-5,6-dihydro-4h-pyrrolo[1,2-b]pyrazol-3-yl)quinolin-7-yl]oxyethyl]morpholine Chemical compound C=1C=C2C(C=3C(=NN4CCCC4=3)C=3N=CC=CC=3)=CC=NC2=CC=1OCCN1CCOCC1 IHLVSLOZUHKNMQ-UHFFFAOYSA-N 0.000 description 4
- JGRPKOGHYBAVMW-UHFFFAOYSA-N 8-hydroxy-5-quinolinecarboxylic acid Chemical compound C1=CC=C2C(C(=O)O)=CC=C(O)C2=N1 JGRPKOGHYBAVMW-UHFFFAOYSA-N 0.000 description 4
- 101000874385 Arabidopsis thaliana Serine carboxypeptidase-like 19 Proteins 0.000 description 4
- 101000631707 Arabidopsis thaliana Spermidine coumaroyl-CoA acyltransferase Proteins 0.000 description 4
- JMIFGARJSWXZSH-UHFFFAOYSA-N DMH1 Chemical compound C1=CC(OC(C)C)=CC=C1C1=CN2N=CC(C=3C4=CC=CC=C4N=CC=3)=C2N=C1 JMIFGARJSWXZSH-UHFFFAOYSA-N 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
- 239000007995 HEPES buffer Substances 0.000 description 4
- 108010074870 Histone Demethylases Proteins 0.000 description 4
- 102000008157 Histone Demethylases Human genes 0.000 description 4
- 101000739506 Homo sapiens Secretin Proteins 0.000 description 4
- 101000701142 Homo sapiens Transcription factor ATOH1 Proteins 0.000 description 4
- 102000010909 Monoamine Oxidase Human genes 0.000 description 4
- 108010062431 Monoamine oxidase Proteins 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- WWGBHDIHIVGYLZ-UHFFFAOYSA-N N-[4-[3-[[[7-(hydroxyamino)-7-oxoheptyl]amino]-oxomethyl]-5-isoxazolyl]phenyl]carbamic acid tert-butyl ester Chemical compound C1=CC(NC(=O)OC(C)(C)C)=CC=C1C1=CC(C(=O)NCCCCCCC(=O)NO)=NO1 WWGBHDIHIVGYLZ-UHFFFAOYSA-N 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 101150058700 Tph1 gene Proteins 0.000 description 4
- 102100029373 Transcription factor ATOH1 Human genes 0.000 description 4
- 230000003213 activating effect Effects 0.000 description 4
- 239000003963 antioxidant agent Substances 0.000 description 4
- 235000006708 antioxidants Nutrition 0.000 description 4
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- JXTHNDFMNIQAHM-UHFFFAOYSA-N dichloroacetic acid Chemical compound OC(=O)C(Cl)Cl JXTHNDFMNIQAHM-UHFFFAOYSA-N 0.000 description 4
- 150000004683 dihydrates Chemical class 0.000 description 4
- 108010054812 diprotin A Proteins 0.000 description 4
- 210000001035 gastrointestinal tract Anatomy 0.000 description 4
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Substances C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 210000000936 intestine Anatomy 0.000 description 4
- 230000035800 maturation Effects 0.000 description 4
- RDSACQWTXKSHJT-NSHDSACASA-N n-[3,4-difluoro-2-(2-fluoro-4-iodoanilino)-6-methoxyphenyl]-1-[(2s)-2,3-dihydroxypropyl]cyclopropane-1-sulfonamide Chemical compound C1CC1(C[C@H](O)CO)S(=O)(=O)NC=1C(OC)=CC(F)=C(F)C=1NC1=CC=C(I)C=C1F RDSACQWTXKSHJT-NSHDSACASA-N 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- FECGNJPYVFEKOD-VMPITWQZSA-N resminostat Chemical compound C1=CC(CN(C)C)=CC=C1S(=O)(=O)N1C=C(\C=C\C(=O)NO)C=C1 FECGNJPYVFEKOD-VMPITWQZSA-N 0.000 description 4
- 210000002955 secretory cell Anatomy 0.000 description 4
- CYOHGALHFOKKQC-UHFFFAOYSA-N selumetinib Chemical compound OCCONC(=O)C=1C=C2N(C)C=NC2=C(F)C=1NC1=CC=C(Br)C=C1Cl CYOHGALHFOKKQC-UHFFFAOYSA-N 0.000 description 4
- 229940076279 serotonin Drugs 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- 238000002054 transplantation Methods 0.000 description 4
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 4
- WAEXFXRVDQXREF-UHFFFAOYSA-N vorinostat Chemical compound ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1 WAEXFXRVDQXREF-UHFFFAOYSA-N 0.000 description 4
- PKXWXXPNHIWQHW-RCBQFDQVSA-N (2S)-2-hydroxy-3-methyl-N-[(2S)-1-[[(5S)-3-methyl-4-oxo-2,5-dihydro-1H-3-benzazepin-5-yl]amino]-1-oxopropan-2-yl]butanamide Chemical compound C1CN(C)C(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@@H](O)C(C)C)C2=CC=CC=C21 PKXWXXPNHIWQHW-RCBQFDQVSA-N 0.000 description 3
- AAUXGXRHLYYHSO-UHFFFAOYSA-N 1-[2-(6,7-dimethoxyquinolin-4-yl)oxy-4,5-dimethylphenyl]ethanone Chemical compound C=12C=C(OC)C(OC)=CC2=NC=CC=1OC1=CC(C)=C(C)C=C1C(C)=O AAUXGXRHLYYHSO-UHFFFAOYSA-N 0.000 description 3
- RWEVIPRMPFNTLO-UHFFFAOYSA-N 2-(2-fluoro-4-iodoanilino)-N-(2-hydroxyethoxy)-1,5-dimethyl-6-oxo-3-pyridinecarboxamide Chemical compound CN1C(=O)C(C)=CC(C(=O)NOCCO)=C1NC1=CC=C(I)C=C1F RWEVIPRMPFNTLO-UHFFFAOYSA-N 0.000 description 3
- KJTYZDORHCDZPS-UHFFFAOYSA-N 4-[5-(6-methylpyridin-2-yl)-1h-pyrazol-4-yl]quinoline Chemical compound CC1=CC=CC(C2=C(C=NN2)C=2C3=CC=CC=C3N=CC=2)=N1 KJTYZDORHCDZPS-UHFFFAOYSA-N 0.000 description 3
- PQXINDBPUDNMPE-UHFFFAOYSA-N 5-(furan-2-yl)-n-(3-imidazol-1-ylpropyl)-1,2-oxazole-3-carboxamide Chemical compound C1=C(C=2OC=CC=2)ON=C1C(=O)NCCCN1C=CN=C1 PQXINDBPUDNMPE-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 102100034111 Activin receptor type-1 Human genes 0.000 description 3
- 108060000903 Beta-catenin Proteins 0.000 description 3
- 102000015735 Beta-catenin Human genes 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 3
- YNXLOPYTAAFMTN-SBUIBGKBSA-N C([C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)C1=CC=C(O)C=C1 Chemical compound C([C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)C1=CC=C(O)C=C1 YNXLOPYTAAFMTN-SBUIBGKBSA-N 0.000 description 3
- NRPYJBRJHGYUMM-UHFFFAOYSA-N CC1=NC(C2=NCC=C2C2=NC3=CC=CN=C3C=C2)=CC=C1 Chemical compound CC1=NC(C2=NCC=C2C2=NC3=CC=CN=C3C=C2)=CC=C1 NRPYJBRJHGYUMM-UHFFFAOYSA-N 0.000 description 3
- SUZLHDUTVMZSEV-UHFFFAOYSA-N Deoxycoleonol Natural products C12C(=O)CC(C)(C=C)OC2(C)C(OC(=O)C)C(O)C2C1(C)C(O)CCC2(C)C SUZLHDUTVMZSEV-UHFFFAOYSA-N 0.000 description 3
- 108010002156 Depsipeptides Proteins 0.000 description 3
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 3
- RFWVETIZUQEJEF-UHFFFAOYSA-N GDC-0623 Chemical compound OCCONC(=O)C=1C=CC2=CN=CN2C=1NC1=CC=C(I)C=C1F RFWVETIZUQEJEF-UHFFFAOYSA-N 0.000 description 3
- 102400000921 Gastrin Human genes 0.000 description 3
- 108010052343 Gastrins Proteins 0.000 description 3
- 101000799140 Homo sapiens Activin receptor type-1 Proteins 0.000 description 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 3
- 239000004472 Lysine Substances 0.000 description 3
- HRNLUBSXIHFDHP-UHFFFAOYSA-N N-(2-aminophenyl)-4-[[[4-(3-pyridinyl)-2-pyrimidinyl]amino]methyl]benzamide Chemical compound NC1=CC=CC=C1NC(=O)C(C=C1)=CC=C1CNC1=NC=CC(C=2C=NC=CC=2)=N1 HRNLUBSXIHFDHP-UHFFFAOYSA-N 0.000 description 3
- QGZYDVAGYRLSKP-UHFFFAOYSA-N N-[7-(hydroxyamino)-7-oxoheptyl]-2-(N-phenylanilino)-5-pyrimidinecarboxamide Chemical compound N1=CC(C(=O)NCCCCCCC(=O)NO)=CN=C1N(C=1C=CC=CC=1)C1=CC=CC=C1 QGZYDVAGYRLSKP-UHFFFAOYSA-N 0.000 description 3
- 230000005913 Notch signaling pathway Effects 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 108091034117 Oligonucleotide Proteins 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 238000009004 PCR Kit Methods 0.000 description 3
- 102100029909 Peptide YY Human genes 0.000 description 3
- 108010088847 Peptide YY Proteins 0.000 description 3
- 108091000080 Phosphotransferase Proteins 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 241000282898 Sus scrofa Species 0.000 description 3
- 108091005735 TGF-beta receptors Proteins 0.000 description 3
- 102000016715 Transforming Growth Factor beta Receptors Human genes 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- ULXXDDBFHOBEHA-CWDCEQMOSA-N afatinib Chemical compound N1=CN=C2C=C(O[C@@H]3COCC3)C(NC(=O)/C=C/CN(C)C)=CC2=C1NC1=CC=C(F)C(Cl)=C1 ULXXDDBFHOBEHA-CWDCEQMOSA-N 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- OMZCMEYTWSXEPZ-UHFFFAOYSA-N canertinib Chemical compound C1=C(Cl)C(F)=CC=C1NC1=NC=NC2=CC(OCCCN3CCOCC3)=C(NC(=O)C=C)C=C12 OMZCMEYTWSXEPZ-UHFFFAOYSA-N 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- AOXOCDRNSPFDPE-UKEONUMOSA-N chembl413654 Chemical compound C([C@H](C(=O)NCC(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](C)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@@H](N)CCC(O)=O)C1=CC=C(O)C=C1 AOXOCDRNSPFDPE-UKEONUMOSA-N 0.000 description 3
- BSMCAPRUBJMWDF-KRWDZBQOSA-N cobimetinib Chemical compound C1C(O)([C@H]2NCCCC2)CN1C(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1F BSMCAPRUBJMWDF-KRWDZBQOSA-N 0.000 description 3
- 229960002271 cobimetinib Drugs 0.000 description 3
- OHCQJHSOBUTRHG-UHFFFAOYSA-N colforsin Natural products OC12C(=O)CC(C)(C=C)OC1(C)C(OC(=O)C)C(O)C1C2(C)C(O)CCC1(C)C OHCQJHSOBUTRHG-UHFFFAOYSA-N 0.000 description 3
- 230000001276 controlling effect Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- FKGKZBBDJSKCIS-UHFFFAOYSA-N diethyl-[[6-[[4-(hydroxycarbamoyl)phenyl]carbamoyloxymethyl]naphthalen-2-yl]methyl]azanium;chloride;hydrate Chemical compound O.[Cl-].C1=CC2=CC(C[NH+](CC)CC)=CC=C2C=C1COC(=O)NC1=CC=C(C(=O)NO)C=C1 FKGKZBBDJSKCIS-UHFFFAOYSA-N 0.000 description 3
- 210000003890 endocrine cell Anatomy 0.000 description 3
- 210000001842 enterocyte Anatomy 0.000 description 3
- INVTYAOGFAGBOE-UHFFFAOYSA-N entinostat Chemical compound NC1=CC=CC=C1NC(=O)C(C=C1)=CC=C1CNC(=O)OCC1=CC=CN=C1 INVTYAOGFAGBOE-UHFFFAOYSA-N 0.000 description 3
- 230000006718 epigenetic regulation Effects 0.000 description 3
- 210000002919 epithelial cell Anatomy 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 230000001976 improved effect Effects 0.000 description 3
- 150000002576 ketones Chemical class 0.000 description 3
- BCFGMOOMADDAQU-UHFFFAOYSA-N lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 description 3
- 238000012423 maintenance Methods 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 208000030159 metabolic disease Diseases 0.000 description 3
- 238000000386 microscopy Methods 0.000 description 3
- SAGZIBJAQGBRQA-UHFFFAOYSA-N n-(oxan-4-yl)-4-[4-(5-pyridin-2-yl-1h-pyrazol-4-yl)pyridin-2-yl]benzamide Chemical compound C=1C=C(C=2N=CC=C(C=2)C2=C(NN=C2)C=2N=CC=CC=2)C=CC=1C(=O)NC1CCOCC1 SAGZIBJAQGBRQA-UHFFFAOYSA-N 0.000 description 3
- IMYVCWQAHSYYOO-UHFFFAOYSA-N n-[4-[(6,7-dimethoxyquinazolin-4-yl)amino]phenyl]benzamide Chemical compound C=12C=C(OC)C(OC)=CC2=NC=NC=1NC(C=C1)=CC=C1NC(=O)C1=CC=CC=C1 IMYVCWQAHSYYOO-UHFFFAOYSA-N 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 150000007530 organic bases Chemical class 0.000 description 3
- 210000000496 pancreas Anatomy 0.000 description 3
- 102000020233 phosphotransferase Human genes 0.000 description 3
- ISWRGOKTTBVCFA-UHFFFAOYSA-N pirfenidone Chemical compound C1=C(C)C=CC(=O)N1C1=CC=CC=C1 ISWRGOKTTBVCFA-UHFFFAOYSA-N 0.000 description 3
- 229960003073 pirfenidone Drugs 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 229960003452 romidepsin Drugs 0.000 description 3
- 159000000000 sodium salts Chemical class 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- RTKIYFITIVXBLE-QEQCGCAPSA-N trichostatin A Chemical compound ONC(=O)/C=C/C(/C)=C/[C@@H](C)C(=O)C1=CC=C(N(C)C)C=C1 RTKIYFITIVXBLE-QEQCGCAPSA-N 0.000 description 3
- 229940121396 wnt pathway inhibitor Drugs 0.000 description 3
- HPTXLHAHLXOAKV-INIZCTEOSA-N (2S)-2-(1,3-dioxo-2-isoindolyl)-3-(1H-indol-3-yl)propanoic acid Chemical compound O=C1C2=CC=CC=C2C(=O)N1[C@H](C(=O)O)CC1=CNC2=CC=CC=C12 HPTXLHAHLXOAKV-INIZCTEOSA-N 0.000 description 2
- CAYGMWMWJUFODP-AYFTZVAISA-N (2r)-2-[(1e,3z,5r,7e,9e,11r)-11-hydroxy-11-[(2s,4r,5s,6s)-4-hydroxy-5-methyl-6-[(e)-prop-1-enyl]oxan-2-yl]-3,5,7-trimethylundeca-1,3,7,9-tetraenyl]-2,3-dihydropyran-6-one Chemical compound C1[C@@H](O)[C@H](C)[C@H](/C=C/C)O[C@@H]1[C@H](O)\C=C\C=C(/C)C[C@@H](C)\C=C(\C)/C=C/[C@@H]1OC(=O)C=CC1 CAYGMWMWJUFODP-AYFTZVAISA-N 0.000 description 2
- VFCRKLWBYMDAED-REWPJTCUSA-N (2s)-2-[[(2s)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl]amino]-n-[1-[1-(2,2-dimethylpropylamino)-2-methylpropan-2-yl]imidazol-4-yl]pentanamide Chemical compound O=C([C@@H](N[C@@H]1CC2=C(F)C=C(F)C=C2CC1)CCC)NC1=CN(C(C)(C)CNCC(C)(C)C)C=N1 VFCRKLWBYMDAED-REWPJTCUSA-N 0.000 description 2
- JWOGUUIOCYMBPV-GMFLJSBRSA-N (3S,6S,9S,12R)-3-[(2S)-Butan-2-yl]-6-[(1-methoxyindol-3-yl)methyl]-9-(6-oxooctyl)-1,4,7,10-tetrazabicyclo[10.4.0]hexadecane-2,5,8,11-tetrone Chemical compound N1C(=O)[C@H](CCCCCC(=O)CC)NC(=O)[C@H]2CCCCN2C(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]1CC1=CN(OC)C2=CC=CC=C12 JWOGUUIOCYMBPV-GMFLJSBRSA-N 0.000 description 2
- HQWTUOLCGKIECB-XZWHSSHBSA-N (6S,9aS)-6-[(4-hydroxyphenyl)methyl]-8-(1-naphthalenylmethyl)-4,7-dioxo-N-(phenylmethyl)-3,6,9,9a-tetrahydro-2H-pyrazino[1,2-a]pyrimidine-1-carboxamide Chemical compound C1=CC(O)=CC=C1C[C@H]1C(=O)N(CC=2C3=CC=CC=C3C=CC=2)C[C@H]2N1C(=O)CCN2C(=O)NCC1=CC=CC=C1 HQWTUOLCGKIECB-XZWHSSHBSA-N 0.000 description 2
- LAMIXXKAWNLXOC-INIZCTEOSA-N (S)-HDAC-42 Chemical compound O=C([C@@H](C(C)C)C=1C=CC=CC=1)NC1=CC=C(C(=O)NO)C=C1 LAMIXXKAWNLXOC-INIZCTEOSA-N 0.000 description 2
- QRDAPCMJAOQZSU-KQQUZDAGSA-N (e)-3-[4-[(e)-3-(3-fluorophenyl)-3-oxoprop-1-enyl]-1-methylpyrrol-2-yl]-n-hydroxyprop-2-enamide Chemical compound C1=C(\C=C\C(=O)NO)N(C)C=C1\C=C\C(=O)C1=CC=CC(F)=C1 QRDAPCMJAOQZSU-KQQUZDAGSA-N 0.000 description 2
- AUGCSOFQTDKPSO-RGVLZGJSSA-N (e)-n-[3-(dimethylamino)propyl]-n'-hydroxy-2-(naphthalen-1-yloxymethyl)oct-2-enediamide Chemical compound C1=CC=C2C(OC/C(C(=O)NCCCN(C)C)=C\CCCCC(=O)NO)=CC=CC2=C1 AUGCSOFQTDKPSO-RGVLZGJSSA-N 0.000 description 2
- BWDQBBCUWLSASG-MDZDMXLPSA-N (e)-n-hydroxy-3-[4-[[2-hydroxyethyl-[2-(1h-indol-3-yl)ethyl]amino]methyl]phenyl]prop-2-enamide Chemical compound C=1NC2=CC=CC=C2C=1CCN(CCO)CC1=CC=C(\C=C\C(=O)NO)C=C1 BWDQBBCUWLSASG-MDZDMXLPSA-N 0.000 description 2
- JUHTXZGCTPDXRU-UHFFFAOYSA-N 1-[4-(1,3-benzodioxol-5-yl)-5-(6-methylpyridin-2-yl)-1h-imidazol-2-yl]bicyclo[2.2.2]octane-4-carboxamide Chemical compound CC1=CC=CC(C2=C(N=C(N2)C23CCC(CC2)(CC3)C(N)=O)C=2C=C3OCOC3=CC=2)=N1 JUHTXZGCTPDXRU-UHFFFAOYSA-N 0.000 description 2
- AXNUEXXEQGQWPA-UHFFFAOYSA-N 2,5-dichloro-N-(2-methyl-4-nitrophenyl)benzenesulfonamide Chemical compound CC1=CC([N+]([O-])=O)=CC=C1NS(=O)(=O)C1=CC(Cl)=CC=C1Cl AXNUEXXEQGQWPA-UHFFFAOYSA-N 0.000 description 2
- WXTMDXOMEHJXQO-UHFFFAOYSA-N 2,5-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 description 2
- QFWCYNPOPKQOKV-UHFFFAOYSA-N 2-(2-amino-3-methoxyphenyl)chromen-4-one Chemical compound COC1=CC=CC(C=2OC3=CC=CC=C3C(=O)C=2)=C1N QFWCYNPOPKQOKV-UHFFFAOYSA-N 0.000 description 2
- GFMMXOIFOQCCGU-UHFFFAOYSA-N 2-(2-chloro-4-iodoanilino)-N-(cyclopropylmethoxy)-3,4-difluorobenzamide Chemical compound C=1C=C(I)C=C(Cl)C=1NC1=C(F)C(F)=CC=C1C(=O)NOCC1CC1 GFMMXOIFOQCCGU-UHFFFAOYSA-N 0.000 description 2
- RNUXIZKXJOGYQP-UHFFFAOYSA-N 2-[3-[[4-(4-methoxyphenyl)-5-pyridin-4-yl-1,2,4-triazol-3-yl]sulfanyl]propyl]benzo[de]isoquinoline-1,3-dione Chemical compound C1=CC(OC)=CC=C1N1C(C=2C=CN=CC=2)=NN=C1SCCCN(C1=O)C(=O)C2=C3C1=CC=CC3=CC=C2 RNUXIZKXJOGYQP-UHFFFAOYSA-N 0.000 description 2
- MDYDGUOQFUQOGE-UHFFFAOYSA-N 2-methylpropanethioic acid S-[7-oxo-7-[(4-phenyl-2-thiazolyl)amino]heptyl] ester Chemical compound S1C(NC(=O)CCCCCCSC(=O)C(C)C)=NC(C=2C=CC=CC=2)=C1 MDYDGUOQFUQOGE-UHFFFAOYSA-N 0.000 description 2
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 2
- RCLQNICOARASSR-SECBINFHSA-N 3-[(2r)-2,3-dihydroxypropyl]-6-fluoro-5-(2-fluoro-4-iodoanilino)-8-methylpyrido[2,3-d]pyrimidine-4,7-dione Chemical compound FC=1C(=O)N(C)C=2N=CN(C[C@@H](O)CO)C(=O)C=2C=1NC1=CC=C(I)C=C1F RCLQNICOARASSR-SECBINFHSA-N 0.000 description 2
- MAUCONCHVWBMHK-UHFFFAOYSA-N 3-[(dimethylamino)methyl]-N-[2-[4-[(hydroxyamino)-oxomethyl]phenoxy]ethyl]-2-benzofurancarboxamide Chemical compound O1C2=CC=CC=C2C(CN(C)C)=C1C(=O)NCCOC1=CC=C(C(=O)NO)C=C1 MAUCONCHVWBMHK-UHFFFAOYSA-N 0.000 description 2
- DSOJSZXQRJGBCW-CABCVRRESA-N 3-[4-[(1r,2s)-2-aminocyclopropyl]phenyl]phenol Chemical compound N[C@H]1C[C@@H]1C1=CC=C(C=2C=C(O)C=CC=2)C=C1 DSOJSZXQRJGBCW-CABCVRRESA-N 0.000 description 2
- ZGXOBLVQIVXKEB-UHFFFAOYSA-N 3-[N-[3-[(dimethylamino)methyl]phenyl]-C-phenylcarbonimidoyl]-2-hydroxy-N,N-dimethyl-1H-indole-6-carboxamide Chemical compound CN(C)CC1=CC(=CC=C1)N=C(C2=CC=CC=C2)C3=C(NC4=C3C=CC(=C4)C(=O)N(C)C)O ZGXOBLVQIVXKEB-UHFFFAOYSA-N 0.000 description 2
- AVZCPICCWKMZDT-UHFFFAOYSA-N 3-[[2-(2-pyridinyl)-6-(1,2,4,5-tetrahydro-3-benzazepin-3-yl)-4-pyrimidinyl]amino]propanoic acid Chemical compound N=1C(NCCC(=O)O)=CC(N2CCC3=CC=CC=C3CC2)=NC=1C1=CC=CC=N1 AVZCPICCWKMZDT-UHFFFAOYSA-N 0.000 description 2
- WBKCKEHGXNWYMO-UHFFFAOYSA-N 3-[[2-(2-pyridinyl)-6-(1,2,4,5-tetrahydro-3-benzazepin-3-yl)-4-pyrimidinyl]amino]propanoic acid ethyl ester Chemical compound N=1C(NCCC(=O)OCC)=CC(N2CCC3=CC=CC=C3CC2)=NC=1C1=CC=CC=N1 WBKCKEHGXNWYMO-UHFFFAOYSA-N 0.000 description 2
- RYKSGWSKILPDDY-UHFFFAOYSA-N 3-[[5-(6-methylpyridin-2-yl)-4-quinoxalin-6-yl-1h-imidazol-2-yl]methyl]benzamide Chemical compound CC1=CC=CC(C2=C(N=C(CC=3C=C(C=CC=3)C(N)=O)N2)C=2C=C3N=CC=NC3=CC=2)=N1 RYKSGWSKILPDDY-UHFFFAOYSA-N 0.000 description 2
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 2
- JHSXDAWGLCZYSM-UHFFFAOYSA-N 4-(4-chloro-2-methylphenoxy)-N-hydroxybutanamide Chemical compound CC1=CC(Cl)=CC=C1OCCCC(=O)NO JHSXDAWGLCZYSM-UHFFFAOYSA-N 0.000 description 2
- WUTVMXLIGHTZJC-OAQYLSRUSA-N 4-[2-(2-chloro-4-fluoroanilino)-5-methyl-4-pyrimidinyl]-N-[(1S)-1-(3-chlorophenyl)-2-hydroxyethyl]-1H-pyrrole-2-carboxamide Chemical compound N1=C(C=2C=C(NC=2)C(=O)N[C@H](CO)C=2C=C(Cl)C=CC=2)C(C)=CN=C1NC1=CC=C(F)C=C1Cl WUTVMXLIGHTZJC-OAQYLSRUSA-N 0.000 description 2
- IZAOBRWCUGOKNH-OAHLLOKOSA-N 4-[2-[(1R)-1-(N-(4-chlorophenyl)sulfonyl-2,5-difluoroanilino)ethyl]-5-fluorophenyl]butanoic acid Chemical compound C=1C=C(Cl)C=CC=1S(=O)(=O)N([C@H](C)C=1C(=CC(F)=CC=1)CCCC(O)=O)C1=CC(F)=CC=C1F IZAOBRWCUGOKNH-OAHLLOKOSA-N 0.000 description 2
- DPDZHVCKYBCJHW-UHFFFAOYSA-N 4-[4-(2,3-dihydro-1,4-benzodioxin-6-yl)-5-(2-pyridinyl)-1H-imidazol-2-yl]benzamide Chemical compound C1=CC(C(=O)N)=CC=C1C1=NC(C=2C=C3OCCOC3=CC=2)=C(C=2N=CC=CC=2)N1 DPDZHVCKYBCJHW-UHFFFAOYSA-N 0.000 description 2
- JZWXMCPARMXZQV-UHFFFAOYSA-N 4-[[butyl(phenylcarbamoyl)amino]methyl]-n-hydroxybenzamide Chemical compound C=1C=CC=CC=1NC(=O)N(CCCC)CC1=CC=C(C(=O)NO)C=C1 JZWXMCPARMXZQV-UHFFFAOYSA-N 0.000 description 2
- QCXJEYYXVJIFCE-UHFFFAOYSA-N 4-acetamidobenzoic acid Chemical compound CC(=O)NC1=CC=C(C(O)=O)C=C1 QCXJEYYXVJIFCE-UHFFFAOYSA-N 0.000 description 2
- UCINOBZMLCREGM-RNNUGBGQSA-N 4-n-[(1r,2s)-2-phenylcyclopropyl]cyclohexane-1,4-diamine;dihydrochloride Chemical compound Cl.Cl.C1CC(N)CCC1N[C@H]1[C@H](C=2C=CC=CC=2)C1 UCINOBZMLCREGM-RNNUGBGQSA-N 0.000 description 2
- ULTTYPMRMMDONC-UHFFFAOYSA-N 5-[(2,5-dihydroxyphenyl)methyl-[(2-hydroxyphenyl)methyl]amino]-2-hydroxybenzoic acid Chemical compound C1=C(O)C(C(=O)O)=CC(N(CC=2C(=CC=CC=2)O)CC=2C(=CC=C(O)C=2)O)=C1 ULTTYPMRMMDONC-UHFFFAOYSA-N 0.000 description 2
- JTDYUFSDZATMKU-UHFFFAOYSA-N 6-(1,3-dioxo-2-benzo[de]isoquinolinyl)-N-hydroxyhexanamide Chemical compound C1=CC(C(N(CCCCCC(=O)NO)C2=O)=O)=C3C2=CC=CC3=C1 JTDYUFSDZATMKU-UHFFFAOYSA-N 0.000 description 2
- JUJPKFNFCWJBCX-UHFFFAOYSA-N 6-[(4-bromothiophen-2-yl)methoxy]-7h-purin-2-amine Chemical compound C=12NC=NC2=NC(N)=NC=1OCC1=CC(Br)=CS1 JUJPKFNFCWJBCX-UHFFFAOYSA-N 0.000 description 2
- PLIVFNIUGLLCEK-UHFFFAOYSA-N 7-[4-(3-ethynylanilino)-7-methoxyquinazolin-6-yl]oxy-n-hydroxyheptanamide Chemical compound C=12C=C(OCCCCCCC(=O)NO)C(OC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 PLIVFNIUGLLCEK-UHFFFAOYSA-N 0.000 description 2
- HJCMDXDYPOUFDY-WHFBIAKZSA-N Ala-Gln Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O HJCMDXDYPOUFDY-WHFBIAKZSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- 241000272517 Anseriformes Species 0.000 description 2
- KHBQMWCZKVMBLN-UHFFFAOYSA-N Benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1 KHBQMWCZKVMBLN-UHFFFAOYSA-N 0.000 description 2
- 102000001893 Bone Morphogenetic Protein Receptors Human genes 0.000 description 2
- 108010040422 Bone Morphogenetic Protein Receptors Proteins 0.000 description 2
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 2
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- 101100287812 Caenorhabditis elegans jmjd-2 gene Proteins 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 239000005461 Canertinib Substances 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 108020004635 Complementary DNA Proteins 0.000 description 2
- 241000699800 Cricetinae Species 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 208000004232 Enteritis Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 108010011459 Exenatide Proteins 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 102100028412 Fibroblast growth factor 10 Human genes 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 210000000712 G cell Anatomy 0.000 description 2
- WMBWREPUVVBILR-UHFFFAOYSA-N GCG Natural products C=1C(O)=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-UHFFFAOYSA-N 0.000 description 2
- LRULVYSBRWUVGR-FCHUYYIVSA-N GSK2879552 Chemical compound C1=CC(C(=O)O)=CC=C1CN1CCC(CN[C@H]2[C@@H](C2)C=2C=CC=CC=2)CC1 LRULVYSBRWUVGR-FCHUYYIVSA-N 0.000 description 2
- DSLZVSRJTYRBFB-UHFFFAOYSA-N Galactaric acid Natural products OC(=O)C(O)C(O)C(O)C(O)C(O)=O DSLZVSRJTYRBFB-UHFFFAOYSA-N 0.000 description 2
- 101800001586 Ghrelin Proteins 0.000 description 2
- 102400000442 Ghrelin-28 Human genes 0.000 description 2
- 102400000326 Glucagon-like peptide 2 Human genes 0.000 description 2
- 101800000221 Glucagon-like peptide 2 Proteins 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 108010051041 HC toxin Proteins 0.000 description 2
- 239000012981 Hank's balanced salt solution Substances 0.000 description 2
- RPTUSVTUFVMDQK-UHFFFAOYSA-N Hidralazin Chemical compound C1=CC=C2C(NN)=NN=CC2=C1 RPTUSVTUFVMDQK-UHFFFAOYSA-N 0.000 description 2
- 102100022537 Histone deacetylase 6 Human genes 0.000 description 2
- 101000917237 Homo sapiens Fibroblast growth factor 10 Proteins 0.000 description 2
- 101000899330 Homo sapiens Histone deacetylase 6 Proteins 0.000 description 2
- 101000615488 Homo sapiens Methyl-CpG-binding domain protein 2 Proteins 0.000 description 2
- 101000602176 Homo sapiens Neurotensin/neuromedin N Proteins 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 2
- 101150089655 Ins2 gene Proteins 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 2
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 2
- 239000002136 L01XE07 - Lapatinib Substances 0.000 description 2
- XXYGTCZJJLTAGH-UHFFFAOYSA-N LGK974 Chemical compound C1=NC(C)=CC(C=2C(=CC(CC(=O)NC=3N=CC(=CC=3)C=3N=CC=NC=3)=CN=2)C)=C1 XXYGTCZJJLTAGH-UHFFFAOYSA-N 0.000 description 2
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 2
- 102000043136 MAP kinase family Human genes 0.000 description 2
- 108091054455 MAP kinase family Proteins 0.000 description 2
- 230000005723 MEK inhibition Effects 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 102100021299 Methyl-CpG-binding domain protein 2 Human genes 0.000 description 2
- 210000004460 N cell Anatomy 0.000 description 2
- BHUZLJOUHMBZQY-YXQOSMAKSA-N N-[4-[(2R,4R,6S)-4-[[(4,5-diphenyl-2-oxazolyl)thio]methyl]-6-[4-(hydroxymethyl)phenyl]-1,3-dioxan-2-yl]phenyl]-N'-hydroxyoctanediamide Chemical compound C1=CC(CO)=CC=C1[C@H]1O[C@@H](C=2C=CC(NC(=O)CCCCCCC(=O)NO)=CC=2)O[C@@H](CSC=2OC(=C(N=2)C=2C=CC=CC=2)C=2C=CC=CC=2)C1 BHUZLJOUHMBZQY-YXQOSMAKSA-N 0.000 description 2
- MVZGYPSXNDCANY-UHFFFAOYSA-N N-[4-[3-chloro-4-[(3-fluorophenyl)methoxy]anilino]-6-quinazolinyl]-2-propenamide Chemical compound FC1=CC=CC(COC=2C(=CC(NC=3C4=CC(NC(=O)C=C)=CC=C4N=CN=3)=CC=2)Cl)=C1 MVZGYPSXNDCANY-UHFFFAOYSA-N 0.000 description 2
- QIAFMBKCNZACKA-UHFFFAOYSA-N N-benzoylglycine Chemical compound OC(=O)CNC(=O)C1=CC=CC=C1 QIAFMBKCNZACKA-UHFFFAOYSA-N 0.000 description 2
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 description 2
- RYYGSXXWQSXKRP-UHFFFAOYSA-N N-hydroxy-1-cyclopentenecarboxamide Chemical compound ONC(=O)C1=CCCC1 RYYGSXXWQSXKRP-UHFFFAOYSA-N 0.000 description 2
- BTYYWOYVBXILOJ-UHFFFAOYSA-N N-{4-[(3-bromophenyl)amino]quinazolin-6-yl}but-2-ynamide Chemical compound C12=CC(NC(=O)C#CC)=CC=C2N=CN=C1NC1=CC=CC(Br)=C1 BTYYWOYVBXILOJ-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 102100037590 Neurotensin/neuromedin N Human genes 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- JWOGUUIOCYMBPV-UHFFFAOYSA-N OT-Key 11219 Natural products N1C(=O)C(CCCCCC(=O)CC)NC(=O)C2CCCCN2C(=O)C(C(C)CC)NC(=O)C1CC1=CN(OC)C2=CC=CC=C12 JWOGUUIOCYMBPV-UHFFFAOYSA-N 0.000 description 2
- HTUBKQUPEREOGA-UHFFFAOYSA-N PD 168393 Chemical compound BrC1=CC=CC(NC=2C3=CC(NC(=O)C=C)=CC=C3N=CN=2)=C1 HTUBKQUPEREOGA-UHFFFAOYSA-N 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 229940123882 Porcupine inhibitor Drugs 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- 238000010802 RNA extraction kit Methods 0.000 description 2
- 238000011530 RNeasy Mini Kit Methods 0.000 description 2
- 101100247004 Rattus norvegicus Qsox1 gene Proteins 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 229940124149 Tankyrase inhibitor Drugs 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- 102000002689 Toll-like receptor Human genes 0.000 description 2
- 108020000411 Toll-like receptor Proteins 0.000 description 2
- 102000040945 Transcription factor Human genes 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 239000013504 Triton X-100 Substances 0.000 description 2
- 229920004890 Triton X-100 Polymers 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- ITBGJNVZJBVPLJ-UHFFFAOYSA-N WAY-316606 Chemical compound FC(F)(F)C1=CC=C(S(=O)(=O)C=2C=CC=CC=2)C=C1S(=O)(=O)NC1CCNCC1 ITBGJNVZJBVPLJ-UHFFFAOYSA-N 0.000 description 2
- KLGQSVMIPOVQAX-UHFFFAOYSA-N XAV939 Chemical compound N=1C=2CCSCC=2C(O)=NC=1C1=CC=C(C(F)(F)F)C=C1 KLGQSVMIPOVQAX-UHFFFAOYSA-N 0.000 description 2
- NGBKFLTYGSREKK-PMACEKPBSA-N Z-Val-Phe-H Chemical compound N([C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C=O)C(=O)OCC1=CC=CC=C1 NGBKFLTYGSREKK-PMACEKPBSA-N 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- LUJZZYWHBDHDQX-QFIPXVFZSA-N [(3s)-morpholin-3-yl]methyl n-[4-[[1-[(3-fluorophenyl)methyl]indazol-5-yl]amino]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]carbamate Chemical compound C=1N2N=CN=C(NC=3C=C4C=NN(CC=5C=C(F)C=CC=5)C4=CC=3)C2=C(C)C=1NC(=O)OC[C@@H]1COCCN1 LUJZZYWHBDHDQX-QFIPXVFZSA-N 0.000 description 2
- QHLITPHIARVDJI-UHFFFAOYSA-N [1-[4-(2-naphthalenyl)-2-pyrimidinyl]-4-piperidinyl]methanamine Chemical compound C1CC(CN)CCN1C1=NC=CC(C=2C=C3C=CC=CC3=CC=2)=N1 QHLITPHIARVDJI-UHFFFAOYSA-N 0.000 description 2
- VHOZWHQPEJGPCC-AZXNYEMZSA-N [4-[[(6s,9s,9as)-1-(benzylcarbamoyl)-2,9-dimethyl-4,7-dioxo-8-(quinolin-8-ylmethyl)-3,6,9,9a-tetrahydropyrazino[2,1-c][1,2,4]triazin-6-yl]methyl]phenyl] dihydrogen phosphate Chemical compound C([C@@H]1N2[C@@H](N(N(C)CC2=O)C(=O)NCC=2C=CC=CC=2)[C@@H](N(C1=O)CC=1C2=NC=CC=C2C=CC=1)C)C1=CC=C(OP(O)(O)=O)C=C1 VHOZWHQPEJGPCC-AZXNYEMZSA-N 0.000 description 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
- 210000004504 adult stem cell Anatomy 0.000 description 2
- 239000012574 advanced DMEM Substances 0.000 description 2
- 229960001686 afatinib Drugs 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 239000000783 alginic acid Substances 0.000 description 2
- 229960001126 alginic acid Drugs 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 150000004781 alginic acids Chemical class 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 108010082820 apicidin Proteins 0.000 description 2
- 229930186608 apicidin Natural products 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- ACWZRVQXLIRSDF-UHFFFAOYSA-N binimetinib Chemical compound OCCONC(=O)C=1C=C2N(C)C=NC2=C(F)C=1NC1=CC=C(Br)C=C1F ACWZRVQXLIRSDF-UHFFFAOYSA-N 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 2
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 2
- 229960001948 caffeine Drugs 0.000 description 2
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 108010007877 calpain inhibitor III Proteins 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 229950002826 canertinib Drugs 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 230000032823 cell division Effects 0.000 description 2
- 230000003915 cell function Effects 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- JUFFVKRROAPVBI-PVOYSMBESA-N chembl1210015 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N[C@H]1[C@@H]([C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@]3(O[C@@H](C[C@H](O)[C@H](O)CO)[C@H](NC(C)=O)[C@@H](O)C3)C(O)=O)O2)O)[C@@H](CO)O1)NC(C)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 JUFFVKRROAPVBI-PVOYSMBESA-N 0.000 description 2
- NKUDGJUBIVEDTF-FYJGNVAPSA-N chembl3104250 Chemical compound C=1C(Cl)=CC=C(O)C=1C(/C)=N/NC(=O)C(C=1)=CC=CC=1S(=O)(=O)N1CCOCC1 NKUDGJUBIVEDTF-FYJGNVAPSA-N 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 229950009221 chidamide Drugs 0.000 description 2
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 2
- 229960001231 choline Drugs 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 238000004624 confocal microscopy Methods 0.000 description 2
- GLNWREBYRLDPQP-MHZLTWQESA-N cyclopentyl (2s)-2-[[4-[[8-(hydroxyamino)-8-oxooctanoyl]amino]phenyl]methylamino]-2-phenylacetate Chemical compound C1=CC(NC(=O)CCCCCCC(=O)NO)=CC=C1CN[C@@H](C=1C=CC=CC=1)C(=O)OC1CCCC1 GLNWREBYRLDPQP-MHZLTWQESA-N 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 2
- 229960003957 dexamethasone Drugs 0.000 description 2
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 2
- 208000010643 digestive system disease Diseases 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- 230000003828 downregulation Effects 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 210000001671 embryonic stem cell Anatomy 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 230000002124 endocrine Effects 0.000 description 2
- 210000000750 endocrine system Anatomy 0.000 description 2
- 230000003511 endothelial effect Effects 0.000 description 2
- 230000019439 energy homeostasis Effects 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 2
- 229960001433 erlotinib Drugs 0.000 description 2
- ULFUJLFTRWWLPO-UHFFFAOYSA-N ethyl 2,7,7-trimethyl-5-oxo-4-(4-phenylphenyl)-1,4,6,8-tetrahydroquinoline-3-carboxylate Chemical compound CCOC(=O)C1=C(C)NC(CC(C)(C)CC2=O)=C2C1C(C=C1)=CC=C1C1=CC=CC=C1 ULFUJLFTRWWLPO-UHFFFAOYSA-N 0.000 description 2
- MMXKVMNBHPAILY-UHFFFAOYSA-N ethyl laurate Chemical compound CCCCCCCCCCCC(=O)OCC MMXKVMNBHPAILY-UHFFFAOYSA-N 0.000 description 2
- 229960001519 exenatide Drugs 0.000 description 2
- XHEFDIBZLJXQHF-UHFFFAOYSA-N fisetin Chemical compound C=1C(O)=CC=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 XHEFDIBZLJXQHF-UHFFFAOYSA-N 0.000 description 2
- 235000012631 food intake Nutrition 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- DSLZVSRJTYRBFB-DUHBMQHGSA-N galactaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O DSLZVSRJTYRBFB-DUHBMQHGSA-N 0.000 description 2
- BGHSOEHUOOAYMY-JTZMCQEISA-N ghrelin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)CN)C1=CC=CC=C1 BGHSOEHUOOAYMY-JTZMCQEISA-N 0.000 description 2
- TWSALRJGPBVBQU-PKQQPRCHSA-N glucagon-like peptide 2 Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(O)=O)[C@@H](C)CC)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)CC)C1=CC=CC=C1 TWSALRJGPBVBQU-PKQQPRCHSA-N 0.000 description 2
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- PSFDQSOCUJVVGF-UHFFFAOYSA-N harman Chemical compound C12=CC=CC=C2NC2=C1C=CN=C2C PSFDQSOCUJVVGF-UHFFFAOYSA-N 0.000 description 2
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 2
- 125000005842 heteroatom Chemical group 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 2
- 238000003125 immunofluorescent labeling Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- ZOAMBXDOGPRZLP-UHFFFAOYSA-N indole-3-acetamide Chemical compound C1=CC=C2C(CC(=O)N)=CNC2=C1 ZOAMBXDOGPRZLP-UHFFFAOYSA-N 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 150000007529 inorganic bases Chemical class 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 210000002490 intestinal epithelial cell Anatomy 0.000 description 2
- 208000002551 irritable bowel syndrome Diseases 0.000 description 2
- JXDYKVIHCLTXOP-UHFFFAOYSA-N isatin Chemical compound C1=CC=C2C(=O)C(=O)NC2=C1 JXDYKVIHCLTXOP-UHFFFAOYSA-N 0.000 description 2
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
- 210000004153 islets of langerhan Anatomy 0.000 description 2
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 229960004891 lapatinib Drugs 0.000 description 2
- 229910052744 lithium Inorganic materials 0.000 description 2
- 229950003489 lomeguatrib Drugs 0.000 description 2
- MJIVRKPEXXHNJT-UHFFFAOYSA-N lutidinic acid Chemical compound OC(=O)C1=CC=NC(C(O)=O)=C1 MJIVRKPEXXHNJT-UHFFFAOYSA-N 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 210000004216 mammary stem cell Anatomy 0.000 description 2
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- IBVRETRIDAQSEM-UHFFFAOYSA-N methyl 3-[4-(4-carbamimidoylbenzoyl)piperazine-1-carbonyl]-5-[(4-carbamimidoylpiperazin-1-yl)methyl]benzoate Chemical compound C=1C(C(=O)N2CCN(CC2)C(=O)C=2C=CC(=CC=2)C(N)=N)=CC(C(=O)OC)=CC=1CN1CCN(C(N)=N)CC1 IBVRETRIDAQSEM-UHFFFAOYSA-N 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- ZAIULUYKQLVQFH-UHFFFAOYSA-N n'-(2-aminophenyl)-n-phenylheptanediamide Chemical compound NC1=CC=CC=C1NC(=O)CCCCCC(=O)NC1=CC=CC=C1 ZAIULUYKQLVQFH-UHFFFAOYSA-N 0.000 description 2
- WXHHICFWKXDFOW-BJMVGYQFSA-N n-(2-amino-5-fluorophenyl)-4-[[[(e)-3-pyridin-3-ylprop-2-enoyl]amino]methyl]benzamide Chemical compound NC1=CC=C(F)C=C1NC(=O)C(C=C1)=CC=C1CNC(=O)\C=C\C1=CC=CN=C1 WXHHICFWKXDFOW-BJMVGYQFSA-N 0.000 description 2
- KSERXGMCDHOLSS-LJQANCHMSA-N n-[(1s)-1-(3-chlorophenyl)-2-hydroxyethyl]-4-[5-chloro-2-(propan-2-ylamino)pyridin-4-yl]-1h-pyrrole-2-carboxamide Chemical compound C1=NC(NC(C)C)=CC(C=2C=C(NC=2)C(=O)N[C@H](CO)C=2C=C(Cl)C=CC=2)=C1Cl KSERXGMCDHOLSS-LJQANCHMSA-N 0.000 description 2
- IQNVEOMHJHBNHC-UHFFFAOYSA-N n-[2-[2-(dimethylamino)ethyl-methylamino]-5-[[4-(1h-indol-3-yl)pyrimidin-2-yl]amino]-4-methoxyphenyl]prop-2-enamide Chemical compound COC1=CC(N(C)CCN(C)C)=C(NC(=O)C=C)C=C1NC1=NC=CC(C=2C3=CC=CC=C3NC=2)=N1 IQNVEOMHJHBNHC-UHFFFAOYSA-N 0.000 description 2
- QDBVSOZTVKXUES-UHFFFAOYSA-N n-[3-(dimethylamino)propyl]-4-(8-hydroxyquinolin-6-yl)benzamide Chemical compound C1=CC(C(=O)NCCCN(C)C)=CC=C1C1=CC(O)=C(N=CC=C2)C2=C1 QDBVSOZTVKXUES-UHFFFAOYSA-N 0.000 description 2
- QSYLKMKIVWJAAK-UHFFFAOYSA-N n-[4-[(2-amino-6-methylpyrimidin-4-yl)amino]phenyl]-4-(quinolin-4-ylamino)benzamide Chemical compound NC1=NC(C)=CC(NC=2C=CC(NC(=O)C=3C=CC(NC=4C5=CC=CC=C5N=CC=4)=CC=3)=CC=2)=N1 QSYLKMKIVWJAAK-UHFFFAOYSA-N 0.000 description 2
- OYKBQNOPCSXWBL-SNAWJCMRSA-N n-hydroxy-3-[(e)-3-(hydroxyamino)-3-oxoprop-1-enyl]benzamide Chemical compound ONC(=O)\C=C\C1=CC=CC(C(=O)NO)=C1 OYKBQNOPCSXWBL-SNAWJCMRSA-N 0.000 description 2
- RFAZNTABYJYOAR-UHFFFAOYSA-N n-hydroxy-4-[2-[n-(2-hydroxyethyl)anilino]-2-oxoethyl]benzamide Chemical compound C=1C=CC=CC=1N(CCO)C(=O)CC1=CC=C(C(=O)NO)C=C1 RFAZNTABYJYOAR-UHFFFAOYSA-N 0.000 description 2
- QRGHOAATPOLDPF-VQFNDLOPSA-N nanatinostat Chemical compound N1=CC(C(=O)NO)=CN=C1N1C[C@@H]([C@@H]2NCC=3N=C4C=CC(F)=CC4=CC=3)[C@@H]2C1 QRGHOAATPOLDPF-VQFNDLOPSA-N 0.000 description 2
- XTEGVFVZDVNBPF-UHFFFAOYSA-N naphthalene-1,5-disulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1S(O)(=O)=O XTEGVFVZDVNBPF-UHFFFAOYSA-N 0.000 description 2
- JWNPDZNEKVCWMY-VQHVLOKHSA-N neratinib Chemical compound C=12C=C(NC(=O)\C=C\CN(C)C)C(OCC)=CC2=NC=C(C#N)C=1NC(C=C1Cl)=CC=C1OCC1=CC=CC=N1 JWNPDZNEKVCWMY-VQHVLOKHSA-N 0.000 description 2
- 210000001178 neural stem cell Anatomy 0.000 description 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- PXQPEWDEAKTCGB-UHFFFAOYSA-N orotic acid Chemical compound OC(=O)C1=CC(=O)NC(=O)N1 PXQPEWDEAKTCGB-UHFFFAOYSA-N 0.000 description 2
- 229910052763 palladium Inorganic materials 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- JHDKZFFAIZKUCU-ZRDIBKRKSA-N pracinostat Chemical compound ONC(=O)/C=C/C1=CC=C2N(CCN(CC)CC)C(CCCC)=NC2=C1 JHDKZFFAIZKUCU-ZRDIBKRKSA-N 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 2
- 229960004919 procaine Drugs 0.000 description 2
- 229940002612 prodrug Drugs 0.000 description 2
- 239000000651 prodrug Substances 0.000 description 2
- UBQKCCHYAOITMY-UHFFFAOYSA-N pyridin-2-ol Chemical compound OC1=CC=CC=N1 UBQKCCHYAOITMY-UHFFFAOYSA-N 0.000 description 2
- YMNAJWHTELQUJU-UHFFFAOYSA-N quinoline-6-carboxamide Chemical compound N1=CC=CC2=CC(C(=O)N)=CC=C21 YMNAJWHTELQUJU-UHFFFAOYSA-N 0.000 description 2
- 239000002464 receptor antagonist Substances 0.000 description 2
- 229940044551 receptor antagonist Drugs 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 229950002821 resminostat Drugs 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- CXMXRPHRNRROMY-UHFFFAOYSA-N sebacic acid Chemical compound OC(=O)CCCCCCCCC(O)=O CXMXRPHRNRROMY-UHFFFAOYSA-N 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- SUVMJBTUFCVSAD-UHFFFAOYSA-N sulforaphane Chemical compound CS(=O)CCCCN=C=S SUVMJBTUFCVSAD-UHFFFAOYSA-N 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 229950009112 tefinostat Drugs 0.000 description 2
- YAPQBXQYLJRXSA-UHFFFAOYSA-N theobromine Chemical compound CN1C(=O)NC(=O)C2=C1N=CN2C YAPQBXQYLJRXSA-UHFFFAOYSA-N 0.000 description 2
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N thiocyanic acid Chemical compound SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 2
- 150000003573 thiols Chemical class 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- PMJIHLSCWIDGMD-UHFFFAOYSA-N tideglusib Chemical compound O=C1SN(C=2C3=CC=CC=C3C=CC=2)C(=O)N1CC1=CC=CC=C1 PMJIHLSCWIDGMD-UHFFFAOYSA-N 0.000 description 2
- WYWHKKSPHMUBEB-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 2
- LIRYPHYGHXZJBZ-UHFFFAOYSA-N trametinib Chemical compound CC(=O)NC1=CC=CC(N2C(N(C3CC3)C(=O)C3=C(NC=4C(=CC(I)=CC=4)F)N(C)C(=O)C(C)=C32)=O)=C1 LIRYPHYGHXZJBZ-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- QAIPRVGONGVQAS-DUXPYHPUSA-N trans-caffeic acid Chemical compound OC(=O)\C=C\C1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-DUXPYHPUSA-N 0.000 description 2
- 230000023750 transforming growth factor beta production Effects 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- TUCIOBMMDDOEMM-RIYZIHGNSA-N tyrphostin B42 Chemical compound C1=C(O)C(O)=CC=C1\C=C(/C#N)C(=O)NCC1=CC=CC=C1 TUCIOBMMDDOEMM-RIYZIHGNSA-N 0.000 description 2
- 238000010200 validation analysis Methods 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- 229960000237 vorinostat Drugs 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- RPQZTTQVRYEKCR-WCTZXXKLSA-N zebularine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)N=CC=C1 RPQZTTQVRYEKCR-WCTZXXKLSA-N 0.000 description 2
- 229940061261 zolinza Drugs 0.000 description 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 2
- NQWVSMVXKMHKTF-JKSUJKDBSA-N (-)-Arctigenin Chemical compound C1=C(OC)C(OC)=CC=C1C[C@@H]1[C@@H](CC=2C=C(OC)C(O)=CC=2)C(=O)OC1 NQWVSMVXKMHKTF-JKSUJKDBSA-N 0.000 description 1
- WMBWREPUVVBILR-WIYYLYMNSA-N (-)-Epigallocatechin-3-o-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-WIYYLYMNSA-N 0.000 description 1
- 229930014124 (-)-epigallocatechin gallate Natural products 0.000 description 1
- 235000004911 (-)-epigallocatechin gallate Nutrition 0.000 description 1
- QIJRTFXNRTXDIP-UHFFFAOYSA-N (1-carboxy-2-sulfanylethyl)azanium;chloride;hydrate Chemical compound O.Cl.SCC(N)C(O)=O QIJRTFXNRTXDIP-UHFFFAOYSA-N 0.000 description 1
- OHRURASPPZQGQM-QSVHVVLASA-N (1r,4s,7z,10s,16e,21r)-7-ethylidene-4,21-di(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetrazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone Chemical compound O1C(=O)[C@H](C(C)C)NC(=O)C(=C/C)/NC(=O)[C@H]2CSSCC\C=C\[C@H]1CC(=O)N[C@H](C(C)C)C(=O)N2 OHRURASPPZQGQM-QSVHVVLASA-N 0.000 description 1
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- LMAFSGDNHVBIHU-XUIWWLCJSA-N (2e)-3-(3-bromo-4-hydroxyphenyl)-n-[2-[2-[[(2e)-3-(3-bromo-4-hydroxyphenyl)-2-hydroxyiminopropanoyl]amino]ethyldisulfanyl]ethyl]-2-hydroxyiminopropanamide Chemical compound C=1C=C(O)C(Br)=CC=1C/C(=N\O)C(=O)NCCSSCCNC(=O)C(=N/O)/CC1=CC=C(O)C(Br)=C1 LMAFSGDNHVBIHU-XUIWWLCJSA-N 0.000 description 1
- YKOCHIUQOBQIAC-YDALLXLXSA-N (2s)-2-[[4-[(3-fluorophenyl)methoxy]phenyl]methylamino]propanamide;methanesulfonic acid Chemical compound CS(O)(=O)=O.C1=CC(CN[C@@H](C)C(N)=O)=CC=C1OCC1=CC=CC(F)=C1 YKOCHIUQOBQIAC-YDALLXLXSA-N 0.000 description 1
- YOKXDNNIFSAXBY-QAETUUGQSA-N (2s)-6-amino-n-[(2s)-1-amino-4-methyl-1-oxopentan-2-yl]-2-[[(2s)-2-[[(2s)-2-amino-4-methylpentanoyl]amino]-3-hydroxypropanoyl]amino]hexanamide Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(N)=O YOKXDNNIFSAXBY-QAETUUGQSA-N 0.000 description 1
- GNYCTMYOHGBSBI-SVZOTFJBSA-N (3s,6r,9s,12r)-6,9-dimethyl-3-[6-[(2s)-oxiran-2-yl]-6-oxohexyl]-1,4,7,10-tetrazabicyclo[10.3.0]pentadecane-2,5,8,11-tetrone Chemical compound C([C@H]1C(=O)N2CCC[C@@H]2C(=O)N[C@H](C(N[C@H](C)C(=O)N1)=O)C)CCCCC(=O)[C@@H]1CO1 GNYCTMYOHGBSBI-SVZOTFJBSA-N 0.000 description 1
- UXOLDMJAFJDQSE-RYFAJOAYSA-N (3s,9s,12r)-3-benzyl-9-[(7r)-7-hydroxy-6-oxooctyl]-6,6-dimethyl-1,4,7,10-tetrazabicyclo[10.3.0]pentadecane-2,5,8,11-tetrone Chemical compound C([C@H]1C(=O)N2CCC[C@@H]2C(=O)N[C@H](C(NC(C)(C)C(=O)N1)=O)CCCCCC(=O)[C@H](O)C)C1=CC=CC=C1 UXOLDMJAFJDQSE-RYFAJOAYSA-N 0.000 description 1
- ATBAETXFFCOZOY-DAXSKMNVSA-N (4z)-4-(2-amino-4-oxo-1h-imidazol-5-ylidene)-2-bromo-1,5,6,7-tetrahydropyrrolo[2,3-c]azepin-8-one Chemical compound N1C(N)=NC(=O)\C1=C/1C(C=C(Br)N2)=C2C(=O)NCC\1 ATBAETXFFCOZOY-DAXSKMNVSA-N 0.000 description 1
- ACEAELOMUCBPJP-UHFFFAOYSA-N (E)-3,4,5-trihydroxycinnamic acid Natural products OC(=O)C=CC1=CC(O)=C(O)C(O)=C1 ACEAELOMUCBPJP-UHFFFAOYSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 1
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- GSQOBTOAOGXIFL-LFIBNONCSA-N (e)-2-cyano-3-(3,4-dihydroxyphenyl)-n-(3-phenylpropyl)prop-2-enamide Chemical compound C1=C(O)C(O)=CC=C1\C=C(/C#N)C(=O)NCCCC1=CC=CC=C1 GSQOBTOAOGXIFL-LFIBNONCSA-N 0.000 description 1
- GWCNJMUSWLTSCW-SFQUDFHCSA-N (e)-2-cyano-3-(3,4-dihydroxyphenyl)-n-(4-phenylbutyl)prop-2-enamide Chemical compound C1=C(O)C(O)=CC=C1\C=C(/C#N)C(=O)NCCCCC1=CC=CC=C1 GWCNJMUSWLTSCW-SFQUDFHCSA-N 0.000 description 1
- HKHOVJYOELRGMV-XYOKQWHBSA-N (e)-2-cyano-3-(3,4-dihydroxyphenyl)-n-phenylprop-2-enamide Chemical compound C1=C(O)C(O)=CC=C1\C=C(/C#N)C(=O)NC1=CC=CC=C1 HKHOVJYOELRGMV-XYOKQWHBSA-N 0.000 description 1
- USOXQZNJFMKTKJ-XVNBXDOJSA-N (e)-2-cyano-3-(3,4-dihydroxyphenyl)prop-2-enamide Chemical compound NC(=O)C(\C#N)=C\C1=CC=C(O)C(O)=C1 USOXQZNJFMKTKJ-XVNBXDOJSA-N 0.000 description 1
- QRPSQQUYPMFERG-LFYBBSHMSA-N (e)-5-[3-(benzenesulfonamido)phenyl]-n-hydroxypent-2-en-4-ynamide Chemical compound ONC(=O)\C=C\C#CC1=CC=CC(NS(=O)(=O)C=2C=CC=CC=2)=C1 QRPSQQUYPMFERG-LFYBBSHMSA-N 0.000 description 1
- BLVQHYHDYFTPDV-VCABWLAWSA-N (e)-n-(2-amino-4-fluorophenyl)-3-[1-[(e)-3-phenylprop-2-enyl]pyrazol-4-yl]prop-2-enamide Chemical compound NC1=CC(F)=CC=C1NC(=O)\C=C\C1=CN(C\C=C\C=2C=CC=CC=2)N=C1 BLVQHYHDYFTPDV-VCABWLAWSA-N 0.000 description 1
- PRXXYMVLYKJITB-IZZDOVSWSA-N (e)-n-(2-aminophenyl)-3-[1-[4-(1-methylpyrazol-4-yl)phenyl]sulfonylpyrrol-3-yl]prop-2-enamide Chemical compound C1=NN(C)C=C1C1=CC=C(S(=O)(=O)N2C=C(\C=C\C(=O)NC=3C(=CC=CC=3)N)C=C2)C=C1 PRXXYMVLYKJITB-IZZDOVSWSA-N 0.000 description 1
- NERXPXBELDBEPZ-RMKNXTFCSA-N (e)-n-[4-[3-chloro-4-[(3-fluorophenyl)methoxy]anilino]-3-cyano-7-ethoxyquinolin-6-yl]-4-(dimethylamino)but-2-enamide Chemical compound C=12C=C(NC(=O)\C=C\CN(C)C)C(OCC)=CC2=NC=C(C#N)C=1NC(C=C1Cl)=CC=C1OCC1=CC=CC(F)=C1 NERXPXBELDBEPZ-RMKNXTFCSA-N 0.000 description 1
- JLOXTZFYJNCPIS-FYWRMAATSA-N (z)-3-amino-3-(4-aminophenyl)sulfanyl-2-[2-(trifluoromethyl)phenyl]prop-2-enenitrile Chemical compound C=1C=CC=C(C(F)(F)F)C=1C(\C#N)=C(/N)SC1=CC=C(N)C=C1 JLOXTZFYJNCPIS-FYWRMAATSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- YYZPXBXVBQSBDG-IJIVKGSJSA-N 1,5-bis[(e)-2-(3,4-dichlorophenyl)ethenyl]-2,4-dinitrobenzene Chemical compound C1=C(\C=C\C=2C=C(Cl)C(Cl)=CC=2)C([N+](=O)[O-])=CC([N+]([O-])=O)=C1\C=C\C1=CC=C(Cl)C(Cl)=C1 YYZPXBXVBQSBDG-IJIVKGSJSA-N 0.000 description 1
- MGUDDBRJHXFTEY-UHFFFAOYSA-N 1-(3-amino-1,2-benzoxazol-5-yl)-6-[4-[2-[(dimethylamino)methyl]imidazol-1-yl]-2-fluorophenyl]-7-fluoroindazole-3-carboxamide Chemical compound CN(C)CC1=NC=CN1C1=CC=C(C=2C(=C3N(C=4C=C5C(N)=NOC5=CC=4)N=C(C3=CC=2)C(N)=O)F)C(F)=C1 MGUDDBRJHXFTEY-UHFFFAOYSA-N 0.000 description 1
- RZUOCXOYPYGSKL-GOSISDBHSA-N 1-[(1s)-1-(4-chloro-3-fluorophenyl)-2-hydroxyethyl]-4-[2-[(2-methylpyrazol-3-yl)amino]pyrimidin-4-yl]pyridin-2-one Chemical compound CN1N=CC=C1NC1=NC=CC(C2=CC(=O)N([C@H](CO)C=3C=C(F)C(Cl)=CC=3)C=C2)=N1 RZUOCXOYPYGSKL-GOSISDBHSA-N 0.000 description 1
- LPFWVDIFUFFKJU-UHFFFAOYSA-N 1-[4-[4-(3,4-dichloro-2-fluoroanilino)-7-methoxyquinazolin-6-yl]oxypiperidin-1-yl]prop-2-en-1-one Chemical compound C=12C=C(OC3CCN(CC3)C(=O)C=C)C(OC)=CC2=NC=NC=1NC1=CC=C(Cl)C(Cl)=C1F LPFWVDIFUFFKJU-UHFFFAOYSA-N 0.000 description 1
- SJJCQDRGABAVBB-UHFFFAOYSA-N 1-hydroxy-2-naphthoic acid Chemical compound C1=CC=CC2=C(O)C(C(=O)O)=CC=C21 SJJCQDRGABAVBB-UHFFFAOYSA-N 0.000 description 1
- YABJJWZLRMPFSI-UHFFFAOYSA-N 1-methyl-5-[[2-[5-(trifluoromethyl)-1H-imidazol-2-yl]-4-pyridinyl]oxy]-N-[4-(trifluoromethyl)phenyl]-2-benzimidazolamine Chemical compound N=1C2=CC(OC=3C=C(N=CC=3)C=3NC(=CN=3)C(F)(F)F)=CC=C2N(C)C=1NC1=CC=C(C(F)(F)F)C=C1 YABJJWZLRMPFSI-UHFFFAOYSA-N 0.000 description 1
- RTBFRGCFXZNCOE-UHFFFAOYSA-N 1-methylsulfonylpiperidin-4-one Chemical compound CS(=O)(=O)N1CCC(=O)CC1 RTBFRGCFXZNCOE-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- FRPZMMHWLSIFAZ-UHFFFAOYSA-N 10-undecenoic acid Chemical compound OC(=O)CCCCCCCCC=C FRPZMMHWLSIFAZ-UHFFFAOYSA-N 0.000 description 1
- 238000011714 129 mouse Methods 0.000 description 1
- WTFWZOSMUGZKNZ-UHFFFAOYSA-N 1H-indol-7-amine Chemical compound NC1=CC=CC2=C1NC=C2 WTFWZOSMUGZKNZ-UHFFFAOYSA-N 0.000 description 1
- AMFYRKOUWBAGHV-UHFFFAOYSA-N 1h-pyrazolo[4,3-b]pyridine Chemical compound C1=CN=C2C=NNC2=C1 AMFYRKOUWBAGHV-UHFFFAOYSA-N 0.000 description 1
- BQCNSTFWSKOWMA-GORDUTHDSA-N 2,5-dihydroxycinnamic acid methyl ester Chemical compound COC(=O)\C=C\C1=CC(O)=CC=C1O BQCNSTFWSKOWMA-GORDUTHDSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 1
- VENLWOFOMJQPFA-SFYZADRCSA-N 2-[(1r,3s)-9-hydroxy-1-methyl-5,10-dioxo-3,4-dihydro-1h-benzo[g]isochromen-3-yl]acetamide Chemical compound O=C1C2=C(O)C=CC=C2C(=O)C2=C1[C@@H](C)O[C@H](CC(N)=O)C2 VENLWOFOMJQPFA-SFYZADRCSA-N 0.000 description 1
- VTJXFTPMFYAJJU-UHFFFAOYSA-N 2-[(3,4-dihydroxyphenyl)methylidene]propanedinitrile Chemical compound OC1=CC=C(C=C(C#N)C#N)C=C1O VTJXFTPMFYAJJU-UHFFFAOYSA-N 0.000 description 1
- RBFDSBJDWZOTGR-UHFFFAOYSA-N 2-[(3,6-dimethyl-4-oxo-6,7-dihydrothieno[3,2-d]pyrimidin-2-yl)sulfanyl]-n-(6-methyl-1,3-benzothiazol-2-yl)acetamide Chemical compound C1=C(C)C=C2SC(NC(=O)CSC3=NC=4CC(SC=4C(=O)N3C)C)=NC2=C1 RBFDSBJDWZOTGR-UHFFFAOYSA-N 0.000 description 1
- QESQGTFWEQMCMH-UHFFFAOYSA-N 2-[(4-oxo-3-phenyl-6,7-dihydrothieno[3,2-d]pyrimidin-2-yl)sulfanyl]-n-(5-phenylpyridin-2-yl)acetamide Chemical compound C=1C=C(C=2C=CC=CC=2)C=NC=1NC(=O)CSC1=NC=2CCSC=2C(=O)N1C1=CC=CC=C1 QESQGTFWEQMCMH-UHFFFAOYSA-N 0.000 description 1
- PHAOTASRLQMKBE-UHFFFAOYSA-N 2-[4,5,6,7-tetrabromo-2-(dimethylamino)benzimidazol-1-yl]acetic acid Chemical compound BrC1=C(Br)C(Br)=C2N(CC(O)=O)C(N(C)C)=NC2=C1Br PHAOTASRLQMKBE-UHFFFAOYSA-N 0.000 description 1
- KOQIAZNBAWFSQM-UHFFFAOYSA-N 2-[4-(3-ethynylanilino)-7-(2-methoxyethoxy)quinazolin-6-yl]oxyethanol Chemical compound C=12C=C(OCCO)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 KOQIAZNBAWFSQM-UHFFFAOYSA-N 0.000 description 1
- WCPTUQOMNJBIET-CALCHBBNSA-N 2-[4-[6-[(3R,5S)-3,5-dimethylpiperazin-1-yl]-4-methylpyridin-3-yl]phenyl]-7-methyl-3H-pyrrolo[2,3-d]pyrimidin-4-one Chemical compound C1[C@@H](C)N[C@@H](C)CN1C1=CC(C)=C(C=2C=CC(=CC=2)C=2NC=3N(C)C=CC=3C(=O)N=2)C=N1 WCPTUQOMNJBIET-CALCHBBNSA-N 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- CBIAKDAYHRWZCU-UHFFFAOYSA-N 2-bromo-4-[(6,7-dimethoxyquinazolin-4-yl)amino]phenol Chemical compound C=12C=C(OC)C(OC)=CC2=NC=NC=1NC1=CC=C(O)C(Br)=C1 CBIAKDAYHRWZCU-UHFFFAOYSA-N 0.000 description 1
- PBIUDEUWYGBHDW-UHFFFAOYSA-N 2-chloro-1-pyridin-3-ylethanone;hydrochloride Chemical compound Cl.ClCC(=O)C1=CC=CN=C1 PBIUDEUWYGBHDW-UHFFFAOYSA-N 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- 229940013085 2-diethylaminoethanol Drugs 0.000 description 1
- NEAQRZUHTPSBBM-UHFFFAOYSA-N 2-hydroxy-3,3-dimethyl-7-nitro-4h-isoquinolin-1-one Chemical compound C1=C([N+]([O-])=O)C=C2C(=O)N(O)C(C)(C)CC2=C1 NEAQRZUHTPSBBM-UHFFFAOYSA-N 0.000 description 1
- DPSHJKZKKFYEHL-UHFFFAOYSA-N 2-hydroxypentanamide Chemical class CCCC(O)C(N)=O DPSHJKZKKFYEHL-UHFFFAOYSA-N 0.000 description 1
- KPGXRSRHYNQIFN-UHFFFAOYSA-N 2-oxoglutaric acid Chemical compound OC(=O)CCC(=O)C(O)=O KPGXRSRHYNQIFN-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 description 1
- OCUQMWSIGPQEMX-UHFFFAOYSA-N 3-[3-[N-[4-[(dimethylamino)methyl]phenyl]-C-phenylcarbonimidoyl]-2-hydroxy-1H-indol-6-yl]-N-ethylprop-2-ynamide Chemical compound CCNC(=O)C#CC1=CC2=C(C=C1)C(=C(N2)O)C(=NC3=CC=C(C=C3)CN(C)C)C4=CC=CC=C4 OCUQMWSIGPQEMX-UHFFFAOYSA-N 0.000 description 1
- NEHSERYKENINRH-UHFFFAOYSA-N 3-[9-cyclopropylnonanoyl(hydroxy)amino]propanoic acid Chemical compound OC(=O)CCN(O)C(=O)CCCCCCCCC1CC1 NEHSERYKENINRH-UHFFFAOYSA-N 0.000 description 1
- WGPXKFOFEXJMBD-UHFFFAOYSA-N 3-[N-[3-[(dimethylamino)methyl]phenyl]-C-phenylcarbonimidoyl]-2-hydroxy-1H-indole-6-carboxamide Chemical compound CN(C)CC1=CC(=CC=C1)N=C(C2=CC=CC=C2)C3=C(NC4=C3C=CC(=C4)C(=O)N)O WGPXKFOFEXJMBD-UHFFFAOYSA-N 0.000 description 1
- LJIFOCRGDDQFJF-UHFFFAOYSA-N 3-[[2-(3-pyridinyl)-6-(1,2,4,5-tetrahydro-3-benzazepin-3-yl)-4-pyrimidinyl]amino]propanoic acid Chemical compound N=1C(NCCC(=O)O)=CC(N2CCC3=CC=CC=C3CC2)=NC=1C1=CC=CN=C1 LJIFOCRGDDQFJF-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- UOQHWNPVNXSDDO-UHFFFAOYSA-N 3-bromoimidazo[1,2-a]pyridine-6-carbonitrile Chemical compound C1=CC(C#N)=CN2C(Br)=CN=C21 UOQHWNPVNXSDDO-UHFFFAOYSA-N 0.000 description 1
- IPICFSFUAKDZEI-UHFFFAOYSA-N 3-methyl-2-[2-[[3-methyl-2-[2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoyloxy]butanoyl]amino]propanoyloxy]butanoic acid Chemical compound CC(C)C(C(O)=O)OC(=O)C(C)NC(=O)C(C(C)C)OC(=O)C(C)NC(=O)OC(C)(C)C IPICFSFUAKDZEI-UHFFFAOYSA-N 0.000 description 1
- AAALVYBICLMAMA-UHFFFAOYSA-N 4,5-dianilinophthalimide Chemical compound C=1C=CC=CC=1NC=1C=C2C(=O)NC(=O)C2=CC=1NC1=CC=CC=C1 AAALVYBICLMAMA-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- RGWSSTALGUXZMU-UHFFFAOYSA-N 4-(dimethylamino)-n-[6-(hydroxyamino)-6-oxohexyl]benzamide Chemical compound CN(C)C1=CC=C(C(=O)NCCCCCC(=O)NO)C=C1 RGWSSTALGUXZMU-UHFFFAOYSA-N 0.000 description 1
- SUVMJBTUFCVSAD-JTQLQIEISA-N 4-Methylsulfinylbutyl isothiocyanate Natural products C[S@](=O)CCCCN=C=S SUVMJBTUFCVSAD-JTQLQIEISA-N 0.000 description 1
- DXLXRNZCYAYUED-UHFFFAOYSA-N 4-[2-[4-(3-quinolin-4-ylpyrazolo[1,5-a]pyrimidin-6-yl)phenoxy]ethyl]morpholine Chemical compound C=1C=C(C2=CN3N=CC(=C3N=C2)C=2C3=CC=CC=C3N=CC=2)C=CC=1OCCN1CCOCC1 DXLXRNZCYAYUED-UHFFFAOYSA-N 0.000 description 1
- XRYJULCDUUATMC-CYBMUJFWSA-N 4-[4-[[(1r)-1-phenylethyl]amino]-7h-pyrrolo[2,3-d]pyrimidin-6-yl]phenol Chemical compound N([C@H](C)C=1C=CC=CC=1)C(C=1C=2)=NC=NC=1NC=2C1=CC=C(O)C=C1 XRYJULCDUUATMC-CYBMUJFWSA-N 0.000 description 1
- CDOVNWNANFFLFJ-UHFFFAOYSA-N 4-[6-[4-(1-piperazinyl)phenyl]-3-pyrazolo[1,5-a]pyrimidinyl]quinoline Chemical compound C1CNCCN1C1=CC=C(C2=CN3N=CC(=C3N=C2)C=2C3=CC=CC=C3N=CC=2)C=C1 CDOVNWNANFFLFJ-UHFFFAOYSA-N 0.000 description 1
- WUBBRNOQWQTFEX-UHFFFAOYSA-N 4-aminosalicylic acid Chemical compound NC1=CC=C(C(O)=O)C(O)=C1 WUBBRNOQWQTFEX-UHFFFAOYSA-N 0.000 description 1
- GAMYYCRTACQSBR-UHFFFAOYSA-N 4-azabenzimidazole Chemical compound C1=CC=C2NC=NC2=N1 GAMYYCRTACQSBR-UHFFFAOYSA-N 0.000 description 1
- FAZZYPIBZBGQSH-UHFFFAOYSA-N 4-ethyl-5-methyl-6h-[1,3]dioxolo[4,5-j]phenanthridine Chemical compound C12=CC=3OCOC=3C=C2CN(C)C2=C1C=CC=C2CC FAZZYPIBZBGQSH-UHFFFAOYSA-N 0.000 description 1
- UWXSAYUXVSFDBQ-CYBMUJFWSA-N 4-n-[3-chloro-4-(1,3-thiazol-2-ylmethoxy)phenyl]-6-n-[(4r)-4-methyl-4,5-dihydro-1,3-oxazol-2-yl]quinazoline-4,6-diamine Chemical compound C[C@@H]1COC(NC=2C=C3C(NC=4C=C(Cl)C(OCC=5SC=CN=5)=CC=4)=NC=NC3=CC=2)=N1 UWXSAYUXVSFDBQ-CYBMUJFWSA-N 0.000 description 1
- ALBQXDHCMLLQMB-UHFFFAOYSA-N 4-phenylbenzenesulfonyl chloride Chemical compound C1=CC(S(=O)(=O)Cl)=CC=C1C1=CC=CC=C1 ALBQXDHCMLLQMB-UHFFFAOYSA-N 0.000 description 1
- OBKXEAXTFZPCHS-UHFFFAOYSA-N 4-phenylbutyric acid Chemical compound OC(=O)CCCC1=CC=CC=C1 OBKXEAXTFZPCHS-UHFFFAOYSA-N 0.000 description 1
- UOVCGJXDGOGOCZ-UHFFFAOYSA-N 5-(2-chlorophenyl)-7-fluoro-8-methoxy-3-methyl-1,2-dihydropyrazolo[3,4-b][1,4]benzodiazepine Chemical compound C1=2C=C(F)C(OC)=CC=2N=C2NNC(C)=C2N=C1C1=CC=CC=C1Cl UOVCGJXDGOGOCZ-UHFFFAOYSA-N 0.000 description 1
- XVECMUKVOMUNLE-UHFFFAOYSA-N 5-(2-phenyl-3-pyrazolo[1,5-a]pyridinyl)-2H-pyrazolo[3,4-c]pyridazin-3-amine Chemical compound C1=C2C(N)=NNC2=NN=C1C(=C1C=CC=CN1N=1)C=1C1=CC=CC=C1 XVECMUKVOMUNLE-UHFFFAOYSA-N 0.000 description 1
- QPTGWITYTSXRJB-UHFFFAOYSA-N 5-(naphthalen-1-ylmethylidene)-2-sulfanylidene-1,3-diazinane-4,6-dione Chemical compound O=C1NC(=S)NC(=O)C1=CC1=CC=CC2=CC=CC=C12 QPTGWITYTSXRJB-UHFFFAOYSA-N 0.000 description 1
- LZZYEMSEMRUPIM-UHFFFAOYSA-N 5-[3,4-difluoro-2-(2-fluoro-4-iodoanilino)phenyl]-n-(2-morpholin-4-ylethyl)-1,3,4-oxadiazol-2-amine Chemical compound C=1C=C(I)C=C(F)C=1NC1=C(F)C(F)=CC=C1C(O1)=NN=C1NCCN1CCOCC1 LZZYEMSEMRUPIM-UHFFFAOYSA-N 0.000 description 1
- FVRYPYDPKSZGNS-UHFFFAOYSA-N 5-[6-(4-methoxyphenyl)pyrazolo[1,5-a]pyrimidin-3-yl]quinoline Chemical compound C1=CC(OC)=CC=C1C1=CN2N=CC(C=3C4=CC=CN=C4C=CC=3)=C2N=C1 FVRYPYDPKSZGNS-UHFFFAOYSA-N 0.000 description 1
- XXSSGBYXSKOLAM-UHFFFAOYSA-N 5-bromo-n-(2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodoanilino)benzamide Chemical compound OCC(O)CONC(=O)C1=CC(Br)=C(F)C(F)=C1NC1=CC=C(I)C=C1F XXSSGBYXSKOLAM-UHFFFAOYSA-N 0.000 description 1
- YHHFKWKMXWRVTJ-XLNRJJMWSA-N 5-chloro-n-[(z)-[phenyl(pyridin-2-yl)methylidene]amino]pyridin-2-amine Chemical compound N1=CC(Cl)=CC=C1N\N=C(C=1N=CC=CC=1)\C1=CC=CC=C1 YHHFKWKMXWRVTJ-XLNRJJMWSA-N 0.000 description 1
- WHSIXKUPQCKWBY-IOSLPCCCSA-N 5-iodotubercidin Chemical compound C1=C(I)C=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O WHSIXKUPQCKWBY-IOSLPCCCSA-N 0.000 description 1
- RZWRYPGAUIOOMK-UHFFFAOYSA-N 5-nitroso-8-quinolinol Chemical compound C1=CN=C2C(O)=CC=C(N=O)C2=C1 RZWRYPGAUIOOMK-UHFFFAOYSA-N 0.000 description 1
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 1
- ICCFXXDUYSPKOL-UHFFFAOYSA-N 7-nitro-4-(1-oxidopyridin-1-ium-2-yl)sulfanyl-2,1,3-benzoxadiazole Chemical compound C12=NON=C2C([N+](=O)[O-])=CC=C1SC1=CC=CC=[N+]1[O-] ICCFXXDUYSPKOL-UHFFFAOYSA-N 0.000 description 1
- WBWFIUAVMCNYPG-BQYQJAHWSA-N 8-(3-chlorostyryl)caffeine Chemical compound N=1C=2N(C)C(=O)N(C)C(=O)C=2N(C)C=1\C=C\C1=CC=CC(Cl)=C1 WBWFIUAVMCNYPG-BQYQJAHWSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 101150101604 ACVR1B gene Proteins 0.000 description 1
- 101150009411 ACVR1C gene Proteins 0.000 description 1
- OONFNUWBHFSNBT-HXUWFJFHSA-N AEE788 Chemical compound C1CN(CC)CCN1CC1=CC=C(C=2NC3=NC=NC(N[C@H](C)C=4C=CC=CC=4)=C3C=2)C=C1 OONFNUWBHFSNBT-HXUWFJFHSA-N 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 239000012110 Alexa Fluor 594 Substances 0.000 description 1
- 239000012099 Alexa Fluor family Substances 0.000 description 1
- RYVZYACBVYKUHD-UHFFFAOYSA-N Alk5 Natural products CC#CC#CCCCCC=CC(=O)NCC(C)C RYVZYACBVYKUHD-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241001550224 Apha Species 0.000 description 1
- YYGRXNOXOVZIKE-UHFFFAOYSA-N Arctigenin Natural products COC1CCC(CC2COC(=O)C2CC3CCC(O)C(C3)OC)CC1OC YYGRXNOXOVZIKE-UHFFFAOYSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- XEAOPVUAMONVLA-QGZVFWFLSA-N Avagacestat Chemical compound C=1C=C(Cl)C=CC=1S(=O)(=O)N([C@H](CCC(F)(F)F)C(=O)N)CC(C(=C1)F)=CC=C1C=1N=CON=1 XEAOPVUAMONVLA-QGZVFWFLSA-N 0.000 description 1
- RFLHBLWLFUFFDZ-UHFFFAOYSA-N BML-210 Chemical compound NC1=CC=CC=C1NC(=O)CCCCCCC(=O)NC1=CC=CC=C1 RFLHBLWLFUFFDZ-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- LMMJFBMMJUMSJS-UHFFFAOYSA-N CH5126766 Chemical compound CNS(=O)(=O)NC1=NC=CC(CC=2C(OC3=CC(OC=4N=CC=CN=4)=CC=C3C=2C)=O)=C1F LMMJFBMMJUMSJS-UHFFFAOYSA-N 0.000 description 1
- PEKZLFZZBGBOPJ-UHFFFAOYSA-N COC=1C=C2C(=NC=NC2=CC=1OC)NC1=C(C=C(C=C1)OC1=CC=CC=C1)C Chemical compound COC=1C=C2C(=NC=NC2=CC=1OC)NC1=C(C=C(C=C1)OC1=CC=CC=C1)C PEKZLFZZBGBOPJ-UHFFFAOYSA-N 0.000 description 1
- LLVZBTWPGQVVLW-SNAWJCMRSA-N CP-724714 Chemical compound C12=CC(/C=C/CNC(=O)COC)=CC=C2N=CN=C1NC(C=C1C)=CC=C1OC1=CC=C(C)N=C1 LLVZBTWPGQVVLW-SNAWJCMRSA-N 0.000 description 1
- 101100264044 Caenorhabditis elegans cwn-2 gene Proteins 0.000 description 1
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 description 1
- LSPHULWDVZXLIL-UHFFFAOYSA-N Camphoric acid Natural products CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 description 1
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 108010038447 Chromogranin A Proteins 0.000 description 1
- 102000010792 Chromogranin A Human genes 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 1
- INQUULPXCZAKMS-XKZIYDEJSA-N DEL-22379 Chemical compound C12=CC(OC)=CC=C2NC=C1\C=C(C1=C2)/C(=O)NC1=CC=C2NC(=O)CCN1CCCCC1 INQUULPXCZAKMS-XKZIYDEJSA-N 0.000 description 1
- NOQGZXFMHARMLW-UHFFFAOYSA-N Daminozide Chemical compound CN(C)NC(=O)CCC(O)=O NOQGZXFMHARMLW-UHFFFAOYSA-N 0.000 description 1
- 239000005975 Daminozide Substances 0.000 description 1
- 101100129232 Danio rerio mafaa gene Proteins 0.000 description 1
- 101100317380 Danio rerio wnt4a gene Proteins 0.000 description 1
- 101100428956 Danio rerio wnt8b gene Proteins 0.000 description 1
- DLVJMFOLJOOWFS-UHFFFAOYSA-N Depudecin Natural products CC(O)C1OC1C=CC1C(C(O)C=C)O1 DLVJMFOLJOOWFS-UHFFFAOYSA-N 0.000 description 1
- 102100030074 Dickkopf-related protein 1 Human genes 0.000 description 1
- 101710099518 Dickkopf-related protein 1 Proteins 0.000 description 1
- 102100030091 Dickkopf-related protein 2 Human genes 0.000 description 1
- 101710099523 Dickkopf-related protein 2 Proteins 0.000 description 1
- 102100037985 Dickkopf-related protein 3 Human genes 0.000 description 1
- 101710099550 Dickkopf-related protein 3 Proteins 0.000 description 1
- 102100037986 Dickkopf-related protein 4 Human genes 0.000 description 1
- 101710099554 Dickkopf-related protein 4 Proteins 0.000 description 1
- 101100073171 Drosophila melanogaster Kdm2 gene Proteins 0.000 description 1
- 101100373143 Drosophila melanogaster Wnt5 gene Proteins 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 108700039887 Essential Genes Proteins 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 229920003134 Eudragit® polymer Polymers 0.000 description 1
- 102000005698 Frizzled receptors Human genes 0.000 description 1
- 108010045438 Frizzled receptors Proteins 0.000 description 1
- 102100025101 GATA-type zinc finger protein 1 Human genes 0.000 description 1
- 101150019176 GDF10 gene Proteins 0.000 description 1
- 102000027587 GPCRs class F Human genes 0.000 description 1
- 108091008884 GPCRs class F Proteins 0.000 description 1
- 102000038624 GSKs Human genes 0.000 description 1
- 108091007911 GSKs Proteins 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 229940125373 Gamma-Secretase Inhibitor Drugs 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 102000000594 Growth Differentiation Factor 10 Human genes 0.000 description 1
- OIFFJDGSLVHPCW-UHFFFAOYSA-N Guayarol Natural products COc1ccc(CC2C(Cc3ccc(O)c(O)c3)COC2=O)cc1OC OIFFJDGSLVHPCW-UHFFFAOYSA-N 0.000 description 1
- 101150092640 HES1 gene Proteins 0.000 description 1
- 108091016366 Histone-lysine N-methyltransferase EHMT1 Proteins 0.000 description 1
- 108700014808 Homeobox Protein Nkx-2.2 Proteins 0.000 description 1
- 101000613625 Homo sapiens Lysine-specific demethylase 4A Proteins 0.000 description 1
- 101000613629 Homo sapiens Lysine-specific demethylase 4B Proteins 0.000 description 1
- 101000855004 Homo sapiens Protein Wnt-7a Proteins 0.000 description 1
- 101000825949 Homo sapiens R-spondin-2 Proteins 0.000 description 1
- ZGSXEXBYLJIOGF-ALFLXDJESA-N IWR-1-endo Chemical compound C=1C=CC2=CC=CN=C2C=1NC(=O)C(C=C1)=CC=C1N1C(=O)[C@@H]2[C@H](C=C3)C[C@H]3[C@@H]2C1=O ZGSXEXBYLJIOGF-ALFLXDJESA-N 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000016624 JmjC domains Human genes 0.000 description 1
- 108050006228 JmjC domains Proteins 0.000 description 1
- 101150051019 Klrg1 gene Proteins 0.000 description 1
- NQWVSMVXKMHKTF-UHFFFAOYSA-N L-Arctigenin Natural products C1=C(OC)C(OC)=CC=C1CC1C(CC=2C=C(OC)C(O)=CC=2)C(=O)OC1 NQWVSMVXKMHKTF-UHFFFAOYSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 1
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- HRJWTAWVFDCTGO-UHFFFAOYSA-N LY-2090314 Chemical compound C1CN(C=23)C=C(C=4C(NC(=O)C=4C=4N5C=CC=CC5=NC=4)=O)C3=CC(F)=CC=2CN1C(=O)N1CCCCC1 HRJWTAWVFDCTGO-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- JMFKTFLARGGXCC-UHFFFAOYSA-N Lazabemide hydrochloride Chemical compound Cl.NCCNC(=O)C1=CC=C(Cl)C=N1 JMFKTFLARGGXCC-UHFFFAOYSA-N 0.000 description 1
- 229940123628 Lysine (K)-specific demethylase 1A inhibitor Drugs 0.000 description 1
- 102100040863 Lysine-specific demethylase 4A Human genes 0.000 description 1
- 102100040860 Lysine-specific demethylase 4B Human genes 0.000 description 1
- 101150084866 MAFA gene Proteins 0.000 description 1
- WYQVAPGDARQUBT-FGWHUCSPSA-N Madecassol Chemical compound O([C@@H]1[C@@H](CO)O[C@H]([C@@H]([C@H]1O)O)OC[C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)OC(=O)[C@]12CC[C@H]([C@@H]([C@H]1C=1[C@@]([C@@]3(CC[C@H]4[C@](C)(CO)[C@@H](O)[C@H](O)C[C@]4(C)[C@H]3CC=1)C)(C)CC2)C)C)[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O WYQVAPGDARQUBT-FGWHUCSPSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- MZOPWQKISXCCTP-UHFFFAOYSA-N Malonoben Chemical compound CC(C)(C)C1=CC(C=C(C#N)C#N)=CC(C(C)(C)C)=C1O MZOPWQKISXCCTP-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- 102000016397 Methyltransferase Human genes 0.000 description 1
- 108060004795 Methyltransferase Proteins 0.000 description 1
- 108090000744 Mitogen-Activated Protein Kinase Kinases Proteins 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 101100108853 Mus musculus Anp32e gene Proteins 0.000 description 1
- 101100396998 Mus musculus Ins1 gene Proteins 0.000 description 1
- 101100072650 Mus musculus Ins2 gene Proteins 0.000 description 1
- 101100485095 Mus musculus Wnt10b gene Proteins 0.000 description 1
- 101100317378 Mus musculus Wnt3 gene Proteins 0.000 description 1
- WTKBRPXPNAKVEQ-UHFFFAOYSA-N N'-(2-aminophenyl)-N-(4-methylphenyl)heptanediamide Chemical compound C1=CC(C)=CC=C1NC(=O)CCCCCC(=O)NC1=CC=CC=C1N WTKBRPXPNAKVEQ-UHFFFAOYSA-N 0.000 description 1
- PTJGLFIIZFVFJV-UHFFFAOYSA-N N'-hydroxy-N-(3-pyridinyl)octanediamide Chemical compound ONC(=O)CCCCCCC(=O)NC1=CC=CN=C1 PTJGLFIIZFVFJV-UHFFFAOYSA-N 0.000 description 1
- IDQPVOFTURLJPT-UHFFFAOYSA-N N,N'-dihydroxyoctanediamide Chemical compound ONC(=O)CCCCCCC(=O)NO IDQPVOFTURLJPT-UHFFFAOYSA-N 0.000 description 1
- UHAXDAKQGVISBZ-UHFFFAOYSA-N N-(cyclopropylmethoxy)-3,4,5-trifluoro-2-(4-iodo-2-methylanilino)benzamide Chemical compound CC1=CC(I)=CC=C1NC1=C(F)C(F)=C(F)C=C1C(=O)NOCC1CC1 UHAXDAKQGVISBZ-UHFFFAOYSA-N 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- APHGZZPEOCCYNO-UHFFFAOYSA-N N-[3-[[5-chloro-2-[4-(4-methyl-1-piperazinyl)anilino]-4-pyrimidinyl]oxy]phenyl]-2-propenamide Chemical compound C1CN(C)CCN1C(C=C1)=CC=C1NC1=NC=C(Cl)C(OC=2C=C(NC(=O)C=C)C=CC=2)=N1 APHGZZPEOCCYNO-UHFFFAOYSA-N 0.000 description 1
- HTLZVHNRZJPSMI-UHFFFAOYSA-N N-ethylpiperidine Chemical compound CCN1CCCCC1 HTLZVHNRZJPSMI-UHFFFAOYSA-N 0.000 description 1
- AJRGHIGYPXNABY-UHFFFAOYSA-N N-hydroxy-1-[(4-methoxyphenyl)methyl]-6-indolecarboxamide Chemical compound C1=CC(OC)=CC=C1CN1C2=CC(C(=O)NO)=CC=C2C=C1 AJRGHIGYPXNABY-UHFFFAOYSA-N 0.000 description 1
- ROJGIRXXBBBMPL-UHFFFAOYSA-N N-hydroxy-2-propylpentanamide Chemical compound CCCC(CCC)C(=O)NO ROJGIRXXBBBMPL-UHFFFAOYSA-N 0.000 description 1
- KPNNXHVGOKRBEF-UHFFFAOYSA-N N-hydroxy-7-(2-naphthalenylthio)heptanamide Chemical compound C1=CC=CC2=CC(SCCCCCCC(=O)NO)=CC=C21 KPNNXHVGOKRBEF-UHFFFAOYSA-N 0.000 description 1
- QSQQPMHPCBLLGX-UHFFFAOYSA-N N-methyl-4-[2-(phenylmethyl)phenoxy]-1-butanamine Chemical compound CNCCCCOC1=CC=CC=C1CC1=CC=CC=C1 QSQQPMHPCBLLGX-UHFFFAOYSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- FTFRZXFNZVCRSK-UHFFFAOYSA-N N4-(3-chloro-4-fluorophenyl)-N6-(1-methyl-4-piperidinyl)pyrimido[5,4-d]pyrimidine-4,6-diamine Chemical compound C1CN(C)CCC1NC1=NC=C(N=CN=C2NC=3C=C(Cl)C(F)=CC=3)C2=N1 FTFRZXFNZVCRSK-UHFFFAOYSA-N 0.000 description 1
- 108010072083 NSC 668036 Proteins 0.000 description 1
- ZCJHPTKRISJQTN-UHFFFAOYSA-N Nanaomycin A Natural products O=C1C2=C(O)C=CC=C2C(=O)C2=C1C(C)OC(CC(O)=O)C2 ZCJHPTKRISJQTN-UHFFFAOYSA-N 0.000 description 1
- VENLWOFOMJQPFA-UHFFFAOYSA-N Nanaomycin C Natural products O=C1C2=C(O)C=CC=C2C(=O)C2=C1C(C)OC(CC(N)=O)C2 VENLWOFOMJQPFA-UHFFFAOYSA-N 0.000 description 1
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 description 1
- 102100038553 Neurogenin-3 Human genes 0.000 description 1
- 101710096141 Neurogenin-3 Proteins 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 102100025036 Norrin Human genes 0.000 description 1
- 101710085992 Norrin Proteins 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
- SUDAHWBOROXANE-VIFPVBQESA-N PD 0325901-Cl Chemical compound OC[C@H](O)CONC(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1F SUDAHWBOROXANE-VIFPVBQESA-N 0.000 description 1
- LSPANGZZENHZNJ-UHFFFAOYSA-N PD-153035 Chemical compound C=12C=C(OC)C(OC)=CC2=NC=NC=1NC1=CC=CC(Br)=C1 LSPANGZZENHZNJ-UHFFFAOYSA-N 0.000 description 1
- ZJOKWAWPAPMNIM-UHFFFAOYSA-N PD-153035 hydrochloride Chemical compound Cl.C=12C=C(OC)C(OC)=CC2=NC=NC=1NC1=CC=CC(Br)=C1 ZJOKWAWPAPMNIM-UHFFFAOYSA-N 0.000 description 1
- KFHMLBXBRCITHF-UHFFFAOYSA-N PD158780 Chemical compound N1=CN=C2C=NC(NC)=CC2=C1NC1=CC=CC(Br)=C1 KFHMLBXBRCITHF-UHFFFAOYSA-N 0.000 description 1
- 102000038030 PI3Ks Human genes 0.000 description 1
- 108091007960 PI3Ks Proteins 0.000 description 1
- BIVQBWSIGJFXLF-UHFFFAOYSA-N PPM-18 Chemical compound C=1C(=O)C2=CC=CC=C2C(=O)C=1NC(=O)C1=CC=CC=C1 BIVQBWSIGJFXLF-UHFFFAOYSA-N 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- DPWPWRLQFGFJFI-UHFFFAOYSA-N Pargyline Chemical compound C#CCN(C)CC1=CC=CC=C1 DPWPWRLQFGFJFI-UHFFFAOYSA-N 0.000 description 1
- BUQLXKSONWUQAC-UHFFFAOYSA-N Parthenolide Natural products CC1C2OC(=O)C(=C)C2CCC(=C/CCC1(C)O)C BUQLXKSONWUQAC-UHFFFAOYSA-N 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 108010079855 Peptide Aptamers Proteins 0.000 description 1
- 241000286209 Phasianidae Species 0.000 description 1
- ZYFVNVRFVHJEIU-UHFFFAOYSA-N PicoGreen Chemical compound CN(C)CCCN(CCCN(C)C)C1=CC(=CC2=[N+](C3=CC=CC=C3S2)C)C2=CC=CC=C2N1C1=CC=CC=C1 ZYFVNVRFVHJEIU-UHFFFAOYSA-N 0.000 description 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 102100020729 Protein Wnt-7a Human genes 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- 101710183548 Pyridoxal 5'-phosphate synthase subunit PdxS Proteins 0.000 description 1
- ODHCTXKNWHHXJC-GSVOUGTGSA-N Pyroglutamic acid Natural products OC(=O)[C@H]1CCC(=O)N1 ODHCTXKNWHHXJC-GSVOUGTGSA-N 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 102000041829 R-spondin family Human genes 0.000 description 1
- 108091078718 R-spondin family Proteins 0.000 description 1
- 102100022763 R-spondin-2 Human genes 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- HDAJDNHIBCDLQF-RUZDIDTESA-N SCH772984 Chemical compound O=C([C@@H]1CCN(C1)CC(=O)N1CCN(CC1)C=1C=CC(=CC=1)C=1N=CC=CN=1)NC(C=C12)=CC=C1NN=C2C1=CC=NC=C1 HDAJDNHIBCDLQF-RUZDIDTESA-N 0.000 description 1
- CDKIEBFIMCSCBB-CALJPSDSSA-N SIS3 Chemical compound Cl.C1C=2C=C(OC)C(OC)=CC=2CCN1C(=O)\C=C\C(C1=CC=CN=C1N1C)=C1C1=CC=CC=C1 CDKIEBFIMCSCBB-CALJPSDSSA-N 0.000 description 1
- IJYPHMXWKKKHGT-VAWYXSNFSA-N SIS3 free base Chemical compound C1C=2C=C(OC)C(OC)=CC=2CCN1C(=O)\C=C\C(C1=CC=CN=C1N1C)=C1C1=CC=CC=C1 IJYPHMXWKKKHGT-VAWYXSNFSA-N 0.000 description 1
- 101000767160 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) Intracellular protein transport protein USO1 Proteins 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- 102100030058 Secreted frizzled-related protein 1 Human genes 0.000 description 1
- 108050007993 Secreted frizzled-related protein 1 Proteins 0.000 description 1
- 102100030054 Secreted frizzled-related protein 2 Human genes 0.000 description 1
- 108050007987 Secreted frizzled-related protein 2 Proteins 0.000 description 1
- 108010086019 Secretin Proteins 0.000 description 1
- 108010087230 Sincalide Proteins 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- VJXBYUITQBTTQM-UFIBWMMISA-N Thailandepsin A Chemical compound C1SSCC\C=C\[C@H]2OC(=O)C[C@H](O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]1NC(=O)[C@@H](CCSC)NC(=O)C2 VJXBYUITQBTTQM-UFIBWMMISA-N 0.000 description 1
- VJXBYUITQBTTQM-MKRKYWAKSA-N Thailandepsin A Natural products CC[C@H](C)[C@H]1NC(=O)[C@H]2CSSCCC=C[C@H](CC(=O)N[C@H](CCSC)C(=O)N2)OC(=O)C[C@@H]1O VJXBYUITQBTTQM-MKRKYWAKSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 102100033663 Transforming growth factor beta receptor type 3 Human genes 0.000 description 1
- RTKIYFITIVXBLE-UHFFFAOYSA-N Trichostatin A Natural products ONC(=O)C=CC(C)=CC(C)C(=O)C1=CC=C(N(C)C)C=C1 RTKIYFITIVXBLE-UHFFFAOYSA-N 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- DVEXZJFMOKTQEZ-JYFOCSDGSA-N U0126 Chemical compound C=1C=CC=C(N)C=1SC(\N)=C(/C#N)\C(\C#N)=C(/N)SC1=CC=CC=C1N DVEXZJFMOKTQEZ-JYFOCSDGSA-N 0.000 description 1
- 101150010310 WNT-4 gene Proteins 0.000 description 1
- 101150109862 WNT-5A gene Proteins 0.000 description 1
- 101150019524 WNT2 gene Proteins 0.000 description 1
- ITTRLTNMFYIYPA-UHFFFAOYSA-N WZ4002 Chemical compound COC1=CC(N2CCN(C)CC2)=CC=C1NC(N=1)=NC=C(Cl)C=1OC1=CC=CC(NC(=O)C=C)=C1 ITTRLTNMFYIYPA-UHFFFAOYSA-N 0.000 description 1
- 102000052547 Wnt-1 Human genes 0.000 description 1
- 108700020987 Wnt-1 Proteins 0.000 description 1
- 108700020986 Wnt-2 Proteins 0.000 description 1
- 102000052556 Wnt-2 Human genes 0.000 description 1
- 102000052549 Wnt-3 Human genes 0.000 description 1
- 108700020985 Wnt-3 Proteins 0.000 description 1
- 102000052548 Wnt-4 Human genes 0.000 description 1
- 108700020984 Wnt-4 Proteins 0.000 description 1
- 102000043366 Wnt-5a Human genes 0.000 description 1
- 108700020483 Wnt-5a Proteins 0.000 description 1
- QAPAJIZPZGWAND-UHFFFAOYSA-N XMD8-92 Chemical compound C=1C=C(NC=2N=C3N(C)C4=CC=CC=C4C(=O)N(C)C3=CN=2)C(OCC)=CC=1N1CCC(O)CC1 QAPAJIZPZGWAND-UHFFFAOYSA-N 0.000 description 1
- 101000770767 Xenopus laevis Protein Wnt-2b-A Proteins 0.000 description 1
- 101100485097 Xenopus laevis wnt11b gene Proteins 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- MXDSJQHFFDGFDK-CYBMUJFWSA-N [4-(3-chloro-2-fluoroanilino)-7-methoxyquinazolin-6-yl] (2r)-2,4-dimethylpiperazine-1-carboxylate Chemical compound C=12C=C(OC(=O)N3[C@@H](CN(C)CC3)C)C(OC)=CC2=NC=NC=1NC1=CC=CC(Cl)=C1F MXDSJQHFFDGFDK-CYBMUJFWSA-N 0.000 description 1
- MBBYVENWMIWJMC-UHFFFAOYSA-N [H]N1C=C(C)N=C1C1=CN=C(CCCNC2=NC=C(C#N)C=C2)N=C1C1=CC=C(C)C=C1Cl Chemical compound [H]N1C=C(C)N=C1C1=CN=C(CCCNC2=NC=C(C#N)C=C2)N=C1C1=CC=C(C)C=C1Cl MBBYVENWMIWJMC-UHFFFAOYSA-N 0.000 description 1
- KOGIVAWHVAXZCL-UHFFFAOYSA-N [H]N1C=C(C)N=C1C1=CN=C(CCCNC2=NC=C(C#N)C=C2)N=C1C1=CC=C(Cl)C=C1Cl Chemical compound [H]N1C=C(C)N=C1C1=CN=C(CCCNC2=NC=C(C#N)C=C2)N=C1C1=CC=C(Cl)C=C1Cl KOGIVAWHVAXZCL-UHFFFAOYSA-N 0.000 description 1
- 229950008805 abexinostat Drugs 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- ODHCTXKNWHHXJC-UHFFFAOYSA-N acide pyroglutamique Natural products OC(=O)C1CCC(=O)N1 ODHCTXKNWHHXJC-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 239000001361 adipic acid Substances 0.000 description 1
- 235000011037 adipic acid Nutrition 0.000 description 1
- 229960000250 adipic acid Drugs 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- USNRYVNRPYXCSP-JUGPPOIOSA-N afatinib dimaleate Chemical compound OC(=O)\C=C/C(O)=O.OC(=O)\C=C/C(O)=O.N1=CN=C2C=C(O[C@@H]3COCC3)C(NC(=O)/C=C/CN(C)C)=CC2=C1NC1=CC=C(F)C(Cl)=C1 USNRYVNRPYXCSP-JUGPPOIOSA-N 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 229940087168 alpha tocopherol Drugs 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229960004909 aminosalicylic acid Drugs 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- JFCQEDHGNNZCLN-UHFFFAOYSA-N anhydrous glutaric acid Natural products OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 229940082992 antihypertensives mao inhibitors Drugs 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229960003121 arginine Drugs 0.000 description 1
- 235000010385 ascorbyl palmitate Nutrition 0.000 description 1
- 229950000847 ascrinvacumab Drugs 0.000 description 1
- WYQVAPGDARQUBT-XCWYDTOWSA-N asiaticoside Natural products O=C(O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@H](O)[C@H](O)[C@H](O[C@H]3[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O3)[C@@H](CO)O2)O1)[C@@]12[C@@H]([C@@H](C)[C@H](C)CC1)C=1[C@](C)([C@@]3(C)[C@@H]([C@@]4(C)[C@H]([C@@](CO)(C)[C@@H](O)[C@H](O)C4)CC3)CC=1)CC2 WYQVAPGDARQUBT-XCWYDTOWSA-N 0.000 description 1
- 229940022757 asiaticoside Drugs 0.000 description 1
- QCYLIQBVLZBPNK-UHFFFAOYSA-N asiaticoside A Natural products O1C(C(=O)C(C)C)=CC(C)C(C2(C(OC(C)=O)CC34C5)C)C1CC2(C)C3CCC(C1(C)C)C45CCC1OC1OCC(O)C(O)C1O QCYLIQBVLZBPNK-UHFFFAOYSA-N 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 229960005261 aspartic acid Drugs 0.000 description 1
- 239000012911 assay medium Substances 0.000 description 1
- 239000007640 basal medium Substances 0.000 description 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
- NCNRHFGMJRPRSK-MDZDMXLPSA-N belinostat Chemical compound ONC(=O)\C=C\C1=CC=CC(S(=O)(=O)NC=2C=CC=CC=2)=C1 NCNRHFGMJRPRSK-MDZDMXLPSA-N 0.000 description 1
- 229960003094 belinostat Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- UPABQMWFWCMOFV-UHFFFAOYSA-N benethamine Chemical compound C=1C=CC=CC=1CNCCC1=CC=CC=C1 UPABQMWFWCMOFV-UHFFFAOYSA-N 0.000 description 1
- 235000012216 bentonite Nutrition 0.000 description 1
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
- KXDAEFPNCMNJSK-UHFFFAOYSA-N benzene carboxamide Natural products NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229960004365 benzoic acid Drugs 0.000 description 1
- 102000012740 beta Adrenergic Receptors Human genes 0.000 description 1
- 108010079452 beta Adrenergic Receptors Proteins 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 108010079292 betaglycan Proteins 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 229960004933 bifemelane Drugs 0.000 description 1
- 230000008236 biological pathway Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- MXJWRABVEGLYDG-UHFFFAOYSA-N bufexamac Chemical compound CCCCOC1=CC=C(CC(=O)NO)C=C1 MXJWRABVEGLYDG-UHFFFAOYSA-N 0.000 description 1
- 229960000962 bufexamac Drugs 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
- HFCFMRYTXDINDK-WNQIDUERSA-N cabozantinib malate Chemical compound OC(=O)[C@@H](O)CC(O)=O.C=12C=C(OC)C(OC)=CC2=NC=CC=1OC(C=C1)=CC=C1NC(=O)C1(C(=O)NC=2C=CC(F)=CC=2)CC1 HFCFMRYTXDINDK-WNQIDUERSA-N 0.000 description 1
- 235000004883 caffeic acid Nutrition 0.000 description 1
- 229940074360 caffeic acid Drugs 0.000 description 1
- MAEVSPLUELJOMM-UHFFFAOYSA-N caffeic acid methyl ester Natural products COC(=O)C=CC1=CC=C(O)C=C1O MAEVSPLUELJOMM-UHFFFAOYSA-N 0.000 description 1
- LSPHULWDVZXLIL-QUBYGPBYSA-N camphoric acid Chemical compound CC1(C)[C@H](C(O)=O)CC[C@]1(C)C(O)=O LSPHULWDVZXLIL-QUBYGPBYSA-N 0.000 description 1
- KHAVLLBUVKBTBG-UHFFFAOYSA-N caproleic acid Natural products OC(=O)CCCCCCCC=C KHAVLLBUVKBTBG-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- SWTUPSNBTSPBIH-UHFFFAOYSA-N cardionogen-1 Chemical compound C1CCCCC1C(S1)=NN2C1=NN=C2C1=CC=CO1 SWTUPSNBTSPBIH-UHFFFAOYSA-N 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000010609 cell counting kit-8 assay Methods 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 230000033026 cell fate determination Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- XRZYELWZLNAXGE-KPKJPENVSA-N chembl539947 Chemical compound CC(C)(C)C1=CC(\C=C(/C#N)C(N)=S)=CC(C(C)(C)C)=C1O XRZYELWZLNAXGE-KPKJPENVSA-N 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 229940074393 chlorogenic acid Drugs 0.000 description 1
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 description 1
- 235000001368 chlorogenic acid Nutrition 0.000 description 1
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 description 1
- QAIPRVGONGVQAS-UHFFFAOYSA-N cis-caffeic acid Natural products OC(=O)C=CC1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-UHFFFAOYSA-N 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- RESIMIUSNACMNW-BXRWSSRYSA-N cobimetinib fumarate Chemical compound OC(=O)\C=C\C(O)=O.C1C(O)([C@H]2NCCCC2)CN1C(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1F.C1C(O)([C@H]2NCCCC2)CN1C(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1F RESIMIUSNACMNW-BXRWSSRYSA-N 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- JNGZXGGOCLZBFB-IVCQMTBJSA-N compound E Chemical compound N([C@@H](C)C(=O)N[C@@H]1C(N(C)C2=CC=CC=C2C(C=2C=CC=CC=2)=N1)=O)C(=O)CC1=CC(F)=CC(F)=C1 JNGZXGGOCLZBFB-IVCQMTBJSA-N 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 210000001100 crypt cell Anatomy 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 239000000625 cyclamic acid and its Na and Ca salt Substances 0.000 description 1
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 1
- 229960001305 cysteine hydrochloride Drugs 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- LVXJQMNHJWSHET-AATRIKPKSA-N dacomitinib Chemical compound C=12C=C(NC(=O)\C=C\CN3CCCCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 LVXJQMNHJWSHET-AATRIKPKSA-N 0.000 description 1
- 229960002887 deanol Drugs 0.000 description 1
- 229960003603 decitabine Drugs 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000017858 demethylation Effects 0.000 description 1
- 238000010520 demethylation reaction Methods 0.000 description 1
- DLVJMFOLJOOWFS-INMLLLKOSA-N depudecin Chemical compound C[C@@H](O)[C@@H]1O[C@H]1\C=C\[C@H]1[C@H]([C@H](O)C=C)O1 DLVJMFOLJOOWFS-INMLLLKOSA-N 0.000 description 1
- 229960005215 dichloroacetic acid Drugs 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 229960005135 eicosapentaenoic acid Drugs 0.000 description 1
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 description 1
- 235000020673 eicosapentaenoic acid Nutrition 0.000 description 1
- 210000002308 embryonic cell Anatomy 0.000 description 1
- JROGBPMEKVAPEH-GXGBFOEMSA-N emetine dihydrochloride Chemical compound Cl.Cl.N1CCC2=CC(OC)=C(OC)C=C2[C@H]1C[C@H]1C[C@H]2C3=CC(OC)=C(OC)C=C3CCN2C[C@@H]1CC JROGBPMEKVAPEH-GXGBFOEMSA-N 0.000 description 1
- 230000002357 endometrial effect Effects 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940095399 enema Drugs 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000002322 enterochromaffin cell Anatomy 0.000 description 1
- 229950005837 entinostat Drugs 0.000 description 1
- VFSWRBJYBQXUTE-UHFFFAOYSA-N epi-Gallocatechin 3-O-gallate Natural products Oc1ccc2C(=O)C(OC(=O)c3cc(O)c(O)c(O)c3)C(Oc2c1)c4cc(O)c(O)c(O)c4 VFSWRBJYBQXUTE-UHFFFAOYSA-N 0.000 description 1
- GTTBEUCJPZQMDZ-UHFFFAOYSA-N erlotinib hydrochloride Chemical compound [H+].[Cl-].C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 GTTBEUCJPZQMDZ-UHFFFAOYSA-N 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- AFAXGSQYZLGZPG-UHFFFAOYSA-N ethanedisulfonic acid Chemical compound OS(=O)(=O)CCS(O)(=O)=O AFAXGSQYZLGZPG-UHFFFAOYSA-N 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- LQPGVGSKBNXQDU-UHFFFAOYSA-N ethyl 3-[[2-pyridin-3-yl-6-(1,2,4,5-tetrahydro-3-benzazepin-3-yl)pyrimidin-4-yl]amino]propanoate Chemical compound N=1C(NCCC(=O)OCC)=CC(N2CCC3=CC=CC=C3CC2)=NC=1C1=CC=CN=C1 LQPGVGSKBNXQDU-UHFFFAOYSA-N 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- HTQBXNHDCUEHJF-URRANESESA-N exendin-4 Chemical compound C([C@@H](C(=O)N[C@@H](C(C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1N=CNC=1)C(C)O)C(C)O)C(C)C)C1=CC=CC=C1 HTQBXNHDCUEHJF-URRANESESA-N 0.000 description 1
- 235000011990 fisetin Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 235000019264 food flavour enhancer Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 229950004003 fresolimumab Drugs 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 239000003540 gamma secretase inhibitor Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000007897 gelcap Substances 0.000 description 1
- 229940045109 genistein Drugs 0.000 description 1
- 235000006539 genistein Nutrition 0.000 description 1
- TZBJGXHYKVUXJN-UHFFFAOYSA-N genistein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O TZBJGXHYKVUXJN-UHFFFAOYSA-N 0.000 description 1
- ZCOLJUOHXJRHDI-CMWLGVBASA-N genistein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 ZCOLJUOHXJRHDI-CMWLGVBASA-N 0.000 description 1
- 229960005219 gentisic acid Drugs 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- GNYCTMYOHGBSBI-UHFFFAOYSA-N helminthsporium carbonum toxin Natural products N1C(=O)C(C)NC(=O)C(C)NC(=O)C2CCCN2C(=O)C1CCCCCC(=O)C1CO1 GNYCTMYOHGBSBI-UHFFFAOYSA-N 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 229960002885 histidine Drugs 0.000 description 1
- 238000002868 homogeneous time resolved fluorescence Methods 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- XGIHQYAWBCFNPY-AZOCGYLKSA-N hydrabamine Chemical compound C([C@@H]12)CC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC[C@@]1(C)CNCCNC[C@@]1(C)[C@@H]2CCC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC1 XGIHQYAWBCFNPY-AZOCGYLKSA-N 0.000 description 1
- 229960002474 hydralazine Drugs 0.000 description 1
- QQLKULDARVNMAL-UHFFFAOYSA-N icotinib Chemical compound C#CC1=CC=CC(NC=2C3=CC=4OCCOCCOCCOC=4C=C3N=CN=2)=C1 QQLKULDARVNMAL-UHFFFAOYSA-N 0.000 description 1
- 229950007440 icotinib Drugs 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- MGXWVYUBJRZYPE-YUGYIWNOSA-N incretin Chemical class C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)[C@@H](C)O)[C@@H](C)CC)C1=CC=C(O)C=C1 MGXWVYUBJRZYPE-YUGYIWNOSA-N 0.000 description 1
- 239000000859 incretin Substances 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 101150032953 ins1 gene Proteins 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 229940084651 iressa Drugs 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 1
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 229940099563 lactobionic acid Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- IQPNAANSBPBGFQ-UHFFFAOYSA-N luteolin Chemical compound C=1C(O)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(O)C(O)=C1 IQPNAANSBPBGFQ-UHFFFAOYSA-N 0.000 description 1
- LRDGATPGVJTWLJ-UHFFFAOYSA-N luteolin Natural products OC1=CC(O)=CC(C=2OC3=CC(O)=CC(O)=C3C(=O)C=2)=C1 LRDGATPGVJTWLJ-UHFFFAOYSA-N 0.000 description 1
- 235000009498 luteolin Nutrition 0.000 description 1
- 229960003646 lysine Drugs 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000012577 media supplement Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229950005555 metelimumab Drugs 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- JDBJJCWRXSVHOQ-UTONKHPSSA-N methanesulfonic acid;(1r)-n-prop-2-ynyl-2,3-dihydro-1h-inden-1-amine Chemical compound CS(O)(=O)=O.C1=CC=C2[C@H](NCC#C)CCC2=C1 JDBJJCWRXSVHOQ-UTONKHPSSA-N 0.000 description 1
- ZFLWDHHVRRZMEI-UHFFFAOYSA-N methyl 2,6-dimethyl-5-nitro-4-[2-(trifluoromethyl)phenyl]-1,4-dihydropyridine-3-carboxylate Chemical compound COC(=O)C1=C(C)NC(C)=C([N+]([O-])=O)C1C1=CC=CC=C1C(F)(F)F ZFLWDHHVRRZMEI-UHFFFAOYSA-N 0.000 description 1
- BQCNSTFWSKOWMA-UHFFFAOYSA-N methyl grevillate Natural products COC(=O)C=CC1=CC(O)=CC=C1O BQCNSTFWSKOWMA-UHFFFAOYSA-N 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- NWFYESYCEQICQP-UHFFFAOYSA-N methylmatairesinol Natural products C1=C(OC)C(OC)=CC=C1CC1C(=O)OCC1CC1=CC=C(O)C(OC)=C1 NWFYESYCEQICQP-UHFFFAOYSA-N 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 238000010208 microarray analysis Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- YHXISWVBGDMDLQ-UHFFFAOYSA-N moclobemide Chemical compound C1=CC(Cl)=CC=C1C(=O)NCCN1CCOCC1 YHXISWVBGDMDLQ-UHFFFAOYSA-N 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000002899 monoamine oxidase inhibitor Substances 0.000 description 1
- VYGYNVZNSSTDLJ-HKCOAVLJSA-N monorden Natural products CC1CC2OC2C=C/C=C/C(=O)CC3C(C(=CC(=C3Cl)O)O)C(=O)O1 VYGYNVZNSSTDLJ-HKCOAVLJSA-N 0.000 description 1
- 230000000921 morphogenic effect Effects 0.000 description 1
- 108091007486 mouse chromogranin A Proteins 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- BYVHZKAHBXINPL-UHFFFAOYSA-N n'-hydroxy-n-(4-iodophenyl)octanediamide Chemical compound ONC(=O)CCCCCCC(=O)NC1=CC=C(I)C=C1 BYVHZKAHBXINPL-UHFFFAOYSA-N 0.000 description 1
- ZNNWCQCQUKAMGL-UHFFFAOYSA-N n-(3-chloro-4-fluorophenyl)-6-[4-(diethylaminomethyl)piperidin-1-yl]pyrimido[5,4-d]pyrimidin-4-amine;dihydrochloride Chemical compound Cl.Cl.C1CC(CN(CC)CC)CCN1C1=NC=C(N=CN=C2NC=3C=C(Cl)C(F)=CC=3)C2=N1 ZNNWCQCQUKAMGL-UHFFFAOYSA-N 0.000 description 1
- LXFKEVQQSKQXPR-UHFFFAOYSA-N n-(6-chloro-1,3-benzothiazol-2-yl)-3-(3,4-dimethoxyphenyl)propanamide Chemical compound C1=C(OC)C(OC)=CC=C1CCC(=O)NC1=NC2=CC=C(Cl)C=C2S1 LXFKEVQQSKQXPR-UHFFFAOYSA-N 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- BASFYRLYJAZPPL-UONOGXRCSA-N n-[(1r,2s)-2-phenylcyclopropyl]piperidin-4-amine Chemical compound N([C@@H]1C[C@H]1C=1C=CC=CC=1)C1CCNCC1 BASFYRLYJAZPPL-UONOGXRCSA-N 0.000 description 1
- ZYQXEVJIFYIBHZ-UHFFFAOYSA-N n-[2-[4-[3-chloro-4-[3-(trifluoromethyl)phenoxy]anilino]pyrrolo[3,2-d]pyrimidin-5-yl]ethyl]-3-hydroxy-3-methylbutanamide Chemical compound C=12N(CCNC(=O)CC(C)(O)C)C=CC2=NC=NC=1NC(C=C1Cl)=CC=C1OC1=CC=CC(C(F)(F)F)=C1 ZYQXEVJIFYIBHZ-UHFFFAOYSA-N 0.000 description 1
- FDMQDKQUTRLUBU-UHFFFAOYSA-N n-[3-[2-[4-(4-methylpiperazin-1-yl)anilino]thieno[3,2-d]pyrimidin-4-yl]oxyphenyl]prop-2-enamide Chemical compound C1CN(C)CCN1C(C=C1)=CC=C1NC1=NC(OC=2C=C(NC(=O)C=C)C=CC=2)=C(SC=C2)C2=N1 FDMQDKQUTRLUBU-UHFFFAOYSA-N 0.000 description 1
- KIISCIGBPUVZBF-UHFFFAOYSA-N n-[3-[5-chloro-2-[4-(4-methylpiperazin-1-yl)anilino]pyrimidin-4-yl]sulfanylphenyl]prop-2-enamide Chemical compound C1CN(C)CCN1C(C=C1)=CC=C1NC1=NC=C(Cl)C(SC=2C=C(NC(=O)C=C)C=CC=2)=N1 KIISCIGBPUVZBF-UHFFFAOYSA-N 0.000 description 1
- NBZFRTJWEIHFPF-UHFFFAOYSA-N n-[3-[7-[(2,5-dimethylpyrazol-3-yl)amino]-1-methyl-2-oxo-4h-pyrimido[4,5-d]pyrimidin-3-yl]-4-methylphenyl]-3-(trifluoromethyl)benzamide Chemical compound N1=C2N(C)C(=O)N(C=3C(=CC=C(NC(=O)C=4C=C(C=CC=4)C(F)(F)F)C=3)C)CC2=CN=C1NC1=CC(C)=NN1C NBZFRTJWEIHFPF-UHFFFAOYSA-N 0.000 description 1
- HUFOZJXAKZVRNJ-UHFFFAOYSA-N n-[3-[[2-[4-(4-acetylpiperazin-1-yl)-2-methoxyanilino]-5-(trifluoromethyl)pyrimidin-4-yl]amino]phenyl]prop-2-enamide Chemical compound COC1=CC(N2CCN(CC2)C(C)=O)=CC=C1NC(N=1)=NC=C(C(F)(F)F)C=1NC1=CC=CC(NC(=O)C=C)=C1 HUFOZJXAKZVRNJ-UHFFFAOYSA-N 0.000 description 1
- BFSRTTWIPACGMI-UHFFFAOYSA-N n-[3-[[2-[4-[[1-(2-fluoroethyl)azetidin-3-yl]amino]-2-methoxyanilino]-5-(trifluoromethyl)pyrimidin-4-yl]amino]phenyl]prop-2-enamide Chemical compound C=1C=C(NC=2N=C(NC=3C=C(NC(=O)C=C)C=CC=3)C(=CN=2)C(F)(F)F)C(OC)=CC=1NC1CN(CCF)C1 BFSRTTWIPACGMI-UHFFFAOYSA-N 0.000 description 1
- WIMITXDBYLKRKB-UHFFFAOYSA-N n-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[2-[(2-methylsulfonylethylamino)methyl]-1,3-thiazol-4-yl]quinazolin-4-amine;dihydrochloride Chemical compound Cl.Cl.S1C(CNCCS(=O)(=O)C)=NC(C=2C=C3C(NC=4C=C(Cl)C(OCC=5C=C(F)C=CC=5)=CC=4)=NC=NC3=CC=2)=C1 WIMITXDBYLKRKB-UHFFFAOYSA-N 0.000 description 1
- GTWJVFFZCKODEV-UHFFFAOYSA-N n-[4-(3-chloro-4-fluoroanilino)-7-[3-methyl-3-(4-methylpiperazin-1-yl)but-1-ynyl]quinazolin-6-yl]prop-2-enamide;4-methylbenzenesulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1.CC1=CC=C(S(O)(=O)=O)C=C1.C1CN(C)CCN1C(C)(C)C#CC1=CC2=NC=NC(NC=3C=C(Cl)C(F)=CC=3)=C2C=C1NC(=O)C=C GTWJVFFZCKODEV-UHFFFAOYSA-N 0.000 description 1
- TUYDDIWQXWTNSW-UHFFFAOYSA-N n-[4-(3-chloro-4-fluoroanilino)-7-methoxyquinazolin-6-yl]prop-2-enamide Chemical compound C=12C=C(NC(=O)C=C)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 TUYDDIWQXWTNSW-UHFFFAOYSA-N 0.000 description 1
- DLPSDPPZXRJQOY-UHFFFAOYSA-N n-[4-(3-chloro-4-fluoroanilino)pyrido[3,4-d]pyrimidin-6-yl]but-2-ynamide Chemical compound N1=CN=C2C=NC(NC(=O)C#CC)=CC2=C1NC1=CC=C(F)C(Cl)=C1 DLPSDPPZXRJQOY-UHFFFAOYSA-N 0.000 description 1
- VOPDXHFYDJAYNS-UHFFFAOYSA-N n-[6-(2-aminoanilino)-6-oxohexyl]-4-methylbenzamide Chemical compound C1=CC(C)=CC=C1C(=O)NCCCCCC(=O)NC1=CC=CC=C1N VOPDXHFYDJAYNS-UHFFFAOYSA-N 0.000 description 1
- VRYZCEONIWEUAV-UHFFFAOYSA-N n-[6-(hydroxyamino)-6-oxohexoxy]-3,5-dimethylbenzamide Chemical compound CC1=CC(C)=CC(C(=O)NOCCCCCC(=O)NO)=C1 VRYZCEONIWEUAV-UHFFFAOYSA-N 0.000 description 1
- HORXBWNTEDOVKN-UHFFFAOYSA-N n-[[4-(4-phenyl-1,3-thiazol-2-yl)oxan-4-yl]methyl]-3-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]benzamide Chemical compound O1C(C(F)(F)F)=NC(C=2C=C(C=CC=2)C(=O)NCC2(CCOCC2)C=2SC=C(N=2)C=2C=CC=CC=2)=N1 HORXBWNTEDOVKN-UHFFFAOYSA-N 0.000 description 1
- LJTSJTWIMOGKRJ-UHFFFAOYSA-N n-hydroxy-4-[(2-methyl-3,4-dihydro-1h-pyrido[4,3-b]indol-5-yl)methyl]benzamide;hydrochloride Chemical compound Cl.C1N(C)CCC2=C1C1=CC=CC=C1N2CC1=CC=C(C(=O)NO)C=C1 LJTSJTWIMOGKRJ-UHFFFAOYSA-N 0.000 description 1
- CCBCHURBDSNSTJ-UHFFFAOYSA-N n-hydroxybutanamide Chemical compound CCCC(=O)NO CCBCHURBDSNSTJ-UHFFFAOYSA-N 0.000 description 1
- JRZGPWOEHDOVMC-UHFFFAOYSA-N n-hydroxynaphthalene-1-carboxamide Chemical compound C1=CC=C2C(C(=O)NO)=CC=CC2=C1 JRZGPWOEHDOVMC-UHFFFAOYSA-N 0.000 description 1
- ZCJHPTKRISJQTN-JGVFFNPUSA-N nanaomycin A Chemical compound O=C1C2=C(O)C=CC=C2C(=O)C2=C1[C@H](C)O[C@@H](CC(O)=O)C2 ZCJHPTKRISJQTN-JGVFFNPUSA-N 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
- 229950008835 neratinib Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 229960002446 octanoic acid Drugs 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 229960002969 oleic acid Drugs 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 229960005010 orotic acid Drugs 0.000 description 1
- DUYJMQONPNNFPI-UHFFFAOYSA-N osimertinib Chemical compound COC1=CC(N(C)CCN(C)C)=C(NC(=O)C=C)C=C1NC1=NC=CC(C=2C3=CC=CC=C3N(C)C=2)=N1 DUYJMQONPNNFPI-UHFFFAOYSA-N 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 229940116315 oxalic acid Drugs 0.000 description 1
- 229940098695 palmitic acid Drugs 0.000 description 1
- WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 229960001779 pargyline Drugs 0.000 description 1
- KTEXNACQROZXEV-PVLRGYAZSA-N parthenolide Chemical compound C1CC(/C)=C/CC[C@@]2(C)O[C@@H]2[C@H]2OC(=O)C(=C)[C@@H]21 KTEXNACQROZXEV-PVLRGYAZSA-N 0.000 description 1
- 229940069510 parthenolide Drugs 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- WVUNYSQLFKLYNI-AATRIKPKSA-N pelitinib Chemical compound C=12C=C(NC(=O)\C=C\CN(C)C)C(OCC)=CC2=NC=C(C#N)C=1NC1=CC=C(F)C(Cl)=C1 WVUNYSQLFKLYNI-AATRIKPKSA-N 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 235000019371 penicillin G benzathine Nutrition 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 229950009215 phenylbutanoic acid Drugs 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000006461 physiological response Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229950002592 pimasertib Drugs 0.000 description 1
- 229950002220 pirlindole Drugs 0.000 description 1
- PVUYTBQAVAYLDE-UHFFFAOYSA-N pirlindole mesylate Chemical compound CS(O)(=O)=O.C1CNC2CCCC3=C2N1C1=CC=C(C)C=C13 PVUYTBQAVAYLDE-UHFFFAOYSA-N 0.000 description 1
- 210000004910 pleural fluid Anatomy 0.000 description 1
- 229960000502 poloxamer Drugs 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- PHXJVRSECIGDHY-UHFFFAOYSA-N ponatinib Chemical compound C1CN(C)CCN1CC(C(=C1)C(F)(F)F)=CC=C1NC(=O)C1=CC=C(C)C(C#CC=2N3N=CC=CC3=NC=2)=C1 PHXJVRSECIGDHY-UHFFFAOYSA-N 0.000 description 1
- 230000023603 positive regulation of transcription initiation, DNA-dependent Effects 0.000 description 1
- WSHYKIAQCMIPTB-UHFFFAOYSA-M potassium;2-oxo-3-(3-oxo-1-phenylbutyl)chromen-4-olate Chemical compound [K+].[O-]C=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 WSHYKIAQCMIPTB-UHFFFAOYSA-M 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 235000013594 poultry meat Nutrition 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- REQCZEXYDRLIBE-UHFFFAOYSA-N procainamide Chemical compound CCN(CC)CCNC(=O)C1=CC=C(N)C=C1 REQCZEXYDRLIBE-UHFFFAOYSA-N 0.000 description 1
- 229960000244 procainamide Drugs 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- QLNJFJADRCOGBJ-UHFFFAOYSA-N propionamide Chemical compound CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 239000000473 propyl gallate Substances 0.000 description 1
- 235000010388 propyl gallate Nutrition 0.000 description 1
- 229940075579 propyl gallate Drugs 0.000 description 1
- 239000011253 protective coating Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- LMAFSGDNHVBIHU-UHFFFAOYSA-N psammaplin A Natural products C=1C=C(O)C(Br)=CC=1CC(=NO)C(=O)NCCSSCCNC(=O)C(=NO)CC1=CC=C(O)C(Br)=C1 LMAFSGDNHVBIHU-UHFFFAOYSA-N 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- BWESROVQGZSBRX-UHFFFAOYSA-N pyrido[3,2-d]pyrimidine Chemical compound C1=NC=NC2=CC=CN=C21 BWESROVQGZSBRX-UHFFFAOYSA-N 0.000 description 1
- 150000003233 pyrroles Chemical class 0.000 description 1
- GZTPJDLYPMPRDF-UHFFFAOYSA-N pyrrolo[3,2-c]pyrazole Chemical compound N1=NC2=CC=NC2=C1 GZTPJDLYPMPRDF-UHFFFAOYSA-N 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 150000003246 quinazolines Chemical class 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- AECPBJMOGBFQDN-YMYQVXQQSA-N radicicol Chemical compound C1CCCC(=O)C[C@H]2[C@H](Cl)C(=O)CC(=O)[C@H]2C(=O)O[C@H](C)C[C@H]2O[C@@H]21 AECPBJMOGBFQDN-YMYQVXQQSA-N 0.000 description 1
- 229930192524 radicicol Natural products 0.000 description 1
- 229960001956 rasagiline mesylate Drugs 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 108091006082 receptor inhibitors Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 229950008933 refametinib Drugs 0.000 description 1
- 230000008672 reprogramming Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- DQZMLPMCOMRJOR-MOVGKWKRSA-N s-[(6s)-7-(1-adamantylamino)-6-[(2-methylpropan-2-yl)oxycarbonylamino]-7-oxoheptyl] 2-methylpropanethioate Chemical compound C1C(C2)CC3CC2CC1(NC(=O)[C@@H](NC(=O)OC(C)(C)C)CCCCCSC(=O)C(C)C)C3 DQZMLPMCOMRJOR-MOVGKWKRSA-N 0.000 description 1
- KXWBUKMWZKTHCV-UHFFFAOYSA-N s-[2-[6-[[4-[3-(dimethylamino)propoxy]phenyl]sulfonylamino]pyridin-3-yl]-2-oxoethyl] ethanethioate Chemical compound C1=CC(OCCCN(C)C)=CC=C1S(=O)(=O)NC1=CC=C(C(=O)CSC(C)=O)C=N1 KXWBUKMWZKTHCV-UHFFFAOYSA-N 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 229950002652 safinamide Drugs 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- DFJSJLGUIXFDJP-UHFFFAOYSA-N sapitinib Chemical compound C1CN(CC(=O)NC)CCC1OC(C(=CC1=NC=N2)OC)=CC1=C2NC1=CC=CC(Cl)=C1F DFJSJLGUIXFDJP-UHFFFAOYSA-N 0.000 description 1
- 229940116353 sebacic acid Drugs 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 229960002101 secretin Drugs 0.000 description 1
- OWMZNFCDEHGFEP-NFBCVYDUSA-N secretin human Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(N)=O)[C@@H](C)O)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)C1=CC=CC=C1 OWMZNFCDEHGFEP-NFBCVYDUSA-N 0.000 description 1
- IYETZZCWLLUHIJ-UTONKHPSSA-N selegiline hydrochloride Chemical compound [Cl-].C#CC[NH+](C)[C@H](C)CC1=CC=CC=C1 IYETZZCWLLUHIJ-UTONKHPSSA-N 0.000 description 1
- 229950010746 selumetinib Drugs 0.000 description 1
- 229950001900 semagacestat Drugs 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 230000007781 signaling event Effects 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 229940126586 small molecule drug Drugs 0.000 description 1
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
- WBHQBSYUUJJSRZ-UHFFFAOYSA-M sodium bisulfate Chemical compound [Na+].OS([O-])(=O)=O WBHQBSYUUJJSRZ-UHFFFAOYSA-M 0.000 description 1
- 229910000342 sodium bisulfate Inorganic materials 0.000 description 1
- 229940100996 sodium bisulfate Drugs 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 229940001584 sodium metabisulfite Drugs 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- VPZRWNZGLKXFOE-UHFFFAOYSA-M sodium phenylbutyrate Chemical compound [Na+].[O-]C(=O)CCCC1=CC=CC=C1 VPZRWNZGLKXFOE-UHFFFAOYSA-M 0.000 description 1
- 229960002232 sodium phenylbutyrate Drugs 0.000 description 1
- 229940001482 sodium sulfite Drugs 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- AEQFSUDEHCCHBT-UHFFFAOYSA-M sodium valproate Chemical class [Na+].CCCC(C([O-])=O)CCC AEQFSUDEHCCHBT-UHFFFAOYSA-M 0.000 description 1
- XLHBNJPXFOZFNJ-BYKQGDNKSA-M sodium;[(2r,3s,5r)-5-(2-amino-6-oxo-3h-purin-9-yl)-3-hydroxyoxolan-2-yl]methyl [(2r,3s,5r)-5-(4-amino-2-oxo-1,3,5-triazin-1-yl)-2-(hydroxymethyl)oxolan-3-yl] phosphate Chemical compound [Na+].O=C1N=C(N)N=CN1[C@@H]1O[C@H](CO)[C@@H](OP([O-])(=O)OC[C@@H]2[C@H](C[C@@H](O2)N2C3=C(C(N=C(N)N3)=O)N=C2)O)C1 XLHBNJPXFOZFNJ-BYKQGDNKSA-M 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 210000001988 somatic stem cell Anatomy 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- ISFPDBUKMJDAJH-UHFFFAOYSA-N splitomicin Chemical compound C1=CC2=CC=CC=C2C2=C1OC(=O)CC2 ISFPDBUKMJDAJH-UHFFFAOYSA-N 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 229960004274 stearic acid Drugs 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- MNQYNQBOVCBZIQ-JQOFMKNESA-A sucralfate Chemical compound O[Al](O)OS(=O)(=O)O[C@@H]1[C@@H](OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](COS(=O)(=O)O[Al](O)O)O[C@H]1O[C@@]1(COS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)O1 MNQYNQBOVCBZIQ-JQOFMKNESA-A 0.000 description 1
- 229960004291 sucralfate Drugs 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 229960005559 sulforaphane Drugs 0.000 description 1
- 235000015487 sulforaphane Nutrition 0.000 description 1
- 230000003319 supportive effect Effects 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 229950011110 tacedinaline Drugs 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229960001367 tartaric acid Drugs 0.000 description 1
- 229950001899 tasquinimod Drugs 0.000 description 1
- ONDYALNGTUAJDX-UHFFFAOYSA-N tasquinimod Chemical compound OC=1C=2C(OC)=CC=CC=2N(C)C(=O)C=1C(=O)N(C)C1=CC=C(C(F)(F)F)C=C1 ONDYALNGTUAJDX-UHFFFAOYSA-N 0.000 description 1
- MURCDOXDAHPNRQ-PJRHAEEISA-N tert-butyl n-[(2s,3r,5s)-6-[[(2s)-1-[[(2s)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-benzyl-3-hydroxy-6-oxo-1-phenylhexan-2-yl]carbamate Chemical compound C([C@@H]([C@H](O)C[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)CC=1C=CC=CC=1)NC(=O)OC(C)(C)C)C1=CC=CC=C1 MURCDOXDAHPNRQ-PJRHAEEISA-N 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- CWPNPYVNPOAMHY-UHFFFAOYSA-N tetrindole mesylate Chemical compound CS(O)(=O)=O.C1CCCCC1C1=CC=C(N2C3=C4CCCC3NCC2)C4=C1 CWPNPYVNPOAMHY-UHFFFAOYSA-N 0.000 description 1
- 108010052012 thailandepsin A Proteins 0.000 description 1
- 229960004559 theobromine Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- 239000005495 thyroid hormone Substances 0.000 description 1
- 229940036555 thyroid hormone Drugs 0.000 description 1
- 229950005284 tideglusib Drugs 0.000 description 1
- 229960003087 tioguanine Drugs 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- FNCMIJWGZNHSBF-UHFFFAOYSA-N trabedersen Chemical compound CC1=CN(C2CC(O)C(COP(=O)(S)OC3CC(OC3COP(=O)(S)OC4CC(OC4COP(=O)(S)OC5CC(OC5COP(=O)(S)OC6CC(OC6COP(=O)(S)OC7CC(OC7COP(=O)(S)OC8CC(OC8COP(=O)(S)OC9CC(OC9COP(=O)(S)OC%10CC(OC%10COP(=O)(S)OC%11CC(OC%11COP(=O)(S)OC%12CC(OC%12COP(=O)(S)OC%13CC(OC%13COP(=O)(S)OC%14CC(OC%14COP(=O)(S)OC%15CC(OC%15CO)N%16C=CC(=NC%16=O)N)n%17cnc%18C(=O)NC(=Nc%17%18)N)n%19cnc%20C(=O)NC(=Nc%19%20)N)N%21C=CC(=NC%21=O)N)n%22cnc%23c(N)ncnc%22%23)N%24C=C(C)C(=O)NC%24=O)n%25cnc%26C(=O)NC(=Nc%25%26)N)N%27C=C(C)C(=O)NC%27=O)N%28C=CC(=NC%28=O)N)N%29C=C(C)C(=O)NC%29=O)n%30cnc%31c(N)ncnc%30%31)N%32C=C(C)C(=O)NC%32=O)N%33C=C(C)C(=O)NC%33=O)O2)C(=O)NC1=O.CC%34=CN(C%35CC(OP(=O)(S)OCC%36OC(CC%36OP(=O)(S)OCC%37OC(CC%37OP(=O)(S)OCC%38OC(CC%38O)n%39cnc%40c(N)ncnc%39%40)N%41C=C(C)C(=O)NC%41=O)n%42cnc%43C(=O)NC(=Nc%42%43)N)C(COP(=O)S)O%35)C(=O)NC%34=O FNCMIJWGZNHSBF-UHFFFAOYSA-N 0.000 description 1
- 229950002824 trabedersen Drugs 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 150000003852 triazoles Chemical class 0.000 description 1
- YFTHZRPMJXBUME-UHFFFAOYSA-N tripropylamine Chemical compound CCCN(CCC)CCC YFTHZRPMJXBUME-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 229960004418 trolamine Drugs 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- GFNNBHLJANVSQV-UHFFFAOYSA-N tyrphostin AG 1478 Chemical compound C=12C=C(OC)C(OC)=CC2=NC=NC=1NC1=CC=CC(Cl)=C1 GFNNBHLJANVSQV-UHFFFAOYSA-N 0.000 description 1
- KXDONFLNGBQLTN-WUXMJOGZSA-N tyrphostin AG 825 Chemical compound COC1=CC(\C=C(/C#N)C(N)=O)=CC(CSC=2SC3=CC=CC=C3N=2)=C1O KXDONFLNGBQLTN-WUXMJOGZSA-N 0.000 description 1
- 229950008878 ulixertinib Drugs 0.000 description 1
- 229960002703 undecylenic acid Drugs 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 229950006605 varlitinib Drugs 0.000 description 1
- 235000019871 vegetable fat Nutrition 0.000 description 1
- 108700026220 vif Genes Proteins 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 235000016804 zinc Nutrition 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- 235000014692 zinc oxide Nutrition 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0613—Cells from endocrine organs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0676—Pancreatic cells
- C12N5/0678—Stem cells; Progenitor cells; Precursor cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0679—Cells of the gastro-intestinal tract
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/38—Vitamins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/60—Buffer, e.g. pH regulation, osmotic pressure
- C12N2500/62—DMSO
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/01—Modulators of cAMP or cGMP, e.g. non-hydrolysable analogs, phosphodiesterase inhibitors, cholera toxin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/065—Modulators of histone acetylation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/11—Epidermal growth factor [EGF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/119—Other fibroblast growth factors, e.g. FGF-4, FGF-8, FGF-10
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/13—Nerve growth factor [NGF]; Brain-derived neurotrophic factor [BDNF]; Cilliary neurotrophic factor [CNTF]; Glial-derived neurotrophic factor [GDNF]; Neurotrophins [NT]; Neuregulins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/15—Transforming growth factor beta (TGF-β)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/155—Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/30—Hormones
- C12N2501/335—Glucagon; Glucagon-like peptide [GLP]; Exendin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/30—Hormones
- C12N2501/38—Hormones with nuclear receptors
- C12N2501/395—Thyroid hormones
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/40—Regulators of development
- C12N2501/415—Wnt; Frizzeled
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/40—Regulators of development
- C12N2501/42—Notch; Delta; Jagged; Serrate
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/70—Enzymes
- C12N2501/71—Oxidoreductases (EC 1.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/70—Enzymes
- C12N2501/72—Transferases (EC 2.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/70—Enzymes
- C12N2501/72—Transferases (EC 2.)
- C12N2501/727—Kinases (EC 2.7.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/999—Small molecules not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/23—Gastro-intestinal tract cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
- C12N2533/90—Substrates of biological origin, e.g. extracellular matrix, decellularised tissue
Definitions
- the enteroendocrine system orchestrates how the body responds to nutrients by employing a diversity of hormones to fine-tune a wide range of physiological responses in the body, thus playing an important role in digestive and metabolic diseases such as Gastrointestinal (GI) disorders, diabetes and obesity.
- Enteroendocrine cells form the largest endocrine system in the body (Grible and Reimann, 2015). EECs are individually dispersed along the crypt-villus axis throughout the intestinal epithelial but only exist in a small percentage ( ⁇ 1%) in vivo (Gunawardene et al., 2011).
- a key function of EECs is to sense luminal contents, particularly nutrients, and to respond by the secretion of a diversity of hormones (e.g.
- GLP-1 which modulate food intake, energy homeostasis and glucose tolerance
- GLP-2 which modulate glucose tolerance
- GLP-1, PYY and GLP-2 secreting hormones
- TLR Toll-like receptors
- EECs may directly orchestrate immune cell function through alteration in number and hormone secretion during inflammation (Worthington, 2015).
- EECs are also believed to play a critical role in metabolic diseases (e.g. diabetes and obesity), and gastrointestinal pathologies such as irritable Bowel syndrome, infectious enteritis and inflammatory bowel disease (Moran, 2008 and Manocha and Kahn, 2012). Thus, there is great interest in EECs for the exploration and development of disease interventions.
- metabolic diseases e.g. diabetes and obesity
- gastrointestinal pathologies such as irritable Bowel syndrome, infectious enteritis and inflammatory bowel disease (Moran, 2008 and Manocha and Kahn, 2012).
- aspects of the disclosure include obtaining a population of enteroendocrine cells (EECs) from a mammalian post-natal cell population, such as a post-natal stem cell population, by treating the population with a plurality of small molecules that upregulate ChgA and promote differentiation of the cells to form the enteroendocrine cells.
- the upregulation of ChgA is such that the fraction of cells expressing CGA in the obtained cell population, as measured by a ChgA Immunostaining Assay, is at least about 1.5%.
- Small molecules that can be used to differentiate the post-natal stem cells into the enteroendocrine cells can include at least one of a Wnt activator, a Notch inhibitor, a Wnt inhibitor, a MEK/ERK inhibitor, a growth factor, a HDAC inhibitor, a Histone Methylation Inhibitor, a Tgf- ⁇ inhibitor, and a NeuroD1 activator.
- aspects of the disclosure also include a method for increasing the insulin expression of a population of mammalian cells by treating the population with a plurality of small molecules that induce the cells to increase the insulin expression.
- the insulin expression level may be increased in the cell population such that, in an Insulin Activity Assay using an Insulin-GFP reporter, the fraction of cells having the Insulin GFP reporter activated is at least about 1%.
- the mammalian cells that can be treated to increase the insulin expression can include post-natal cells or enteroendocrine cells, such as post-natal stem cells, post-natal multipotent progeny cells, and enteroendocrine cells.
- Small molecules that can be used for the treatment to increase the expression of insulin in the cells can include a DNA methylation inhibitor, a Tgf- ⁇ inhibitor, and a NeuroD1 activator.
- compositions for treating disease states with the EECs and/or insulin producing cells described herein are also included according to an aspect of the disclosure. Also, populations of cells corresponding to the obtained EECS and/or insulin producing cells are also included according to an aspect of the disclosure, as are kits containing the small molecules for use in preparing the EEC and/or insulin producing cells.
- FIG. 1 shows an increase in differentiation of enteroendocrine cells (EEC) from ISCs using a Notch inhibitor.
- FIG. 2 shows mRNA expression of ChgA in cultured intestinal stem cells.
- FIG. 3 shows a 96-well screening platform for small molecules that increase EEC differentiation.
- FIG. 4 shows positive hits from small molecules screening results.
- FIG. 5 shows validation of the positive hits using small molecules and intestinal stem cells differentiated under END conditions.
- FIG. 6 shows MAPK/ERK or EGFR inhibitors specifically increase EEC differentiation.
- FIG. 7 shows small molecules Gefitinib (Ge), AS703026 (As) or PD0325901 (Pd) decrease Ngn3 expression during EEC differentiation, and that R-Spondin 1 promotes Ngn3 expression.
- FIG. 8 shows an optimized differentiation protocol
- FIG. 9 shows Ngn3 expression at 24 h during EEC differentiation.
- FIG. 10 shows expression of key markers of EEC during differentiation at day 3.
- FIG. 11 shows a time course study of key genes during EEC differentiation.
- FIG. 12 shows a 2-step protocol with increased EEC marker ChgA expression after 5 days differentiation.
- FIG. 13 shows a 2-step protocol with increased EEC differentiation by staining EEC marker ChgA following 5 days differentiation. Scale bar: 50 ⁇ m.
- FIG. 14 shows improvement of the differentiation protocol by additional small molecules.
- FIG. 15 shows Tubastatin A (Tu) increases EEC differentiation when added in Step 1 of the differentiation protocol.
- FIG. 16 shows Tranylcypromine increased EEC differentiation when added at both steps in differentiation.
- FIG. 17 shows that removal of EGF further increased differentiation of EEC.
- FIG. 18 shows an improved differentiation protocol.
- FIG. 19 shows highly efficient EEC differentiation from ISC. Scale bars: 20 ⁇ m.
- FIG. 20 shows functional L cells (GLP-1) generated from ISC.
- FIG. 21 shows additional factors, including Wnt-059 and ISX-9 and their combination, increase EEC differentiation.
- FIG. 22 shows expression of functional EEC markers under multiple conditions.
- FIG. 23 shows a differentiation protocol for EEC differentiation from ISC.
- FIG. 24 shows the combination of 5-Aza (5), 616452 (6), and Wnt-059 (C) induce Insulin-GFP expression in differentiated intestinal stem cells at day 5.
- FIG. 25 shows a dose response of 5-Aza in inducing insulin-GFP expression at day 5.
- FIG. 26 shows a dose response of 616452 in inducing insulin-GFP expression at day 5.
- FIG. 27 shows that ISX-9 (I) further increased insulin-GFP expression after 5 days in culture.
- FIG. 28 shows a dose response of ISX-9 in inducing insulin-GFP expression at day 5.
- FIG. 29 shows a FACS analysis of Insulin-GFP expression of cells in multiple conditions after 5 days in culture.
- FIG. 30 shows GFP and brightfield of cells treated without or with drugs at day 7.
- FIG. 31 shows gene expression data.
- FIG. 32 shows treatment of cells with low (2 mM) and high (20 mM) concentration of glucose induce different levels of insulin release.
- FIG. 33 shows a flow diagram of a differentiation protocol.
- FIG. 34 shows a model of in vivo EEC differentiation controlled by Wnt and Notch pathways.
- FIG. 35 shows that a combination of Notch and EGFR/MEK/ERK inhibition and Wnt inactivation (by R-Spondin1 withdraw) induces specification of ISCs towards EEC direction as determined by immunostaining against ChgA.
- FIG. 36 shows that removing EGF and/or Noggin from the combination induced higher level ChgA expression, while adding the Wnt pathway inhibitor IWP 2 (or I) or GSK3 ⁇ inhibitor CHIR99021 (or C) did not further increase differentiation towards EEC.
- FIG. 37 shows the morphology of cell colonies in multiple differentiation conditions.
- FIG. 38 shows the morphology of cell colonies in multiple differentiation conditions. Note the prominent lumen of colonies with dead cells in conditions of Notch, MEK inhibition and Wnt inactivation (D.Pd condition) as well as Notch/MEK/Wnt inhibition (D.Pd.C59 condition). While 2-step differentiation condition (ENRD-END.Pd) induced less cell death.
- FIGS. 39A-39E show that additional small molecules increase EEC differentiation.
- FIG. 39A mRNA expression of Gip, Gcg, Cck for cells differentiated in multiple conditions, with or without the addition of Tubastatin A (Tu) in step 1.
- FIG. 39B mRNA expression of Gip, Gcg and Cck for cells differentiation in multiple conditions with or without Tranylcypromine (Tc) added in Step 1, Step 2 or both steps.
- FIG. 39C Dose dependent induction of EEC markers (ChgA, Gcg, Gip, Tph1) for Tranylcypromine.
- FIG. 39D mRNA expression of multiple EEC markers (Gip, Gcg, Cck) for cells differentiated in multiple conditions.
- FIG. 39E mRNA expression of Lyz1 for cells differentiated in multiple conditions.
- FIGS. 40A-40E show that protocol optimization results in high efficient differentiation of EECs from ISCs.
- FIG. 40A mRNA expression of markers for goblet cell (Muc2), Paneth cell (Lyz1) and EECs (ChgA, Gcg, Gip, Cck, Tph1, Sst, Sct, and Pyy) with or without the addition of Wnt pathway inhibitor Wnt-059 (C59) and Tgf- ⁇ pathway inhibitor Repsox (Rep) at multiple time points.
- S1, S2 represent Step 1 and Step 2 of 2-step differentiation protocol. 0 h or 12 h indicates the time points of adding C59. ENR was used as control for spontaneous differentiation.
- FIG. 40B mRNA expression of markers for goblet cell (Muc2), Paneth cell (Lyz1) and EECs (ChgA, Gcg, Gip, Cck, Tph1, Sst, Sct, and Pyy) with or without the addition of Wnt pathway
- FIG. 40C expression level of multiple genes comparing with their corresponding peak levels (Sox9, Math1, Ngn3, and NeuroD1 at day 2, ChgA at day 5, see FIG. 40D ).
- FIG. 40E Immunostaining of differentiated EEC cells.
- FIGS. 41A-41C show that protocol optimization results in high efficient differentiation of EECs from ISCs.
- FIG. 41A mRNA expression of multiple genes in conditions with or without Repsox. Basal condition used was ENR.D.Tu.Tc-D.Pd.Tc.C59. Repsox was added in Step 2.
- FIG. 41B mRNA expression of multiple genes in conditions as indicated.
- FIG. 41C Morphology of differentiated cell colonies. Arrows indicate dead cells expelled from the colonies.
- FIG. 42 shows that RepSox and FGF10 increased Insulin mRNA expression when added in Stage 1.
- FIG. 43 shows that longer 5Aza treatment increased Insulin mRNA expression.
- FIG. 44 shows that delayed addition of Wnt-059 in Stage 2 increased Insulin mRNA expression.
- FIG. 45 shows that BayK 8644 increased Insulin mRNA expression when added in Stage 1.
- FIG. 46 shows dose-dependent activity of BayK 8644 in promoting Insulin expression.
- FIG. 47 shows that BayK 8644 increased Insulin mRNA expression when added in Stages 1-3.
- FIG. 48 shows dose-dependent activity of DAPT in promoting Insulin expression.
- FIG. 49 shows that IOX1 increased insulin and Nkx6.1 expression.
- FIG. 50 shows a dose response of RepSox in promoting insulin and Nkx6.1 expression.
- FIG. 51 shows a dose response of ISX9 in promoting insulin and Nkx6.1 expression.
- FIG. 52 shows a dose response of Wnt-059 in promoting insulin and Nkx6.1 expression.
- FIG. 53 shows that DMH-1 increased insulin and Nkx6.1 expression level when added in Stage 2-3.
- FIG. 54 shows that Dexamethasone increased insulin and Nkx6.1 expression level when added in Stage 2-3.
- FIG. 55 shows that T3 increased Insulin mRNA expression when added in Stage 3.
- FIG. 56 shows that T3 and N-acetylcysteine (N-Alc) increased Insulin mRNA expression when added in Stage 3.
- FIG. 57 shows that CHIR99021 (CHIR) increased Insulin mRNA expression when added in Stage 3.
- FIG. 58 shows that Exendin-4 and Aurora Kinase Inhibitor II, as well as Forskolin increased Insulin mRNA expression.
- FIG. 59 shows that GC1 can replace T3 in promoting Insulin mRNA expression.
- FIG. 60 shows Insulin-GFP expression and morphology of islet-like structures obtained using combination of factors, from gastrointestinal stem cells.
- FIG. 61 shows a diagram of a cell culture process.
- the term “approximately” or “about” refers to a range of values that fall within 25%, 20%, 19%, 18%, 17%, 16%, 15%, 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, or less in either direction (greater than or less than) of the stated reference value unless otherwise stated or otherwise evident from the context (except where such number would exceed 100% of a possible value).
- administering refers to introducing a substance into a subject. In some embodiments, administration is oral, or by injection. In certain embodiments “causing to be administered” refers to administration of a second component after a first component has already been administered (e.g., at a different time and/or by a different actor).
- an “antibody” refers to an immunoglobulin polypeptide, or fragment thereof, having immunogen binding ability.
- an “agonist” is an agent that causes an increase in the expression or activity of a target gene, protein, or a pathway, respectively. Therefore, an agonist can bind to and activate its cognate receptor in some fashion, which directly or indirectly brings about this physiological effect on the target gene or protein. An agonist can also increase the activity of a pathway through modulating the activity of pathway components, for example, through inhibiting the activity of negative regulators of a pathway. Therefore, a “Wnt agonist” can be defined as an agent that increases the activity of Wnt pathway, which can be measured by increased TCF/LEF-mediated transcription in a cell.
- a “Wnt agonist” can be a true Wnt agonist that bind and activate a Frizzled receptor family member, including any and all of the Wnt family proteins, an inhibitor of intracellular beta-catenin degradation, and activators of TCF/LEF.
- a “Notch agonist” can be defined as an agent that increase the activity of Notch pathway, which can be determined by measuring the transcriptional activity of Notch.
- an “antagonist” refers to an agent that binds to a receptor, and which in turn decreases or eliminates binding by other molecules.
- Cell Density as used herein in connection with a specific cell type is the mean number of that cell type per area in a Representative Microscopy Sample.
- the cell types may include but are not limited to Lgr5 + cells, enteroendocrine cells, or insulin producing cells.
- the Cell Density may be assessed with a given cell type in a given sample, organ or tissue.
- Cell Differentiation refers to the process by which a cell becomes specialized to perform a specific function, such as in the conversion of post-natal stem cells into cells having a more specialized function.
- Lgr5+ intestinal stem cells are differentiated into enteroendocrine cells.
- ChgA Immunostaining Assay is an assay used to determine the fraction of cells in a cell population that express ChgA by an immunostaining method.
- a ChgA immunostaining assay a cell culture medium in which a cell population has been treated is removed, and the sample is washed with PBS. Organoids or cell colonies cultured in Matrigel are fixed directly by adding 4% PFA and incubating for 20 mins at room temperature. The Matrigel is then mechanically disrupted, and the cells are transferred to BSA-coated Eppendorf tubes.
- Samples are washed with PBS, permeabilized with 0.25% Triton X-100 for 30 minutes, and stained with primary antibody against Chromogranin A (e.g. anti-chromogranin A, sc-13090, Santa Cruz) and appropriate secondary antibodies (e.g. Alexa Fluor conjugated secondary antibodies, such as Alexa Fluor 594 conjugated Donkey anti-Rabbit antibody, A-21207; Life Technologies). Images are acquired by confocal microscopy.
- Chromogranin A e.g. anti-chromogranin A, sc-13090, Santa Cruz
- secondary antibodies e.g. Alexa Fluor conjugated secondary antibodies, such as Alexa Fluor 594 conjugated Donkey anti-Rabbit antibody, A-21207; Life Technologies.
- CHARM99021 is a chemical composition having the chemical formula C 22 H 18 Cl 2 N 8 and the following alternate names: CT 99021; 6-[[2-[[4-(2,4-dichlorophenyl)-5-(5-methyl-1H-imidazol-2-yl)-2-pyrimidinyl]amino]ethyl]amino]-3-pyridinecarbonitrile. Its chemical structure is as follows:
- “Complementary nucleic acid sequence” refers to a nucleic acid sequence capable of hybridizing with another nucleic acid sequence comprised of complementary nucleotide base pairs.
- Cross-Sectional Cell Density as used herein in connection with a specific cell type is the mean number of that cell type per area of cross section through a tissue in a Representative Microscopy Sample.
- “Decreasing” and “decreases” refer to decreasing by at least 5%, for example, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 99 or 100%, for example, as compared to the level of reference, and includes decreases by at least 1-fold, for example, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 30, 40, 50, 60, 70, 80, 90, 100, 200, 500, 1000-fold or more, for example, as compared to the level of a reference.
- EGFR inhibitor is substance that inhibits the epidermal growth factor receptor.
- Examples of EGFR inhibitors include Erlotinib HCl (OSI-744), Gefitinib (ZD1839), Lapatinib (GW-572016) Ditosylate, Afatinib (BIBW2992), Neratinib (HKI-272), Canertinib (CI-1033), Lapatinib, AG-490 (Tyrphostin B42), CP-724714, Dacomitinib (PF299804, PF299), WZ4002, AZD8931 (Sapitinib), CUDC-101, AG-1478 (Tyrphostin AG-1478), PD153035 HCl, Pelitinib (EKB-569), AC480 (BMS-599626), AEE788 (NVP-AEE788), OSI-420, WZ3146 WZ8040, AST-1306, Rociletinib (CO
- Enteroendocrine cells refers to cells that are specialized endocrine cells of the gastrointestinal tract and pancreas, and can be found in the intestinal tract, stomach and pancreas.
- the enteroendocrine cells form the largest endocrine system in the body, and can sense luminal contents, particularly nutrients, and respond by the secretion of a diversity of hormones (e.g. GLP-1) which modulate food intake, energy homeostasis and glucose tolerance.
- GLP-1 e.g. GLP-1
- Specific types of enteroendocrine cell are often classified according to the expression of hormones within the specific enteroendocrine cell subset, such as cells that express GLP-1, SHT, SST, gastrin, CCK, SCT, NTS, PYY, Gastrin and Ghrelin, among others.
- enteroendocrine cells have also been sometimes referred to as K cells, I cells, L cells, G cells, Enterochromaffin cells, N cells and S cells, but increasingly the hormone expression of the cells is used to identify the cell subtypes, as set forth above.
- Enteroendocrine cells can be identified by expression of ChgA marker, which can be detected by assays such as the mRNA ChgA Expression Assay and ChgA Immunostaining Assay described herein.
- Endgraft or “engraftment” refers to the process of stem or progenitor cell incorporation into a tissue of interest in vivo through contact with existing cells of the tissue.
- Epithelial progenitor cell refers to a multipotent cell which has the potential to become restricted to cell lineages resulting in epithelial cells.
- Epithelial stem cell refers to a multipotent cell which has the potential to become committed to multiple cell lineages, including cell lineages resulting in epithelial cells.
- “Fragment” refers to a portion, e.g., of a polypeptide or nucleic acid molecule. This portion contains, for example, at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, or 90% of the entire length of the reference nucleic acid molecule or polypeptide.
- a fragment may contain 10, 20, 30, 40, 50, 60, 70, 80, 90, or 100, 200, 300, 400, 500, 600, 700, 800, 900, or 1000 nucleotides or amino acids.
- “Growth factor” refers to a substance capable of stimulating cellular growth, proliferation or differentiation.
- GSK3beta As used interchangeably herein are acronyms for glycogen synthase kinase 3 beta.
- GSK3beta inhibitor is a substance that inhibits the activity of GSK3beta.
- HDAC histone deacetylase
- HDAC inhibitor is a substance that inhibits the activity of HDAC.
- Histone Methylation Inhibitor is a substance that inhibits histone methylation.
- Hybridize refers to pairing to form a double-stranded molecule between complementary nucleotide bases (e.g., adenine (A) forms a base pair with thymine (T), as does guanine (G) with cytosine (C) in DNA) under suitable conditions of stringency.
- adenine (A) forms a base pair with thymine (T)
- G guanine
- C cytosine
- an “inhibitor” refers to an agent that causes a decrease in the expression or activity, e.g., of a target gene, a protein, or a pathway.
- an “Wnt inhibitor” refers an agent that causes a decrease in the activity of Wnt signaling pathway, which can be for example a Wnt receptor inhibitor, a Wnt receptor antagonist, a Porcupine inhibitor which inhibits Wnt secretion, or a Tankyrase inhibitor, or a drug that interferes with ⁇ -catenin interactions.
- An “antagonist” can be an inhibitor, but is more specifically an agent that binds to a receptor, and which in turn decreases or eliminates binding by other molecules.
- Increasing” and “increases” refer to increasing by at least 5%, for example, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 99, 100% or more, for example, as compared to the level of a reference, and includes increases by at least 1-fold, for example, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 30, 40, 50, 60, 70, 80, 90, 100, 200, 500, 1000-fold or more, for example, as compared to the level of a as compared to the level of a reference standard.
- Insulin Activity Assay is an assay used to determine the extent to which insulin gene transcription, translation or insulin release has been activated in a cell population.
- the initial cells are isolated from the intestine of an Insulin-GFP mouse such as B6.Cg-Tg (Ins1-EGFP)1Hara/J mouse (also referred to as the MIT-GFP mouse, Jackson lab stock no.: 006864).
- Intestinal crypts are isolated from the proximal half of the intestine.
- crypts are entrapped in 40 ⁇ l of Matrigel and cultured in 24-well plates with 500 ⁇ l of crypt culture media (Advanced DMEM/F12 with media Supplements (1X N2, 1X B27, 2 mM Glutamax, 10 mM HEPES, 1 mM N-acetylcysteine, and 100 U/ml Penicillin/100 ⁇ g/ml Streptomycin)), and supplemented with growth factors (50 ng/ml EGF, 100 ng/ml Noggin, and 500 ng/ml R-Spondin1) and small molecules (5 ⁇ M CHIR99021 and 1.25 mM VPA) to obtain an enriched population of intestinal stem cells.
- crypt culture media Advanced DMEM/F12 with media Supplements (1X N2, 1X B27, 2 mM Glutamax, 10 mM HEPES, 1 mM N-acetylcysteine, and 100 U/ml Penicillin/100 ⁇ g/ml
- the cells are then passaged for 1-2 times to create a starting cell population for the assay.
- the cells are incubated with appropriate culture media (e.g. aforementioned crypt culture media), growth factors and/or other agents being tested.
- Appropriate culture media including crypt culture media as well as the agents being assessed, are added into each well and incubated with the cells for a period of 2-10 days with media change every 2 days.
- the fraction of insulin-GFP positive cells i.e., cells in which the insulin-GFP reporter is activated
- the average insulin activity of a cell population can be measured by measuring the average mRNA expression level of insulin of the population normalized using suitable references or housekeeping genes (e.g., using mRNA expression of Hprt as a baseline).
- “Intestinal stem cell” refers to a multipotent cell of intestinal lineage which has the potential to become committed to multiple cell lineages, including cell lineages resulting in intestinal cells such as enteroendocrine cells, enterocyte cells, goblet cells and paneth cells.
- isolated refers to a material that is free to varying degrees from components which normally accompany it as found in its native state. “Isolate” denotes a degree of separation from original source or surroundings.
- Lgr5 is an acronym for the Leucine-rich repeat-containing G-protein coupled receptor 5, also known as G-protein coupled receptor 49 (GPR49) or G-protein coupled receptor 67 (GPR67). It is a protein that in humans is encoded by the Lgr5 gene.
- Lgr5+ cell or “Lgr5-positive cell” as used herein is a cell that expresses Lgr5.
- Lgr5 ⁇ cell as used herein is a cell that is not Lgr5+.
- “Mammal” refers to any mammal including but not limited to human, mouse, rat, sheep, monkey, goat, rabbit, hamster, horse, cow or pig.
- Multipotent progeny cell refers to refers to a cell that is already more specific than a stem cell, meaning it has the tendency to differentiate into a specific type of cell, but still retains the ability to differentiate into multiple different but limited cell types.
- the multipotent progeny cell may be a multipotent cell that has been differentiated from a stem cell but has not yet differentiated into a “target” cell type.
- MEK/ERK inhibitor is a substance that inhibits the MEK/ERK signaling pathway.
- Examples of MEK inhibitors include Arctigenin, BIX 02189, 10Z-Hymenialdisine, PD 0325901, PD 184352, PD 198306, PD 334581, PD 98059, SL 327, U0126, Selumetinib (AZD6244), Trametinib (GSK1120212), PD184352 (CI-1040), PD98059, Pimasertib (AS-703026), BIX 02188, TAK-733, AZD8330, Binimetinib (MEK162, ARRY-162, ARRY-438162), PD318088, Refametinib (RDEA119, Bay 86-9766), BI-847325, Cobimetinib (GDC-0973, RG7420), GDC-0623, and APS-2-79.
- ERK inhibitors include SCH772984, DEL-22379, VX-11e, ERKS-IN-1, XMD8-92, SC1 (Pluripotin), Ulixertinib (BVD-523, VRT75227, FR 180204, GDC-0994, BIX 02189, TCS ERK 11e, TMCB, and Eicosapentaenoic Acid.
- mRNA ChgA Expression Assay refers to an assay used to determine the relative ChgA mRNA expression level in a cell population.
- the assay can determine ChgA mRNA expression level of a differentiated cell population following treatment with agents being tested, as compared to an untested population of post-natal stem cells.
- the cells were collected and the RNA is extracted from the cells using an RNA extraction kit (such as RNeasy Mini kit, Qiagen).
- ChgA expression level is then assessed by Quantitative real-time PCR using a one-step qPCR kit (such as QuantiTech Probe PCR kit, Qiagen) and ChgA primers and probes (such as commercially available Taqman probe for mouse ChgA, Life Technologies).
- a one-step qPCR kit such as QuantiTech Probe PCR kit, Qiagen
- ChgA primers and probes such as commercially available Taqman probe for mouse ChgA, Life Technologies.
- mRNA Insulin Expression Assay refers to an assay used to determine the relative insulin mRNA expression level of a cell population.
- the assay can determine the insulin mRNA level expressed in a cell population treated to increase the expression of insulin in the cells, as compared to an untreated population of cells.
- the cells were collected and the RNA is extracted from the cells using an RNA extraction kit (such as RNeasy Mini kit, Qiagen).
- the insulin expression level is then assessed by Quantitative real-time PCR using a one-step qPCR kit (such as QuantiTech Probe PCR kit, Qiagen) and Ins1 or Ins2 primers and probes (such as the commercially available TaqMan probe for mouse Ins1 and Ins2, Life Technologies).
- the relative insulin mRNA expression can be determined relative to a baseline or other marker, such as Hprt mRNA expression level or other baseline marker.
- NeuroD1 activator is a substance that activates NeuroD1.
- Non-human mammal refers to any mammal that is not a human.
- Notch inhibitor refers to an inhibitor of the Notch signaling pathway.
- Neurogenin-3 refers to Neurogenin-3, a protein expressed in endocrine progenitor cells and associated with enteroendocrine differentiation.
- Ngn3 Assay is an assay used to determine the extent of expression of Ngn3 in cells, such as cells subjected to a differentiation protocol.
- RNA is isolated from cells that have been cultured according to a differentiation protocol, and quantitative real-time PCR is performed using commercially available primers and probes (such as Taqman probes) to determine an extent of Ngn3 expression in the cells.
- number of cells can be 0, 1, or more cells.
- Organoid or “epithelial organoid” refers to a cell cluster or aggregate that resembles an organ, or part of an organ, and possesses cell types relevant to that particular organ.
- “Population” of cells refers to any number of cells greater than 1, and even at least 1 ⁇ 10 3 cells, at least 1 ⁇ 10 4 cells, at least at least 1 ⁇ 10 5 cells, at least 1 ⁇ 10 6 cells, at least 1 ⁇ 10 7 cells, at least 1 ⁇ 10 8 cells, at least 1 ⁇ 10 9 cells, or at least 1 ⁇ 10 10 cells.
- Post-natal cell refers to a non-embryonic cell.
- Post-natal cells can include at least one of post-natal stem cells, post-natal progenitor cells, and post-natal multipotent progeny cells, as well as one or more cells differentiated from these cells, such as enteroendocrine cells (EECs).
- EECs enteroendocrine cells
- Post-natal stem cell refers to non-embryonic stem cells that have the capacity to self renew and to differentiate into multiple cell lineages. Post-natal stem cells may also be referred to as adult stem cells or somatic stem cells. Post-natal stem cells can include intestinal stem cells, epithelial stem cells, hematopoietic stem cells, mammary stem cells, mesenchymal stem cells, endothelial stem cells and neural stem cells.
- Progenitor cell refers to a cell that, like a stem cell, has the tendency to differentiate into a specific type of cell, but is already more specific than a stem cell and is pushed to differentiate into its “target” cell.
- Reference means a standard or control condition (e.g., untreated with a test agent or combination of test agents).
- sample refers to a volume or mass obtained, provided, and/or subjected to analysis.
- a sample is or comprises a tissue sample, cell sample, a fluid sample, and the like.
- a sample is taken from (or is) a subject (e.g., a human or animal subject).
- a tissue sample is or comprises brain, hair (including roots), buccal swabs, blood, saliva, semen, muscle, or from any internal organs, or cancer, precancerous, or tumor cells associated with any one of these.
- a fluid may be, but is not limited to, urine, blood, ascites, pleural fluid, spinal fluid, and the like.
- a body tissue can include, but is not limited to, brain, skin, muscle, endometrial, uterine, and cervical tissue or cancer, precancerous, or tumor cells associated with any one of these.
- Self-renewal refers to the process by which a stem cell divides to generate one (asymmetric division) or two (symmetric division) daughter cells with development potentials that are indistinguishable from those of the mother cell. Self-renewal involves both proliferation and the maintenance of an undifferentiated state.
- “Small molecule” as referred to herein refers to an organic compound that can participate in regulating biological pathways, and is a non-nucleic acid, is typically non-peptidic and non-oligomeric, and may have a molecular weight of less than 1500 daltons.
- “Stem cell” refers to a multipotent cell having the capacity to self renew and to differentiate into multiple cell lineages.
- “Stem Cell Markers” as used herein can be defined as gene products (e.g. protein, RNA, etc) that are specifically expressed in stem cells.
- One type of stem cell marker is gene products that directly and specifically support the maintenance of stem cell identity. Examples include Lgr5 and Sox2. Additional stem cell markers can be identified using assays that were described in the literature. To determine whether a gene is required for maintenance of stem cell identity, gain-of-function and loss-of-function studies can be used. In gain-of-function studies, over expression of specific gene product (the stem cell marker) would help maintain the stem cell identity. While in loss-of-function studies, removal of the stem cell marker would cause loss of the stem cell identity or induced the differentiation of stem cells.
- Another type of stem cell marker is a gene that is only expressed in stem cells but does not necessarily have a specific function to maintain the identity of stem cells. This type of marker can be identified by comparing the gene expression signature of sorted stem cells and non-stem cells by assays such as micro-array and qPCR. This type of stem cell marker can be found in the literature (e.g. Liu Q. et al., Int J Biochem Cell Biol. 2015 March; 60:99-111. http://www.ncbi.nlm.nih.gov/pubmed/25582750).
- Potential stem cell markers include Ccdc121, Gdf10, Opcm1, Phex, etc.
- the expression of stem cell markers such as Lgr5 or Sox2 in a given cell or cell population can be measured using assays such as qPCR, immunohistochemistry, western blot, and RNA hybridization.
- the expression of stem cell markers can also be measured using transgenic cells expressing reporters which can indicate the expression of the given stem cell markers, e.g. Lgr5-GFP or Sox2-GFP. Flow cytometry analysis can then be used to measure the activity of reporter expression. Fluorescence microscopy can also be used to directly visualize the expression of reporters.
- the expression of stem cell markers may further be determined using microarray analysis for global gene expression profile analysis.
- the gene expression profile of a given cell population or purified cell population can be compared with the gene expression profile of the stem cell to determine similarity between the 2 cell populations.
- Stem cell function can be measured by colony forming assay or sphere forming assay, self-renewal assay and differentiation assay.
- colony (or sphere) forming assay when cultured in appropriate culture media, the stem cell should be able to form colonies, on cell culture surface (e.g. cell culture dish) or embedded in cell culture substrate (e.g. Matrigel) or be able to form spheres when cultured in suspension.
- single stem cells are seeded at low cell density in appropriate culture media and allowed to proliferate for a given period of time (7-10 days). The colonies formed are then counted and scored for stem cell marker expression as an indicator of stemness of the original cell. Optionally, the colonies that formed are then picked and passaged to test their self-renewal and differentiation potential.
- stem cell marker e.g., Lgr5
- the cells should maintain stem cell marker (e.g., Lgr5) expression over at least one (e.g., 1, 2, 3, 4, 5, 10, 20, etc.) cell divisions.
- Subject includes humans and mammals (e.g., mice, rats, pigs, cats, dogs, and horses).
- subjects are mammals, particularly primates, especially humans.
- subjects are livestock such as cattle, sheep, goats, cows, swine, and the like; poultry such as chickens, ducks, geese, turkeys, and the like; and domesticated animals particularly pets such as dogs and cats.
- subject mammals will be, for example, rodents (e.g., mice, rats, hamsters), rabbits, primates, or swine such as inbred pigs and the like.
- “Synergy” or “synergistic effect” is an effect which is greater than the sum of each of the effects taken separately; a greater than additive effect.
- TgfBeta inhibitor (Tgf- ⁇ inhibitor) as used herein is a substance that reduces activity of the TgfBeta pathway.
- An example of a TgfBeta inhibitor can be a TgfBeta receptor inhibitor, which may include but is not limited to Alk4, Alk7 and Alk5/TgfBeta-RI.
- tissue is an ensemble of similar cells from the same origin that together carry out a specific function.
- Treating as used herein in connection with a cell population means delivering a substance to the population to effect an outcome.
- the substance may be directly (or even indirectly) delivered to the population.
- the substance may be delivered by administration to the host subject.
- valproic acid has chemical formula C 8 H 16 O 2 and the following alternate name: 2-propylpentanoic acid.
- the sodium salt of valproic acid can also be used in place of VPA, and the term “VPA” is used interchangeable herein to refer to VPA or pharmaceutically acceptable salts thereof, such as the sodium salt. Its chemical structure is as follows:
- Wnt activation as used herein in connection with a substance or composition is an activation of the Wnt signaling pathway.
- Wnt activator refers to a substance that activates the Wnt signaling pathway.
- Wnt inhibitor refers to a substance that inhibits the Wnt signaling pathway, which can be for example a Wnt receptor inhibitor, Wnt receptor antagonist, a Porcupine inhibitor which inhibits Wnt secretion, or a Tankyrase inhibitor, or a drug that interfere with ⁇ -catenin interactions.
- Wnt inhibitors include Wnt-059, IWP-2, IWR-1-endo, AZ6102, FH535, WIKI4, ICG-001, XAV-939, PRI-724, LGK-974, YA1797K, KY02111, Cardionogen 1, and IWP 12, etc.
- phrases “pharmaceutically acceptable” is employed herein to refer to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.
- pharmaceutically acceptable carrier includes without limitation any adjuvant, carrier, excipient, glidant, sweetening agent, diluent, preservative, dye/colorant, flavor enhancer, surfactant, wetting agent, dispersing agent, suspending agent, stabilizer, isotonic agent, solvent, surfactant, or emulsifier which has been approved by the United States Food and Drug Administration as being acceptable for use in humans or domestic animals.
- Examples of pharmaceutically acceptable carriers include, but are not limited to, to sugars, such as lactose, glucose and sucrose; starches, such as corn starch and potato starch; cellulose, and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; tragacanth; malt; gelatin; talc; cocoa butter, waxes, animal and vegetable fats, paraffins, silicones, bentonites, silicic acid, zinc oxide; oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil; glycols, such as propylene glycol; polyols, such as glycerin, sorbitol, mannitol and polyethylene glycol; esters, such as ethyl oleate and ethyl laurate; agar; buffering agents, such as magnesium hydroxide and aluminum hydroxide; alginic acid; pyrogen-free water
- “Pharmaceutically acceptable salt” includes both acid and base addition salts.
- “Pharmaceutically acceptable acid addition salt” refers to those salts which retain the biological effectiveness and properties of the free bases, which are not biologically or otherwise undesirable, and which are formed with inorganic acids such as, but are not limited to, hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid and the like, and organic acids such as, but not limited to, acetic acid, 2,2-dichloroacetic acid, adipic acid, alginic acid, ascorbic acid, aspartic acid, benzenesulfonic acid, benzoic acid, 4-acetamidobenzoic acid, camphoric acid, camphor-10-sulfonic acid, capric acid, caproic acid, caprylic acid, carbonic acid, cinnamic acid, citric acid, cyclamic acid, dodecylsulfuric acid, ethane-1,2-disulfonic acid, ethanesulfonic acid, 2-hydroxyethanesulfonic
- “Pharmaceutically acceptable base addition salt” refers to those salts which retain the biological effectiveness and properties of the free acids, which are not biologically or otherwise undesirable. These salts are prepared from addition of an inorganic base or an organic base to the free acid. Salts derived from inorganic bases include, but are not limited to, the sodium, potassium, lithium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, aluminum salts and the like. For example, inorganic salts include, but are not limited to, ammonium, sodium, potassium, calcium, and magnesium salts.
- Salts derived from organic bases include, but are not limited to, salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines and basic ion exchange resins, such as ammonia, isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, diethanolamine, ethanolamine, deanol, 2-dimethylaminoethanol, 2-diethylaminoethanol, dicyclohexylamine, lysine, arginine, histidine, caffeine, procaine, hydrabamine, choline, betaine, benethamine, benzathine, ethylenediamine, glucosamine, methylglucamine, theobromine, triethanolamine, tromethamine, purines, piperazine, piperidine, N-ethylpiperidine, polyamine resins and the like.
- Example organic bases used in certain embodiments include
- wetting agents such as sodium lauryl sulfate and magnesium stearate, as well as coloring agents, release agents, coating agents, sweetening, flavoring and perfuming agents, preservatives and antioxidants can also be present in the compositions (e.g., pharmaceutical compositions).
- antioxidants examples include: (1) water soluble antioxidants, such as ascorbic acid, cysteine hydrochloride, sodium bisulfate, sodium metabisulfite, sodium sulfite and the like; (2) oil-soluble antioxidants, such as ascorbyl palmitate, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), lecithin, propyl gallate, alpha-tocopherol, and the like; and (3) metal chelating agents, such as citric acid, ethylenediamine tetraacetic acid (EDTA), sorbitol, tartaric acid, phosphoric acid, and the like.
- water soluble antioxidants such as ascorbic acid, cysteine hydrochloride, sodium bisulfate, sodium metabisulfite, sodium sulfite and the like
- oil-soluble antioxidants such as ascorbyl palmitate, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), le
- the present disclosure relates to methods for forming enteroendocrine cells (EECs) from a mammalian post-natal cell population, such as a post-natal stem cell population, by treating with a plurality of small molecules that are capable of activating and/or deactivating pathways and mechanisms that lead to differentiation of the post-natal cell population into EECs.
- the pathways and mechanisms acted on by the small molecules can include, but are not limited to, Wnt signaling pathways, Notch signaling pathways, EGFR pathways, MEK/ERF signaling pathways, mechanisms acted on by growth factors, Histone Methylation pathways, the Tgf- ⁇ signaling pathway, and NeuroD1 pathways.
- aspects of the disclosure provide small molecule combinations that can promote differentiation of the post-natal cells such as post-natal stem cells, into EECs, as well as signal the differentiation into a particular EEC cell type.
- the present disclosure also relates to methods for increasing the insulin expression in a population of mammalian cells, by treating the population with a plurality of small molecules that are capable of activating and/or deactivating pathways and mechanisms that lead to increased insulin expression on the cells.
- the cells treated by the small molecule can be either post-natal cells (such as post-natal stem cells or multipotent progeny cells) or enteroendocrine cells, such as EECs that have been differentiated from post-natal cells such as post-natal stem cells, by the method described above.
- the pathways and mechanisms acted on by the small molecules to increase the insulin production can include, but are not limited to, any of the signaling pathways discussed for EEC differentiation above, such as for example Wnt and Notch signaling pathways, and in particular including small molecules that act to inhibit and/or activate DNA methylation pathways, Tgf- ⁇ signaling pathways and NeuroD1 pathways.
- aspects of the disclosure provide for small molecule combinations that promote insulin expression in the cells, and that induce cells in the treated population to become insulin producing cells.
- the plurality of small molecules is provided such that expression of the differentiation marker ChgA is upregulated due to differentiation of the cells.
- the expression of ChgA is upregulated such that the fraction of cells expressing ChgA in the cell population that has been treated with the small molecules, as measured in a ChgA Immunostaining Assay, is at least about 1.5%.
- the fraction of cells expressing ChgA as measured by the ChgA Immunostaining Assay may even be at least about 10%, and even at least about 50%, such as a fraction of cells is in a range of from about 60% to about 100%. In one embodiment, the fraction of cells expressing ChgA may be in a range of from about 1.5% to about 100%.
- the ChgA mRNA expression in the differentiated cell population may be at least about 10 times the ChgA mRNA expression in the initial post-natal cell population.
- the ChgA mRNA expression may even be at least 100 times the ChgA mRNA expression in the initial post-natal cell population, and may even be in the range of from about 1000 times to 1,000,000 times the ChgA mRNA expression in the initial post-natal cell population.
- the ChgA mRNA expression may be in a range of from about 10 to about 1,000,000 times the number of cells expressing ChgA in the initial post-natal cell population.
- the differentiation of the cells to form the EECs using the small molecule can provide a highly pure population of enteroendocrine cells, with a significant number of the post-natal cells, such as post-natal stem cells, being converted to the enteroendocrine cells.
- This ability to convert the post-natal stem cells into EECs in large quantities is significant, because intestinal EECs are restricted to the mucosa, predominantly in its deeper half, and typically comprise only a small minority of the overall epithelial cell population, such as less than 1%.
- treatment with the small molecules as described herein converts the post-natal cells into the enteroendocrine cells such that percentage of cells expressing the ChgA marker for EECs is at least 2% of the total cell population, and even as high as 90% to even 100% of the cell population, such as from about 60% to about 90% of the total cell population, and even from about 70% to about 80% of the total cell population.
- a final cell population having about 80% EECs has been achieved (see, e.g., FIG. 40 ).
- the percentage of cells expressing ChgA in the obtained cell population is increased as compared to the initial post-natal cell population is an increase in the fraction of ChgA expressing cells of from at least 0.1% to at least 1%, and even an increase of at least about 5%, such as an increase of at least about 10%, and even an increase of at least about 50%, such as at least about 100%.
- the post-natal cells that are treated by the small molecules include post-natal stem cells that are non-embryonic stem cells, such as adult stem cells that have the capacity to self-renew and to differentiate into multiple cell lineages, and can also include multipotent progeny cells and/or progenitor cells.
- the post-natal stem cells can include intestinal stem cells, epithelial stem cells, hematopoietic stem cells, mammary stem cells, mesenchymal stem cells, endothelial stem cells and neural stem cells, which often have conserved signaling and development pathways.
- the post-natal stem cells are intestinal stem cells, and may be identified by the marker Lgr5.
- Lgr5 is a Leucine-rich repeat-containing G-protein coupled receptor 5, also known as G-protein coupled receptor 49 (GPR49) or G-protein coupled receptor 67 (GPR67), and in humans is encoded by the Lgr5 gene.
- GPR49 G-protein coupled receptor 49
- GPR67 G-protein coupled receptor 67
- the cells being treated may be either these post-natal stem cells and/or cells that have been further specified, such as multipotent progeny cells and/or progenitor cells and/or enteroendocrine cells.
- Treatment of a population of cells with a plurality of small molecules can also be performed to provide a significant increase in the insulin expression of the cells.
- the insulin expression can be increased by treatment with the small molecules such that, as measured by an Insulin Activity Assay, the fraction of cells having the Insulin GFP reporter activated in the treated cells is at least about 1%, and even at least about 20%. In one embodiment, the fraction of cells having the Insulin GFP reporter activated is in a range of from about 20% to about 100%.
- the treatment with the plurality of small molecules may be capable of increasing the insulin expression with respect to the initial cell population, as determined by an mRNA Insulin Expression Assay, to a level substantially greater than a baseline level.
- the mRNA Insulin Expression Assay may provide a mRNA insulin expression level that is in the range of at least about 1 fold and even at least about 2 fold as compared to a standard using Hprt mRNA levels (where the insulin level of islet cells is typically about 100 fold of the Hprt level), thus demonstrating that the cells are being successfully converted into insulin expressing cells. As shown in FIG.
- a 2 ⁇ 10 7 fold increase in insulin expression can be achieved as compared to the expression in stem cells, when an arbitrary control Ct value is set for stem cell samples in qPCR (in a case where Insulin mRNA is undetectable at or above the set Ct value in stem cell samples).
- an insulin mRNA expression level as measured by an mRNA Insulin Expression Assay as compared to insulin mRNA levels in islet cells is believed to provide at least about 0.01%, such as at least about 0.1%, an even at least about 1%, up to at least about 10%, and even 100% or 200% of the insulin mRNA activity as compared to the islets.
- subjecting a cell population to treatment with the plurality of small molecules can provide a resulting cell population where at least about 1% of the obtained cells are insulin producing cells, and the number of insulin producing cells in the obtained cell population may even be in a range of from about 1% to about 20% of the total cell population.
- Treatment of a population of EECs with a plurality of small molecules can also be performed to generate subset populations comprising, for example, L-cells, K-cells, I-cells, G-cells, EC-cells, N-cells, and S-cells.
- the population of mammalian cells treated by the small molecules can be an in vitro population, such as a population of cells dispersed in a cell culture medium.
- An in vitro population of cells may also be in the form of organoids, which is a cell cluster or aggregate that resembles an organ, or part of an organ, and possesses cell types relevant to that particular organ (Sato, 2009).
- the population of mammalian cells treated by the small molecules may be an in vivo population, such as in vivo treatment of a human or other mammal to treat a disease state.
- the population of mammalian cells treated by the small molecules may be an ex vivo population, such as a population of cells obtained (e.g., isolated, derived) from a human or other mammal (e.g., a human or other mammal in need of treatment).
- a proposed mechanism for one embodiment for the differentiation of EECs from post-natal cells is provided in FIG. 34 .
- the EECs can be specified from the stem cells.
- the mechanism as shown provides for activating the Wnt pathway while inhibiting the Notch pathway, and then inhibiting both the Notch and Wnt pathways to form EECs.
- Other mechanisms and/or pathways may also be activated and/or inhibited, as described below, to further specify differentiation along the pathway towards EECs (as opposed to goblet cells, enterocytes, Paneth cells, etc.), and other mechanisms and/or pathways may also be used to further specify particular types of EECs, and/or EEC function.
- FIG. 34 shows Wnt inhibition, in some embodiments it may be possible to provide the differentiation to EEC without requiring addition of a Wnt inhibitor. Also, while FIG.
- EEC 34 illustrates a two stage method for obtaining EECS, certain embodiments may also provide for just a single stage of treatment, or even 3 or more stages of treatment to achieve the EECs.
- Particular types of EECs that might be specified can include cells that express GLP-1, SHT, SST, gastrin, CCK, SCT, NTS, PYY, and ghrelin, among others.
- treatment of the mammalian cells may result in differentiation along a similar pathway as that shown in FIG. 34 , such as from post-natal stem cells to EECs, with the resulting cells being those that provide increased insulin production, and/or the treatment may be performed on EECs themselves, to convert these cells into cells with increased insulin production. That is, the treatment to increase insulin production of the cells can be performed simultaneously with, before, or after differentiation of post-natal stem cells into EECS, or can be performed on cells at a differentiation stage in between stem cells and EECS, as well on the post-natal stem cells or EECs themselves. Accordingly, the treatment to increase insulin production can be performed on a mammalian cell population that comprises at least one of post-natal stem cells (such as Lgr5+ cells), progenitor cells and differentiated enteroendocrine cells.
- post-natal stem cells such as Lgr5+ cells
- FIG. 34 also shows the different types of intestinal cells, such as EECs, enterocytes, goblet cells, Paneth cells and stem cells and a general configuration of such cells as found in the crypts of the intestine.
- EEC enteroendocrine
- the plurality of small molecules provided to treat the post-natal cell population includes a small molecule that acts to activate and/or inhibit the Wnt pathway.
- the Wnt signaling pathway is a signal transduction pathway activated by binding of a Wnt protein ligand to a Frizzled family receptor.
- Wnt activators that can be provided as a part of a treatment can include, for example, at least one of R-Spondin 1, Wnt3a, Gsk inhibitors such as at least one of CHIR99021, LY2090314, NP031112 (Tideglusib), lithium, A1070722, SKL2001, and other agents capable of activating the Wnt signaling pathway.
- a Wnt activator provided as a part of a plurality of small molecules can be R-Spondin 1, which is a protein belonging to the R-Spondin family.
- Wnt inhibitors that can be provided as a part of a treatment can include, for example, at least one of Wnt-059, Dkk family proteins (such as at least one of Dkk-1, Dkk2, Dkk3 and Dkk4), sFRPs (such as at least one of sFRP-1 and sFRP-2), antibodies against Wnt receptors such as OMP-18R5, other small molecule Wnt inhibitors such as LGK974, CWP232291, PRI-724, IQR-1, IWP2, IWP-L6, ICG-001, WIKI4, Ky02111, FH535, XAV939, NSC668036, FJ9, 3289-8625, and others (Kahn, 2014).
- a Wnt inhibitor provided as a part of a plurality of small molecules for treatment can be Wnt-059, which has the following chemical structure:
- Derivatives and/or pharmaceutically acceptable salts of the Wnt activator and/or Wnt inhibitor may also be provided.
- Wnt agonists which may be suitable as Wnt activators can be found in the following Table.
- the plurality of small molecules provided to treat the post-natal cell population to achieve differentiation to EECs, and/or to treat a cell population to increase the insulin expression thereof includes a small molecule that acts to inhibit the Notch pathway.
- Notch inhibitors that can be provided as a part of a treatment can include, for example, at least one of DAPT; LY411575; MDL-28170; R04929097; L-685458 ((5S)-(t-Butoxycarbonylamino)-6-phenyl-(4R)hydroxy-(2R)benzylhexanoyl)-L-leu-L-phe-amide); BMS-708163 (Avagacestat); BMS-299897 (2-[(1R)-1-[[(4-Chlorophenyl)sulfonyl](2,5-difluorophenyl)amino]ethyl-5-fluorobenzenebutanoic acid); M-0752; Y
- a Notch inhibitor provided as a part of a plurality of small molecules can be DAPT, also known as N—[N-(3,5-Difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester.
- DAPT also known as N—[N-(3,5-Difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester.
- Derivatives and/or pharmaceutically acceptable salts of the Notch inhibitor may also be provided.
- the plurality of small molecules provided for treatment may also include a small molecule that acts to inhibit the MEK/ERK pathway.
- This can include inhibitors of the core Ras-Raf-MEK-ERK signaling cascade, as well as inhibitors of proteins upstream or downstream of this core signaling cascade, such as EGF receptor (EGFR) inhibitors.
- EGFR EGF receptor
- MEK/ERK inhibitors provided for treatment can include, for example, at least one of PD0325901, AZD8330 (ARRY-424704), Refametinib (BAY 86-9766, RDEA119), Cobimetinib (GDC-0973, XL-518, RG7421), E6201, MEK162 (ARRY-438162), Pimasertib (AS703026, MSC1936369B), R04987655 (CH4987655), RO5126766 (CH5126766), Selumetinib (AZD6244, ARRY-142,886), TAK-733, Trametinib (GSK1120212), and GDC-0623, WX-554 (Zhao and Adjei, 2014), and may also and/or alternatively include EGFR inhibitors such as Erlotinib, Gefitinib, Lapatinib, Afatinib, Neratinib, AZ5104, Afatinib
- a MEK/ERK inhibitor provided as a part of a plurality of small molecules can be PD0325901, also known as N-[(2R)-2,3-Dihydroxypropoxyl]-3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]-benzamide.
- Derivatives and/or pharmaceutically acceptable salts of the MEK/ERK inhibitor may also be provided.
- the plurality of small molecules provided for treatment may also include a small molecules corresponding to various growth factors, such as at least one of epidermal growth factor (EGF) and Noggin.
- the growth factors provided as a part of the small molecules for treatment include EGF and/or Noggin.
- Derivatives and/or pharmaceutically acceptable salts of the growth factors may also be provided.
- the plurality of small molecules can include an HDAC Inhibitor (Histone deacetylase inhibitor).
- HDAC inhibitor that can be provided as a part of the plurality of small molecules for treatment can include Tubastatin A, ACY1215, Valproic acid, SAHA, Trichostatin A, SHBA, CBHA, LAQ-824, PDX-101, LBH-589, ITF2357, PCI-24781, Compound 7 (ChemieTek), JNK-24681585 (Quisinostat) SB939 (Pracinostat), 4SC-201 (Resminostat), Tefinostat (CHR-2845), CHR-3996, CG200745, Depsipeptide (Romidepsin), Butyrate, MS-275, MGCD0103 and CI994, among others.
- an HDAC inhibitor provided for treatment can be Tubastatin A, also called N-Hydroxy-4-(2-methyl-1,2,3,4-tetrahydro-pyrido[4,3-b]indol-5-ylmethyl)benzamide hydrochloride. Derivatives and/or pharmaceutically acceptable salts of the HDAC inhibitor may also be provided.
- HDAC inhibitors can be found in the following Table.
- a Histone Methylation inhibitor (e.g., Histone demethylase (HDM) inhibitor) that can be provided as a part of the plurality of small molecules for treatment can include at least one of Tranylcypromine, GSK-2879552, GSK-LSD1, SP-2509, GSK J4, 2,4-Pyridinedicarboxylic Acid, ML324, IOX 1, OG-L002, CBB1007, GSK J1, GSK J2, and GSK J5, among others.
- a Histone Methylation inhibitor provided for treatment can be Tranylcypromine.
- a Histone Methylation inhibitor provided for treatment can be a lysine-specific histone demethylase (LSD1).
- Histone Methylation inhibitors include: JmjC-domain demethylase: Jmjd2, Jmjd2C, Jmjd3; Lysine-specific demethylase: LSD1 inhibitors such as Tranylcypromine (LSD1), RN 1 (LSD 1), GSK2879552 (LSD1), CBB1003 (LSD1), OG-L002 (LSD1), CBB1007 (LSD1), 2,4-Pyridinedicarboxylic Acid (LSD), SP2509 (LSD1), ORY-1001 (RG-6016), GSK LSD1 (LSD1); Jmjd: Daminozide (Jmjd), GSK J1 (Jmjd3/UTX), GSK J4 (Jmjd3), IOX 1 (Jmjd), JIB 04 (Jmjd), NSC 6368
- a Tgf- ⁇ inhibitor that can be provided as a part of the plurality of small molecules for treatment can include at least one of 616452 (Repsox), LY-364947, SB-505124, A-83-01, SB-431542, TGF- ⁇ RI Kinase Inhibitor VII, SB-525334, TGF- ⁇ RI Kinase Inhibitor IX, GW788388, LY2109761, Galunisertib (LY2157299), EW-7197, Pirfenidone, K02288, D 4476, R 268712, A77-01, and SM16, as well as antibodies against Tgf- ⁇ receptors.
- a Tgf- ⁇ inhibitor provided for treatment can be 616452, also referred to as RepSox, with the chemical formula 2-[3-(6-methyl-2-pyridinyl)-1H-pyrazol-4-yl]-1,5naphthyridine. Derivatives and/or pharmaceutically acceptable salts of the Histone Methylation inhibitor may also be provided.
- Tgf- ⁇ inhibitors Further examples of Tgf- ⁇ inhibitors can be found in the following Table
- a NeuroD1 activator that can be provided as a part of the plurality of small molecules for treatment can include ISX-9 and other Isoxazole molecules (Schneider, 2008).
- the NeuroD1 activator provided for treatment can be ISX-9, with the chemical formula N-cyclopropyl-5-(2-thienyl)-3-isoxazolecarboxamide. Derivatives and/or pharmaceutically acceptable salts of the Neuro D1 activator may also be provided.
- the plurality of small molecules provided for treatment may also include one or more monoamine oxidase (MAO) inhibitors.
- MAO inhibitors include Safinamide Mesylate, Rasagiline Mesylate, Tranylcypromine, Moclobemide (Ro 111163), Isatin, 8-(3-Chlorostyryl)caffeine, Bifemelane hydrochloride, (R)-( ⁇ )-Deprenyl hydrochloride, Harmane, Lazabemide hydrochloride, Pirlindole mesylate, RN 1 dihydrochloride, and Tetrindole mesylate, among others.
- the plurality of small molecules provided for treatment may also include one or more BMP receptor (including ALK2) inhibitors.
- BMP receptor (including ALK2) inhibitors include DMH-1, DMH2, Dorspmrphin, K 02288, LDN 193189, and ML 347.
- a plurality of small molecules that has been shown to be effective in increasing insulin expression of cells is a plurality of small molecules comprising at least one of a DNA methylation inhibitor, a Tgf- ⁇ inhibitor, and a NeuroD1 activator.
- all three small molecules are provided together as a part of a treatment to increase insulin production in a cell population.
- the Tgf- ⁇ inhibitor and NeuroD1 activator may be any of those discussed above, and/or their derivatives and/or the pharmaceutically acceptable salts thereof, and in particular may correspond to 616452 and ISX-9.
- the structure of 616452 (Repsox) is as follows:
- the DNA Methylation inhibitor can comprise at least one of 5-Azacytidine, 5-Aza-2-deoxycytidine, RG 108, SGI 1027, Nanaomycin A, Zebularine, Lomeguatrib, SGI-110, and Nanaomycin C, among others.
- Examples of DNA methylation inhibitors are described in U.S. Pat. No. 8,207,142, Canada Patent No. 2,454,147, and WO 2012/087889, each of which is specifically incorporated herein by reference.
- the DNA Methylation inhibitor comprises 5-Azacytidine. Derivatives and/or pharmaceutically acceptable salts of the DNA Methylation inhibitor may also be provided.
- DNA methylation inhibitors include: DNA analog 5-Azacytidine, Zebularine, Decitabine; DNMT inhibitor: Caffeic acid purum, Chlorogenic acid, ( ⁇ )-Epigallocatechin gallate (EGCG), Hydralazine, Procainamide, Procaine, Psammaplin A, RG108, Fisetin, Lomeguatrib, SGI 1027, 5-Iodotubercidin, 6-Thioguanine, MG98, DC-05, and DC-517.
- DNMT inhibitors Caffeic acid purum, Chlorogenic acid, ( ⁇ )-Epigallocatechin gallate (EGCG), Hydralazine, Procainamide, Procaine, Psammaplin A, RG108, Fisetin, Lomeguatrib, SGI 1027, 5-Iodotubercidin, 6-Thioguanine, MG98, DC-05, and DC-517.
- Table 1 presents a list of molecules, their abbreviation as otherwise used in the description herein, and examples of the final concentration of each reagent when used in in vitro experiments described herein.
- EGF E 50 ng/ml Noggin N 100 ng/ml R-Spondin1 R 500 ng/ml CHIR99021 Chir, C 5 ⁇ M Valproic Acid Sodium Salt VPA, V 1.25 mM DAPT D 5 ⁇ M Tubastatin A Tu 10 ⁇ M Tranylcypromine Tranyl, Ty 2 ⁇ M ISX-9 ISX, I 10 ⁇ M Wnt-C59 C59, C 5 ⁇ M PD0325901 Pd 1 ⁇ M 616452/Repsox 6 5 ⁇ M 5-Azacytidine 5-Aza, 5 1 ⁇ M
- the treatment performed using the plurality of small molecules can be performed in several stages, such as a first and second stage, or even more stages.
- the number of stages used for treatment can be selected according to the differentiation and/or insulin expression increasing method to be performed, as well as with respect to the type of small molecules being used and the pathways being activated and/or inhibited.
- a first stage may be performed to contact the post-natal cells population with one or more first small molecules that upregulate Ngn3, and in a second stage the post-natal cell population may be contacted with one or more second small molecules that downregulate Ngn3 to decrease Ngn3 expression in the cells.
- first and second stages may promote differentiation of the post-natal cells such as post-natal stem cells towards the formation of EECs.
- first through third stages may be performed to treat cells to upregulate insulin and increase expression.
- a treatment to differentiate post-natal cells such as post-natal stem cells to EECs can comprise first and second stages, with a first stage including contacting the cells with first small molecules including a Notch inhibitor and a Wnt activator, and the second stage including contacting the cells with second small molecules including a Notch inhibitor and at least one of an EGFR inhibitor and a MEK/ERK inhibitor.
- the first stage may provide R-Spondin1 and DAPT
- the second stage may provide DAPT and PD0325901.
- the second stage may also optionally include a Wnt inhibitor, such as Wnt-059.
- the first and second stages may also include one or more growth factors, such as EGF and/or Noggin.
- the first stage further comprises contacting the cells with at least one of an HDAC inhibitor, a Histone Methylation Inhibitor, and a NeuroD1 Activator, such as at least one of Tubastatin A, Tranylcypromine and ISX-9.
- the second stage may further comprise contacting the cells with a Tgf- ⁇ inhibitor such as 616452, and/or contacting the cells with a histone methylation inhibitor, such as Tranylcypromine.
- a treatment to increase insulin expression in a cell population can comprise first, second and third stages, with a first stage including contacting the cells with first small molecules including a Notch inhibitor, a Wnt activator and a DNA methylation inhibitor, a second stage including contacting the cells with second small molecules including a Notch inhibitor, optionally a Wnt inhibitor, a Tgf- ⁇ inhibitor, and a NeuroD1 activator, and a third stage including contacting the cells with third small molecules including a Notch inhibitor, optionally a Wnt inhibitor, a MEK/ERK inhibitor, and a Tgf- ⁇ inhibitor.
- the first stage may provide R-Spondin1, DAPT, and at least one of 5-Azacytidine and 5-Aza-2-deoxycytidine
- the second stage may provide DAPT, Wnt-059, 616452 and ISX-9
- the third stage may provide DAPT, Wnt-059, 6116452, and PD0325901.
- the first, second and/or third stages may also include one or more growth factors, such as EGF and/or Noggin.
- the first stage further comprises contacting the cells with at least one of an HDAC inhibitor, a Histone Methylation Inhibitor, and a NeuroD1 Activator, such as at least one of Tubastatin A, Tranylcypromine and ISX-9.
- the second stage may further comprise contacting the cells with a histone methylation inhibitor, such as Tranylcypromine.
- the small molecules may be provided in different combinations, and in different stages of treatment, to provide for differentiation of post-natal cells such as post-natal stem cells to EECs and/or increased expression of insulin.
- Some embodiments of small molecule combinations for treatment are described below.
- a method of differentiation can comprise treating mammalian post-natal cells such as post-natal stem cells with a plurality of small molecules including a Notch inhibitor (e.g. DAPT), a MEK/ERK inhibitor (e.g., PD0325901) and one or more growth factors (e.g., EGF and Noggin).
- a Notch inhibitor e.g. DAPT
- MEK/ERK inhibitor e.g., PD0325901
- growth factors e.g., EGF and Noggin
- a method of differentiation can comprise a first stage with a first set of small molecules including a Notch inhibitor (e.g. DAPT), a Wnt activator (e.g. R-Spondin1), and one or more growth factors (e.g., EGF and Noggin), and a second stage with a Notch inhibitor (e.g. DAPT), a MEK/ERK inhibitor (e.g., PD0325901), and one or more growth factors (e.g., EGF and Noggin).
- a Notch inhibitor e.g. DAPT
- Wnt activator e.g. R-Spondin1
- growth factors e.g., EGF and Noggin
- DAPT Notch inhibitor
- MEK/ERK inhibitor e.g., PD0325901
- growth factors e.g., EGF and Noggin
- a method of differentiation can comprise a first stage with a first set of small molecules including a Notch inhibitor (e.g. DAPT), a Wnt activator (e.g. R-Spondin1), and one or more growth factors (e.g., EGF and Noggin), a HDAC inhibitor (e.g. Tubastatin A) and a Histone Methylation inhibitor (e.g. Tranylcypromine), and a second stage with a Notch inhibitor (e.g. DAPT), a MEK/ERK inhibitor (e.g., PD0325901), and a Histone Methylation inhibitor (e.g. Tranylcypromine).
- a Notch inhibitor e.g. DAPT
- Wnt activator e.g. R-Spondin1
- growth factors e.g., EGF and Noggin
- HDAC inhibitor e.g. Tubastatin A
- Histone Methylation inhibitor e.g. Tr
- a method of differentiation can comprise a first stage with a first set of small molecules including a Notch inhibitor (e.g. DAPT), a Wnt activator (e.g. R-Spondin1), and one or more growth factors (e.g., EGF and Noggin), a HDAC inhibitor (e.g. Tubastatin A) and a Histone Methylation inhibitor (e.g. Tranylcypromine), and a second stage with a Notch inhibitor (e.g. DAPT), a MEK/ERK inhibitor (e.g., PD0325901), a Histone Methylation inhibitor (e.g. Tranylcypromine), and a Wnt inhibitor (e.g., WNT-059).
- a Notch inhibitor e.g. DAPT
- Wnt activator e.g. R-Spondin1
- growth factors e.g., EGF and Noggin
- HDAC inhibitor e.g. Tuba
- a method of differentiation can comprise a first stage with a first set of small molecules including a Notch inhibitor (e.g. DAPT), a Wnt activator (e.g. R-Spondin1), and one or more growth factors (e.g., EGF and Noggin), a HDAC inhibitor (e.g. Tubastatin A), a Histone Methylation inhibitor (e.g. Tranylcypromine), and a NeuroD1 activator (e.g. ISX9), and a second stage with a Notch inhibitor (e.g. DAPT), a MEK/ERK inhibitor (e.g., PD0325901), a Histone Methylation inhibitor (e.g. Tranylcypromine), a Wnt inhibitor (e.g., WNT-059), and a Tgf- ⁇ inhibitor (e.g., 616452).
- a Notch inhibitor e.g. DAPT
- Wnt activator e.g.
- a method for increasing insulin in a cell population can comprise contacting the cells with small molecules including a DNA methylation inhibitor (e.g. 5-Azacytidine and/or 5-Aza2-deoxycytidine), a Tgf- ⁇ inhibitor (e.g. 616452), and a NeuroD1 activator (e.g. ISX-9).
- a DNA methylation inhibitor e.g. 5-Azacytidine and/or 5-Aza2-deoxycytidine
- Tgf- ⁇ inhibitor e.g. 616452
- a NeuroD1 activator e.g. ISX-9
- a method for increasing insulin in a cell population includes a three stage process including, in a first stage, contacting the cells with a Notch inhibitor (e.g. DAPT), a Wnt activator (e.g. R-Spondin1), and a DNA methylation inhibitor (e.g. 5-Azacytidine and/or 5-Aza2-deoxycytidine), in a second stage contacting the cells with a Notch inhibitor (e.g. DAPT), a Wnt inhibitor (e.g. Wnt-059), a Tgf- ⁇ inhibitor (e.g. 616452), and a NeuroD1 activator (e.g.
- a Notch inhibitor e.g. DAPT
- Wnt activator e.g. R-Spondin1
- a DNA methylation inhibitor e.g. 5-Azacytidine and/or 5-Aza2-deoxycytidine
- a Notch inhibitor e.g. DAPT
- a Notch inhibitor e.g. DAPT
- Wnt inhibitor e.g. Wnt-059
- Tgf- ⁇ inhibitor e.g. 616452
- MEK/ERK inhibitor e.g., PD0325901
- Growth factors such as EGF and Noggin can also be provided in the first stage
- the Histone Methylation inhibitor e.g., Tranylcypromine
- a HDAC inhibitor e.g. Tubastatin A
- a NeuroD1 activator e.g. ISX-9
- a cell population having a relatively high content of EECs By performing treatment of post-natal cells such as post-natal stem cells to differentiate cells into enteroendocrine cells, a cell population having a relatively high content of EECs can be obtained.
- a cell population having enteroendocrine cells derived from post-natal cells such as post-natal stem cells can be provided by treatment with the plurality of small molecules, wherein a fraction the enteroendocrine cells is at least about 1% of the total cell population.
- the fraction of the enteroendocrine cells in the cell population may be at least about 10%, such as from 20% to 100% of the total cell population.
- the cells of the cell population may also be cryopreserved for use in further in vitro or in vivo applications.
- the cell population is non-sorted, meaning that the cell population has not been filtered or otherwise sorted to achieve the density of the cells.
- the differentiated cells may be capable of expressing 5-HT and/or GLP-1, as shown in the Examples included herewith.
- the method of increasing insulin production described herein can result in a cell population having a relatively high fraction of insulin producing cells, such as a fraction of insulin producing cells that is at least about 0.05% of the total cell population, and even at least about 1% of the total cell population.
- kits that provide a cell culture medium, such as matrigel, along with a cell population targeted for the treatment method, and a plurality of small molecules.
- the kits may also include instructions for using the kit, and other items of equipment to facilitate carrying out the treatment methods.
- a kit includes a cell culture medium, mammalian post-natal cells such as post-natal stem cells, and a plurality of small molecules that upregulate ChgA and differentiate the post-natal cells.
- a kit includes a cell culture medium, mammalian cells, and a plurality of small molecules that increase insulin production in the cells.
- aspects of the disclosure are further directed to the treatment of disease states in a mammal, such as a human, using the treatment methods described herein.
- a disease state characterized by insufficient endocrine or enteroendocrine cell products is treated, such as at least one of obesity, diabetes, irritable bowel syndrome, infectious enteritis, and inflammatory bowel disease.
- a disease state characterized by insufficient insulin production is treated, such as at least one of obesity, and Type I diabetes.
- Treatment of the disease state is achieved by way of administering a plurality of small molecules corresponding to any of the small molecules and/or small molecule combinations described above, to a mammal in need of such treatment.
- all of the small molecules in a plurality of small molecules are administered (e.g., delivered) to a mammal (e.g., human) in need of such treatment simultaneously (e.g., in a single administration step).
- the small molecules in a plurality of small molecules are administered (e.g., delivered) to a mammal (e.g., human) in need of such treatment in multiple administrations (e.g., as part of a multi-step process).
- a plurality of molecules is delivered in vivo to epithelium in a subject, thereby inducing cell differentiation in situ.
- the plurality is delivered to multiple tissues (e.g., stomach, small intestine, colon, oral mucsosa).
- compositions comprising the plurality of small molecules can be prepared, by providing the plurality of small molecules with a pharmaceutically acceptable excipient.
- the small molecules can be prepared as a part of a pharmaceutical composition that is capable of providing a protective formulation such that the small molecules are inhibited from breaking down when administered (e.g., orally) until they reach the target area.
- the formulation may provide a protective coating such that the plurality of small molecules can be made to pass through the stomach to the intestine, where treatment can occur.
- a formulation can include polymeric materials such as poloxamer, and can also include pH sensitive polymers such as eudragit, to provide for release of the small molecules at a target area of the body.
- the formulation may also be such that release of one of more of the small molecules is controlled, for example to control the onset of release a small molecule, or to control the duration of release of a small molecule at a target area.
- the formulation can include other compounds that can coat the stomach or gut, such as sucralfate.
- a pharmaceutical composition could be administered orally, such as by a pill, gelcap, liquid, etc.
- other methods of administration can include via a device (e.g. a stent), as well as by a suppository, enema, and/or by a patch.
- a cell population obtained by a method described herein may be administered by a cell therapy, such as via infusion, injection, on implant, within or on a carrier material, and may be combined with materials or devices that may be immune isolating (e.g. allogenic transplantation).
- a cell therapy such as via infusion, injection, on implant, within or on a carrier material, and may be combined with materials or devices that may be immune isolating (e.g. allogenic transplantation).
- a pharmaceutical composition for treatment of a disease state characterized by insufficient insulin production can comprise a DNA methylation inhibitor, a Tgf- ⁇ inhibitor, and a NeuroD1 activator, and/or a derivative and/or pharmaceutically acceptable salt thereof, in combination with a pharmaceutically acceptable excipient.
- the composition can include 616452, ISX-9, and at least one of 5-Azacytidine and 5-Aza-2′ deoxycytidine, and/or a derivative and/or pharmaceutically acceptable salt thereof, in combination with a pharmaceutically acceptable excipient.
- the composition formulation is further devised such that it provides a therapeutically effective amount of the small molecule combination that is effective for treatment of the disease state in the mammal being treated.
- the invention relates to a method of preparing a population of cells for transplantation into a subject (e.g., a human) in need thereof.
- the method comprises a) isolating a population of cells (e.g., from tissue from a subject) comprising Lgr5+ cells; b) treating the cells with one or more molecules that target one or more processes selected from wnt activation, notch inhibition, Tgf ⁇ inhibition, and epigenetic regulation (e.g., LSD1 inhibition and/or HDAC inhibition), or any combination thereof, and c) treating the cells with one or more molecules that target one or more processes selected from wnt inhibition, EGFR inhibition, MEK inhibition, ERK inhibition, epigenetic regulation (e.g.
- the cells can be treated with the molecules for various periods of time, such as, for example, greater than or equal to about 4, 8, 24, 48, 96, or 192 hrs. Generally, the molecule(s) used in steps b) and c) are used at greater than or equal to about 10, 25, 50, 100, 500, or 1000% of their IC50 values.
- the molecules can be administered simultaneously (e.g., in one step) or separately (e.g., successively).
- the method of preparing a population of cells for transplantation comprises treating a population of progenitor cells (e.g., transit amplifying cells) according to steps b) and/or c) of the preceding paragraph.
- the method can include both of steps b) and c), or it can include step c) without step b).
- the method can include both of steps b) and c), or step b) without step c), or step c) without step b).
- the method of preparing a population of cells for transplantation further comprises d) delivering the treated population of cells to a subject.
- the cell populations described herein are used for screening of compounds for a variety of purposes (e.g., for enhancing efficiencies of EECs and their subset populations, for controlling size and functions of EECs and their subset populations in vivo, for controlling incretin expression, such as GLP-1 and/or GLP-2 expression, insulin expression, and serotonin expression, for toxicity testing).
- purposes e.g., for enhancing efficiencies of EECs and their subset populations, for controlling size and functions of EECs and their subset populations in vivo, for controlling incretin expression, such as GLP-1 and/or GLP-2 expression, insulin expression, and serotonin expression, for toxicity testing.
- Lgr5-EGFP-IRES-CreERT2 B6.129 mice and Insulin-GFP (Ins-GFP, B6.Cg-Tg(Ins1-EGFP)1Hara/J) mice were obtained from Jackson Labs, and 6- to 12-week-old mice were used for crypt cell isolation. Animal experimental procedures were approved by the Committee on Animal Care (CAC) at MIT.
- CAC Committee on Animal Care
- Crypts were isolated as previously described (Yin et al., Nature Methods, 2014).
- the proximal half of the small intestine was harvested, opened longitudinally and washed with cold PBS to remove luminal content.
- the tissue was then cut into 2 mm to 4 mm pieces with scissors and further washed 5-10 times with cold PBS by pipetting up and down using a 10 mL pipette.
- Tissue fragments were incubated with 2 mM EDTA in PBS for 30 min on ice. After removal of EDTA, tissue fragments were washed with PBS to release crypts.
- the crypts were then collected, washed, and used for cell culture. Released crypts were collected and passed through a 70 ⁇ m cell strainer. Isolated crypts were embedded in Matrigel and plated at the center of wells in a 24-well plate.
- Isolated crypts or single cells were cultured as previously described. 200-300 crypts were mixed with 40 ⁇ l of Matrigel and plated at the center of wells in a 24-well plate. Following polymerization of Matrigel, 500 ⁇ l of crypt culture media (Advanced DMEM/F12 with N2, B27, Glutamax, HEPES, and N-acetylcysteine) containing growth factors (EGF, Noggin, R-Spondin 1) and small molecules (CHIR99021 and VPA) were provided. For cell differentiation experiments, the cell culture media was changed to media containing growth factors and small molecules as listed in Table 2 following the differentiation protocol as described below. Media were changed every 1-2 days depending on the differentiation condition used.
- crypt culture media Advanced DMEM/F12 with N2, B27, Glutamax, HEPES, and N-acetylcysteine
- growth factors EGF, Noggin, R-Spondin 1
- small molecules CHIR99021 and VPA
- the cells were collected in 1.5-ml Eppendorf tubes and washed with basic assay medium (HBSS supplemented with 10 mM HEPES, 0.1% fatty acid-free BSA, and no glucose, pH 7.4). The cells were incubated in the basic medium for 2 h in a thermomixer at 300 rpm. The cells were then washed and incubated in 50 ⁇ l of basic medium containing 1 mg/ml diprotin A (Sigma-Aldrich) for 1 h, and the supernatant was collected. The cells were then incubated in 50 ⁇ l of basic medium containing 1 mg/ml diprotin A and 10 mM glucose for 1 h, and the supernatant was collected.
- basic assay medium HBSS supplemented with 10 mM HEPES, 0.1% fatty acid-free BSA, and no glucose, pH 7.4
- the cells were incubated in the basic medium for 2 h in a thermomixer at 300 rpm. The cells were then washed and
- Organoids from 24-well plate were collected in 1.5-ml protein Lobind Eppendorf tubes (1 well per tube) and incubated in basal medium (Hanks' balanced salt solution (Life Technologies) supplemented with 10 mmol/L HEPES, 0.1% fatty acid-free BSA, and no glucose, PH 7.4) for 2 hours in a thermomixer at 300 rotations per minute. Organoids were then washed and incubated in 100 ⁇ l basal solution containing 1 mg/ml Diprotin A (Sigma-Aldrich) for 1 hour. the supernatant was collected and the organoids were further incubated in 100 ⁇ l basal solution containing 1 mg/ml Diprotin A and 10 mM glucose for 1 hour.
- basal medium Hors' balanced salt solution (Life Technologies) supplemented with 10 mmol/L HEPES, 0.1% fatty acid-free BSA, and no glucose, PH 7.4
- the cells and organoids were then lysed in CelLytic M buffer (Sigma-Aldrich). GLP-1 concentrations in the supernatant were determined by ELISA (Multi-Species GLP-1 total ELISA, Millipore). DNA content in the cell lysate was quantified using the PicoGreen Kit and used to normalize GLP-1 content.
- the cells were collected in 1.5-ml Eppendorf tubes and washed with Krebs-Ringer buffer (KRB) supplemented with 0.25% BSA, and without glucose. The cells were then incubated with KRB containing either 2 mM or 20 mM glucose for 1 h at 37° C. Supernatant was collected and insulin was measured using HTRF insulin assay (Cisbio).
- KRB Krebs-Ringer buffer
- Notch Inhibitor Increases Enteroendocrine Cells (EEC) Differentiation from ISCs ( FIG. 1 )
- Intestinal stem cells can be cultured in 3D Matrigel to form organoids, in which stem cells spontaneously differentiate and generate to all intestinal epithelial cell types, including EEC.
- Notch inhibition with small molecule ⁇ -secretase inhibitor (DAPT) increases EEC differentiation, with around 5%-10% of the stem cells turned into EECs, as shown in FIG. 1 , where immunostaining of EEC marker ChgA under organoid culture conditions (ENR), or in the presence of Notch inhibitor DAPT (ENRD) conditions.
- DAPI was used for nucleus staining.
- FIG. 2 Screening System for EEC Differentiation
- the END condition was used as a basal condition for small molecule screening.
- FIG. 3 96-Well Screening Platform for Small Molecules that Increase EEC Differentiation
- a 96-well screening system was further employed with qPCR for ChgA expression as an indicator of EEC differentiation for screening small molecule libraries, as shown in FIG. 3 , where Lgr5 intestinal stem cells were expanded and passaged into a 96 well plate. Cells were then cultured with EGF, Noggin, and DAPT (END), as well as small molecules. After 2-3 days of differentiation, the cells lysed and ChgA expression was measured by qRT-PCR.
- Exemplary screening results were recorded, as shown in FIG. 4 .
- the EGFR inhibitor Gefitinib and the MEK/ERK pathway inhibitor AS703026 increased ChgA expression.
- Small molecules were further validated using a 24-well plate culture and the differentiation system.
- EGFR inhibitors e.g., Gefitinib
- MEK/ERK inhibitors e.g., AS703026 and PD0325901
- EGFR inhibitors e.g., Gefitinib
- MEK/ERK inhibitors e.g., AS703026 and PD0325901
- EGFR inhibitors e.g., Gefitinib
- MEK/ERK inhibitors e.g., AS703026 and PD0325901
- EEC generation was also confirmed by immunostaining against ChgA ( FIG. 35 ).
- a combination of Notch and EGFR/MEK/ERK inhibition and Wnt inactivation was used to induce specification of ISCs towards EEC direction. Further removing EGF and/or Noggin from the combination induced higher level ChgA expression ( FIG. 36 ), but a higher cell apoptosis level was observed in these conditions ( FIG. 37 ).
- Adding the Wnt pathway inhibitor IWP 2 (or I) or GSK3P inhibitor CHIR99021 (or C) did not further increase differentiation towards EEC ( FIG. 36 ).
- MAPK/ERK or EGFR Inhibitors Specifically Increase EEC Differentiation ( FIG. 6 )
- Intestinal stem cells were cultured under multiple conditions, and small molecules AS703026 (As), Gefitinib (Ge) and PD0325901 (Pd) specifically increased the expression of enteroendocrine cell marker ChgA.
- Small Molecules (e.g., as, Ge, and Pd) Decrease Ngn3 Expression During EEC Differentiation, and R-Spondin1 Promotes Ngn3 Expression ( FIG. 7 )
- Ngn3 was shown to be essential for the specification of EECs. There has been prior speculation that Ngn3 positive secretory progenitors differentiate to EECs (Genes Dev. 2002). Examination of Ngn3 expression levels during in vitro differentiation of intestinal stem cells surprisingly revealed that removal of R-spondin1 induced strong reduction of Ngn3 expression, while the addition of Gefitinib (Ge), AS703026 (As), or PD0325901 (Pd) further decreased Ngn3 expression, which was not significant in the presence of R-Spondin 1, as shown in FIG. 7 , where intestinal stem cells were cultured for 2 days under multiple conditions, and the mRNA levels of Ngn3 were measured.
- Gefitinib Gefitinib
- As AS703026
- Pd PD0325901
- Ngn3 expression is subsequently downregulated thereafter during the maturation of EECs. This is consistent with the transit expression of Ngn3 during EEC specification (Genes Dev. 2002).
- a 2-step differentiation protocol was tested aiming to increase Ngn3 expression and subsequent EEC differentiation.
- An initial (first) prime step with R-Spondin 1 and Notch inhibitor DAPT was added to permit the upregulation of Ngn3, followed by a second step without Wnt activation and with small molecules (e.g., Pd) to allow terminal differentiation of EECs, as shown in FIG. 8 , where an initial step with the presence of R-spondin1 was added to the differentiation protocol to increase Ngn3 expression in step 1.
- Ngn3 expression was measured after 24 hours under multiple conditions. In the presence of R-spondin1 and Notch inhibitor DAPT, Ngn3 expression was greatly induced, as shown in FIG. 9 , where the combination of R-Spondin 1 and Notch inhibitor DAPT increased Ngn3 expression.
- a time course study of EEC marker expression suggested the 2-step differentiation protocol effectively increased Ngn3 levels in the first step and decreased Ngn3 and increased ChgA levels during the 2nd step.
- NeuroD1 showed an intermediate change trend compared with Ngn3 and ChgA, suggesting NeuroD1 expressed after Ngn3, but before ChgA.
- the 2-step protocol induced highest ChgA expression following 5 days of treatment, as shown in FIG. 11 , and effectively induced EEC differentiation from ISCs, as shown in FIG. 12 (2-step protocol increased EEC marker ChgA expression after 5 days differentiation) and FIG. 13 (2-Step protocol increased EEC differentiation by staining EEC marker ChgA following 5 days differentiation), with less cell apoptosis ( FIG. 38 ) than direct Wnt, Notch and MEK/ERK inactivation (D.Pd or D.Pd. C59 condition).
- Tubastatin A Increases EEC Differentiation when Added in Step 1 of the Differentiation Protocol ( FIG. 15 )
- Tubastatin A was applied in step 1, but Tranylcypromine was applied in both steps during the differentiation. Under these conditions, both compounds increased EEC marker ChgA expression following 5 days of the 2-step differentiation protocol, and the expression of markers for K cell (Gip), L cell (Gcg), and I cell (Cck) were also increased, as shown in FIG. 15 with mRNA expression of markers for cells including goblet cells (Muc2), enteroendocrine cells (ChgA), Paneth cells (Lyz1) and K-cells (Gip); and as shown in FIG.
- markers of multiple cell types including goblet cells (Muc2), enteroendocrine cells (ChgA), Paneth cells (Lyz1), K-cells (Gip), L-cells (Gcg) and I-cells (Cck); and as shown in FIGS. 39A-39C .
- Tranylcypromine also significantly decreased the expression of Goblet cell (Muc2) and Paneth cell (Lyz1) markers, suggesting specific induction of EEC differentiation, further indicated in FIG. 16 .
- EGF e.g., ChgA, Gip, Gcg, and CCK
- FIG. 17 and FIG. 39D where intestinal stem cells were differentiated in multiple conditions for 5 days and markers for enteroendocrine cells such as ChgA, Gip, Gcg and Cck were measured by qPCR, but there tended to be more dead cells in the lumen of the differentiated cell colony when EGF was removed in both steps, likely due to EGF's role in promoting cell survival (e.g., PI3K). Therefore, EGF was kept in the first step of the differentiation process. The effect of Noggin in step 2 was marginal thus it was removed from the composition.
- EEC marker viz., ChgA, Gip, Gcg, and CCK
- EECs generated from intestinal stem cells were differentiated using the conditions identified and shown in FIG. 18 .
- Immunofluorescence staining was performed against markers for EECs.
- EECs intestinal organoid culture
- only very few cells differentiated to EECs indicated by the number of ChgA+ or GLP-1+ cells in the organoids, as shown in FIG. 19 , top panel, where ISCs were expanded under ENRCV conditions and further differentiated in conditions, as indicated.
- Immunostaining against markers for enteroendocrine cells (e.g., ChgA) or multiple subtypes of EEC were also performed.
- DAPI was used for nucleus staining.
- EECs Under controlled differentiation conditions, most of the cells turned to EECs following a 5 day differentiation protocol, and the generation of EEC subtypes was also elevated (see FIG. 19 ). Interestingly, most of the EECs appear to be serotonin secreting cells, indicated by strong 5-HT staining (see FIG. 19 ). GLP-1 release from differentiated L cells was further tested. Other EEC subtypes also existed at higher frequency, as identified by positive staining of markers such as GLP-1, GIP, and SST.
- the differentiation protocol significantly increased GLP-1 secretion from the organoids, and 10 mM glucose stimulation induced a 5-fold increase of GLP-1 secretion, as shown in FIG. 20 (Functional L cell (GLP-1) generated from ISC), where secretion of GLP-1 was measured in cells cultured in conditions, as indicated, and suggesting that these EECs were mature and functional ( FIG. 40C ).
- Wnt signaling activity is required in the first step of induction, while not necessary in the second step of EEC specification.
- the 1st step with Wnt activation increased Ngn3 expression, it also induced Paneth cell differentiation, which further may secret Wnt ligand and activate Wnt pathway in step 2.
- This is consistent with higher level of Paneth cell marker Lyz1 expression comparing with the END.Pd condition, where the initial Wnt inactivation step prevented the generation of Paneth cell in the first place ( FIG. 39E ).
- a small molecule inhibitor Wnt-059 or C59
- C59 effectively decreased Paneth cell marker Lyz1 expression suggesting it prevented Paneth cell differentiation in step 2. And it further increased ChgA expression indicating higher level of EEC differentiation ( FIG. 40A ). Delayed addition of C59 for 12-24 hours in step 2 further increases ChgA expression possibility due to higher level of Ngn3 induction in step 1 ( FIG. 40A ). Similarly, addition of Tgf-inhibitor (Repsox, Rep) greatly promoted ChgA expression and decreased goblet cell marker Muc2 expression ( FIG. 40A , FIG. 41A ).
- Repsox also greatly increased the expression of mature EEC markers (Gcg, Gip, Cck, Tph1, Sst, Sct, Pyy), in a range of 120 ⁇ (Tph1), 300 ⁇ (Sct), 430 ⁇ (Cck), 800 ⁇ (Gip), up to 15,000 ⁇ (Pyy) over the expression level in the ENR condition. It was found that adding Repsox in step 1 is sufficient to induce comparable level of ChgA with adding it in both steps, but the expression of mature EEC markers was greatly reduced ( FIG. 41B ), suggesting Tgf- ⁇ inhibition induces both EEC specification and further maturation. Interestingly, the addition of Repsox induce the colonies to expel apoptotic cells from the lumen ( FIG. 41C ), and form high purity EEC cell colonies.
- FIG. 40C The stem cell gene Lgr5 was slightly upregulated at day 2 likely due to increase in Paneth cell differentiation or Notch downregulation (Tian et al., 2015). Sox9 expression was implicated in the regulation of ISC and EEC differentiation (Formeister et al., 2009), and plays an important role in pancreas endocrine cell differentiation, partially by induction of Ngn3 expression. It was found that Sox9 was initially upregulated and then downregulated starting from day 2, which showed a similar expression pattern as Lgr5.
- Sox9 expression was maintained at a relatively high level compare with Lgr5, consistent with its expression in EECs (Formeister et al., 2009).
- the expression of multiple Notch target genes was similarly regulated, including Math1/Atoh1, Ngn3, and NeuroD1, which included an initial upregulation phase and then a downregulation phase.
- the expression of ChgA continuously increased, consistent with gradually increased EEC differentiation.
- the upregulation rates of these genes to reach peak levels day 2 for Sox9, Math1, Ngn3, NeuroD1 and day 5 for ChgA
- the order of Sox9, Math1, Ngn3, NeuroD1, and ChgA FIG. 40D ). This likely reflects the natural gene regulation process of these genes.
- Additional molecules were identified that can further increase EEC differentiation, as shown in FIG. 21 , where small molecules including Wnt-059 and ISX-9 and their combination further increased ChgA expression of the differentiated cells. Control: previous differentiation conditions.
- Tgf- ⁇ inhibitor 616452 was found to greatly increase the expression of functional EEC markers such as Gip, Gcg, Cck, Pyy, among others, while ISX9 decreased their expression, as in FIG. 22 showing relative expression to reference gene Hprt. As such, the differentiation protocol was adjusted to include 616452 and remove ISX9 at later stages, as in FIG. 23 , showing the differentiation protocol for EEC differentiation from ISC.
- EEC and insulin producing beta cells share many similarities, recent data indicates that EECs can be converted to insulin producing cells with additional small molecules.
- Insulin-GFP cells isolated from Insulin-GFP transgenic mice were used to identify small molecules able to induce insulin production.
- Insulin-GFP positive cells were observed when the cells were cultured in the presence of Tgf- ⁇ inhibitor 616452, with about 1% of cells becoming GFP positive.
- Wnt inhibitor Wnt-059 and a DNA methylation inhibitor 5-Aza (5-Azacytidine) subsequently increased the percentage of Insulin-GFP+ cells, as in FIG. 24 , showing FACS analysis of GFP+ cell percentage and quantification of GFP+ cell number in one well of 24-well plate.
- the combination of 56C (5-Aza, 616452, Wnt-059) results in the highest number of GFP+ cells (see FIG. 24 ).
- ISX9 (I) in the combination was also found to further increase the number of GFP+ cells (see FIG. 27 ), and a concentration of 10 ⁇ M was used, as in FIG. 28 , where dose response data for ISX-9 in inducing insulin-GFP expression at day 5 is shown.
- Wnt signaling was also tested in the two steps of conversion. Increasing Wnt activation in Step 1 by adding CHIR99021 did not increase GFP expression, while the combination of R-Spondin1 and Wnt-059 results in highest number of GFP+ cells in the system, as shown in FIG. 29 , where N: none; CHIR: CHIR99201; and C59: Wnt-059.
- Example 29 Under the conditions as in Example 29, and after 7 days of differentiation, up to 20% of the cells expressed Insulin-GFP, as shown in FIG. 30 , where control: cells cultured in EEC differentiation condition. (ENR.D.Tu.Ty at day 1 and D.Pd.Ty.C59 from Day 2). drugs added include 5-Aza, 616452, and ISX9; Pd was added at day 4 instead of day 2; and scale bars: 200 ⁇ m.
- Cells turned on expression of major transcription factors that are important for insulin expression, such as Pdx1, Ngn3, Mafa, NeuroD1, Nkx6.1, and Nkx2.2, and greatly increased insulin mRNA expression, as shown in FIG. 31 , where control conditions were ENR.D.Tu.Ty.5Aza.616452.ISX9, with 5Aza removed from Day 2; for drug treatment, cells were first cultured with ENR.D.Tu.Ty.5Aza.616452.ISX9, and changed to D.Ty.616452.ISX9.C59 conditions at Day 2, with Pd0325901 added at Day 4; and at day 0, all cells were cultured under ENR.CV conditions.
- control conditions were ENR.D.Tu.Ty.5Aza.616452.ISX9, with 5Aza removed from Day 2; for drug treatment, cells were first cultured with ENR.D.Tu.Ty.5Aza.616452.ISX9, and changed to D.
- Factors in blue and green represent important factors. Orange indicates supportive factors. Also listed are key events during differentiation, and key markers for each stage, as shown in FIG. 33 .
- Notch pathway The activity of Notch pathway is modulated through trans-activation or cis-inhibition.
- the Notch pathway is activated through binding of a Notch receptor with Notch Ligands (DLLs) on neighbor cells (i.e., secretory cells such as Paneth cells, EEC and goblet cells, or secretory cell progenirors). Lose contact with these cells leads to Notch inactivation, which is further enhanced through cis-inhibition.
- DLLs Notch Ligands
- the Wnt pathway is activated through a Wnt ligand gradient derived from cells in the laminal limba, or Paneth cells located at the bottom of crypts. Leave the crypt bottom leads to Wnt inactivation.
- Notch inactivation also leads to derepression of the Wnt signaling pathway, while attenuation of the Wnt pathway rescues the phenotype associated with Notch blockade.
- Notch inactivation induced Atoh1 expression and further induced Ngn3 upregulation when Wnt pathway is (moderately) activated (i.e., when Wnt is deactivated before Notch inactivation, Atoh1 will be induced, but not Ngn3, leading to goblet cell differentiation).
- Ngn3 positive cells further differentiate to EEC upon Wnt inactivation. And continuously (strong) Wnt activation upon Notch inactivation leads to Paneth cell fate.
- Small molecule drugs such as 5-Aza, Tgf-b inhibitor, ISX-9, or other drugs may act on multiple cell types, including the stem cells, progenitor cells, or differentiated enteroendocrine cells and induce insulin expression in these cells, as shown in FIG. 34 .
- Notch pathway has been shown to determine absorptive or secretory differentiation, and its inactivation is necessary for the specification of secretory cells including goblet cells, Paneth cells, tufts cells and enteroendocrine cells.
- Wnt pathway plays important role in goblet cell and Paneth cell fate determination, with its activation inducing Paneth cell fate and its inactivation inducing goblet cell fate. The role of Wnt in EEC differentiation has been less clear. As described herein, Wnt activation is important for Ngn3 expression for the specification of EEC, and subsequent Wnt inactivation helps further differentiation of EEC and maturation of multiple EEC subtypes ( FIG. 34 ).
- the differentiation of intestinal stem cells in vivo is a dynamic process, where the cells move upwards (except for Paneth cells) during differentiation.
- the signaling gradient along the crypt-villus axis influences the fate determination for the differentiating stem and progenitor cells during the differentiation/migration process.
- the R-Spondin/Lgr signaling module prolong the Wnt activation when the stem cells left contact with niche cells—the Paneth cells (Farin et al, 2016, Nature). This mechanism permits the induction of Ngn3 expression upon Notch inactivation.
- the sequence and level of Wnt/Notch inactivation seems to play a role in the fate determination of secretory progenitors. And the location of secretory progenitor cells correspondingly help the cells make the choice. For instance, earlier inactivation of Notch in the presence of low level of Wnt activation may favor a EEC fate due to induction of Ngn3 (e.g. at the +4 position), and earlier inactivation of Wnt signaling followed by inactivation of Notch signaling may promote goblet cell differentiation due to low level of Ngn3 induction (e.g. above +4 position), while strong activation of Wnt signaling and Notch inactivation favors Paneth cell fate (e.g. in the crypts).
- the differentiation of EEC and other intestinal epithelial cell types from intestinal stem cells is a spatially and temporally preciously controlled process.
- Wnt and Notch pathways play an instrumental role in stem cell differentiation including EECs
- other signaling pathways also participate in the differentiation process.
- the inhibition of EGFR/MEK/ERK signaling cascade increased the level of EEC differentiation, and inhibition of Tgf- ⁇ also greatly promoted the EEC specification and maturation.
- Epigenetic regulation also takes part in the differentiation process such as HDAC and Histone demethylation. The specific combination of these pathways controls the fate of ISCs and progenitors.
- a 3-stage process was developed, specifically, Day 0-1 as Stage 1, Day 1-3 as Stage 2, Day 3-5 as Stage 3. After Stage 3, the cells turn on significant level of Insulin expression as indicated by Ins-EGFP expression and qPCR for Insulin mRNA expression.
- the cells can be further cultured for 1-2 weeks, as Stage 4. For each stage, a set of specific combination of small molecules (and/or growth factors) were added. The objective was to optimize the reprogramming protocol to increase insulin expression, specifically Insulin mRNA expression for each stage, by screening and testing new small molecules (or growth factors).
- RepSox(616452) was previously added in Stages 2-3. It was found that when RepSox(616452) was added starting from Stage 1 (i.e. added in Stage 1-3), Insulin mRNA (Ins2) was increased as compared when RepSox was added in Stage 2-3. When combined with FGF10 (added in Stage 1), Insulin expression was further increased, as shown in FIG. 42 .
- BayK 8644 which is an L-type Ca2+ channel activator, increased Insulin mRNA expression when added in Stage 1, as shown in FIG. 45 .
- BayK 8644 showed highested activity when used at 2 ( FIG. 46 ).
- BayK 8644 treatment showed highest activity when added in Stages 1-3 ( FIG. 47 ).
- the optimal concentration of DAPT was 5 ( FIG. 48 ).
- Nkx6.1 is an important transcription factor for Insulin expression and Islet function. Additional factors were tested for an ability to increase Nkx6.1 expression as well as Insulin expression.
- IOX1 which is a Histone demethylase JMJD inhibitor, increased Insulin and Nkx6.1 expression when used at 5-10 ⁇ M ( FIG. 49 )
- RepSox and ISX9 were also tested to identify optimal concentration in promoting insulin and Nkx6.1 expression. It was found that the optimal dose of RepSox was 10-15 ⁇ M and ISX9 was 10-20 ⁇ M in promoting Insulin and Nkx6.1 expression ( FIGS. 50-51 ).
- the optimal dose was 5 ( FIG. 52 ).
- BMP Bone Morphogenic Protein
- Dexamethasone also increased Nkx6.1 and Insulin expression when added in Stages 2-3 ( FIG. 54 ).
- Vitamin C had beneficial effects when added in Stage 2-3.
- T3 Triiodothyronine
- pVc Vitamin C
- N-Acetylcysteine (2 mM) also increased Insulin mRNA expression, and further increased Insulin expression when combined with T3, as shown in FIG. 56 .
- Exendin-4 Exendin-4
- AKi Aurora Kinase Inhibitor II
- thyroid hormone beta-receptor agonist GC-1 was used to replace T3 and showed a similar effect in promoting insulin mRNA expression ( FIG. 59 ).
- insulin expression and insulin-GFP expression was induced in 5 days from intestinal stem cells. Continue culturing the cells further increased insulin expression level and led to islet-like cell colonies as shown in FIG. 60 .
- FIG. 61 a modified flow diagram for EEC differentiation was developed ( FIG. 61 ) as indicated below.
Abstract
Description
- This application is a divisional of U.S. application Ser. No. 15/400,877, filed Jan. 6, 2017, which claims the benefit of U.S. Provisional Application No. 62/276,814, filed on Jan. 8, 2016. The entire teachings of the above applications are incorporated herein by reference.
- This invention was made with Government support under Grant No. R01 DE013023 awarded by the National Institutes of Health. The Government has certain rights in the invention.
- The enteroendocrine system orchestrates how the body responds to nutrients by employing a diversity of hormones to fine-tune a wide range of physiological responses in the body, thus playing an important role in digestive and metabolic diseases such as Gastrointestinal (GI) disorders, diabetes and obesity. Enteroendocrine cells (EECs) form the largest endocrine system in the body (Grible and Reimann, 2015). EECs are individually dispersed along the crypt-villus axis throughout the intestinal epithelial but only exist in a small percentage (˜1%) in vivo (Gunawardene et al., 2011). A key function of EECs is to sense luminal contents, particularly nutrients, and to respond by the secretion of a diversity of hormones (e.g. GLP-1) which modulate food intake, energy homeostasis and glucose tolerance (Furness, 2013). It is also suggested that EECs play a key role in gastric bypass surgery by secreting hormones such as GLP-1, PYY and GLP-2 (Mumphrey, 2013). Accordingly, EECs are a therapeutic target in diabetes and obesity. Furthermore, mounting evidence demonstrates an immunoregulatory function of EECs in innate immunity (Moran, 2008). EECs express functional Toll-like receptors (TLR) and directly respond to metabolites produced by commensal bacteria (Bogunovic, 2007). Recent evidence also suggests that EECs may directly orchestrate immune cell function through alteration in number and hormone secretion during inflammation (Worthington, 2015). EECs are also believed to play a critical role in metabolic diseases (e.g. diabetes and obesity), and gastrointestinal pathologies such as irritable Bowel syndrome, infectious enteritis and inflammatory bowel disease (Moran, 2008 and Manocha and Kahn, 2012). Thus, there is great interest in EECs for the exploration and development of disease interventions.
- However, the study of enteroendocrine cells has been hindered by the relative lack of ability to culture EECs in vitro, as well as by the dispersed distribution of EEC and relative scarcity (1%) of EECs in intestinal epithelium. In particular, the knowledge of signals that control the differentiation and function of EEC are largely unknown. Furthermore, direct in vitro study of EECs has not been possible, because they are terminally differentiated cells that do not divide. Thus, due to the dispersed distribution and scarcity (1%) of EECs in the gut epithelium, it has been difficult to study the function and regulation of EECs in situ (Sternini, Anselmi and Rosengut, 2008 and Gunawerdene, Corfe and Staton, 2011).
- Accordingly, there remains a need for in vitro EEC culture to allow for investigation of metabolic and digestive diseases. There is also a need for the ability to modulate the function of EECs and obtain specific EEC sub-types, such as for use in the discovery and implementation of the treatment of disease states.
- Aspects of the disclosure include obtaining a population of enteroendocrine cells (EECs) from a mammalian post-natal cell population, such as a post-natal stem cell population, by treating the population with a plurality of small molecules that upregulate ChgA and promote differentiation of the cells to form the enteroendocrine cells. The upregulation of ChgA is such that the fraction of cells expressing CGA in the obtained cell population, as measured by a ChgA Immunostaining Assay, is at least about 1.5%. Small molecules that can be used to differentiate the post-natal stem cells into the enteroendocrine cells can include at least one of a Wnt activator, a Notch inhibitor, a Wnt inhibitor, a MEK/ERK inhibitor, a growth factor, a HDAC inhibitor, a Histone Methylation Inhibitor, a Tgf-β inhibitor, and a NeuroD1 activator.
- Aspects of the disclosure also include a method for increasing the insulin expression of a population of mammalian cells by treating the population with a plurality of small molecules that induce the cells to increase the insulin expression. The insulin expression level may be increased in the cell population such that, in an Insulin Activity Assay using an Insulin-GFP reporter, the fraction of cells having the Insulin GFP reporter activated is at least about 1%. The mammalian cells that can be treated to increase the insulin expression can include post-natal cells or enteroendocrine cells, such as post-natal stem cells, post-natal multipotent progeny cells, and enteroendocrine cells. Small molecules that can be used for the treatment to increase the expression of insulin in the cells can include a DNA methylation inhibitor, a Tgf-β inhibitor, and a NeuroD1 activator.
- Methods and/or compositions for treating disease states with the EECs and/or insulin producing cells described herein are also included according to an aspect of the disclosure. Also, populations of cells corresponding to the obtained EECS and/or insulin producing cells are also included according to an aspect of the disclosure, as are kits containing the small molecules for use in preparing the EEC and/or insulin producing cells.
- The patent or application file contains at least one drawing executed in color. Copies of this patent or patent application publication with color drawing(s) will be provided by the Office upon request and payment of the necessary fee.
- The foregoing will be apparent from the following more particular description of example embodiments of the invention, as illustrated in the accompanying drawings in which like reference characters refer to the same parts throughout the different views. The drawings are not necessarily to scale, emphasis instead being placed upon illustrating embodiments of the present invention.
-
FIG. 1 shows an increase in differentiation of enteroendocrine cells (EEC) from ISCs using a Notch inhibitor. -
FIG. 2 shows mRNA expression of ChgA in cultured intestinal stem cells. -
FIG. 3 shows a 96-well screening platform for small molecules that increase EEC differentiation. -
FIG. 4 shows positive hits from small molecules screening results. -
FIG. 5 shows validation of the positive hits using small molecules and intestinal stem cells differentiated under END conditions. -
FIG. 6 shows MAPK/ERK or EGFR inhibitors specifically increase EEC differentiation. -
FIG. 7 shows small molecules Gefitinib (Ge), AS703026 (As) or PD0325901 (Pd) decrease Ngn3 expression during EEC differentiation, and that R-Spondin 1 promotes Ngn3 expression. -
FIG. 8 shows an optimized differentiation protocol. -
FIG. 9 shows Ngn3 expression at 24 h during EEC differentiation. -
FIG. 10 shows expression of key markers of EEC during differentiation atday 3. -
FIG. 11 shows a time course study of key genes during EEC differentiation. -
FIG. 12 shows a 2-step protocol with increased EEC marker ChgA expression after 5 days differentiation. -
FIG. 13 shows a 2-step protocol with increased EEC differentiation by staining EEC marker ChgA following 5 days differentiation. Scale bar: 50 μm. -
FIG. 14 shows improvement of the differentiation protocol by additional small molecules. -
FIG. 15 shows Tubastatin A (Tu) increases EEC differentiation when added inStep 1 of the differentiation protocol. -
FIG. 16 shows Tranylcypromine increased EEC differentiation when added at both steps in differentiation. -
FIG. 17 shows that removal of EGF further increased differentiation of EEC. -
FIG. 18 shows an improved differentiation protocol. -
FIG. 19 shows highly efficient EEC differentiation from ISC. Scale bars: 20 μm. -
FIG. 20 shows functional L cells (GLP-1) generated from ISC. -
FIG. 21 shows additional factors, including Wnt-059 and ISX-9 and their combination, increase EEC differentiation. -
FIG. 22 shows expression of functional EEC markers under multiple conditions. -
FIG. 23 shows a differentiation protocol for EEC differentiation from ISC. -
FIG. 24 shows the combination of 5-Aza (5), 616452 (6), and Wnt-059 (C) induce Insulin-GFP expression in differentiated intestinal stem cells atday 5. -
FIG. 25 shows a dose response of 5-Aza in inducing insulin-GFP expression atday 5. -
FIG. 26 shows a dose response of 616452 in inducing insulin-GFP expression atday 5. -
FIG. 27 shows that ISX-9 (I) further increased insulin-GFP expression after 5 days in culture. -
FIG. 28 shows a dose response of ISX-9 in inducing insulin-GFP expression atday 5. -
FIG. 29 shows a FACS analysis of Insulin-GFP expression of cells in multiple conditions after 5 days in culture. -
FIG. 30 shows GFP and brightfield of cells treated without or with drugs atday 7. -
FIG. 31 shows gene expression data. -
FIG. 32 shows treatment of cells with low (2 mM) and high (20 mM) concentration of glucose induce different levels of insulin release. -
FIG. 33 shows a flow diagram of a differentiation protocol. -
FIG. 34 shows a model of in vivo EEC differentiation controlled by Wnt and Notch pathways. -
FIG. 35 shows that a combination of Notch and EGFR/MEK/ERK inhibition and Wnt inactivation (by R-Spondin1 withdraw) induces specification of ISCs towards EEC direction as determined by immunostaining against ChgA. -
FIG. 36 shows that removing EGF and/or Noggin from the combination induced higher level ChgA expression, while adding the Wnt pathway inhibitor IWP 2 (or I) or GSK3β inhibitor CHIR99021 (or C) did not further increase differentiation towards EEC. -
FIG. 37 shows the morphology of cell colonies in multiple differentiation conditions. -
FIG. 38 shows the morphology of cell colonies in multiple differentiation conditions. Note the prominent lumen of colonies with dead cells in conditions of Notch, MEK inhibition and Wnt inactivation (D.Pd condition) as well as Notch/MEK/Wnt inhibition (D.Pd.C59 condition). While 2-step differentiation condition (ENRD-END.Pd) induced less cell death. -
FIGS. 39A-39E show that additional small molecules increase EEC differentiation.FIG. 39A . mRNA expression of Gip, Gcg, Cck for cells differentiated in multiple conditions, with or without the addition of Tubastatin A (Tu) instep 1.FIG. 39B . mRNA expression of Gip, Gcg and Cck for cells differentiation in multiple conditions with or without Tranylcypromine (Tc) added inStep 1,Step 2 or both steps.FIG. 39C . Dose dependent induction of EEC markers (ChgA, Gcg, Gip, Tph1) for Tranylcypromine.FIG. 39D . mRNA expression of multiple EEC markers (Gip, Gcg, Cck) for cells differentiated in multiple conditions.FIG. 39E . mRNA expression of Lyz1 for cells differentiated in multiple conditions. -
FIGS. 40A-40E show that protocol optimization results in high efficient differentiation of EECs from ISCs.FIG. 40A . mRNA expression of markers for goblet cell (Muc2), Paneth cell (Lyz1) and EECs (ChgA, Gcg, Gip, Cck, Tph1, Sst, Sct, and Pyy) with or without the addition of Wnt pathway inhibitor Wnt-059 (C59) and Tgf-β pathway inhibitor Repsox (Rep) at multiple time points. S1, S2 representStep 1 andStep 2 of 2-step differentiation protocol. 0 h or 12 h indicates the time points of adding C59. ENR was used as control for spontaneous differentiation.FIG. 40B . Time-course study of multiple genes in 2-step differentiation process.FIG. 40C . expression level of multiple genes comparing with their corresponding peak levels (Sox9, Math1, Ngn3, and NeuroD1 atday 2, ChgA atday 5, seeFIG. 40D ).FIG. 40E . Immunostaining of differentiated EEC cells. -
FIGS. 41A-41C show that protocol optimization results in high efficient differentiation of EECs from ISCs.FIG. 41A . mRNA expression of multiple genes in conditions with or without Repsox. Basal condition used was ENR.D.Tu.Tc-D.Pd.Tc.C59. Repsox was added inStep 2.FIG. 41B . mRNA expression of multiple genes in conditions as indicated.FIG. 41C . Morphology of differentiated cell colonies. Arrows indicate dead cells expelled from the colonies. -
FIG. 42 shows that RepSox and FGF10 increased Insulin mRNA expression when added inStage 1. -
FIG. 43 shows that longer 5Aza treatment increased Insulin mRNA expression. -
FIG. 44 shows that delayed addition of Wnt-059 inStage 2 increased Insulin mRNA expression. -
FIG. 45 shows thatBayK 8644 increased Insulin mRNA expression when added inStage 1. -
FIG. 46 shows dose-dependent activity ofBayK 8644 in promoting Insulin expression. -
FIG. 47 shows thatBayK 8644 increased Insulin mRNA expression when added in Stages 1-3. -
FIG. 48 shows dose-dependent activity of DAPT in promoting Insulin expression. -
FIG. 49 shows that IOX1 increased insulin and Nkx6.1 expression. -
FIG. 50 . shows a dose response of RepSox in promoting insulin and Nkx6.1 expression. -
FIG. 51 shows a dose response of ISX9 in promoting insulin and Nkx6.1 expression. -
FIG. 52 shows a dose response of Wnt-059 in promoting insulin and Nkx6.1 expression. -
FIG. 53 shows that DMH-1 increased insulin and Nkx6.1 expression level when added in Stage 2-3. -
FIG. 54 shows that Dexamethasone increased insulin and Nkx6.1 expression level when added in Stage 2-3. -
FIG. 55 shows that T3 increased Insulin mRNA expression when added inStage 3. -
FIG. 56 shows that T3 and N-acetylcysteine (N-Alc) increased Insulin mRNA expression when added inStage 3. -
FIG. 57 shows that CHIR99021 (CHIR) increased Insulin mRNA expression when added inStage 3. -
FIG. 58 shows that Exendin-4 and Aurora Kinase Inhibitor II, as well as Forskolin increased Insulin mRNA expression. -
FIG. 59 . shows that GC1 can replace T3 in promoting Insulin mRNA expression. -
FIG. 60 shows Insulin-GFP expression and morphology of islet-like structures obtained using combination of factors, from gastrointestinal stem cells. -
FIG. 61 shows a diagram of a cell culture process. - In this application, the use of “or” means “and/or” unless stated otherwise. As used in this application, the term “comprise” and variations of the term, such as “comprising” and “comprises,” are not intended to exclude other additives, components, integers or steps. As used in this application, the terms “about” and “approximately” are used as equivalents. Any numerals used in this application with or without about/approximately are meant to cover any normal fluctuations appreciated by one of ordinary skill in the relevant art. In certain embodiments, the term “approximately” or “about” refers to a range of values that fall within 25%, 20%, 19%, 18%, 17%, 16%, 15%, 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, or less in either direction (greater than or less than) of the stated reference value unless otherwise stated or otherwise evident from the context (except where such number would exceed 100% of a possible value).
- “Administration” refers to introducing a substance into a subject. In some embodiments, administration is oral, or by injection. In certain embodiments “causing to be administered” refers to administration of a second component after a first component has already been administered (e.g., at a different time and/or by a different actor).
- An “antibody” refers to an immunoglobulin polypeptide, or fragment thereof, having immunogen binding ability.
- As used herein, an “agonist” is an agent that causes an increase in the expression or activity of a target gene, protein, or a pathway, respectively. Therefore, an agonist can bind to and activate its cognate receptor in some fashion, which directly or indirectly brings about this physiological effect on the target gene or protein. An agonist can also increase the activity of a pathway through modulating the activity of pathway components, for example, through inhibiting the activity of negative regulators of a pathway. Therefore, a “Wnt agonist” can be defined as an agent that increases the activity of Wnt pathway, which can be measured by increased TCF/LEF-mediated transcription in a cell. Therefore, a “Wnt agonist” can be a true Wnt agonist that bind and activate a Frizzled receptor family member, including any and all of the Wnt family proteins, an inhibitor of intracellular beta-catenin degradation, and activators of TCF/LEF. A “Notch agonist” can be defined as an agent that increase the activity of Notch pathway, which can be determined by measuring the transcriptional activity of Notch.
- An “antagonist” refers to an agent that binds to a receptor, and which in turn decreases or eliminates binding by other molecules.
- “Cell Density” as used herein in connection with a specific cell type is the mean number of that cell type per area in a Representative Microscopy Sample. The cell types may include but are not limited to Lgr5+ cells, enteroendocrine cells, or insulin producing cells. The Cell Density may be assessed with a given cell type in a given sample, organ or tissue.
- “Cell Differentiation” refers to the process by which a cell becomes specialized to perform a specific function, such as in the conversion of post-natal stem cells into cells having a more specialized function. In an embodiment, Lgr5+ intestinal stem cells are differentiated into enteroendocrine cells.
- “ChgA Immunostaining Assay” as used herein is an assay used to determine the fraction of cells in a cell population that express ChgA by an immunostaining method. In an example of a ChgA immunostaining assay, a cell culture medium in which a cell population has been treated is removed, and the sample is washed with PBS. Organoids or cell colonies cultured in Matrigel are fixed directly by adding 4% PFA and incubating for 20 mins at room temperature. The Matrigel is then mechanically disrupted, and the cells are transferred to BSA-coated Eppendorf tubes. Samples are washed with PBS, permeabilized with 0.25% Triton X-100 for 30 minutes, and stained with primary antibody against Chromogranin A (e.g. anti-chromogranin A, sc-13090, Santa Cruz) and appropriate secondary antibodies (e.g. Alexa Fluor conjugated secondary antibodies, such as Alexa Fluor 594 conjugated Donkey anti-Rabbit antibody, A-21207; Life Technologies). Images are acquired by confocal microscopy.
- “CHIR99021” is a chemical composition having the chemical formula C22H18Cl2N8 and the following alternate names: CT 99021; 6-[[2-[[4-(2,4-dichlorophenyl)-5-(5-methyl-1H-imidazol-2-yl)-2-pyrimidinyl]amino]ethyl]amino]-3-pyridinecarbonitrile. Its chemical structure is as follows:
- “Complementary nucleic acid sequence” refers to a nucleic acid sequence capable of hybridizing with another nucleic acid sequence comprised of complementary nucleotide base pairs.
- “Cross-Sectional Cell Density” as used herein in connection with a specific cell type is the mean number of that cell type per area of cross section through a tissue in a Representative Microscopy Sample.
- “Decreasing” and “decreases” refer to decreasing by at least 5%, for example, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 99 or 100%, for example, as compared to the level of reference, and includes decreases by at least 1-fold, for example, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 30, 40, 50, 60, 70, 80, 90, 100, 200, 500, 1000-fold or more, for example, as compared to the level of a reference.
- “EGFR inhibitor” is substance that inhibits the epidermal growth factor receptor. Examples of EGFR inhibitors include Erlotinib HCl (OSI-744), Gefitinib (ZD1839), Lapatinib (GW-572016) Ditosylate, Afatinib (BIBW2992), Neratinib (HKI-272), Canertinib (CI-1033), Lapatinib, AG-490 (Tyrphostin B42), CP-724714, Dacomitinib (PF299804, PF299), WZ4002, AZD8931 (Sapitinib), CUDC-101, AG-1478 (Tyrphostin AG-1478), PD153035 HCl, Pelitinib (EKB-569), AC480 (BMS-599626), AEE788 (NVP-AEE788), OSI-420, WZ3146 WZ8040, AST-1306, Rociletinib (CO-1686, AVL-301), Genistein, Varlitinib, Icotinib, TAK-285, WHI-P154, PD168393, CNX-2006, Tyrphostin 9, AG-18, Poziotinib (HM781-36B), AZD3759, Osimertinib (AZD9291), Afatinib (BIBW2992) Dimaleate, Erlotinib, Olmutinib (HM61713, BI 1482694), CL-387785 (EKI-785), NSC228155, AZ5104, AG490, AG 494, AG 555, AG 556, AG 825, AG 879, AG 99, AP 24534, AV 412, BIBU 1361, BIBX 1382, BMS 599626, Canertinib, CGP 52411, GW 583340, HDS 029, HKI 357, Iressa, JNJ 28871063, Lavendustin A, Methyl 2,5-dihydroxycinnamate, PD 158780, PF 6274484, PKI 166, R 1530, RAF 265, and XL 184, among others.
- “Eliminate” means to decrease to a level that is undetectable.
- “Enteroendocrine cells” refers to cells that are specialized endocrine cells of the gastrointestinal tract and pancreas, and can be found in the intestinal tract, stomach and pancreas. The enteroendocrine cells form the largest endocrine system in the body, and can sense luminal contents, particularly nutrients, and respond by the secretion of a diversity of hormones (e.g. GLP-1) which modulate food intake, energy homeostasis and glucose tolerance. Specific types of enteroendocrine cell are often classified according to the expression of hormones within the specific enteroendocrine cell subset, such as cells that express GLP-1, SHT, SST, gastrin, CCK, SCT, NTS, PYY, Gastrin and Ghrelin, among others. The different subsets of enteroendocrine have also been sometimes referred to as K cells, I cells, L cells, G cells, Enterochromaffin cells, N cells and S cells, but increasingly the hormone expression of the cells is used to identify the cell subtypes, as set forth above. Enteroendocrine cells can be identified by expression of ChgA marker, which can be detected by assays such as the mRNA ChgA Expression Assay and ChgA Immunostaining Assay described herein.
- “Engraft” or “engraftment” refers to the process of stem or progenitor cell incorporation into a tissue of interest in vivo through contact with existing cells of the tissue.
- “Epithelial progenitor cell” refers to a multipotent cell which has the potential to become restricted to cell lineages resulting in epithelial cells.
- “Epithelial stem cell” refers to a multipotent cell which has the potential to become committed to multiple cell lineages, including cell lineages resulting in epithelial cells.
- “Fragment” refers to a portion, e.g., of a polypeptide or nucleic acid molecule. This portion contains, for example, at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, or 90% of the entire length of the reference nucleic acid molecule or polypeptide. A fragment may contain 10, 20, 30, 40, 50, 60, 70, 80, 90, or 100, 200, 300, 400, 500, 600, 700, 800, 900, or 1000 nucleotides or amino acids.
- “Growth factor” refers to a substance capable of stimulating cellular growth, proliferation or differentiation.
- “GSK3beta,” “GSK3β,” and “GSK3B” as used interchangeably herein are acronyms for
glycogen synthase kinase 3 beta. - “GSK3beta inhibitor” is a substance that inhibits the activity of GSK3beta.
- “HDAC” as used herein is an acronym for histone deacetylase.
- “HDAC inhibitor” is a substance that inhibits the activity of HDAC.
- “Histone Methylation Inhibitor” is a substance that inhibits histone methylation.
- “Hybridize” refers to pairing to form a double-stranded molecule between complementary nucleotide bases (e.g., adenine (A) forms a base pair with thymine (T), as does guanine (G) with cytosine (C) in DNA) under suitable conditions of stringency. (See, e.g., Wahl, G. M. and S. L. Berger (1987) Methods Enzymol. 152:399; Kimmel, A. R. (1987) Methods Enzymol. 152:507).
- An “inhibitor” refers to an agent that causes a decrease in the expression or activity, e.g., of a target gene, a protein, or a pathway. For example, an “Wnt inhibitor” refers an agent that causes a decrease in the activity of Wnt signaling pathway, which can be for example a Wnt receptor inhibitor, a Wnt receptor antagonist, a Porcupine inhibitor which inhibits Wnt secretion, or a Tankyrase inhibitor, or a drug that interferes with β-catenin interactions. An “antagonist” can be an inhibitor, but is more specifically an agent that binds to a receptor, and which in turn decreases or eliminates binding by other molecules.
- “Increasing” and “increases” refer to increasing by at least 5%, for example, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 99, 100% or more, for example, as compared to the level of a reference, and includes increases by at least 1-fold, for example, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 30, 40, 50, 60, 70, 80, 90, 100, 200, 500, 1000-fold or more, for example, as compared to the level of a as compared to the level of a reference standard.
- “Insulin Activity Assay” as used herein is an assay used to determine the extent to which insulin gene transcription, translation or insulin release has been activated in a cell population. In an exemplary Insulin Activity Assay, the initial cells are isolated from the intestine of an Insulin-GFP mouse such as B6.Cg-Tg (Ins1-EGFP)1Hara/J mouse (also referred to as the MIT-GFP mouse, Jackson lab stock no.: 006864). Intestinal crypts are isolated from the proximal half of the intestine. Approximately 200 crypts are entrapped in 40 μl of Matrigel and cultured in 24-well plates with 500 μl of crypt culture media (Advanced DMEM/F12 with media Supplements (1X N2, 1X B27, 2 mM Glutamax, 10 mM HEPES, 1 mM N-acetylcysteine, and 100 U/ml Penicillin/100 μg/ml Streptomycin)), and supplemented with growth factors (50 ng/ml EGF, 100 ng/ml Noggin, and 500 ng/ml R-Spondin1) and small molecules (5 μM CHIR99021 and 1.25 mM VPA) to obtain an enriched population of intestinal stem cells. The cells are then passaged for 1-2 times to create a starting cell population for the assay. To test the capacity of agents to activate insulin gene transcription, translation or insulin release, the cells are incubated with appropriate culture media (e.g. aforementioned crypt culture media), growth factors and/or other agents being tested. Appropriate culture media, including crypt culture media as well as the agents being assessed, are added into each well and incubated with the cells for a period of 2-10 days with media change every 2 days. The fraction of insulin-GFP positive cells (i.e., cells in which the insulin-GFP reporter is activated) can be quantified using a flow cytometer to measure the fraction of GFP+ cell population present in the total cell population. Also, the average insulin activity of a cell population can be measured by measuring the average mRNA expression level of insulin of the population normalized using suitable references or housekeeping genes (e.g., using mRNA expression of Hprt as a baseline).
- “Intestinal stem cell” refers to a multipotent cell of intestinal lineage which has the potential to become committed to multiple cell lineages, including cell lineages resulting in intestinal cells such as enteroendocrine cells, enterocyte cells, goblet cells and paneth cells.
- “Isolated” refers to a material that is free to varying degrees from components which normally accompany it as found in its native state. “Isolate” denotes a degree of separation from original source or surroundings.
- “Lgr5” is an acronym for the Leucine-rich repeat-containing G-protein coupled
receptor 5, also known as G-protein coupled receptor 49 (GPR49) or G-protein coupled receptor 67 (GPR67). It is a protein that in humans is encoded by the Lgr5 gene. - “Lgr5+ cell” or “Lgr5-positive cell” as used herein is a cell that expresses Lgr5. “Lgr5− cell” as used herein is a cell that is not Lgr5+.
- “Mammal” refers to any mammal including but not limited to human, mouse, rat, sheep, monkey, goat, rabbit, hamster, horse, cow or pig.
- “Multipotent progeny cell” refers to refers to a cell that is already more specific than a stem cell, meaning it has the tendency to differentiate into a specific type of cell, but still retains the ability to differentiate into multiple different but limited cell types. The multipotent progeny cell may be a multipotent cell that has been differentiated from a stem cell but has not yet differentiated into a “target” cell type.
- “MEK/ERK inhibitor” is a substance that inhibits the MEK/ERK signaling pathway. Examples of MEK inhibitors include Arctigenin, BIX 02189, 10Z-Hymenialdisine, PD 0325901, PD 184352, PD 198306, PD 334581, PD 98059, SL 327, U0126, Selumetinib (AZD6244), Trametinib (GSK1120212), PD184352 (CI-1040), PD98059, Pimasertib (AS-703026), BIX 02188, TAK-733, AZD8330, Binimetinib (MEK162, ARRY-162, ARRY-438162), PD318088, Refametinib (RDEA119, Bay 86-9766), BI-847325, Cobimetinib (GDC-0973, RG7420), GDC-0623, and APS-2-79. Examples of ERK inhibitors include SCH772984, DEL-22379, VX-11e, ERKS-IN-1, XMD8-92, SC1 (Pluripotin), Ulixertinib (BVD-523, VRT75227, FR 180204, GDC-0994, BIX 02189, TCS ERK 11e, TMCB, and Eicosapentaenoic Acid.
- “mRNA ChgA Expression Assay” refers to an assay used to determine the relative ChgA mRNA expression level in a cell population. For example, the assay can determine ChgA mRNA expression level of a differentiated cell population following treatment with agents being tested, as compared to an untested population of post-natal stem cells. In an example of an mRNA ChgA Expression Assay, the cells were collected and the RNA is extracted from the cells using an RNA extraction kit (such as RNeasy Mini kit, Qiagen). The ChgA expression level is then assessed by Quantitative real-time PCR using a one-step qPCR kit (such as QuantiTech Probe PCR kit, Qiagen) and ChgA primers and probes (such as commercially available Taqman probe for mouse ChgA, Life Technologies).
- “mRNA Insulin Expression Assay” refers to an assay used to determine the relative insulin mRNA expression level of a cell population. For example, the assay can determine the insulin mRNA level expressed in a cell population treated to increase the expression of insulin in the cells, as compared to an untreated population of cells. In an exemplary mRNA Insulin Expression Assay, the cells were collected and the RNA is extracted from the cells using an RNA extraction kit (such as RNeasy Mini kit, Qiagen). The insulin expression level is then assessed by Quantitative real-time PCR using a one-step qPCR kit (such as QuantiTech Probe PCR kit, Qiagen) and Ins1 or Ins2 primers and probes (such as the commercially available TaqMan probe for mouse Ins1 and Ins2, Life Technologies). The relative insulin mRNA expression can be determined relative to a baseline or other marker, such as Hprt mRNA expression level or other baseline marker.
- “NeuroD1 activator” is a substance that activates NeuroD1.
- “Non-human mammal”, as used herein, refers to any mammal that is not a human.
- “Notch inhibitor” refers to an inhibitor of the Notch signaling pathway.
- “Ngn3” refers to Neurogenin-3, a protein expressed in endocrine progenitor cells and associated with enteroendocrine differentiation.
- “Ngn3 Assay” as used herein is an assay used to determine the extent of expression of Ngn3 in cells, such as cells subjected to a differentiation protocol. In an exemplary Ngn3 Assay, RNA is isolated from cells that have been cultured according to a differentiation protocol, and quantitative real-time PCR is performed using commercially available primers and probes (such as Taqman probes) to determine an extent of Ngn3 expression in the cells.
- As used in relevant context herein, the term “number” of cells can be 0, 1, or more cells.
- “Organoid” or “epithelial organoid” refers to a cell cluster or aggregate that resembles an organ, or part of an organ, and possesses cell types relevant to that particular organ.
- “Population” of cells refers to any number of cells greater than 1, and even at least 1×103 cells, at least 1×104 cells, at least at least 1×105 cells, at least 1×106 cells, at least 1×107 cells, at least 1×108 cells, at least 1×109 cells, or at least 1×1010 cells.
- “Post-natal cell” refers to a non-embryonic cell. Post-natal cells can include at least one of post-natal stem cells, post-natal progenitor cells, and post-natal multipotent progeny cells, as well as one or more cells differentiated from these cells, such as enteroendocrine cells (EECs).
- “Post-natal stem cell” refers to non-embryonic stem cells that have the capacity to self renew and to differentiate into multiple cell lineages. Post-natal stem cells may also be referred to as adult stem cells or somatic stem cells. Post-natal stem cells can include intestinal stem cells, epithelial stem cells, hematopoietic stem cells, mammary stem cells, mesenchymal stem cells, endothelial stem cells and neural stem cells.
- “Progenitor cell” as used herein refers to a cell that, like a stem cell, has the tendency to differentiate into a specific type of cell, but is already more specific than a stem cell and is pushed to differentiate into its “target” cell.
- “Reference” means a standard or control condition (e.g., untreated with a test agent or combination of test agents).
- The term “sample” refers to a volume or mass obtained, provided, and/or subjected to analysis. In some embodiments, a sample is or comprises a tissue sample, cell sample, a fluid sample, and the like. In some embodiments, a sample is taken from (or is) a subject (e.g., a human or animal subject). In some embodiments, a tissue sample is or comprises brain, hair (including roots), buccal swabs, blood, saliva, semen, muscle, or from any internal organs, or cancer, precancerous, or tumor cells associated with any one of these. A fluid may be, but is not limited to, urine, blood, ascites, pleural fluid, spinal fluid, and the like. A body tissue can include, but is not limited to, brain, skin, muscle, endometrial, uterine, and cervical tissue or cancer, precancerous, or tumor cells associated with any one of these.
- “Self-renewal” refers to the process by which a stem cell divides to generate one (asymmetric division) or two (symmetric division) daughter cells with development potentials that are indistinguishable from those of the mother cell. Self-renewal involves both proliferation and the maintenance of an undifferentiated state.
- “Small molecule” as referred to herein refers to an organic compound that can participate in regulating biological pathways, and is a non-nucleic acid, is typically non-peptidic and non-oligomeric, and may have a molecular weight of less than 1500 daltons.
- “Stem cell” refers to a multipotent cell having the capacity to self renew and to differentiate into multiple cell lineages.
- “Stem Cell Markers” as used herein can be defined as gene products (e.g. protein, RNA, etc) that are specifically expressed in stem cells. One type of stem cell marker is gene products that directly and specifically support the maintenance of stem cell identity. Examples include Lgr5 and Sox2. Additional stem cell markers can be identified using assays that were described in the literature. To determine whether a gene is required for maintenance of stem cell identity, gain-of-function and loss-of-function studies can be used. In gain-of-function studies, over expression of specific gene product (the stem cell marker) would help maintain the stem cell identity. While in loss-of-function studies, removal of the stem cell marker would cause loss of the stem cell identity or induced the differentiation of stem cells. Another type of stem cell marker is a gene that is only expressed in stem cells but does not necessarily have a specific function to maintain the identity of stem cells. This type of marker can be identified by comparing the gene expression signature of sorted stem cells and non-stem cells by assays such as micro-array and qPCR. This type of stem cell marker can be found in the literature (e.g. Liu Q. et al., Int J Biochem Cell Biol. 2015 March; 60:99-111. http://www.ncbi.nlm.nih.gov/pubmed/25582750). Potential stem cell markers include Ccdc121, Gdf10, Opcm1, Phex, etc. The expression of stem cell markers such as Lgr5 or Sox2 in a given cell or cell population can be measured using assays such as qPCR, immunohistochemistry, western blot, and RNA hybridization. The expression of stem cell markers can also be measured using transgenic cells expressing reporters which can indicate the expression of the given stem cell markers, e.g. Lgr5-GFP or Sox2-GFP. Flow cytometry analysis can then be used to measure the activity of reporter expression. Fluorescence microscopy can also be used to directly visualize the expression of reporters. The expression of stem cell markers may further be determined using microarray analysis for global gene expression profile analysis. The gene expression profile of a given cell population or purified cell population can be compared with the gene expression profile of the stem cell to determine similarity between the 2 cell populations. Stem cell function can be measured by colony forming assay or sphere forming assay, self-renewal assay and differentiation assay. In a colony (or sphere) forming assay, when cultured in appropriate culture media, the stem cell should be able to form colonies, on cell culture surface (e.g. cell culture dish) or embedded in cell culture substrate (e.g. Matrigel) or be able to form spheres when cultured in suspension. In a colony/sphere forming assay, single stem cells are seeded at low cell density in appropriate culture media and allowed to proliferate for a given period of time (7-10 days). The colonies formed are then counted and scored for stem cell marker expression as an indicator of stemness of the original cell. Optionally, the colonies that formed are then picked and passaged to test their self-renewal and differentiation potential. In a self-renewal assay, when cultured in appropriate culture media, the cells should maintain stem cell marker (e.g., Lgr5) expression over at least one (e.g., 1, 2, 3, 4, 5, 10, 20, etc.) cell divisions.
- “Subject” includes humans and mammals (e.g., mice, rats, pigs, cats, dogs, and horses). In many embodiments, subjects are mammals, particularly primates, especially humans. In some embodiments, subjects are livestock such as cattle, sheep, goats, cows, swine, and the like; poultry such as chickens, ducks, geese, turkeys, and the like; and domesticated animals particularly pets such as dogs and cats. In some embodiments (e.g., particularly in research contexts) subject mammals will be, for example, rodents (e.g., mice, rats, hamsters), rabbits, primates, or swine such as inbred pigs and the like.
- “Synergy” or “synergistic effect” is an effect which is greater than the sum of each of the effects taken separately; a greater than additive effect.
- “TgfBeta inhibitor” (Tgf-β inhibitor) as used herein is a substance that reduces activity of the TgfBeta pathway. An example of a TgfBeta inhibitor can be a TgfBeta receptor inhibitor, which may include but is not limited to Alk4, Alk7 and Alk5/TgfBeta-RI.
- “Tissue” is an ensemble of similar cells from the same origin that together carry out a specific function.
- “Treating” as used herein in connection with a cell population means delivering a substance to the population to effect an outcome. In the case of in vitro populations, the substance may be directly (or even indirectly) delivered to the population. In the case of in vivo populations, the substance may be delivered by administration to the host subject.
- “Valproic acid” (VPA) has chemical formula C8H16O2 and the following alternate name: 2-propylpentanoic acid. The sodium salt of valproic acid can also be used in place of VPA, and the term “VPA” is used interchangeable herein to refer to VPA or pharmaceutically acceptable salts thereof, such as the sodium salt. Its chemical structure is as follows:
- “Wnt activation” as used herein in connection with a substance or composition is an activation of the Wnt signaling pathway.
- “Wnt activator” as used herein refers to a substance that activates the Wnt signaling pathway.
- “Wnt inhibitor” as used herein refers to a substance that inhibits the Wnt signaling pathway, which can be for example a Wnt receptor inhibitor, Wnt receptor antagonist, a Porcupine inhibitor which inhibits Wnt secretion, or a Tankyrase inhibitor, or a drug that interfere with β-catenin interactions. Examples of Wnt inhibitors include Wnt-059, IWP-2, IWR-1-endo, AZ6102, FH535, WIKI4, ICG-001, XAV-939, PRI-724, LGK-974, YA1797K, KY02111,
Cardionogen 1, andIWP 12, etc. - The phrase “pharmaceutically acceptable” is employed herein to refer to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.
- As used herein “pharmaceutically acceptable carrier, diluent or excipient” includes without limitation any adjuvant, carrier, excipient, glidant, sweetening agent, diluent, preservative, dye/colorant, flavor enhancer, surfactant, wetting agent, dispersing agent, suspending agent, stabilizer, isotonic agent, solvent, surfactant, or emulsifier which has been approved by the United States Food and Drug Administration as being acceptable for use in humans or domestic animals. Examples of pharmaceutically acceptable carriers include, but are not limited to, to sugars, such as lactose, glucose and sucrose; starches, such as corn starch and potato starch; cellulose, and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; tragacanth; malt; gelatin; talc; cocoa butter, waxes, animal and vegetable fats, paraffins, silicones, bentonites, silicic acid, zinc oxide; oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil; glycols, such as propylene glycol; polyols, such as glycerin, sorbitol, mannitol and polyethylene glycol; esters, such as ethyl oleate and ethyl laurate; agar; buffering agents, such as magnesium hydroxide and aluminum hydroxide; alginic acid; pyrogen-free water; isotonic saline; Ringer's solution; ethyl alcohol; phosphate buffer solutions; and any other compatible substances employed in pharmaceutical formulations.
- “Pharmaceutically acceptable salt” includes both acid and base addition salts.
- “Pharmaceutically acceptable acid addition salt” refers to those salts which retain the biological effectiveness and properties of the free bases, which are not biologically or otherwise undesirable, and which are formed with inorganic acids such as, but are not limited to, hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid and the like, and organic acids such as, but not limited to, acetic acid, 2,2-dichloroacetic acid, adipic acid, alginic acid, ascorbic acid, aspartic acid, benzenesulfonic acid, benzoic acid, 4-acetamidobenzoic acid, camphoric acid, camphor-10-sulfonic acid, capric acid, caproic acid, caprylic acid, carbonic acid, cinnamic acid, citric acid, cyclamic acid, dodecylsulfuric acid, ethane-1,2-disulfonic acid, ethanesulfonic acid, 2-hydroxyethanesulfonic acid, formic acid, fumaric acid, galactaric acid, gentisic acid, glucoheptonic acid, gluconic acid, glucuronic acid, glutamic acid, glutaric acid, 2-oxo-glutaric acid, glycerophosphoric acid, glycolic acid, hippuric acid, isobutyric acid, lactic acid, lactobionic acid, lauric acid, maleic acid, malic acid, malonic acid, mandelic acid, methanesulfonic acid, mucic acid, naphthalene-1,5-disulfonic acid, naphthalene-2-sulfonic acid, 1-hydroxy-2-naphthoic acid, nicotinic acid, oleic acid, orotic acid, oxalic acid, palmitic acid, pamoic acid, propionic acid, pyroglutamic acid, pyruvic acid, salicylic acid, 4-aminosalicylic acid, sebacic acid, stearic acid, succinic acid, tartaric acid, thiocyanic acid, toluenesulfonic acid, trifluoroacetic acid, undecylenic acid, and the like.
- “Pharmaceutically acceptable base addition salt” refers to those salts which retain the biological effectiveness and properties of the free acids, which are not biologically or otherwise undesirable. These salts are prepared from addition of an inorganic base or an organic base to the free acid. Salts derived from inorganic bases include, but are not limited to, the sodium, potassium, lithium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, aluminum salts and the like. For example, inorganic salts include, but are not limited to, ammonium, sodium, potassium, calcium, and magnesium salts. Salts derived from organic bases include, but are not limited to, salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines and basic ion exchange resins, such as ammonia, isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, diethanolamine, ethanolamine, deanol, 2-dimethylaminoethanol, 2-diethylaminoethanol, dicyclohexylamine, lysine, arginine, histidine, caffeine, procaine, hydrabamine, choline, betaine, benethamine, benzathine, ethylenediamine, glucosamine, methylglucamine, theobromine, triethanolamine, tromethamine, purines, piperazine, piperidine, N-ethylpiperidine, polyamine resins and the like. Example organic bases used in certain embodiments include isopropylamine, diethylamine, ethanolamine, trimethylamine, dicyclohexylamine, choline and caffeine.
- Wetting agents, emulsifiers and lubricants, such as sodium lauryl sulfate and magnesium stearate, as well as coloring agents, release agents, coating agents, sweetening, flavoring and perfuming agents, preservatives and antioxidants can also be present in the compositions (e.g., pharmaceutical compositions).
- Examples of pharmaceutically-acceptable antioxidants include: (1) water soluble antioxidants, such as ascorbic acid, cysteine hydrochloride, sodium bisulfate, sodium metabisulfite, sodium sulfite and the like; (2) oil-soluble antioxidants, such as ascorbyl palmitate, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), lecithin, propyl gallate, alpha-tocopherol, and the like; and (3) metal chelating agents, such as citric acid, ethylenediamine tetraacetic acid (EDTA), sorbitol, tartaric acid, phosphoric acid, and the like.
- A description of example embodiments of the disclosure follows.
- The present disclosure relates to methods for forming enteroendocrine cells (EECs) from a mammalian post-natal cell population, such as a post-natal stem cell population, by treating with a plurality of small molecules that are capable of activating and/or deactivating pathways and mechanisms that lead to differentiation of the post-natal cell population into EECs. The pathways and mechanisms acted on by the small molecules can include, but are not limited to, Wnt signaling pathways, Notch signaling pathways, EGFR pathways, MEK/ERF signaling pathways, mechanisms acted on by growth factors, Histone Methylation pathways, the Tgf-β signaling pathway, and NeuroD1 pathways. In particular, aspects of the disclosure provide small molecule combinations that can promote differentiation of the post-natal cells such as post-natal stem cells, into EECs, as well as signal the differentiation into a particular EEC cell type.
- The present disclosure also relates to methods for increasing the insulin expression in a population of mammalian cells, by treating the population with a plurality of small molecules that are capable of activating and/or deactivating pathways and mechanisms that lead to increased insulin expression on the cells. The cells treated by the small molecule can be either post-natal cells (such as post-natal stem cells or multipotent progeny cells) or enteroendocrine cells, such as EECs that have been differentiated from post-natal cells such as post-natal stem cells, by the method described above. The pathways and mechanisms acted on by the small molecules to increase the insulin production can include, but are not limited to, any of the signaling pathways discussed for EEC differentiation above, such as for example Wnt and Notch signaling pathways, and in particular including small molecules that act to inhibit and/or activate DNA methylation pathways, Tgf-β signaling pathways and NeuroD1 pathways. In particular, aspects of the disclosure provide for small molecule combinations that promote insulin expression in the cells, and that induce cells in the treated population to become insulin producing cells.
- In differentiating the post-natal cells such as post-natal stem cells to EECS, the plurality of small molecules is provided such that expression of the differentiation marker ChgA is upregulated due to differentiation of the cells. The expression of ChgA is upregulated such that the fraction of cells expressing ChgA in the cell population that has been treated with the small molecules, as measured in a ChgA Immunostaining Assay, is at least about 1.5%. The fraction of cells expressing ChgA as measured by the ChgA Immunostaining Assay may even be at least about 10%, and even at least about 50%, such as a fraction of cells is in a range of from about 60% to about 100%. In one embodiment, the fraction of cells expressing ChgA may be in a range of from about 1.5% to about 100%. Furthermore, as measured by an mRNA ChgA Expression Assay, the ChgA mRNA expression in the differentiated cell population may be at least about 10 times the ChgA mRNA expression in the initial post-natal cell population. The ChgA mRNA expression may even be at least 100 times the ChgA mRNA expression in the initial post-natal cell population, and may even be in the range of from about 1000 times to 1,000,000 times the ChgA mRNA expression in the initial post-natal cell population. In one embodiment, the ChgA mRNA expression may be in a range of from about 10 to about 1,000,000 times the number of cells expressing ChgA in the initial post-natal cell population.
- The differentiation of the cells to form the EECs using the small molecule can provide a highly pure population of enteroendocrine cells, with a significant number of the post-natal cells, such as post-natal stem cells, being converted to the enteroendocrine cells. This ability to convert the post-natal stem cells into EECs in large quantities is significant, because intestinal EECs are restricted to the mucosa, predominantly in its deeper half, and typically comprise only a small minority of the overall epithelial cell population, such as less than 1%. In contrast, treatment with the small molecules as described herein converts the post-natal cells into the enteroendocrine cells such that percentage of cells expressing the ChgA marker for EECs is at least 2% of the total cell population, and even as high as 90% to even 100% of the cell population, such as from about 60% to about 90% of the total cell population, and even from about 70% to about 80% of the total cell population. As disclosed herein, a final cell population having about 80% EECs has been achieved (see, e.g.,
FIG. 40 ). In one embodiment, the percentage of cells expressing ChgA in the obtained cell population is increased as compared to the initial post-natal cell population is an increase in the fraction of ChgA expressing cells of from at least 0.1% to at least 1%, and even an increase of at least about 5%, such as an increase of at least about 10%, and even an increase of at least about 50%, such as at least about 100%. - The post-natal cells that are treated by the small molecules include post-natal stem cells that are non-embryonic stem cells, such as adult stem cells that have the capacity to self-renew and to differentiate into multiple cell lineages, and can also include multipotent progeny cells and/or progenitor cells. The post-natal stem cells can include intestinal stem cells, epithelial stem cells, hematopoietic stem cells, mammary stem cells, mesenchymal stem cells, endothelial stem cells and neural stem cells, which often have conserved signaling and development pathways. In one embodiment, the post-natal stem cells are intestinal stem cells, and may be identified by the marker Lgr5. Lgr5 is a Leucine-rich repeat-containing G-protein coupled
receptor 5, also known as G-protein coupled receptor 49 (GPR49) or G-protein coupled receptor 67 (GPR67), and in humans is encoded by the Lgr5 gene. When treating cells with small molecules to increase insulin expression, the cells being treated may be either these post-natal stem cells and/or cells that have been further specified, such as multipotent progeny cells and/or progenitor cells and/or enteroendocrine cells. - Treatment of a population of cells with a plurality of small molecules can also be performed to provide a significant increase in the insulin expression of the cells. In one embodiment, the insulin expression can be increased by treatment with the small molecules such that, as measured by an Insulin Activity Assay, the fraction of cells having the Insulin GFP reporter activated in the treated cells is at least about 1%, and even at least about 20%. In one embodiment, the fraction of cells having the Insulin GFP reporter activated is in a range of from about 20% to about 100%. According to a different type of measure, the treatment with the plurality of small molecules may be capable of increasing the insulin expression with respect to the initial cell population, as determined by an mRNA Insulin Expression Assay, to a level substantially greater than a baseline level. For example, in comparing with Hprt mRNA (as a reference gene for expression levels in qPCR), the mRNA Insulin Expression Assay may provide a mRNA insulin expression level that is in the range of at least about 1 fold and even at least about 2 fold as compared to a standard using Hprt mRNA levels (where the insulin level of islet cells is typically about 100 fold of the Hprt level), thus demonstrating that the cells are being successfully converted into insulin expressing cells. As shown in
FIG. 31 herein, a 2×107 fold increase in insulin expression can be achieved as compared to the expression in stem cells, when an arbitrary control Ct value is set for stem cell samples in qPCR (in a case where Insulin mRNA is undetectable at or above the set Ct value in stem cell samples). Furthermore, an insulin mRNA expression level as measured by an mRNA Insulin Expression Assay as compared to insulin mRNA levels in islet cells, is believed to provide at least about 0.01%, such as at least about 0.1%, an even at least about 1%, up to at least about 10%, and even 100% or 200% of the insulin mRNA activity as compared to the islets. According to one embodiment, subjecting a cell population to treatment with the plurality of small molecules can provide a resulting cell population where at least about 1% of the obtained cells are insulin producing cells, and the number of insulin producing cells in the obtained cell population may even be in a range of from about 1% to about 20% of the total cell population. - Treatment of a population of EECs with a plurality of small molecules can also be performed to generate subset populations comprising, for example, L-cells, K-cells, I-cells, G-cells, EC-cells, N-cells, and S-cells.
- The population of mammalian cells treated by the small molecules can be an in vitro population, such as a population of cells dispersed in a cell culture medium. An in vitro population of cells may also be in the form of organoids, which is a cell cluster or aggregate that resembles an organ, or part of an organ, and possesses cell types relevant to that particular organ (Sato, 2009). Alternatively, the population of mammalian cells treated by the small molecules may be an in vivo population, such as in vivo treatment of a human or other mammal to treat a disease state. In another alternative, the population of mammalian cells treated by the small molecules may be an ex vivo population, such as a population of cells obtained (e.g., isolated, derived) from a human or other mammal (e.g., a human or other mammal in need of treatment). A proposed mechanism for one embodiment for the differentiation of EECs from post-natal cells such as post-natal stem cells, is provided in
FIG. 34 . Without being limited by any particular theory, it is presently believed that by controlling the Wnt and Notch pathways, and optionally other pathways, the EECs can be specified from the stem cells. In particular, in the mechanism as shown provides for activating the Wnt pathway while inhibiting the Notch pathway, and then inhibiting both the Notch and Wnt pathways to form EECs. Other mechanisms and/or pathways may also be activated and/or inhibited, as described below, to further specify differentiation along the pathway towards EECs (as opposed to goblet cells, enterocytes, Paneth cells, etc.), and other mechanisms and/or pathways may also be used to further specify particular types of EECs, and/or EEC function. For example, whileFIG. 34 shows Wnt inhibition, in some embodiments it may be possible to provide the differentiation to EEC without requiring addition of a Wnt inhibitor. Also, whileFIG. 34 illustrates a two stage method for obtaining EECS, certain embodiments may also provide for just a single stage of treatment, or even 3 or more stages of treatment to achieve the EECs. Particular types of EECs that might be specified can include cells that express GLP-1, SHT, SST, gastrin, CCK, SCT, NTS, PYY, and ghrelin, among others. - In embodiments of the method of increasing insulin production of mammalian cells as described herein, treatment of the mammalian cells may result in differentiation along a similar pathway as that shown in
FIG. 34 , such as from post-natal stem cells to EECs, with the resulting cells being those that provide increased insulin production, and/or the treatment may be performed on EECs themselves, to convert these cells into cells with increased insulin production. That is, the treatment to increase insulin production of the cells can be performed simultaneously with, before, or after differentiation of post-natal stem cells into EECS, or can be performed on cells at a differentiation stage in between stem cells and EECS, as well on the post-natal stem cells or EECs themselves. Accordingly, the treatment to increase insulin production can be performed on a mammalian cell population that comprises at least one of post-natal stem cells (such as Lgr5+ cells), progenitor cells and differentiated enteroendocrine cells. -
FIG. 34 also shows the different types of intestinal cells, such as EECs, enterocytes, goblet cells, Paneth cells and stem cells and a general configuration of such cells as found in the crypts of the intestine. This figure shows that, as discussed above, the enteroendocrine (EEC) cells are typically located in such crypts, and are only present in a small percentage of the total cells therein (<1%), and thus it has been difficult to test mechanisms for disease treatment in the absence of an in vitro method for obtaining an EEC population of cells. - As discussed above, in one embodiment the plurality of small molecules provided to treat the post-natal cell population (such as a post-natal stem cell population) to achieve differentiation to EECs, and/or to treat a cell population to increase the insulin expression thereof, includes a small molecule that acts to activate and/or inhibit the Wnt pathway. The Wnt signaling pathway is a signal transduction pathway activated by binding of a Wnt protein ligand to a Frizzled family receptor. Wnt activators that can be provided as a part of a treatment can include, for example, at least one of R-Spondin 1, Wnt3a, Gsk inhibitors such as at least one of CHIR99021, LY2090314, NP031112 (Tideglusib), lithium, A1070722, SKL2001, and other agents capable of activating the Wnt signaling pathway. In one embodiment, a Wnt activator provided as a part of a plurality of small molecules can be R-Spondin 1, which is a protein belonging to the R-Spondin family. Wnt inhibitors that can be provided as a part of a treatment can include, for example, at least one of Wnt-059, Dkk family proteins (such as at least one of Dkk-1, Dkk2, Dkk3 and Dkk4), sFRPs (such as at least one of sFRP-1 and sFRP-2), antibodies against Wnt receptors such as OMP-18R5, other small molecule Wnt inhibitors such as LGK974, CWP232291, PRI-724, IQR-1, IWP2, IWP-L6, ICG-001, WIKI4, Ky02111, FH535, XAV939, NSC668036, FJ9, 3289-8625, and others (Kahn, 2014). In one embodiment, a Wnt inhibitor provided as a part of a plurality of small molecules for treatment can be Wnt-059, which has the following chemical structure:
- Derivatives and/or pharmaceutically acceptable salts of the Wnt activator and/or Wnt inhibitor may also be provided.
- Further Examples of Wnt agonists which may be suitable as Wnt activators can be found in the following Table.
-
TABLE Wnt Agonist Column A Column B Wnt Ligand Wnt1/Int-1 Wnt-2/Irp (Int-I-related protein) Wnt-2b/13 Wnt-3/Int-4 Wnt-3a Wnt-4 Wnt-5a Wnt-5b Wnt-6 Wnt-7a Wnt-7b Wnt-8a/8d Wnt-8b Wnt-9a/14 Wnt-9b/14b/15 Wnt-10a Wnt-10b/12 Wnt-11 Wnt-16 Wnt Related Protein R- Spondin 1/2/3/4Norrin GSK3b inhibitor Other Wnt modulator (hetero)arylpyrimidines Wnt Agonist IQ 1 DCA QS 11 WASP-1, ZINC00087877 WAY 316606, HCl WAY-262611, HCl HLY78 SKL2001 Cpd1 Cpd2 cmpd 109 ISX 9Cmpd 71 Cmpd 2Selumetinib (AZD6244) Radicicol (hetero)arylpyrimidines Wnt Agonist WAY 316606, HCl WAY-262611, HCl SKL2001 ISX 9 - In one embodiment the plurality of small molecules provided to treat the post-natal cell population to achieve differentiation to EECs, and/or to treat a cell population to increase the insulin expression thereof, includes a small molecule that acts to inhibit the Notch pathway. Notch inhibitors that can be provided as a part of a treatment can include, for example, at least one of DAPT; LY411575; MDL-28170; R04929097; L-685458 ((5S)-(t-Butoxycarbonylamino)-6-phenyl-(4R)hydroxy-(2R)benzylhexanoyl)-L-leu-L-phe-amide); BMS-708163 (Avagacestat); BMS-299897 (2-[(1R)-1-[[(4-Chlorophenyl)sulfonyl](2,5-difluorophenyl)amino]ethyl-5-fluorobenzenebutanoic acid); M-0752; YO-01027; MDL28170 (Sigma); LY41 1575 (N-2((2S)-2-(3,5-difluorophenyl)-2-hydroxyethanoyl)-N1-((7S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl)-1-alaninamide); ELN-46719 (2-hydroxy-valeric acid amide analog of LY41 1575; PF-03084014 ((S)-2-((S)-5,7-difluoro-1,2,3,4-tetrahydronaphthalen-3-ylamino)-N-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1H-imidazol-4-yl)pentanamide); Compound E ((2S)-2-{[(3,5-Diflurophenyl)acetyl]amino}-N-[(3S)-1-methyl-2-oxo-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepin-3-yl]propanamide; and Semagacestat (LY450139; (2S)-2-hydroxy-3-methyl-N-((1 S)-1-methyl-2-{[(1 S)-3-methyl-2-oxo-2,3,4,5-tetrahydro-1H-3-benzazepin-1-yl]amino}-2-oxoethyl)butanamide). In one embodiment, a Notch inhibitor provided as a part of a plurality of small molecules can be DAPT, also known as N—[N-(3,5-Difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester. Derivatives and/or pharmaceutically acceptable salts of the Notch inhibitor may also be provided.
- The plurality of small molecules provided for treatment may also include a small molecule that acts to inhibit the MEK/ERK pathway. This can include inhibitors of the core Ras-Raf-MEK-ERK signaling cascade, as well as inhibitors of proteins upstream or downstream of this core signaling cascade, such as EGF receptor (EGFR) inhibitors. MEK/ERK inhibitors provided for treatment can include, for example, at least one of PD0325901, AZD8330 (ARRY-424704), Refametinib (BAY 86-9766, RDEA119), Cobimetinib (GDC-0973, XL-518, RG7421), E6201, MEK162 (ARRY-438162), Pimasertib (AS703026, MSC1936369B), R04987655 (CH4987655), RO5126766 (CH5126766), Selumetinib (AZD6244, ARRY-142,886), TAK-733, Trametinib (GSK1120212), and GDC-0623, WX-554 (Zhao and Adjei, 2014), and may also and/or alternatively include EGFR inhibitors such as Erlotinib, Gefitinib, Lapatinib, Afatinib, Neratinib, AZ5104, Afatinib, PD 153035, CL-387785, AST-1306, PD 168393, Canertinib, and other EGFR inhibitors, as well as Ras and Raf inhibitors. In one embodiment, a MEK/ERK inhibitor provided as a part of a plurality of small molecules can be PD0325901, also known as N-[(2R)-2,3-Dihydroxypropoxyl]-3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]-benzamide. Derivatives and/or pharmaceutically acceptable salts of the MEK/ERK inhibitor may also be provided.
- The plurality of small molecules provided for treatment may also include a small molecules corresponding to various growth factors, such as at least one of epidermal growth factor (EGF) and Noggin. In one embodiment, the growth factors provided as a part of the small molecules for treatment include EGF and/or Noggin. Derivatives and/or pharmaceutically acceptable salts of the growth factors may also be provided. In another embodiment, the plurality of small molecules can include an HDAC Inhibitor (Histone deacetylase inhibitor). An HDAC inhibitor that can be provided as a part of the plurality of small molecules for treatment can include Tubastatin A, ACY1215, Valproic acid, SAHA, Trichostatin A, SHBA, CBHA, LAQ-824, PDX-101, LBH-589, ITF2357, PCI-24781, Compound 7 (ChemieTek), JNK-24681585 (Quisinostat) SB939 (Pracinostat), 4SC-201 (Resminostat), Tefinostat (CHR-2845), CHR-3996, CG200745, Depsipeptide (Romidepsin), Butyrate, MS-275, MGCD0103 and CI994, among others. In one embodiment, an HDAC inhibitor provided for treatment can be Tubastatin A, also called N-Hydroxy-4-(2-methyl-1,2,3,4-tetrahydro-pyrido[4,3-b]indol-5-ylmethyl)benzamide hydrochloride. Derivatives and/or pharmaceutically acceptable salts of the HDAC inhibitor may also be provided.
- Further examples of HDAC inhibitors can be found in the following Table.
-
TABLE HDAC Inhibitors Column A Column B Class Agent Hydroxamates Trichostatin A (TSA) Hydroxamates SAHA (Zolinza, vorinostat) Hydroxamates 4-iodo-SAHA Hydroxamates SBHA Hydroxamates CBHA Hydroxamates LAQ-824 Hydroxamates PDX-101 (belinostat) Hydroxamates LBH-589 (panobinostat) Hydroxamates ITF2357 (Givinostat) Hydroxamates PCI-34051 Hydroxamates PCI-24781 (Abexinostat) Hydroxamates Tubastatin A Hydroxamates CUDC-101 Hydroxamates Compound 7 Hydroxamates Oxamflatin Hydroxamates ITF2357 Hydroxamates Bufexamac Hydroxamates APHA Compound 8 Hydroxamates JNJ-26481585 (Quisinostat) Hydroxamates Suberoylanilide-d5 Hydroxamic Acid Hydroxamates HDAC Inhibitor XXIV Hydroxamates Tubacin Hydroxamates Butyrylhydroxamic acid Hydroxamates 1-Naphthohydroxamic Acid Hydroxamates MC 1568 Hydroxamates SB939 (Pracinostat) Hydroxamates 4SC-201 (Resminostat) Hydroxamates Tefinostat (CHR-2845) Hydroxamates CHR-3996 Hydroxamates CG200745 Cyclic peptide Depsipeptide (Romidepsin, FK-228, FR 901228) Cyclic peptide Trapoxin A Cyclic peptide HC Toxin Aliphatic Acid Valproic Acid Aliphatic Acid VAHA Aliphatic Acid Phenyl butyrate Aliphatic Acid Butyrate Aliphatic Acid AN-9 Benzamides MS-275 (Entinostat) Benzamides MGCD0103 (Mocetinostat) Benzamides CI994 (Tacedinaline; PD-123654; GOE-5549; Acetyldinaline) Benzamides BML-210 Hydroxamates M 344 Benzamides Chidamide Hydroxamates 4-(dimethylamino)-N-[6-(hydroxyamino)-6- oxohexyl]-benzamide Miscellaneous Luteolin Prodrug of thiol PTACH Miscellaneous L-Carnitine Miscellaneous Biphenyl-4-sulfonyl chloride Miscellaneous SIRT1/2 Inhibitor VII Hydroxamates (S)-HDAC-42 Hydroxamates Indole-3-acetamide Miscellaneous NSC 3852 Miscellaneous PPM-18 Miscellaneous Ratjadone A, Synthetic Benzamides N-(2-Aminophenyl)-N′-phenylheptanediamide Miscellaneous Dihydrochlamydocin Miscellaneous 7-Aminoindole Miscellaneous Apicidin Miscellaneous Parthenolide Hydroxamates HNHA Miscellaneous Splitomicin Benzamides RGFP109 Benzamides RGFP136 Benzamides RGFP966 Benzamides 4SC-202 Hydroxamates ACY1215 Miscellaneous ME-344 Miscellaneous Sulforaphane CF3Methyl Ketones 6H CF3Methyl Ketones 27 Aryl Ketones 25 Non classical 5 Nexturastat A Droxinostat AR-42 Romidepsin (FK228, Depsipeptide) Scriptaid Sodium Phenylbutyrate TMP269 Thailandepsin A BRD9757 LMK235 HPOB CAY10603 Tasquinimod HDAC6 Inhibitor III HDAC Inhibitor XXIV HDAC Inhibitor IV HDAC Inhibitor XIX HDAC Inhibitor XXII HDAC Inhibitor VII HDAC Inhibitor II HDAC Inhibitor VI (−)-Depudecin KD 5170 TC-H 106 TCS HDAC6 20b Pyroxamide Chidamide HDAC-IN-1 HC Toxin Hydroxamates SAHA (Zolinza, vorinostat) Hydroxamates LBH-589 (panobinostat) Hydroxamates JNJ-26481585 (Quisinostat) Cyclic peptide Depsipeptide (Romidepsin, FK-228, FR 901228) Benzamides MGCD0103 (mocetinostat) Prodrug of thiol PTACH Miscellaneous Ratjadone A, Synthetic Miscellaneous Apicidin CF3Methyl Ketones 27 Non classical 5 Nexturastat A Droxinostat Scriptaid BRD9757 HPOB CAY10603 HDAC6 Inhibitor III Hydroxamates ACY1215 Hydroxamates Tubastatin A Hydroxamates Tubacin Hydroxamates Trichostatin A (TSA) - A Histone Methylation inhibitor (e.g., Histone demethylase (HDM) inhibitor) that can be provided as a part of the plurality of small molecules for treatment can include at least one of Tranylcypromine, GSK-2879552, GSK-LSD1, SP-2509, GSK J4, 2,4-Pyridinedicarboxylic Acid, ML324,
IOX 1, OG-L002, CBB1007, GSK J1, GSK J2, and GSK J5, among others. In one embodiment, a Histone Methylation inhibitor provided for treatment can be Tranylcypromine. In an embodiment, a Histone Methylation inhibitor provided for treatment can be a lysine-specific histone demethylase (LSD1). Derivatives and/or pharmaceutically acceptable salts of the Histone Methylation inhibitor may also be provided. Examples of Histone Methylation inhibitors include: JmjC-domain demethylase: Jmjd2, Jmjd2C, Jmjd3; Lysine-specific demethylase: LSD1 inhibitors such as Tranylcypromine (LSD1), RN 1 (LSD 1), GSK2879552 (LSD1), CBB1003 (LSD1), OG-L002 (LSD1), CBB1007 (LSD1), 2,4-Pyridinedicarboxylic Acid (LSD), SP2509 (LSD1), ORY-1001 (RG-6016), GSK LSD1 (LSD1); Jmjd: Daminozide (Jmjd), GSK J1 (Jmjd3/UTX), GSK J4 (Jmjd3), IOX 1 (Jmjd), JIB 04 (Jmjd), NSC 636819 (KDM4A/KDM4B), TC-E 5002 (KDM2/7), Pargyline, ML324 (Jmjd2); - A Tgf-β inhibitor that can be provided as a part of the plurality of small molecules for treatment can include at least one of 616452 (Repsox), LY-364947, SB-505124, A-83-01, SB-431542, TGF-βRI Kinase Inhibitor VII, SB-525334, TGF-βRI Kinase Inhibitor IX, GW788388, LY2109761, Galunisertib (LY2157299), EW-7197, Pirfenidone, K02288, D 4476, R 268712, A77-01, and SM16, as well as antibodies against Tgf-β receptors. In one embodiment, a Tgf-β inhibitor provided for treatment can be 616452, also referred to as RepSox, with the chemical formula 2-[3-(6-methyl-2-pyridinyl)-1H-pyrazol-4-yl]-1,5naphthyridine. Derivatives and/or pharmaceutically acceptable salts of the Histone Methylation inhibitor may also be provided.
- Further examples of Tgf-β inhibitors can be found in the following Table
-
TGF-β Inhibitors Class Agent Alternative Name Tgf-beta-R1 inhibitor LY-364947 616451, TGF-β RI Kinase Inhibitor I, CAS 396129- 53-6, [3-(Pyridin-2-yl)-4-(4-quinonyl)]-1H-pyrazole, ALK5 Inhibitor I, LY-364947, HTS-466284 Tgf-beta-R1 inhibitor Repsox 616452, TGF-β RI Kinase Inhibitor II, CAS 446859- 33-2, 2-(3-(6-Methylpyridin-2-yl)-1H-pyrazol-4-yl)- 1,5-naphthyridine Tgf-beta-R1 inhibitor SB-505124 616453, TGF-β RI Kinase Inhibitor III, CAS 356559- 13-22-(5-Benzo[1,3]dioxol-4-yl-2-tert-butyl-1H- imidazol-4-yl)-6-methylpyridine, HCl, ALK5 Inhibitor III, SB-505124, HCl Tgf-beta-R1 inhibitor A-83-01 616454, TGF-β RI Kinase Inhibitor IV - CAS 909910- 43-6, 3-(6-Methylpyridin-2-yl)-4-(4-quinolyl)-1- phenylthiocarbamoyl-1H-pyrazole, A-83-01, ALK5 Inhibitor IV Tgf-beta-R1 inhibitor SD-208 616456, TGF-β RI Kinase Inhibitor V, CAS 627536- 09-8, 2-(5-Chloro-2-fluorophenyl)pteridin-4- yl)pyridin-4-yl amine, SD-208, ALK5 Inhibitor V Tgf-beta-R1 inhibitor SB-431542 616461, TGF-β RI Kinase Inhibitor VI, SB431542 - CAS 301836-41-9, 4-[4-(3,4- Methylenedioxyphenyl)-5-(2-pyridyl)-1H-imidazol- 2-yl]benzamide, Dihydrate, 4-[4-(1,3-Benzodioxol- 5-yl)-5-(2-pyridyl)-1H-imidazol-2-yl]benzamide, Dihydrate Tgf-beta-R1 inhibitor TGF-β RI Kinase 616458, TGF-β RI Kinase Inhibitor VII - CAS Inhibitor VII 666729-57-3, 1-(2-((6,7-Dimethoxy-4- quinolyl)oxy)-(4,5-dimethylphenyl)-1-ethanone, ALK5 Inhibitor VII Tgf-beta-R1 inhibitor SB-525334 616459, TGF-β RI Kinase Inhibitor VIII - CAS 356559-20-1, SB-525334, 6-(2-tert-Butyl-5-(6- methyl-pyridin-2-yl)-1H-imidazol-4-yl)- quinoxaline, ALK5 Inhibitor VIII Tgf-beta-R1 inhibitor TGF-β RI Kinase 616463, TGF-β RI Kinase Inhibitor IX, 4-((4-((2,6- Inhibitor IX Dimethylpyridin-3-yl)oxy)pyridin-2- yl)amino)benzenesulfonamide, ALK5 Inhibitor IX Tgf-beta-R1 inhibitor GW788388 4-(4-(3-(pyridin-2-yl)-1H-pyrazol-4-yl)pyridin-2-yl)- N-(tetrahydro-2H-pyran-4-yl)benzamide Tgf-beta-R1 inhibitor LY2109761 7-(2-morpholinoethoxy)-4-(2-(pyridin-2-yl)-5,6- dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline Tgf-beta-R1 inhibitor Galunisertib 4-(2-(6-methylpyridin-2-yl)-5,6-dihydro-4H- (LY2157299) pyrrolo[1,2-b]pyrazol-3-yl)quinoline-6- carboxamide Tgf-beta-R1 inhibitor EW-7197 N-(2-fluorophenyl)-5-(6-methyl-2-pyridinyl)-4- [1,2,4]triazolo[1,5-a]pyridin-6-yl-1H-imidazole-2- methanamine Tgfb production Pirfenidone 2(1H)-Pyridinone, 5-methyl-1-phenyl- inhibitor Tgf-beta-R1 inhibitor K02288 3-[(6-Amino-5-(3,4,5-trimethoxyphenyl)-3- pyridinyl]phenol Tgf-beta-R1 inhibitor D 4476 4-[4-(2,3-Dihydro-1,4-benzodioxin-6-yl)-5-(2- pyridinyl)-1H-imidazol-2-yl]benzamide Tgf-beta-R1 inhibitor R 268712 4-[2-Fluoro-5-[3-(6-methyl-2-pyridinyl)-1H- pyrazol-4-yl]phenyl]-1H-pyrazole-1-ethanol Other ITD 1 4-[1,1′-Biphenyl]-4-yl-1,4,5,6,7,8-hexahydro-2,7,7- trimethyl-5-oxo-3-quinolinecarboxylic acid ethyl ester Smad3 inhibitor SIS3 1,2,3,4-Tetrahydro-6,7-dimethoxy-2-[(2E)-3-(1- phenyl-1H-pyrrolo[2,3-b]pyridin-3-yl)-1-oxo-2- propenyl]-isoquinoline hydrochloride Tgf-beta-R1 inhibitor A77-01 4-[5-(6-methylpyridin-2-yl)-1H-pyrazol-4- yl]quinoline Other Asiaticoside Tgf-beta-R1 inhibitor SM16 4-(5-(benzo[d][1,3]dioxol-5-yl)-4-(6-methylpyridin- 2-yl)-1H-imidazol-2-yl)bicyclo[2.2.2]octane-1- carboxamide Tgf-beta antibody ID11 Tgf-beta antibody 2G7 Tgf-beta antibody GC-1008 Fresolimumab Tgf-beta antibody CAT-152 Lerdelimimab Tgf-beta antibody CAT-192 Metelimumab TGf-beta Receptor PF-03446962 antibody Tgf-beta antibody SR-2F Tgf-beta antibody 2G7 Tgf-beta antibody LY2382770 Tgf-beta antibody IMC-TR1 Tgf-beta antibody STX-100 TGF-beta antagonist TGF-PRII: Fc Recombinant protein betaglycan/TGF- PRIII Oligonucleotide AP12009 Trabedersen, antisense molecule inhibitor Oligonucleotide AP11014 inhibitor Oligonucleotide AP15012 inhibitor LY-550410 LY-580276 LY-364947 LY-2109761 LY-2157299 Galunisertib LY-573636 Is this TGF b inhibitor/YES SB- 505124 SB-431542 SB-525234 SD-208 SD-093 Ki-26894 NPC-30345 SX-007 IN-1130 pyrrole-imidazole Gene siliencing polyamide EW-7203 EW-7195 Structure EW-7197 GW6604 U.S. Pat. No. Pyrrole derivatives as pharmaceutical agents 7,087,626 U.S. Pat. No. Quinazoline derivatives as medicaments 6,476,031 U.S. Pat. No. Antibodies to TGF-β 7,723,486, and EP 0945464 Peptide Trx-xFoxHIb Smad-interacting peptide aptamers Peptide Trx-Lefl Peptide Distertide (pI44) Peptide pI7 Peptide LSKL dihydropyrrlipyrazole- See US Patent U.S. based scaffold Pat. No. 8,298,825 B1 imidazole-based See US Patent U.S. scaffold Pat. No. 8,298,825 B1 pyrazolopyridine-based See US Patent U.S. scaffold Pat. No. 8,298,825 B1 pyrazole-based scaffold See US Patent U.S. Pat. No. 8,298,825 B1 imidazopyridine-based See US Patent U.S. scaffold Pat. No. 8,298,825 B1 triazole-based scaffold See US Patent U.S. Pat. No. 8,298,825 B1 pyridopyrimidine-based See US Patent U.S. scaffold Pat. No. 8,298,825 B1 pyrrolopyrazole-based See US Patent U.S. scaffold Pat. No. 8,298,825 B1 isothiazole-based See US Patent U.S. scaffold Pat. No. 8,298,825 B1 oxazole-based scaffold See US Patent U.S. Pat. No. 8,298,825 B1 Tgf-beta-R1 inhibitor Repsox 616452, TGF-β RI Kinase Inhibitor II, CAS 446859- 33-2, 2-(3-(6-Methylpyridin-2-yl)-1H-pyrazol-4-yl)- 1,5-naphthyridine Tgf-beta-R1 inhibitor Galunisertib 4-(2-(6-methylpyridin-2-yl)-5,6-dihydro-4H- (LY2157299) pyrrolo[1,2-b]pyrazol-3-yl)quinoline-6- carboxamide Tgf-beta-R1 inhibitor EW-7197 N-(2-fluorophenyl)-5-(6-methyl-2-pyridinyl)-4- [1,2,4]triazolo[1,5-a]pyridin-6-yl-1H-imidazole-2- methanamine Tgfb production Pirfenidone 2(1H)-Pyridinone, 5-methyl-1-phenyl- inhibitor LY-2157299 Galunisertib Tgf-beta-R1 inhibitor SB-505124 616453, TGF-β RI Kinase Inhibitor III, CAS 356559- 13-22-(5-Benzo[1,3]dioxol-4-yl-2-tert-butyl-1H- imidazol-4-yl)-6-methylpyridine, HCl, ALK5 Inhibitor III, SB-505124, HCl Tgf-beta-R1 inhibitor SB-525334 616459, TGF-β RI Kinase Inhibitor VIII - CAS 356559-20-1, SB-525334, 6-(2-tert-Butyl-5-(6- methyl-pyridin-2-yl)-1H-imidazol-4-yl)- quinoxaline, ALK5 Inhibitor VIII Tgf-beta-R1 inhibitor TGF-β RI Kinase 616463, TGF-β RI Kinase Inhibitor IX, 4-((4-((2,6- Inhibitor IX Dimethylpyridin-3-yl)oxy)pyridin-2- yl)amino)benzenesulfonamide, ALK5 Inhibitor IX Tgf-beta-R1 inhibitor R 268712 4-[2-Fluoro-5-[3-(6-methyl-2-pyridinyl)-1H- pyrazol-4-yl]phenyl]-1H-pyrazole-1-ethanol SB- 505124 Pyridine, 2-[4-(1,3-benzodioxol-5-yl)-2-(1,1- dimethylethyl)-1H-imidazol-5-yl]-6-methyl-, hydrochloride (1:1) SD-208 IN-1130 EW-7197 Tgf-beta-R1 inhibitor A-83-01 616454, TGF-β RI Kinase Inhibitor IV - CAS 909910- 43-6, 3-(6-Methylpyridin-2-yl)-4-(4-quinolyl)-1- phenylthiocarbamoyl-1H-pyrazole, A-83-01, ALK5 Inhibitor IV Tgf-beta-R1 inhibitor SB-431542 616461, TGF-β RI Kinase Inhibitor VI, SB431542 - CAS 301836-41-9, 4-[4-(3,4- Methylenedioxyphenyl)-5-(2-pyridyl)-1H-imidazol- 2-yl]benzamide, Dihydrate, 4-[4-(1,3-Benzodioxol- 5-yl)-5-(2-pyridyl)-1H-imidazol-2-yl]benzamide, Dihydrate Tgf-beta-R1 inhibitor R 268712 4-[2-Fluoro-5-[3-(6-methyl-2-pyridinyl)-1H- pyrazol-4-yl]phenyl]-1H-pyrazole-1-ethanol - A NeuroD1 activator that can be provided as a part of the plurality of small molecules for treatment can include ISX-9 and other Isoxazole molecules (Schneider, 2008). In one embodiment, the NeuroD1 activator provided for treatment can be ISX-9, with the chemical formula N-cyclopropyl-5-(2-thienyl)-3-isoxazolecarboxamide. Derivatives and/or pharmaceutically acceptable salts of the Neuro D1 activator may also be provided.
- The plurality of small molecules provided for treatment may also include one or more monoamine oxidase (MAO) inhibitors. Examples of MAO inhibitors include Safinamide Mesylate, Rasagiline Mesylate, Tranylcypromine, Moclobemide (Ro 111163), Isatin, 8-(3-Chlorostyryl)caffeine, Bifemelane hydrochloride, (R)-(−)-Deprenyl hydrochloride, Harmane, Lazabemide hydrochloride, Pirlindole mesylate,
RN 1 dihydrochloride, and Tetrindole mesylate, among others. - The plurality of small molecules provided for treatment may also include one or more BMP receptor (including ALK2) inhibitors. Example of BMP receptor (including ALK2) inhibitors include DMH-1, DMH2, Dorspmrphin, K 02288, LDN 193189, and ML 347.
- In the treatment of cells to increase insulin expression, a plurality of small molecules that has been shown to be effective in increasing insulin expression of cells is a plurality of small molecules comprising at least one of a DNA methylation inhibitor, a Tgf-β inhibitor, and a NeuroD1 activator. In one embodiment, all three small molecules are provided together as a part of a treatment to increase insulin production in a cell population. The Tgf-β inhibitor and NeuroD1 activator may be any of those discussed above, and/or their derivatives and/or the pharmaceutically acceptable salts thereof, and in particular may correspond to 616452 and ISX-9. The structure of 616452 (Repsox) is as follows:
- The DNA Methylation inhibitor can comprise at least one of 5-Azacytidine, 5-Aza-2-deoxycytidine, RG 108, SGI 1027, Nanaomycin A, Zebularine, Lomeguatrib, SGI-110, and Nanaomycin C, among others. Examples of DNA methylation inhibitors are described in U.S. Pat. No. 8,207,142, Canada Patent No. 2,454,147, and WO 2012/087889, each of which is specifically incorporated herein by reference. In one embodiment, the DNA Methylation inhibitor comprises 5-Azacytidine. Derivatives and/or pharmaceutically acceptable salts of the DNA Methylation inhibitor may also be provided. Additional examples of DNA methylation inhibitors (e.g., DNA methyl transferase (DNMT) inhibitors) include: DNA analog 5-Azacytidine, Zebularine, Decitabine; DNMT inhibitor: Caffeic acid purum, Chlorogenic acid, (−)-Epigallocatechin gallate (EGCG), Hydralazine, Procainamide, Procaine, Psammaplin A, RG108, Fisetin, Lomeguatrib, SGI 1027, 5-Iodotubercidin, 6-Thioguanine, MG98, DC-05, and DC-517.
- Table 1 below presents a list of molecules, their abbreviation as otherwise used in the description herein, and examples of the final concentration of each reagent when used in in vitro experiments described herein.
-
TABLE 1 Summary of growth factors and small molecules used in study Reagent Name Abbreviation Final Concentration EGF E 50 ng/ ml Noggin N 100 ng/ml R- Spondin1 R 500 ng/ml CHIR99021 Chir, C 5 μM Valproic Acid Sodium Salt VPA, V 1.25 mM DAPT D 5 μM Tubastatin A Tu 10 μM Tranylcypromine Tranyl, Ty 2 μM ISX-9 ISX, I 10 μM Wnt-C59 C59, C 5 μM PD0325901 Pd 1 μM 616452/ Repsox 6 5 μM 5-Azacytidine 5-Aza, 5 1 μM - According to one embodiment, the treatment performed using the plurality of small molecules can be performed in several stages, such as a first and second stage, or even more stages. The number of stages used for treatment can be selected according to the differentiation and/or insulin expression increasing method to be performed, as well as with respect to the type of small molecules being used and the pathways being activated and/or inhibited. For example, in a method of treatment to differentiate post-natal cells such as post-natal stem cells into EECs, a first stage may be performed to contact the post-natal cells population with one or more first small molecules that upregulate Ngn3, and in a second stage the post-natal cell population may be contacted with one or more second small molecules that downregulate Ngn3 to decrease Ngn3 expression in the cells. The first and second stages according to this embodiment may promote differentiation of the post-natal cells such as post-natal stem cells towards the formation of EECs. In an embodiment of a method of increasing insulin, first through third stages may be performed to treat cells to upregulate insulin and increase expression.
- According to one aspect, a treatment to differentiate post-natal cells such as post-natal stem cells to EECs can comprise first and second stages, with a first stage including contacting the cells with first small molecules including a Notch inhibitor and a Wnt activator, and the second stage including contacting the cells with second small molecules including a Notch inhibitor and at least one of an EGFR inhibitor and a MEK/ERK inhibitor. For example, the first stage may provide R-Spondin1 and DAPT, whereas the second stage may provide DAPT and PD0325901. The second stage may also optionally include a Wnt inhibitor, such as Wnt-059. The first and second stages may also include one or more growth factors, such as EGF and/or Noggin.
- According to yet another aspect, the first stage further comprises contacting the cells with at least one of an HDAC inhibitor, a Histone Methylation Inhibitor, and a NeuroD1 Activator, such as at least one of Tubastatin A, Tranylcypromine and ISX-9. The second stage may further comprise contacting the cells with a Tgf-β inhibitor such as 616452, and/or contacting the cells with a histone methylation inhibitor, such as Tranylcypromine.
- In one embodiment, a treatment to increase insulin expression in a cell population can comprise first, second and third stages, with a first stage including contacting the cells with first small molecules including a Notch inhibitor, a Wnt activator and a DNA methylation inhibitor, a second stage including contacting the cells with second small molecules including a Notch inhibitor, optionally a Wnt inhibitor, a Tgf-β inhibitor, and a NeuroD1 activator, and a third stage including contacting the cells with third small molecules including a Notch inhibitor, optionally a Wnt inhibitor, a MEK/ERK inhibitor, and a Tgf-β inhibitor. For example, the first stage may provide R-Spondin1, DAPT, and at least one of 5-Azacytidine and 5-Aza-2-deoxycytidine, whereas the second stage may provide DAPT, Wnt-059, 616452 and ISX-9, and the third stage may provide DAPT, Wnt-059, 6116452, and PD0325901. The first, second and/or third stages may also include one or more growth factors, such as EGF and/or Noggin.
- According to yet another aspect, the first stage further comprises contacting the cells with at least one of an HDAC inhibitor, a Histone Methylation Inhibitor, and a NeuroD1 Activator, such as at least one of Tubastatin A, Tranylcypromine and ISX-9. The second stage may further comprise contacting the cells with a histone methylation inhibitor, such as Tranylcypromine.
- As described herein, the small molecules may be provided in different combinations, and in different stages of treatment, to provide for differentiation of post-natal cells such as post-natal stem cells to EECs and/or increased expression of insulin. Some embodiments of small molecule combinations for treatment are described below.
- According to one aspect, a method of differentiation can comprise treating mammalian post-natal cells such as post-natal stem cells with a plurality of small molecules including a Notch inhibitor (e.g. DAPT), a MEK/ERK inhibitor (e.g., PD0325901) and one or more growth factors (e.g., EGF and Noggin). The treatment can be conducted in a single phase.
- According to another aspect, a method of differentiation can comprise a first stage with a first set of small molecules including a Notch inhibitor (e.g. DAPT), a Wnt activator (e.g. R-Spondin1), and one or more growth factors (e.g., EGF and Noggin), and a second stage with a Notch inhibitor (e.g. DAPT), a MEK/ERK inhibitor (e.g., PD0325901), and one or more growth factors (e.g., EGF and Noggin).
- According to another aspect, a method of differentiation can comprise a first stage with a first set of small molecules including a Notch inhibitor (e.g. DAPT), a Wnt activator (e.g. R-Spondin1), and one or more growth factors (e.g., EGF and Noggin), a HDAC inhibitor (e.g. Tubastatin A) and a Histone Methylation inhibitor (e.g. Tranylcypromine), and a second stage with a Notch inhibitor (e.g. DAPT), a MEK/ERK inhibitor (e.g., PD0325901), and a Histone Methylation inhibitor (e.g. Tranylcypromine).
- According to another aspect, a method of differentiation can comprise a first stage with a first set of small molecules including a Notch inhibitor (e.g. DAPT), a Wnt activator (e.g. R-Spondin1), and one or more growth factors (e.g., EGF and Noggin), a HDAC inhibitor (e.g. Tubastatin A) and a Histone Methylation inhibitor (e.g. Tranylcypromine), and a second stage with a Notch inhibitor (e.g. DAPT), a MEK/ERK inhibitor (e.g., PD0325901), a Histone Methylation inhibitor (e.g. Tranylcypromine), and a Wnt inhibitor (e.g., WNT-059).
- According to another aspect, a method of differentiation can comprise a first stage with a first set of small molecules including a Notch inhibitor (e.g. DAPT), a Wnt activator (e.g. R-Spondin1), and one or more growth factors (e.g., EGF and Noggin), a HDAC inhibitor (e.g. Tubastatin A), a Histone Methylation inhibitor (e.g. Tranylcypromine), and a NeuroD1 activator (e.g. ISX9), and a second stage with a Notch inhibitor (e.g. DAPT), a MEK/ERK inhibitor (e.g., PD0325901), a Histone Methylation inhibitor (e.g. Tranylcypromine), a Wnt inhibitor (e.g., WNT-059), and a Tgf-β inhibitor (e.g., 616452).
- In one embodiment, a method for increasing insulin in a cell population can comprise contacting the cells with small molecules including a DNA methylation inhibitor (e.g. 5-Azacytidine and/or 5-Aza2-deoxycytidine), a Tgf-β inhibitor (e.g. 616452), and a NeuroD1 activator (e.g. ISX-9). The cell population can be contacted with the molecules in a single stage, or can be contacted with one or more of the molecules in a plurality of stages.
- In yet another aspect, a method for increasing insulin in a cell population includes a three stage process including, in a first stage, contacting the cells with a Notch inhibitor (e.g. DAPT), a Wnt activator (e.g. R-Spondin1), and a DNA methylation inhibitor (e.g. 5-Azacytidine and/or 5-Aza2-deoxycytidine), in a second stage contacting the cells with a Notch inhibitor (e.g. DAPT), a Wnt inhibitor (e.g. Wnt-059), a Tgf-β inhibitor (e.g. 616452), and a NeuroD1 activator (e.g. ISX-9), and in a third stage contacting the cells with a Notch inhibitor (e.g. DAPT), a Wnt inhibitor (e.g. Wnt-059), a Tgf-β inhibitor (e.g. 616452), and a MEK/ERK inhibitor (e.g., PD0325901). Growth factors such as EGF and Noggin can also be provided in the first stage, and the Histone Methylation inhibitor (e.g., Tranylcypromine) can be provided in the first and second stages. A HDAC inhibitor (e.g. Tubastatin A) and/or a NeuroD1 activator (e.g. ISX-9) can also be provided in the first stage.
- By performing treatment of post-natal cells such as post-natal stem cells to differentiate cells into enteroendocrine cells, a cell population having a relatively high content of EECs can be obtained. According to one aspect, a cell population having enteroendocrine cells derived from post-natal cells such as post-natal stem cells can be provided by treatment with the plurality of small molecules, wherein a fraction the enteroendocrine cells is at least about 1% of the total cell population. In another aspect, the fraction of the enteroendocrine cells in the cell population may be at least about 10%, such as from 20% to 100% of the total cell population. The cells of the cell population may also be cryopreserved for use in further in vitro or in vivo applications. The cell population is non-sorted, meaning that the cell population has not been filtered or otherwise sorted to achieve the density of the cells. According to one aspect, the differentiated cells may be capable of expressing 5-HT and/or GLP-1, as shown in the Examples included herewith.
- Also, the method of increasing insulin production described herein can result in a cell population having a relatively high fraction of insulin producing cells, such as a fraction of insulin producing cells that is at least about 0.05% of the total cell population, and even at least about 1% of the total cell population.
- The method for treating cells described herein can be performed by use of kits that provide a cell culture medium, such as matrigel, along with a cell population targeted for the treatment method, and a plurality of small molecules. The kits may also include instructions for using the kit, and other items of equipment to facilitate carrying out the treatment methods. In one embodiment, a kit includes a cell culture medium, mammalian post-natal cells such as post-natal stem cells, and a plurality of small molecules that upregulate ChgA and differentiate the post-natal cells. In another embodiment, a kit includes a cell culture medium, mammalian cells, and a plurality of small molecules that increase insulin production in the cells.
- Aspects of the disclosure are further directed to the treatment of disease states in a mammal, such as a human, using the treatment methods described herein. According to one aspect, a disease state characterized by insufficient endocrine or enteroendocrine cell products is treated, such as at least one of obesity, diabetes, irritable bowel syndrome, infectious enteritis, and inflammatory bowel disease. In another aspect, a disease state characterized by insufficient insulin production is treated, such as at least one of obesity, and Type I diabetes. Treatment of the disease state is achieved by way of administering a plurality of small molecules corresponding to any of the small molecules and/or small molecule combinations described above, to a mammal in need of such treatment. In an embodiment, all of the small molecules in a plurality of small molecules are administered (e.g., delivered) to a mammal (e.g., human) in need of such treatment simultaneously (e.g., in a single administration step). In another embodiment, the small molecules in a plurality of small molecules are administered (e.g., delivered) to a mammal (e.g., human) in need of such treatment in multiple administrations (e.g., as part of a multi-step process).
- In some embodiments, a plurality of molecules is delivered in vivo to epithelium in a subject, thereby inducing cell differentiation in situ. In particular embodiments, the plurality is delivered to multiple tissues (e.g., stomach, small intestine, colon, oral mucsosa).
- According to yet another aspect, pharmaceutical compositions comprising the plurality of small molecules can be prepared, by providing the plurality of small molecules with a pharmaceutically acceptable excipient. In one embodiment, the small molecules can be prepared as a part of a pharmaceutical composition that is capable of providing a protective formulation such that the small molecules are inhibited from breaking down when administered (e.g., orally) until they reach the target area. For example, the formulation may provide a protective coating such that the plurality of small molecules can be made to pass through the stomach to the intestine, where treatment can occur. Such a formulation can include polymeric materials such as poloxamer, and can also include pH sensitive polymers such as eudragit, to provide for release of the small molecules at a target area of the body. The formulation may also be such that release of one of more of the small molecules is controlled, for example to control the onset of release a small molecule, or to control the duration of release of a small molecule at a target area. Also, the formulation can include other compounds that can coat the stomach or gut, such as sucralfate. While a pharmaceutical composition could be administered orally, such as by a pill, gelcap, liquid, etc., other methods of administration can include via a device (e.g. a stent), as well as by a suppository, enema, and/or by a patch. In another embodiment, a cell population obtained by a method described herein may be administered by a cell therapy, such as via infusion, injection, on implant, within or on a carrier material, and may be combined with materials or devices that may be immune isolating (e.g. allogenic transplantation).
- In one embodiment, a pharmaceutical composition for treatment of a disease state characterized by insufficient insulin production can comprise a DNA methylation inhibitor, a Tgf-β inhibitor, and a NeuroD1 activator, and/or a derivative and/or pharmaceutically acceptable salt thereof, in combination with a pharmaceutically acceptable excipient. For example the composition can include 616452, ISX-9, and at least one of 5-Azacytidine and 5-Aza-2′ deoxycytidine, and/or a derivative and/or pharmaceutically acceptable salt thereof, in combination with a pharmaceutically acceptable excipient. The composition formulation is further devised such that it provides a therapeutically effective amount of the small molecule combination that is effective for treatment of the disease state in the mammal being treated.
- In another aspect, the invention relates to a method of preparing a population of cells for transplantation into a subject (e.g., a human) in need thereof. In one embodiment of this aspect, the method comprises a) isolating a population of cells (e.g., from tissue from a subject) comprising Lgr5+ cells; b) treating the cells with one or more molecules that target one or more processes selected from wnt activation, notch inhibition, Tgfβ inhibition, and epigenetic regulation (e.g., LSD1 inhibition and/or HDAC inhibition), or any combination thereof, and c) treating the cells with one or more molecules that target one or more processes selected from wnt inhibition, EGFR inhibition, MEK inhibition, ERK inhibition, epigenetic regulation (e.g. LSD1 inhibition), monoamine oxidase (MAO) inhibition, and notch inhibition, or any combination thereof. For each of steps b) and c), the cells can be treated with the molecules for various periods of time, such as, for example, greater than or equal to about 4, 8, 24, 48, 96, or 192 hrs. Generally, the molecule(s) used in steps b) and c) are used at greater than or equal to about 10, 25, 50, 100, 500, or 1000% of their IC50 values. When multiple molecules are used to treat the cells in steps b) and c), the molecules can be administered simultaneously (e.g., in one step) or separately (e.g., successively).
- In another embodiment, the method of preparing a population of cells for transplantation comprises treating a population of progenitor cells (e.g., transit amplifying cells) according to steps b) and/or c) of the preceding paragraph. According to this embodiment, the method can include both of steps b) and c), or it can include step c) without step b). When administering molecules to an in vivo population, the method can include both of steps b) and c), or step b) without step c), or step c) without step b).
- In additional embodiments, the method of preparing a population of cells for transplantation further comprises d) delivering the treated population of cells to a subject.
- In some embodiments, the cell populations described herein are used for screening of compounds for a variety of purposes (e.g., for enhancing efficiencies of EECs and their subset populations, for controlling size and functions of EECs and their subset populations in vivo, for controlling incretin expression, such as GLP-1 and/or GLP-2 expression, insulin expression, and serotonin expression, for toxicity testing).
- Mice
- Lgr5-EGFP-IRES-CreERT2, B6.129 mice and Insulin-GFP (Ins-GFP, B6.Cg-Tg(Ins1-EGFP)1Hara/J) mice were obtained from Jackson Labs, and 6- to 12-week-old mice were used for crypt cell isolation. Animal experimental procedures were approved by the Committee on Animal Care (CAC) at MIT.
- Crypt Isolation
- Crypts were isolated as previously described (Yin et al., Nature Methods, 2014). The proximal half of the small intestine was harvested, opened longitudinally and washed with cold PBS to remove luminal content. The tissue was then cut into 2 mm to 4 mm pieces with scissors and further washed 5-10 times with cold PBS by pipetting up and down using a 10 mL pipette. Tissue fragments were incubated with 2 mM EDTA in PBS for 30 min on ice. After removal of EDTA, tissue fragments were washed with PBS to release crypts. The crypts were then collected, washed, and used for cell culture. Released crypts were collected and passed through a 70 μm cell strainer. Isolated crypts were embedded in Matrigel and plated at the center of wells in a 24-well plate.
- Cell Culture
- Isolated crypts or single cells were cultured as previously described. 200-300 crypts were mixed with 40 μl of Matrigel and plated at the center of wells in a 24-well plate. Following polymerization of Matrigel, 500 μl of crypt culture media (Advanced DMEM/F12 with N2, B27, Glutamax, HEPES, and N-acetylcysteine) containing growth factors (EGF, Noggin, R-Spondin 1) and small molecules (CHIR99021 and VPA) were provided. For cell differentiation experiments, the cell culture media was changed to media containing growth factors and small molecules as listed in Table 2 following the differentiation protocol as described below. Media were changed every 1-2 days depending on the differentiation condition used.
-
TABLE 2 Small molecules and growth factors used in study Abbre- Name viation Concentration Company Cat # EGF E 50 ng/ml ThermoFisher PHG0311 Noggin N 100 ng/ml Peprotech 250-38 R-Spondin 1 R 500 ng/ml Peprotech 120-38 CHIR99021 C 4 uM Selleckchem S1263 VPA V 1.5 mM Sigma P4543 (Vaproic Acid Sodium Salt) DAPT D 5 uM Selleckchem S2215 IWP 2 I 2 uM Tocris 3533 Repsox Rep 5 uM Tocris 3742 Tubastatin A Tu 10 uM Selleckchem S8049 Tranylcypromine Tc 1.5 uM Tocris 3852 PD0325901 Pd 1 uM Selleckchem S1036 AS-703026 As 1 uM Cayman 11226 Gefitinib Ge 1 uM Cayman 13166 Wnt- C59 C59 5 uM Selleckchem S7037 - Immunostaining
- Differentiated cell colonies were collected by gently pipetting into a 1.5 ml protein Lobind Eppendorf tube. Cell culture medium was removed, and samples were washed with PBS. Organoids or cell colonies cultured in Matrigel were fixed by directly adding 4% PFA and incubating for 10-30 min at room temperature. Matrigel was then mechanically disrupted, and cells were transferred into BSA-coated Eppendorf tubes. Samples were washed with PBS, permeabilized with 0.25% Triton X-100 for 30 min and stained with primary and secondary antibodies. Antibodies used are listed in Table 3. Images were acquired by confocal microscopy (Zeiss LSM 710) or by inverted microscope (EVOS; Advanced Microscopy Group).
-
TABLE 3 Antibodies Used in Study Antibody Vendor Species Cat # Dilution ChgA Santa Cruz Goat sc-1488 1:100 ChgA Santa Cruz Rabbit sc-13090 1:100 GIP Santa Cruz Goat sc-23554 1:100 GLP-1 Abcam Rabbit ab22625 1:100 5-HT Immunostar Rabbit 20080 1:400 SST Santa Cruz Goat sc-7819 1:200 Secretin Santa Cruz Goat sc-21023 1:50 CCK-8 Immunostar Rabbit 20078 1:200 Anti- Invitrogen Donkey A-21206 1:400 Rabbit Anti-Goat Invitrogen Donkey A-11055 1:400 Anti-Goat Invitrogen Donkey A-11058 1:400 Anti- Invitrogen Donkey A-21207 1:400 Rabbit - RNA Extraction and qPCR
- Organoids or differentiated cells were harvested and RNA was extracted using RNeasy Micro Kit (Qiagen) according to the manufacturer's instruction. Quantitative real-time PCR was performed with QuantiTect Probe PCR kit (Qiagen) using commercially available primers and TaqMan probes (Life Technologies).
- GLP-1 Secretion/Release Assay
- The cells were collected in 1.5-ml Eppendorf tubes and washed with basic assay medium (HBSS supplemented with 10 mM HEPES, 0.1% fatty acid-free BSA, and no glucose, pH 7.4). The cells were incubated in the basic medium for 2 h in a thermomixer at 300 rpm. The cells were then washed and incubated in 50 μl of basic medium containing 1 mg/ml diprotin A (Sigma-Aldrich) for 1 h, and the supernatant was collected. The cells were then incubated in 50 μl of basic medium containing 1 mg/ml diprotin A and 10 mM glucose for 1 h, and the supernatant was collected. Organoids from 24-well plate were collected in 1.5-ml protein Lobind Eppendorf tubes (1 well per tube) and incubated in basal medium (Hanks' balanced salt solution (Life Technologies) supplemented with 10 mmol/L HEPES, 0.1% fatty acid-free BSA, and no glucose, PH 7.4) for 2 hours in a thermomixer at 300 rotations per minute. Organoids were then washed and incubated in 100 μl basal solution containing 1 mg/ml Diprotin A (Sigma-Aldrich) for 1 hour. the supernatant was collected and the organoids were further incubated in 100 μl basal solution containing 1 mg/ml Diprotin A and 10 mM glucose for 1 hour. The cells and organoids were then lysed in CelLytic M buffer (Sigma-Aldrich). GLP-1 concentrations in the supernatant were determined by ELISA (Multi-Species GLP-1 total ELISA, Millipore). DNA content in the cell lysate was quantified using the PicoGreen Kit and used to normalize GLP-1 content.
- Insulin Release Assay
- The cells were collected in 1.5-ml Eppendorf tubes and washed with Krebs-Ringer buffer (KRB) supplemented with 0.25% BSA, and without glucose. The cells were then incubated with KRB containing either 2 mM or 20 mM glucose for 1 h at 37° C. Supernatant was collected and insulin was measured using HTRF insulin assay (Cisbio).
- Notch Inhibitor Increases Enteroendocrine Cells (EEC) Differentiation from ISCs (
FIG. 1 ) - Intestinal stem cells can be cultured in 3D Matrigel to form organoids, in which stem cells spontaneously differentiate and generate to all intestinal epithelial cell types, including EEC. Notch inhibition with small molecule γ-secretase inhibitor (DAPT) increases EEC differentiation, with around 5%-10% of the stem cells turned into EECs, as shown in
FIG. 1 , where immunostaining of EEC marker ChgA under organoid culture conditions (ENR), or in the presence of Notch inhibitor DAPT (ENRD) conditions. DAPI was used for nucleus staining. - Screening System for EEC Differentiation (
FIG. 2 ) - To further increase the differentiation efficiency, multiple combinations of growth factors and Wnt/Notch modulators as used in the stem cell expansion and differentiation system were tested to identify a basal combination with the highest differentiation efficiency. The combination of EGF, Noggin, and DAPT (END), but without R-spondin1 or other Wnt activators/inhibitors, induced high levels of ChgA expression, as shown in
FIG. 2 , where mRNA expression of ChgA was measured for intestinal stem cells cultured under multiple conditions, including growth factors EGF (E), Noggin (N), R-spoindin 1 (R), and differentiation combinations of Wnt activator CHIR99021 (C), VPA, and Wnt inhibitor IWP-2 (I), or Notch inhibitor DAPT (D). - In conclusion, the END condition was used as a basal condition for small molecule screening.
- 96-Well Screening Platform for Small Molecules that Increase EEC Differentiation (
FIG. 3 ) - A 96-well screening system was further employed with qPCR for ChgA expression as an indicator of EEC differentiation for screening small molecule libraries, as shown in
FIG. 3 , where Lgr5 intestinal stem cells were expanded and passaged into a 96 well plate. Cells were then cultured with EGF, Noggin, and DAPT (END), as well as small molecules. After 2-3 days of differentiation, the cells lysed and ChgA expression was measured by qRT-PCR. - Positive Screening Hits (
FIG. 4 ) - Exemplary screening results were recorded, as shown in
FIG. 4 . The EGFR inhibitor Gefitinib and the MEK/ERK pathway inhibitor AS703026 increased ChgA expression. - Validation of Positive Hits (
FIG. 5 ) - Small molecules were further validated using a 24-well plate culture and the differentiation system. EGFR inhibitors (e.g., Gefitinib) or MEK/ERK inhibitors (e.g., AS703026 and PD0325901) possessed similar activity in promoting ChgA expression, and the expression of Goblet cell marker (Muc2) and Paneth cell marker (Lyz1) were not similarly increased, suggesting specific induction in the direction of EEC, as shown in
FIG. 5 , where intestinal stem cells were differentiated under END conditions with the addition of small molecules. The expression of markers of secretory lineage cells including goblet cells (Muc2), enteroendocrine cells (ChgA), and Paneth cells (Lyz1) were measured. - EEC generation was also confirmed by immunostaining against ChgA (
FIG. 35 ). In this condition, a combination of Notch and EGFR/MEK/ERK inhibition and Wnt inactivation (by R-Spondin1 withdraw) was used to induce specification of ISCs towards EEC direction. Further removing EGF and/or Noggin from the combination induced higher level ChgA expression (FIG. 36 ), but a higher cell apoptosis level was observed in these conditions (FIG. 37 ). Adding the Wnt pathway inhibitor IWP 2 (or I) or GSK3P inhibitor CHIR99021 (or C) did not further increase differentiation towards EEC (FIG. 36 ). - MAPK/ERK or EGFR Inhibitors Specifically Increase EEC Differentiation (
FIG. 6 ) - Intestinal stem cells were cultured under multiple conditions, and small molecules AS703026 (As), Gefitinib (Ge) and PD0325901 (Pd) specifically increased the expression of enteroendocrine cell marker ChgA.
- Small Molecules (e.g., as, Ge, and Pd) Decrease Ngn3 Expression During EEC Differentiation, and R-Spondin1 Promotes Ngn3 Expression (
FIG. 7 ) - During secretory cell differentiation, Ngn3 was shown to be essential for the specification of EECs. There has been prior speculation that Ngn3 positive secretory progenitors differentiate to EECs (Genes Dev. 2002). Examination of Ngn3 expression levels during in vitro differentiation of intestinal stem cells surprisingly revealed that removal of R-spondin1 induced strong reduction of Ngn3 expression, while the addition of Gefitinib (Ge), AS703026 (As), or PD0325901 (Pd) further decreased Ngn3 expression, which was not significant in the presence of R-
Spondin 1, as shown inFIG. 7 , where intestinal stem cells were cultured for 2 days under multiple conditions, and the mRNA levels of Ngn3 were measured. - Optimized Differentiation Protocol (
FIG. 8 ) - While Wnt signaling (under the provision of R-Spondin1) encourages initial specification of EECs to promote Ngn3 expression, Ngn3 expression is subsequently downregulated thereafter during the maturation of EECs. This is consistent with the transit expression of Ngn3 during EEC specification (Genes Dev. 2002). Thus, a 2-step differentiation protocol was tested aiming to increase Ngn3 expression and subsequent EEC differentiation. An initial (first) prime step with R-
Spondin 1 and Notch inhibitor DAPT was added to permit the upregulation of Ngn3, followed by a second step without Wnt activation and with small molecules (e.g., Pd) to allow terminal differentiation of EECs, as shown inFIG. 8 , where an initial step with the presence of R-spondin1 was added to the differentiation protocol to increase Ngn3 expression instep 1. - Ngn3 Expression at 24 h During EEC Differentiation (
FIG. 9 ) - Ngn3 expression was measured after 24 hours under multiple conditions. In the presence of R-spondin1 and Notch inhibitor DAPT, Ngn3 expression was greatly induced, as shown in
FIG. 9 , where the combination of R-Spondin 1 and Notch inhibitor DAPT increased Ngn3 expression. - Expression of Key Markers of EEC During Differentiation at Day 3 (
FIG. 10 ) - Switching of the culture media to conditions without Wnt agonist or R-
Spondin 1 and with Pd for an additional 2 days showed the Ngn3 expression level was decreased and the ChgA expression was upregulated compared to conditions with R-spondin1 or without Pd, as shown inFIG. 10 , where the 2-step differentiation protocol decreased Ngn3 expression and increased ChgA expression atDay 3. The late stage EEC marker NeuroD1 was also increased, further shown inFIG. 10 . - Time Course Study of Key Genes During EEC Differentiation (
FIGS. 11, 12 and 13 ) - A time course study of EEC marker expression suggested the 2-step differentiation protocol effectively increased Ngn3 levels in the first step and decreased Ngn3 and increased ChgA levels during the 2nd step. NeuroD1 showed an intermediate change trend compared with Ngn3 and ChgA, suggesting NeuroD1 expressed after Ngn3, but before ChgA. The 2-step protocol induced highest ChgA expression following 5 days of treatment, as shown in
FIG. 11 , and effectively induced EEC differentiation from ISCs, as shown inFIG. 12 (2-step protocol increased EEC marker ChgA expression after 5 days differentiation) andFIG. 13 (2-Step protocol increased EEC differentiation by staining EEC marker ChgA following 5 days differentiation), with less cell apoptosis (FIG. 38 ) than direct Wnt, Notch and MEK/ERK inactivation (D.Pd or D.Pd. C59 condition). - Further Improvement of Differentiation Protocol by Additional Small Molecules (
FIG. 14 ) - In an effort to increase Ngn3 levels during the first step for promotion of differentiation of EEC, factors that increased Ngn3 expression were identified via additional screening under ENRD conditions. More than 80 small molecules and growth factors were screened, and Tubastatin A and Tranylcypromine were found to increase Ngn3 expression, as shown in
FIG. 14 , where following 2 days of differentiation, Tranylcypromine (Tranyl) increased both Ngn3 and ChgA levels, while Tubastatin A increased Ngn3 levels, but decreased ChgA levels. However, while Tranylcypromine also increased ChgA expression, it was noted that Tubastatin A decreased ChgA expression (also shown inFIG. 14 ). - Tubastatin A (Tu) Increases EEC Differentiation when Added in
Step 1 of the Differentiation Protocol (FIG. 15 ) - Tubastatin A was applied in
step 1, but Tranylcypromine was applied in both steps during the differentiation. Under these conditions, both compounds increased EEC marker ChgA expression following 5 days of the 2-step differentiation protocol, and the expression of markers for K cell (Gip), L cell (Gcg), and I cell (Cck) were also increased, as shown inFIG. 15 with mRNA expression of markers for cells including goblet cells (Muc2), enteroendocrine cells (ChgA), Paneth cells (Lyz1) and K-cells (Gip); and as shown inFIG. 16 with mRNA expression of markers of multiple cell types including goblet cells (Muc2), enteroendocrine cells (ChgA), Paneth cells (Lyz1), K-cells (Gip), L-cells (Gcg) and I-cells (Cck); and as shown inFIGS. 39A-39C . - It is worth noting that the addition of Tranylcypromine also significantly decreased the expression of Goblet cell (Muc2) and Paneth cell (Lyz1) markers, suggesting specific induction of EEC differentiation, further indicated in
FIG. 16 . - Removing EGF Further Increased Differentiation of EEC (
FIG. 17 ) - In addition, as Pd/As targets the MEK/ERK pathway, which is one of the downstream targets of the EGF pathway, the effect of EGF was tested in the differentiation. Removing EGF from the media further increased EEC marker (viz., ChgA, Gip, Gcg, and CCK) expression, as shown in
FIG. 17 andFIG. 39D , where intestinal stem cells were differentiated in multiple conditions for 5 days and markers for enteroendocrine cells such as ChgA, Gip, Gcg and Cck were measured by qPCR, but there tended to be more dead cells in the lumen of the differentiated cell colony when EGF was removed in both steps, likely due to EGF's role in promoting cell survival (e.g., PI3K). Therefore, EGF was kept in the first step of the differentiation process. The effect of Noggin instep 2 was marginal thus it was removed from the composition. - Improved Differentiation Protocol (
FIG. 18 ) - To characterize EECs generated from intestinal stem cells, the cells were differentiated using the conditions identified and shown in
FIG. 18 . - Highly Efficient EEC Differentiation from ISC (
FIG. 19 ) - Immunofluorescence staining was performed against markers for EECs. In intestinal organoid culture (ENR conditions), only very few cells differentiated to EECs, indicated by the number of ChgA+ or GLP-1+ cells in the organoids, as shown in
FIG. 19 , top panel, where ISCs were expanded under ENRCV conditions and further differentiated in conditions, as indicated. Immunostaining against markers for enteroendocrine cells (e.g., ChgA) or multiple subtypes of EEC were also performed. DAPI was used for nucleus staining. These findings were consistent with previous reports (Diabetes, 2014). Under controlled differentiation conditions, most of the cells turned to EECs following a 5 day differentiation protocol, and the generation of EEC subtypes was also elevated (seeFIG. 19 ). Interestingly, most of the EECs appear to be serotonin secreting cells, indicated by strong 5-HT staining (seeFIG. 19 ). GLP-1 release from differentiated L cells was further tested. Other EEC subtypes also existed at higher frequency, as identified by positive staining of markers such as GLP-1, GIP, and SST. The differentiation protocol significantly increased GLP-1 secretion from the organoids, and 10 mM glucose stimulation induced a 5-fold increase of GLP-1 secretion, as shown inFIG. 20 (Functional L cell (GLP-1) generated from ISC), where secretion of GLP-1 was measured in cells cultured in conditions, as indicated, and suggesting that these EECs were mature and functional (FIG. 40C ). - In EEC differentiation, Wnt signaling activity is required in the first step of induction, while not necessary in the second step of EEC specification. In the 2-step differentiation protocol described herein, although the 1st step with Wnt activation increased Ngn3 expression, it also induced Paneth cell differentiation, which further may secret Wnt ligand and activate Wnt pathway in
step 2. This is consistent with higher level of Paneth cell marker Lyz1 expression comparing with the END.Pd condition, where the initial Wnt inactivation step prevented the generation of Paneth cell in the first place (FIG. 39E ). Thus, inhibiting Wnt signaling with a small molecule inhibitor (Wnt-059 or C59) instep 2 was tested. C59 effectively decreased Paneth cell marker Lyz1 expression suggesting it prevented Paneth cell differentiation instep 2. And it further increased ChgA expression indicating higher level of EEC differentiation (FIG. 40A ). Delayed addition of C59 for 12-24 hours instep 2 further increases ChgA expression possibility due to higher level of Ngn3 induction in step 1 (FIG. 40A ). Similarly, addition of Tgf-inhibitor (Repsox, Rep) greatly promoted ChgA expression and decreased goblet cell marker Muc2 expression (FIG. 40A ,FIG. 41A ). Rep also greatly increased the expression of mature EEC markers (Gcg, Gip, Cck, Tph1, Sst, Sct, Pyy), in a range of 120× (Tph1), 300× (Sct), 430× (Cck), 800× (Gip), up to 15,000× (Pyy) over the expression level in the ENR condition. It was found that adding Repsox instep 1 is sufficient to induce comparable level of ChgA with adding it in both steps, but the expression of mature EEC markers was greatly reduced (FIG. 41B ), suggesting Tgf-β inhibition induces both EEC specification and further maturation. Interestingly, the addition of Repsox induce the colonies to expel apoptotic cells from the lumen (FIG. 41C ), and form high purity EEC cell colonies. - Using the optimized differentiation (
FIG. 40B ), the change in expression of key differentiation genes during the differentiation process was tested (FIG. 40C ). The stem cell gene Lgr5 was slightly upregulated atday 2 likely due to increase in Paneth cell differentiation or Notch downregulation (Tian et al., 2015). Sox9 expression was implicated in the regulation of ISC and EEC differentiation (Formeister et al., 2009), and plays an important role in pancreas endocrine cell differentiation, partially by induction of Ngn3 expression. It was found that Sox9 was initially upregulated and then downregulated starting fromday 2, which showed a similar expression pattern as Lgr5. Sox9 expression was maintained at a relatively high level compare with Lgr5, consistent with its expression in EECs (Formeister et al., 2009). The expression of Hes1, which is a downstream gene of activated Notch signaling, was downregulated. The expression of multiple Notch target genes was similarly regulated, including Math1/Atoh1, Ngn3, and NeuroD1, which included an initial upregulation phase and then a downregulation phase. And the expression of ChgA continuously increased, consistent with gradually increased EEC differentiation. Interestingly, the upregulation rates of these genes to reach peak levels (day 2 for Sox9, Math1, Ngn3, NeuroD1 andday 5 for ChgA) were different, with the order of Sox9, Math1, Ngn3, NeuroD1, and ChgA (FIG. 40D ). This likely reflects the natural gene regulation process of these genes. - Immunofluorescence staining was performed to identify different EEC subtypes generated in our cultures. A high frequency of multiple EEC subtypes was found to exist in the colonies, identified by positive staining for GIP, GLP1, Serotonin, CCK, SCT and SST (
FIG. 40E ). Interestingly, it was found that 2 populations of ChgA positive cells in the differentiated EEC colonies, where a ChgA highly expressed population colocalize with serotonin expressing cells, and a ChgA low population colocalize with GLP-1, GIP, CCK, SST, and SCT expressing cells (FIG. 40E ). - Additional Factors Increase EEC Differentiation (
FIG. 21 ) - Additional molecules were identified that can further increase EEC differentiation, as shown in
FIG. 21 , where small molecules including Wnt-059 and ISX-9 and their combination further increased ChgA expression of the differentiated cells. Control: previous differentiation conditions. - Expression of Functional EEC Marker Under Multiple Conditions (
FIG. 22 ) - Tgf-
β inhibitor 616452 was found to greatly increase the expression of functional EEC markers such as Gip, Gcg, Cck, Pyy, among others, while ISX9 decreased their expression, as inFIG. 22 showing relative expression to reference gene Hprt. As such, the differentiation protocol was adjusted to include 616452 and remove ISX9 at later stages, as inFIG. 23 , showing the differentiation protocol for EEC differentiation from ISC. - Converting ChgA Positive EEC Cells to Insulin Producing Cells
- The combination of 5-Aza (5), 616452 (6) and Wnt-059 (C) induce Insulin-GFP expression in differentiated intestinal stem cells at day 5 (
FIG. 24 ) - Because EEC and insulin producing beta cells share many similarities, recent data indicates that EECs can be converted to insulin producing cells with additional small molecules. Insulin-GFP cells isolated from Insulin-GFP transgenic mice were used to identify small molecules able to induce insulin production. During EEC differentiation from ISCs, Insulin-GFP positive cells were observed when the cells were cultured in the presence of Tgf-
β inhibitor 616452, with about 1% of cells becoming GFP positive. Further addition of Wnt inhibitor Wnt-059 and a DNA methylation inhibitor 5-Aza (5-Azacytidine) subsequently increased the percentage of Insulin-GFP+ cells, as inFIG. 24 , showing FACS analysis of GFP+ cell percentage and quantification of GFP+ cell number in one well of 24-well plate. Notably, the combination of 56C (5-Aza, 616452, Wnt-059) results in the highest number of GFP+ cells (seeFIG. 24 ). - Dose Response of 5-Aza in Inducing Insulin-GFP Expression at
Day 5, and Dose Response of 616452 in Inducing Insulin-GFP Expression at Day 5 (FIG. 25 ) - Small molecules 5-Aza and 616452 also induced cell death in the culture, thus, the optimal concentration of 5-Aza (see
FIG. 25 ) and 616452 (seeFIG. 26 ) was determined. From this, 0.5-1 μM of 5-Aza and 5 μM of 616452 were used in future experiments. - ISX-9 (I) Further Increased Insulin-GFP Expression after 5 Days in Culture (
FIG. 27 ) - The addition of ISX9 (I) in the combination was also found to further increase the number of GFP+ cells (see
FIG. 27 ), and a concentration of 10 μM was used, as inFIG. 28 , where dose response data for ISX-9 in inducing insulin-GFP expression atday 5 is shown. - FACS Analysis of Insulin-GFP Expression of Cells in Multiple Conditions after 5 Days in Culture (
FIG. 29 ) - Wnt signaling was also tested in the two steps of conversion. Increasing Wnt activation in
Step 1 by adding CHIR99021 did not increase GFP expression, while the combination of R-Spondin1 and Wnt-059 results in highest number of GFP+ cells in the system, as shown inFIG. 29 , where N: none; CHIR: CHIR99201; and C59: Wnt-059. - GFP and Brightfield of Cells Treated without or with Drugs at Day 7 (
FIG. 30 ) - Under the conditions as in Example 29, and after 7 days of differentiation, up to 20% of the cells expressed Insulin-GFP, as shown in
FIG. 30 , where control: cells cultured in EEC differentiation condition. (ENR.D.Tu.Ty atday 1 and D.Pd.Ty.C59 from Day 2). drugs added include 5-Aza, 616452, and ISX9; Pd was added atday 4 instead ofday 2; and scale bars: 200 μm. - Gene Expression in the Process (
FIG. 31 ) - Cells turned on expression of major transcription factors that are important for insulin expression, such as Pdx1, Ngn3, Mafa, NeuroD1, Nkx6.1, and Nkx2.2, and greatly increased insulin mRNA expression, as shown in
FIG. 31 , where control conditions were ENR.D.Tu.Ty.5Aza.616452.ISX9, with 5Aza removed fromDay 2; for drug treatment, cells were first cultured with ENR.D.Tu.Ty.5Aza.616452.ISX9, and changed to D.Ty.616452.ISX9.C59 conditions atDay 2, with Pd0325901 added atDay 4; and atday 0, all cells were cultured under ENR.CV conditions. - Treatment of Cells with Low (2 mM) and High (20 mM) Concentration of Glucose Induce Different Level of Insulin Release (
FIG. 32 ) - Release of insulin from the differentiated cells was tested. Treatment of the cells with glucose induced dose dependent insulin release, suggesting these cells are functional and responsive to glucose, as shown in
FIG. 32 . - Flow Diagram of Differentiation Protocol (
FIG. 33 ) - Factors in blue and green represent important factors. Orange indicates supportive factors. Also listed are key events during differentiation, and key markers for each stage, as shown in
FIG. 33 . - Model of In Vivo EEC Differentiation Controlled by Wnt and Notch Pathways (
FIG. 34 ) - The activity of Notch pathway is modulated through trans-activation or cis-inhibition. The Notch pathway is activated through binding of a Notch receptor with Notch Ligands (DLLs) on neighbor cells (i.e., secretory cells such as Paneth cells, EEC and goblet cells, or secretory cell progenirors). Lose contact with these cells leads to Notch inactivation, which is further enhanced through cis-inhibition. The Wnt pathway is activated through a Wnt ligand gradient derived from cells in the laminal propria, or Paneth cells located at the bottom of crypts. Leave the crypt bottom leads to Wnt inactivation. Notch inactivation also leads to derepression of the Wnt signaling pathway, while attenuation of the Wnt pathway rescues the phenotype associated with Notch blockade. (Tian et al., Cell Reports, 2015). For EEC differentiation, Notch inactivation induced Atoh1 expression and further induced Ngn3 upregulation when Wnt pathway is (moderately) activated (i.e., when Wnt is deactivated before Notch inactivation, Atoh1 will be induced, but not Ngn3, leading to goblet cell differentiation). Ngn3 positive cells further differentiate to EEC upon Wnt inactivation. And continuously (strong) Wnt activation upon Notch inactivation leads to Paneth cell fate. Small molecule drugs such as 5-Aza, Tgf-b inhibitor, ISX-9, or other drugs may act on multiple cell types, including the stem cells, progenitor cells, or differentiated enteroendocrine cells and induce insulin expression in these cells, as shown in
FIG. 34 . - Temporally Combined Chemical Control of High Efficiency Enteroendocrine Cell Differentiation.
- In the study described hereinabove, several signaling pathways that play important roles in the specification of EEC were identified. Notch pathway has been shown to determine absorptive or secretory differentiation, and its inactivation is necessary for the specification of secretory cells including goblet cells, Paneth cells, tufts cells and enteroendocrine cells. Further down the differentiation road, Wnt pathway plays important role in goblet cell and Paneth cell fate determination, with its activation inducing Paneth cell fate and its inactivation inducing goblet cell fate. The role of Wnt in EEC differentiation has been less clear. As described herein, Wnt activation is important for Ngn3 expression for the specification of EEC, and subsequent Wnt inactivation helps further differentiation of EEC and maturation of multiple EEC subtypes (
FIG. 34 ). - The differentiation of intestinal stem cells in vivo is a dynamic process, where the cells move upwards (except for Paneth cells) during differentiation. The signaling gradient along the crypt-villus axis influences the fate determination for the differentiating stem and progenitor cells during the differentiation/migration process. While the specification of stem/progenitor cells initiates above the crypt bottom, where cell membrane bounded Wnt ligand (secreted by Paneth cells) was diluted through cell division, the R-Spondin/Lgr signaling module prolong the Wnt activation when the stem cells left contact with niche cells—the Paneth cells (Farin et al, 2016, Nature). This mechanism permits the induction of Ngn3 expression upon Notch inactivation. Thus, the sequence and level of Wnt/Notch inactivation seems to play a role in the fate determination of secretory progenitors. And the location of secretory progenitor cells correspondingly help the cells make the choice. For instance, earlier inactivation of Notch in the presence of low level of Wnt activation may favor a EEC fate due to induction of Ngn3 (e.g. at the +4 position), and earlier inactivation of Wnt signaling followed by inactivation of Notch signaling may promote goblet cell differentiation due to low level of Ngn3 induction (e.g. above +4 position), while strong activation of Wnt signaling and Notch inactivation favors Paneth cell fate (e.g. in the crypts). Thus, the differentiation of EEC and other intestinal epithelial cell types from intestinal stem cells is a spatially and temporally preciously controlled process.
- While Wnt and Notch pathways play an instrumental role in stem cell differentiation including EECs, other signaling pathways also participate in the differentiation process. As described herein, the inhibition of EGFR/MEK/ERK signaling cascade increased the level of EEC differentiation, and inhibition of Tgf-β also greatly promoted the EEC specification and maturation. Epigenetic regulation also takes part in the differentiation process such as HDAC and Histone demethylation. The specific combination of these pathways controls the fate of ISCs and progenitors.
- Based on the protocol to convert gastrointestinal stem cells into insulin producing cells, a 3-stage process was developed, specifically, Day 0-1 as
Stage 1, Day 1-3 asStage 2, Day 3-5 asStage 3. AfterStage 3, the cells turn on significant level of Insulin expression as indicated by Ins-EGFP expression and qPCR for Insulin mRNA expression. Optionally, the cells can be further cultured for 1-2 weeks, asStage 4. For each stage, a set of specific combination of small molecules (and/or growth factors) were added. The objective was to optimize the reprogramming protocol to increase insulin expression, specifically Insulin mRNA expression for each stage, by screening and testing new small molecules (or growth factors). - RepSox(616452) was previously added in Stages 2-3. It was found that when RepSox(616452) was added starting from Stage 1 (i.e. added in Stage 1-3), Insulin mRNA (Ins2) was increased as compared when RepSox was added in Stage 2-3. When combined with FGF10 (added in Stage 1), Insulin expression was further increased, as shown in
FIG. 42 . - It was found that when extending the treatment time of 5Aza (5-aza-2′-deoxycytidine) from
Stage 1 only to Stage 1 andStage 2, Insulin mRNA expression was slightly increased (FIG. 43 ). - In
Stage 2, when the addition of Wnt-059 was delayed for 12 hours, Insulin mRNA expression was increased. This delayed Wnt inhibition may have permitted a higher level of Ngn3 expression in the cells (as Ngn3 expression requires Wnt activity), which further increases Insulin mRNA expression (FIG. 44 ). - Another small molecule,
BayK 8644, which is an L-type Ca2+ channel activator, increased Insulin mRNA expression when added inStage 1, as shown inFIG. 45 . -
BayK 8644 showed highested activity when used at 2 (FIG. 46 ). -
BayK 8644 treatment showed highest activity when added in Stages 1-3 (FIG. 47 ). - The optimal concentration of DAPT was 5 (
FIG. 48 ). - Nkx6.1 is an important transcription factor for Insulin expression and Islet function. Additional factors were tested for an ability to increase Nkx6.1 expression as well as Insulin expression.
- IOX1, which is a Histone demethylase JMJD inhibitor, increased Insulin and Nkx6.1 expression when used at 5-10 μM (
FIG. 49 ) - The effects of RepSox and ISX9 were also tested to identify optimal concentration in promoting insulin and Nkx6.1 expression. It was found that the optimal dose of RepSox was 10-15 μM and ISX9 was 10-20 μM in promoting Insulin and Nkx6.1 expression (
FIGS. 50-51 ). - For Wnt-059, the optimal dose was 5 (
FIG. 52 ). - In addition, it was found that the Bone Morphogenic Protein (BMP) ALK2 receptor inhibitor DMH-1 increased the expression of Nkx6.1 as well as insulin, when added in Stages 2-3 (
FIG. 53 ). - In addition, Dexamethasone also increased Nkx6.1 and Insulin expression when added in Stages 2-3 (
FIG. 54 ). - Vitamin C had beneficial effects when added in Stage 2-3.
- The ability of additional small molecules (growth factors) to promote insulin expression in
Stage 3 was further tested. - When small molecule T3 (Triiodothyronine) was added in
Stage 3, it greatly increased Insulin mRNA expression. While Vitamin C (pVc) did not show such effect, as shown inFIG. 55 . - Similarly, additional molecules including N-Acetylcysteine (2 mM) also increased Insulin mRNA expression, and further increased Insulin expression when combined with T3, as shown in
FIG. 56 . - It was also found that by switching Wnt-059 with CHIR99021 (CHIR) in
Stage 3, insulin mRNA was greatly increased, as shown inFIG. 57 . When CHIR and T3 are combined, Insulin mRNA was further increased. - Additional small molecules or factors including Exendin-4 (Ex4) and Aurora Kinase Inhibitor II (AKi) were identified to increase Insulin mRNA expression, as shown in
FIG. 58 . It was also found that Forskolin (50-100 μM) improved cell survival when added inStage 3. - In addition, thyroid hormone beta-receptor agonist GC-1 was used to replace T3 and showed a similar effect in promoting insulin mRNA expression (
FIG. 59 ). - By using a combination of these identified factors, insulin expression and insulin-GFP expression was induced in 5 days from intestinal stem cells. Continue culturing the cells further increased insulin expression level and led to islet-like cell colonies as shown in
FIG. 60 . - For continuing culture of Islet-like Insulin expression cell colonies, it was found that the addition of Forskolin increased cell survival. Factors including DAPT, PD0325901, BayK8644, DMH-1 could be removed without much influence, as shown in
FIG. 61 . - Additional data for EEC differentiation.
- Based on observations as described herein, a modified flow diagram for EEC differentiation was developed (
FIG. 61 ) as indicated below. - Major Differences:
-
- 1. Add RepSox(616452) start from
Day 0 instead ofDay 1. - 2. ISX-9 changed to optional, and not used in protocol as described in EEC-V6.docx.
- 3. Repsox changed to essential factors as it greatly increased EEC differentiation as described in EEC-V6.docx.
- 4. Wnt-059 added at 36 h from
Day 0.
- 1. Add RepSox(616452) start from
- From the foregoing description, it will be apparent that variations and modifications may be made to the disclosure described herein to adopt it to various usages and conditions. Methods and materials are described herein for use in the present disclosure; other, suitable methods and materials known in the art can also be used. The materials, methods, and examples are illustrative only and not intended to be limiting. Such embodiments are also within the scope of the following claims. The recitation of a listing of elements in any definition of a variable herein includes definitions of that variable as any single element or combination (or subcombination) of listed elements. The recitation of an embodiment herein includes that embodiment as any single embodiment or in combination with any other embodiments or portions thereof. The teachings of all patents, published applications and references cited herein are incorporated by reference in their entirety. While this invention has been particularly shown and described with references to example embodiments thereof, it will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the scope of the invention encompassed by the appended claims.
- The teachings of all patents, published applications and references cited herein are incorporated by reference in their entirety.
- While this invention has been particularly shown and described with references to example embodiments thereof, it will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the scope of the invention encompassed by the appended claims.
-
- Barker, N., van Es, J. H., Kuipers, J., Kujala, P., van den Born, M., Cozijnsen, M., Haegebarth, A., Korving, J., Begthel, H., Peters, P. J., et al. (2007). Identification of stem cells in small intestine and colon by marker gene Lgr5. Nature 449, 1003-1007.
- Farin, H. F., Van Es, J. H., and Clevers, H. (2012). Redundant sources of Wnt regulate intestinal stem cells and promote formation of Paneth cells. Gastroenterology 143, 1518-1529 e1517.
- Formeister, E. J., Sionas, A. L., Lorance, D. K., Barkley, C. L., Lee, G. H., and Magness, S. T. (2009). Distinct SOX9 levels differentially mark stem/progenitor populations and enteroendocrine cells of the small intestine epithelium. Am J Physiol Gastrointest Liver Physiol 296, G1108-1118.
- Furness, J. B., Rivera, L. R., Cho, H. J., Bravo, D. M., and Callaghan, B. (2013). The gut as a sensory organ. Nat
Rev Gastroenterol Hepatol 10, 729-740. - Gribble, F. M., and Reimann, F. (2015). Enteroendocrine Cells: Chemosensors in the Intestinal Epithelium. Annu Rev Physiol.
- Gunawardene, A. R., Corfe, B. M., and Staton, C. A. (2011). Classification and functions of enteroendocrine cells of the lower gastrointestinal tract. Int J Exp Pathol 92, 219-231.
- Lee, C. S., Perreault, N., Brestelli, J. E., and Kaestner, K. H. (2002).
Neurogenin 3 is essential for the proper specification of gastric enteroendocrine cells and the maintenance of gastric epithelial cell identity. Genes Dev 16, 1488-1497. - Sato, T., and Clevers, H. (2013). Growing self-organizing mini-guts from a single intestinal stem cell: mechanism and applications. Science 340, 1190-1194.
- Sato, T., van Es, J. H., Snippert, H. J., Stange, D. E., Vries, R. G., van den Born, M., Barker, N., Shroyer, N. F., van de Wetering, M., and Clevers, H. (2011). Paneth cells constitute the niche for Lgr5 stem cells in intestinal crypts. Nature 469, 415-418.
- Sato, T., Vries, R. G., Snippert, H. J., van de Wetering, M., Barker, N., Stange, D. E., van Es, J. H., Abo, A., Kujala, P., Peters, P. J., et al. (2009). Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche. Nature 459, 262-265.
- Tian, H., Biehs, B., Chiu, C., Siebel, C. W., Wu, Y., Costa, M., de Sauvage, F. J., and Klein, O. D. (2015). Opposing activities of Notch and Wnt signaling regulate intestinal stem cells and gut homeostasis.
Cell Rep 11, 33-42. - VanDussen, K. L., Carulli, A. J., Keeley, T. M., Patel, S. R., Puthoff, B. J., Magness, S. T., Tran, I. T., Maillard, I., Siebel, C., Kolterud, A., et al. (2012). Notch signaling modulates proliferation and differentiation of intestinal crypt base columnar stem cells. Development 139, 488-497.
- Yin, X., Farin, H. F., van Es, J. H., Clevers, H., Langer, R., and Karp, J. M. (2014). Niche-independent high-purity cultures of Lgr5+ intestinal stem cells and their progeny.
Nat Methods 11, 106-112. - Mumphrey, M. B., et al., Roux-en-Y gastric bypass surgery increases number but not density of CCK-, GLP-1-, 5-HT-, and neurotensin-expressing enteroendocrine cells in rats. Neurogastroenterol Motil, 2013. 25(1): p. e70-9.
- Moran, G. W., et al., Enteroendocrine cells: neglected players in gastrointestinal disorders? Therap Adv Gastroenterol, 2008. 1(1): p. 51-60.
- Bogunovic, M., et al., Enteroendocrine cells express functional Toll-like receptors. Am J Physiol Gastrointest Liver Physiol, 2007. 292(6): p. G1770-83.
- Worthington, J. J., The intestinal immunoendocrine axis: novel cross-talk between enteroendocrine cells and the immune system during infection and inflammatory disease. Biochem Soc Trans, 2015. 43(4): p. 727-33.
- Manocha, M. and W. I. Khan, Serotonin and GI Disorders: An Update on Clinical and Experimental Studies. Clin Transl Gastroenterol, 2012. 3: p. e13.
- Sternini, C., L. Anselmi, and E. Rozengurt, Enteroendocrine cells: a site of ‘taste’ in gastrointestinal chemosensing. Curr Opin Endocrinol Diabetes Obes, 2008. 15(1): p. 73-8.
- van der Flier, L. G. and H. Clevers, Stem cells, self-renewal, and differentiation in the intestinal epithelium. Annu Rev Physiol, 2009. 71: p. 241-60.
- Petersen, N., et al., Generation of L cells in mouse and human small intestine organoids. Diabetes, 2014. 63(2): p. 410-20.
- Beucher, A., et al., The homeodomain-containing transcription factors Arx and Pax4 control enteroendocrine subtype specification in mice. PLoS One, 2012. 7(5): p. e36449.
Claims (30)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/334,933 US20210363491A1 (en) | 2016-01-08 | 2021-05-31 | Production of insulin producing cells |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662276814P | 2016-01-08 | 2016-01-08 | |
US15/400,877 US11021687B2 (en) | 2016-01-08 | 2017-01-06 | Production of differentiated enteroendocrine cells and insulin producing cells |
US17/334,933 US20210363491A1 (en) | 2016-01-08 | 2021-05-31 | Production of insulin producing cells |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/400,877 Division US11021687B2 (en) | 2016-01-08 | 2017-01-06 | Production of differentiated enteroendocrine cells and insulin producing cells |
Publications (1)
Publication Number | Publication Date |
---|---|
US20210363491A1 true US20210363491A1 (en) | 2021-11-25 |
Family
ID=57956378
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/400,877 Active US11021687B2 (en) | 2016-01-08 | 2017-01-06 | Production of differentiated enteroendocrine cells and insulin producing cells |
US17/334,933 Pending US20210363491A1 (en) | 2016-01-08 | 2021-05-31 | Production of insulin producing cells |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/400,877 Active US11021687B2 (en) | 2016-01-08 | 2017-01-06 | Production of differentiated enteroendocrine cells and insulin producing cells |
Country Status (7)
Country | Link |
---|---|
US (2) | US11021687B2 (en) |
EP (1) | EP3400286A1 (en) |
JP (2) | JP2019506153A (en) |
CN (1) | CN108779437A (en) |
AU (1) | AU2017205194A1 (en) |
CA (1) | CA3010610A1 (en) |
WO (1) | WO2017120543A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11369607B2 (en) | 2014-09-03 | 2022-06-28 | The Brigham And Women's Hospital, Inc. | Compositions, systems, and methods for generating inner ear hair cells for treatment of hearing loss |
US11617745B2 (en) | 2018-08-17 | 2023-04-04 | Frequency Therapeutics, Inc. | Compositions and methods for generating hair cells by downregulating FOXO |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011140441A2 (en) | 2010-05-06 | 2011-11-10 | Children's Hospital Medical Center | Methods and systems for converting precursor cells into intestinal tissues through directed differentiation |
EP3702443B1 (en) | 2013-03-14 | 2022-01-19 | The Brigham and Women's Hospital, Inc. | Compositions and methods for epithelial stem cell expansion and culture |
ES2860423T3 (en) | 2014-05-28 | 2021-10-05 | Childrens Hospital Med Ct | Methods and Systems for Converting Stem Cells to Gastric Tissues by Targeted Differentiation |
US11584916B2 (en) | 2014-10-17 | 2023-02-21 | Children's Hospital Medical Center | Method of making in vivo human small intestine organoids from pluripotent stem cells |
GB201603569D0 (en) | 2016-03-01 | 2016-04-13 | Koninklijke Nederlandse Akademie Van Wetenschappen | Improved differentiation method |
US11260130B2 (en) | 2016-03-02 | 2022-03-01 | Frequency Therapeutics, Inc. | Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using a GSK3 inhibitor: IV |
US10213511B2 (en) | 2016-03-02 | 2019-02-26 | Frequency Therapeutics, Inc. | Thermoreversible compositions for administration of therapeutic agents |
US10201540B2 (en) | 2016-03-02 | 2019-02-12 | Frequency Therapeutics, Inc. | Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using GSK3 inhibitors: I |
US11066650B2 (en) | 2016-05-05 | 2021-07-20 | Children's Hospital Medical Center | Methods for the in vitro manufacture of gastric fundus tissue and compositions related to same |
GB201610748D0 (en) * | 2016-06-20 | 2016-08-03 | Koninklijke Nederlandse Akademie Van Wetenschappen | Improved diffrentation method |
EP3548507A4 (en) | 2016-12-05 | 2020-07-15 | Children's Hospital Medical Center | Colonic organoids and methods of making and using same |
WO2018125746A1 (en) | 2016-12-30 | 2018-07-05 | Frequency Therapeutics, Inc. | 1h-pyrrole-2,5-dione compounds and methods of using them to induce self-renewal of stem/progenitor supporting cells |
US10383881B2 (en) | 2016-12-30 | 2019-08-20 | Frequency Therapeutics, Inc. | 1,5-dihydro-2H-pyrrol-2-one compounds and methods of using same |
IL271195B2 (en) | 2017-06-14 | 2024-04-01 | Semma Therapeutics Inc | Devices and methods for delivering therapeutics |
WO2019067506A1 (en) * | 2017-09-26 | 2019-04-04 | Board Of Regents, The University Of Texas System | Biochemical and biomechanical conditioning for enhancing personalized mesenchymal stem cell therapies |
BR112020009275A2 (en) | 2017-11-15 | 2020-10-27 | Semma Therapeutics, Inc. | islet cell manufacturing compositions and methods of use |
CN111684058B (en) * | 2018-02-09 | 2023-07-28 | 公立大学法人名古屋市立大学 | Method for inducing differentiation from pluripotent stem cells into intestinal epithelial cells |
WO2019169351A1 (en) * | 2018-03-02 | 2019-09-06 | Semma Therapeutics, Inc. | Methods of enhancing stem cell differentiation into beta cells |
WO2020022483A1 (en) * | 2018-07-27 | 2020-01-30 | 富士フイルム株式会社 | Method for producing intestinal epithelial cells and intestinal epithelial cells |
AU2019320072A1 (en) | 2018-08-10 | 2021-02-25 | Vertex Pharmaceuticals Incorporated | Stem cell derived islet differentiation |
CN113195707A (en) | 2018-08-17 | 2021-07-30 | 频率治疗公司 | Compositions and methods for generating hair cells by upregulation of JAG-1 |
WO2020112883A1 (en) * | 2018-11-30 | 2020-06-04 | Massachusetts Eye And Ear Infirmary | Inhibition of lysine demethylase 1 (lsd1) induces differentiation of hair cells |
CN110055220B (en) * | 2019-01-29 | 2021-03-30 | 中国人民解放军军事科学院军事医学研究院 | Method for inducing differentiation of hematopoietic stem cells into megakaryocytes |
KR102035481B1 (en) * | 2019-04-12 | 2019-10-23 | 한국지질자원연구원 | A composition for prevention, improvement and treatment of inflammatory bowel disease comprising a clay mineral complex |
CN110564677B (en) * | 2019-08-09 | 2022-09-09 | 上海泉生生物科技有限公司 | Inducer for inducing pluripotent stem cells to differentiate into beating cardiac muscle cells and application thereof |
CN111358790B (en) * | 2019-12-25 | 2021-03-16 | 江苏省肿瘤医院 | Application of NSC228155 in preparation of medicine for preventing and treating acute kidney injury |
WO2021257678A1 (en) * | 2020-06-17 | 2021-12-23 | The Children's Medical Center Corporation | Compositions and methods for regulating enteroendocrine cell differentiation and uses thereof |
CN114107175B (en) * | 2021-11-22 | 2024-01-02 | 北京大学 | Organoid culture method for inducing growth of intestinal organoids by mechanical stretching |
WO2023097513A1 (en) * | 2021-11-30 | 2023-06-08 | Hangzhou Reprogenix Bioscience, Inc. | Method of generating functional islets from pluripotent stem cells |
CN116270635A (en) * | 2021-12-13 | 2023-06-23 | 清华大学 | Use of heterocyclic compounds for reducing adverse effects caused by chemotherapeutic agents |
CN114480274A (en) * | 2021-12-30 | 2022-05-13 | 中国人民解放军海军军医大学第一附属医院 | Method for directionally differentiating Pan cells in intestinal organoid |
CN114732908A (en) * | 2022-03-03 | 2022-07-12 | 西北农林科技大学 | Application of HDAC6 inhibitor in severe infection |
Family Cites Families (121)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5059591B1 (en) | 1983-05-26 | 2000-04-25 | Liposome Co Inc | Drug preparations of reduced toxicity |
US5571714A (en) | 1988-12-22 | 1996-11-05 | Celtrix Pharmaceuticals, Inc. | Monoclonal antibodies which bind both transforming growth factors β1 and β2 and methods of use |
US5731144A (en) | 1990-06-11 | 1998-03-24 | Nexstar Pharmaceuticals, Inc. | High affinity TGFβ nucleic acid ligands |
US5731424A (en) | 1990-06-11 | 1998-03-24 | Nexstar Pharmaceuticals, Inc. | High affinity TGFβ nucleic acid ligands and inhibitors |
US6124449A (en) | 1990-06-11 | 2000-09-26 | Nexstar Pharmaceuticals, Inc. | High affinity TGFβ nucleic acid ligands and inhibitors |
US5561163A (en) | 1990-08-31 | 1996-10-01 | Deprenyl Animal Health, Inc. | Treating hearing loss with deprenyl |
US5421818A (en) | 1993-10-18 | 1995-06-06 | Inner Ear Medical Delivery Systems, Inc. | Multi-functional inner ear treatment and diagnostic system |
GB9601081D0 (en) | 1995-10-06 | 1996-03-20 | Cambridge Antibody Tech | Specific binding members for human transforming growth factor beta;materials and methods |
US5837681A (en) | 1996-02-23 | 1998-11-17 | Amgen Inc. | Method for treating sensorineural hearing loss using glial cell line-derived neurotrophic factor (GDNF) protein product |
US6593290B1 (en) | 1996-11-01 | 2003-07-15 | Genentech, Inc. | Treatment of inner ear hair cells |
US6045528A (en) | 1997-06-13 | 2000-04-04 | Intraear, Inc. | Inner ear fluid transfer and diagnostic system |
US6177434B1 (en) | 1997-12-16 | 2001-01-23 | The United States Of America As Represented By The Secretary Of The Navy | Prevention or reversal of sensorineural hearing loss (SNHL) through biologic mechanisms |
US6806358B1 (en) | 1997-12-16 | 2004-10-19 | University Of California San Diego | Peptide inhibitor of TGF-β growth factors |
EP1060160A2 (en) | 1998-02-27 | 2000-12-20 | THE UNITED STATES GOVERNMENT as represented by THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | Disubstituted lavendustin a analogs and pharmaceutical compositions comprising the analogs |
GB9809869D0 (en) | 1998-05-09 | 1998-07-08 | Medical Res Council | Inhibition of protein kinases |
US6184226B1 (en) | 1998-08-28 | 2001-02-06 | Scios Inc. | Quinazoline derivatives as inhibitors of P-38 α |
ES2146552B1 (en) | 1998-11-24 | 2001-04-16 | Inst Cientifico Tecnol Navarra | INHIBITING PEPTIDES OF TGF / 31 |
AU4206200A (en) | 1999-04-05 | 2000-10-23 | Adherex Technologies Inc. | Compounds and methods for stimulating beta-catenin mediated gene expression and differentiation |
US6492497B1 (en) | 1999-04-30 | 2002-12-10 | Cambridge Antibody Technology Limited | Specific binding members for TGFbeta1 |
IL152721A0 (en) | 2000-05-11 | 2003-06-24 | Consejo Superior Investigacion | Heterocyclic compounds and pharmaceutical compositions for inhibition of glycogen synthase kinase containing the same |
US6509318B1 (en) | 2000-09-29 | 2003-01-21 | The Regents Of The University Of California | TGF-B inhibitors and methods |
US20050287128A1 (en) | 2001-05-18 | 2005-12-29 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of TGF-beta and TGF-beta receptor gene expression using short interfering nucleic acid (siNA) |
US20050227936A1 (en) | 2001-05-18 | 2005-10-13 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of TGF-beta and TGF-beta receptor gene expression using short interfering nucleic acid (siNA) |
EA007782B1 (en) | 2001-05-24 | 2007-02-27 | Эли Лилли Энд Компани | Novel pyrrole derivatives as pharmaceutical agents |
WO2003012051A2 (en) | 2001-07-31 | 2003-02-13 | The State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of The University Of Oregon | Inhibitor of dna methylation |
US20030028905A1 (en) | 2001-07-31 | 2003-02-06 | Petra Knaus | Mutant forms of the TGF-beta type II receptor which bind all TGF-beta isoforms |
BR0213792A (en) | 2001-11-01 | 2004-12-07 | Janssen Pharmaceutica Nv | Heteroaryl amines as glycogen synthase kinase 3beta inhibitors (gsk3 inhibitors) |
SE0200979D0 (en) | 2002-03-28 | 2002-03-28 | Astrazeneca Ab | New compounds |
US20040006030A1 (en) | 2002-07-02 | 2004-01-08 | Isis Pharmaceuticals Inc. | Antisense modulation of TGF-beta 2 expression |
EP1506191A1 (en) | 2002-05-15 | 2005-02-16 | Smithkline Beecham Corporation | Benzoxazine and benzoxazinone substituted triazoles |
WO2003097615A1 (en) | 2002-05-17 | 2003-11-27 | Scios, Inc. | TREATMENT OF FIBROPROLIFERATIVE DISORDERS USING TGF-β INHIBITORS |
US7190468B2 (en) | 2002-07-17 | 2007-03-13 | Hewlett-Packard Development Company, L.P. | Background document rendering system and method |
WO2004013135A1 (en) | 2002-07-31 | 2004-02-12 | Smithkline Beecham Corporation | 2-phenylpyridin-4-yl derivatives as alk5 inhibitors |
EP1739087A1 (en) | 2002-08-02 | 2007-01-03 | Vertex Pharmaceuticals Incorporated | Pyrazole compositions useful as inhibitors of gsk-3 |
WO2004013140A1 (en) | 2002-08-02 | 2004-02-12 | Vertex Pharmaceuticals Incorporated | Pyrazole compositions useful as inhibitors of gsk-3 |
UA80296C2 (en) | 2002-09-06 | 2007-09-10 | Biogen Inc | Imidazolopyridines and methods of making and using the same |
AU2003268156A1 (en) | 2002-09-17 | 2004-04-08 | Eli Lilly And Company | Novel pyrazolopyridine derivatves as pharmaceutical agents |
CA2497971A1 (en) | 2002-09-18 | 2004-04-01 | Pfizer Products Inc. | Triazole derivatives as transforming growth factor (tgf) inhibitors |
WO2004026865A1 (en) | 2002-09-18 | 2004-04-01 | Pfizer Products Inc. | Novel isothiazole and isoxazole compounds as transforming growth factor (tgf) inhibitors |
AU2003291149A1 (en) | 2002-11-22 | 2004-06-18 | Scios, Inc. | USE OF TFG-Beta INHIBITORSTO COUNTERACT PATHOLOGIC CHANGES IN THE LEVEL OR FUNCTION OF STEROID/THYROID RECEPTORS |
EP1590347A1 (en) | 2003-01-27 | 2005-11-02 | Pfizer Products Inc. | Isothiazole derivatives |
ES2305744T3 (en) | 2003-03-12 | 2008-11-01 | Millennium Pharmaceuticals, Inc. | DERIVATIVES OF QUINAZOLINE AS INHIBITORS AND TGF-BETA. |
WO2004087056A2 (en) | 2003-03-28 | 2004-10-14 | Scios Inc. | BI-CYCLIC PYRIMIDINE INHIBITORS OF TGFβ |
ES2389258T3 (en) | 2003-06-17 | 2012-10-24 | Millennium Pharmaceuticals, Inc. | Compositions and methods to inhibit TGF-s |
GB0316756D0 (en) | 2003-07-17 | 2003-08-20 | Bp Chem Int Ltd | Process |
WO2005009287A2 (en) | 2003-07-21 | 2005-02-03 | University Of Maryland, Baltimore | Drug delivery to the inner ear and methods of using same |
US20060229266A1 (en) | 2003-08-13 | 2006-10-12 | Kumar Nalin M | Silencing of tgf-beta receptor type II expression by sirna |
JP4688680B2 (en) | 2003-10-28 | 2011-05-25 | 独立行政法人理化学研究所 | TGF-β signal transduction pathway inhibitor |
US8673634B2 (en) | 2003-11-13 | 2014-03-18 | Massachusetts Eye & Ear Infirmary | Method for the treatment of hearing loss |
GB0327908D0 (en) | 2003-12-02 | 2004-01-07 | Neuropharma Sa | GSK-3 inhibitors isolated from marine organisms |
EP1708712A1 (en) | 2003-12-24 | 2006-10-11 | Scios, Inc. | Treatment of malignant gliomas with tgf-beta inhibitors |
US7368445B2 (en) | 2004-03-01 | 2008-05-06 | Eli Lilly And Company | Fused pyrazole derivatives as TGF-β signal transduction inhibitors for the treatment of fibrosis and neoplasms |
AR048335A1 (en) | 2004-03-24 | 2006-04-19 | Chugai Pharmaceutical Co Ltd | THERAPEUTIC AGENTS FOR INTERNAL EAR DISORDERS CONTAINING AN IL-6 ANTAGONIST AS AN ACTIVE INGREDIENT |
CA2568028A1 (en) | 2004-05-24 | 2005-12-08 | Auris Medical, Llc. | Combined otic aspirator and medication dispenser |
GB0418328D0 (en) | 2004-08-17 | 2004-09-22 | Imp College Innovations Ltd | Cancer methods and medicaments |
JP2007176795A (en) | 2004-08-18 | 2007-07-12 | Univ Nihon | TGF-beta GENE EXPRESSION INHIBITOR |
US8771754B2 (en) | 2004-09-17 | 2014-07-08 | Vanderbilt University | Use of GSK3 inhibitors in combination with radiation therapies |
CN101163502A (en) | 2005-02-08 | 2008-04-16 | 根茨美公司 | Antibodies to tgf-beta |
GB0505970D0 (en) | 2005-03-23 | 2005-04-27 | Univ Edinburgh | Culture medium containing kinase inhibitor, and uses thereof |
ES2369282T3 (en) | 2005-03-25 | 2011-11-29 | Tibotec Pharmaceuticals | HCV HETEROBICYCLIC INHIBITORS. |
CN103356706B (en) | 2005-03-31 | 2016-01-20 | 斯丹姆涅恩有限公司 | Promote without scar healing or the cosmetic preparation improving skin appearance |
JP5345388B2 (en) | 2005-06-30 | 2013-11-20 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | Cyclic anilino-pyridinotriazine |
ES2542425T3 (en) | 2005-07-22 | 2015-08-05 | Eli Lilly And Company | Pyrrolo [1,2-b] pyrazole substituted pyridinoquinoline monohydrate as a TBF-beta inhibitor |
EP1749523A1 (en) | 2005-07-29 | 2007-02-07 | Neuropharma, S.A. | GSK-3 inhibitors |
JP2009511061A (en) * | 2005-10-14 | 2009-03-19 | リージェンツ オブ ザ ユニバーシティ オブ ミネソタ | Differentiation of non-embryonic stem cells into cells with pancreatic phenotype |
CN101340927A (en) | 2005-10-24 | 2009-01-07 | 西玛生物医学信息公司 | Application of TGF-beta1 inhibitory polypeptide on immune response modifier preparation |
US7951845B2 (en) | 2006-01-19 | 2011-05-31 | The Regents Of The University Of Michigan | Composition and method of treating hearing loss |
ITMI20060181A1 (en) | 2006-02-03 | 2007-08-04 | Univ Padova | TGF-B MODULATORS AND THEIR USE |
TW200800203A (en) | 2006-03-08 | 2008-01-01 | Astrazeneca Ab | New use |
EP1993611A4 (en) | 2006-03-16 | 2013-05-22 | Alnylam Pharmaceuticals Inc | RNAi MODULATION OF TGF-BETA AND THERAPEUTIC USES THEREOF |
ES2725601T3 (en) * | 2006-04-28 | 2019-09-25 | Lifescan Inc | Differentiation of human embryonic stem cells |
WO2008023239A1 (en) | 2006-08-23 | 2008-02-28 | Pfizer Products Inc. | Pyrimidone compounds as gsk-3 inhibitors |
AU2007334260A1 (en) | 2006-11-15 | 2008-06-26 | Massachusetts Eye & Ear Infirmary | Generation of inner ear cells |
ES2446269T3 (en) | 2006-12-19 | 2014-03-06 | The Board Of Trustees Of The University Of Illinois | 3-Benzofuranyl-4-indolyl-maleimides as potent inhibitors of GSK-3 for neurodegenerative disorders |
WO2009017455A1 (en) | 2007-07-30 | 2009-02-05 | Astrazeneca Ab | A new combination of (a) an alpha-4-beta-2 -neuronal nicotinic agonist and (b) a gsk3 inhibitor |
WO2009017453A1 (en) | 2007-07-30 | 2009-02-05 | Astrazeneca Ab | New therapeutic combination of an antipsychotic and a gsk3 inhibitor 958 |
EP2197876A1 (en) | 2007-08-29 | 2010-06-23 | Glaxosmithkline LLC | Thiazole and oxazole kinase inhibitors |
WO2009035522A1 (en) | 2007-09-14 | 2009-03-19 | Albert Einstein College Of Medicine Of Yeshiva University | Use of gamma secretase inhibitors and notch pathway inhibitors for treatment and prevention of renal disease |
MX2010010165A (en) | 2008-03-17 | 2010-11-25 | Scripps Research Inst | Combined chemical and genetic approaches for generation of induced pluripotent stem cells. |
EP2278999A4 (en) | 2008-04-21 | 2015-04-22 | Otonomy Inc | Auris formulations for treating otic diseases and conditions |
US20090270497A1 (en) | 2008-04-24 | 2009-10-29 | Pharmacyclics, Inc. | Treatment of Non-Localized Inflammation with pan-HDAC Inhibitors |
US8822410B2 (en) | 2008-05-19 | 2014-09-02 | Children's Medical Center Corporation | Tympanic membrane permeating ear drops and uses thereof |
US8496957B2 (en) | 2008-07-21 | 2013-07-30 | Otonomy, Inc | Controlled release auris sensory cell modulator compositions and methods for the treatment of otic disorders |
US8298825B1 (en) | 2008-08-25 | 2012-10-30 | The General Hospital Corporation | TGF-beta receptor inhibitors to enhance direct reprogramming |
US20120059021A1 (en) | 2008-11-11 | 2012-03-08 | University Of Washington | Compositions and methods for treating cancer and methods for predicting a response to such treatments |
JP5809061B2 (en) | 2008-11-24 | 2015-11-10 | マサチューセッツ・アイ・アンド・イア・インファーマリー | Pathways for producing hair cells |
EP2376626A4 (en) | 2008-12-13 | 2012-10-17 | Dna Microarray | MICROENVIRONMENT NICHE ASSAY FOR CiPS SCREENING |
WO2010075551A1 (en) | 2008-12-24 | 2010-07-01 | Massachusetts Institute Of Technology | Compositions of modulators of the wnt/beta-catenin pathway and benzamide and/or hydroxamic acid derivatives to treat bipolar disorder |
US9752124B2 (en) | 2009-02-03 | 2017-09-05 | Koninklijke Nederlandse Akademie Van Wetenschappen | Culture medium for epithelial stem cells and organoids comprising the stem cells |
GB201111244D0 (en) | 2011-06-30 | 2011-08-17 | Konink Nl Akademie Van Wetenschappen Knaw | Culture media for stem cells |
EP2412800A1 (en) * | 2010-07-29 | 2012-02-01 | Koninklijke Nederlandse Akademie van Wetenschappen | Liver organoid, uses thereof and culture method for obtaining them |
US8071591B2 (en) | 2009-03-11 | 2011-12-06 | Kyorin Pharmaceutical Co., Ltd. | 7-cycloalkylaminoquinolones as GSK-3 inhibitors |
WO2011019957A1 (en) | 2009-08-12 | 2011-02-17 | University Of Southern California | Method for formation of induced pluripotent stem cells |
EP3567103B1 (en) | 2009-10-31 | 2023-09-06 | Genesis Technologies Limited | Methods for reprogramming cells and uses thereof |
US20110135756A1 (en) | 2009-12-08 | 2011-06-09 | University Of Washington | Compositions and methods for protecting sensory hair cells |
KR20120098855A (en) | 2009-12-28 | 2012-09-05 | 아우디오쿠레 파르마 게엠베하 | beta -CARBOLINES FOR TREATMENT OF HEARING DAMAGES AND VERTIGO |
CN102812017A (en) | 2010-01-19 | 2012-12-05 | 阿斯利康(瑞典)有限公司 | Pyrazine derivatives |
EP2550355B1 (en) | 2010-03-22 | 2016-11-16 | Takara Bio Europe AB | Directed differentiation and maturation of pluripotent cells into hepatocyte like cells by modulation of wnt-signalling pathway |
CA2800498C (en) * | 2010-03-31 | 2021-11-16 | The Scripps Research Institute | Reprogramming cells |
CN109593814A (en) * | 2010-05-12 | 2019-04-09 | 哥伦比亚大学纽约管理委员会 | Screening analysis, the method and pharmaceutical composition for identifying medicament |
EP2636731B1 (en) | 2010-11-02 | 2016-07-13 | National University Corporation Kumamoto University | Method of producing intestinal cells |
WO2012087889A2 (en) | 2010-12-20 | 2012-06-28 | The Ohio State University Research Foundation | Dna methylation inhibitors |
US9157064B2 (en) | 2011-01-24 | 2015-10-13 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for generating inner ear cells in vitro |
SG11201400666PA (en) | 2011-09-14 | 2014-09-26 | Samumed Llc | Indazole-3-carboxamides and their use as wnt/b-catenin signaling pathway inhibitors |
US9347042B2 (en) | 2011-10-06 | 2016-05-24 | Keio University | Method for producing corneal endothelial cell |
LT2838888T (en) | 2012-02-24 | 2017-08-10 | Asd Therapeutics Partners Llc | Thiadiazolidinediones as gsk-3 inhibitors |
US9457009B2 (en) | 2012-05-31 | 2016-10-04 | The United States Of America As Represented By The Department Of Veterans Affairs | Methods and compositions for preventing and treating auditory dysfunctions |
TW201406758A (en) | 2012-06-28 | 2014-02-16 | Daiichi Sankyo Co Ltd | Tricyclic compounds |
GB201212960D0 (en) | 2012-07-20 | 2012-09-05 | Common Services Agency | Erythroid production |
EP2892523B1 (en) | 2012-09-07 | 2019-05-01 | Massachusetts Eye & Ear Infirmary | Methods and compositions for regenerating hair cells and/or supporting cells |
WO2014050779A1 (en) | 2012-09-25 | 2014-04-03 | 第一三共株式会社 | Combination of gsk3 inhibitor and anti-dr5 antibody |
PL2909204T3 (en) | 2012-10-12 | 2019-07-31 | The Broad Institute, Inc. | Gsk3 inhibitors and methods of use thereof |
CN105143445B (en) | 2012-11-29 | 2020-07-07 | 宝生物欧洲公司 | Maturation of hepatocyte-like cells derived from human pluripotent stem cells |
US20140248696A1 (en) | 2013-03-01 | 2014-09-04 | Wisconsin Alumni Research Foundation | Methods of maintaining, expanding, and diffrentiating neuronal subtype specific progenitors |
EP3702443B1 (en) | 2013-03-14 | 2022-01-19 | The Brigham and Women's Hospital, Inc. | Compositions and methods for epithelial stem cell expansion and culture |
US10603295B2 (en) | 2014-04-28 | 2020-03-31 | Massachusetts Eye And Ear Infirmary | Sensorineural hair cell differentiation |
WO2015175783A1 (en) * | 2014-05-15 | 2015-11-19 | International Stem Cell Corporation | Chemical differentiation of pluripotentstem cells into retinal epithelial cells |
IL299964A (en) | 2014-09-03 | 2023-03-01 | Massachusetts Inst Technology | Compositions, systems, and methods for generating inner ear hair cells for treatment of hearing loss |
CN104726395B (en) * | 2015-03-20 | 2018-03-23 | 深圳市人民医院 | It is a kind of to induce the method that people's induced multi-potent stem cell directed differentiation is pancreatic cell |
EP3350313A4 (en) * | 2015-09-15 | 2019-06-12 | Agency For Science, Technology And Research (A*star) | Derivation of liver organoids from human pluripotent stem cells |
WO2019183572A1 (en) * | 2018-03-23 | 2019-09-26 | Refuge Biotechnologies, Inc. | Gene regulation via conditional nuclear localization of gene modulating polypeptides |
-
2017
- 2017-01-06 CN CN201780010026.6A patent/CN108779437A/en active Pending
- 2017-01-06 JP JP2018535116A patent/JP2019506153A/en not_active Ceased
- 2017-01-06 WO PCT/US2017/012631 patent/WO2017120543A1/en active Application Filing
- 2017-01-06 CA CA3010610A patent/CA3010610A1/en active Pending
- 2017-01-06 AU AU2017205194A patent/AU2017205194A1/en not_active Abandoned
- 2017-01-06 EP EP17702699.4A patent/EP3400286A1/en not_active Withdrawn
- 2017-01-06 US US15/400,877 patent/US11021687B2/en active Active
-
2021
- 2021-05-31 US US17/334,933 patent/US20210363491A1/en active Pending
- 2021-12-21 JP JP2021207458A patent/JP2022048143A/en not_active Withdrawn
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11369607B2 (en) | 2014-09-03 | 2022-06-28 | The Brigham And Women's Hospital, Inc. | Compositions, systems, and methods for generating inner ear hair cells for treatment of hearing loss |
US11617745B2 (en) | 2018-08-17 | 2023-04-04 | Frequency Therapeutics, Inc. | Compositions and methods for generating hair cells by downregulating FOXO |
Also Published As
Publication number | Publication date |
---|---|
CA3010610A1 (en) | 2017-07-13 |
CN108779437A (en) | 2018-11-09 |
EP3400286A1 (en) | 2018-11-14 |
JP2022048143A (en) | 2022-03-25 |
AU2017205194A1 (en) | 2018-07-19 |
WO2017120543A1 (en) | 2017-07-13 |
JP2019506153A (en) | 2019-03-07 |
US11021687B2 (en) | 2021-06-01 |
US20170349884A1 (en) | 2017-12-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20210363491A1 (en) | Production of insulin producing cells | |
US20210301254A1 (en) | Compositions And Methods For Epithelial Stem Cell Expansion And Culture | |
McLean et al. | Clonal expansion of Lgr5-positive cells from mammalian cochlea and high-purity generation of sensory hair cells | |
US10383881B2 (en) | 1,5-dihydro-2H-pyrrol-2-one compounds and methods of using same | |
KR102493376B1 (en) | Compositions, systems, and methods for generating inner ear hair cells for treatment of hearing loss | |
US20190093079A1 (en) | Methods for controlled proliferation of stem cells / generating inner ear hair cells using gsk-3-alpha inhibitors | |
CA3014662A1 (en) | Methods for controlled proliferation of vestibular stem cells / generating inner ear hair cells using wnt and tgf-beta inhibition | |
Zhang et al. | Activation of Wnt signaling increases numbers of enteric neurons derived from neonatal mouse and human progenitor cells | |
US20180256590A1 (en) | Methods for controlled proliferation of stem cells / generating inner ear hair cells using 3-(pyridin-2-yl)-1h-indol-2-ol based compounds | |
Huot | Notch Serves as a Molecular Brake on Myogenesis, Protein Synthesis, and Growth in Skeletal Muscle |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: THE BRIGHAM AND WOMEN'S HOSPITAL, INC., MASSACHUSETTS Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:KARP, JEFFREY MICHAEL;YIN, XIAOLEI;REEL/FRAME:056614/0264 Effective date: 20170327 Owner name: MASSACHUSETTS INSTITUTE OF TECHNOLOGY, MASSACHUSETTS Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:LANGER, ROBERT SAMUEL;REEL/FRAME:056614/0250 Effective date: 20200205 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
AS | Assignment |
Owner name: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT, MARYLAND Free format text: CONFIRMATORY LICENSE;ASSIGNOR:MASSACHUSETTS INSTITUTE OF TECHNOLOGY;REEL/FRAME:065775/0641 Effective date: 20210727 |